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Introduction: Prognosis in Traumatic Brain Injury (TBI) can be made using 
prognostic models (the IMPACT and CRASH models) or brain injury 
biomarkers (S100B). Current prognostic models are derived from historic 
datasets recruited from heterogeneous countries in terms of trauma care and for 
the purpose of clinical trials.  
Objective: To construct a prognostic model suitable for British trauma care, to 
compare the prognostic performance of prognostic models with S100B and to 
assess the  combination of prognosticators from the constructed models with 
S100B.  
Methods: A dataset of 802 TBI cases from the Trauma Audit and Research 
Network (TARN), Manchester, UK was used to construct the prognostic 
models.. During the modelling, criteria  for well-developed models as per the 
literature review were followed such as the dataset being large, the variables 
being selected from the literature and  missing information being  imputed. A 
further dataset of TBI cases was used to validate these models Moreover, the 
resulting models were run on a dataset of 100 TBI cases who had their serum 
S100B recorded at 24 hours to compare their performance with S100B.  
Results: Two prognostic models were constructed (models A and B) to predict 
the discharge survival. Both models share age, admission Glasgow Coma Scale 
(GCS), admission pupillary reactivity and presence/absence of hypoxia and 
lowblood pressure (on admission) and brain stem injury. However, model A 
includes Injury Severity Score (ISS) which is replaced with cause of injury, 
extracranial injury, brain swelling and interaction of cause of injury and age in 
model B. Both models have high performance either on the derivation dataset 
(Area Under the ROC Curve (AUC) of model A: 0.92 and AUC of model B: 
0.93) or the external validation set from a  later time period in TARN (AUC of 
model A: 0.92 and AUC of model B: 0.82). Furthermore, in the S100B dataset, it 
appears that the performance of prognostic models is not significantly different 
to that of S100B (for example, AUC of model A in this dataset: 0.64 versus 0.69 
of the model just including S100B for survival prediction).  A combination of 
S100B and models prognosticators improved performance and S100 improved 
the performance of models A and B.  
Discussion: The proposed prognostic models have very high AUCs and since 
they have been validated on a different TBI dataset from TARN, they are valid 
to be used for the purpose of the British trauma care benchmarking. 
Unfortunately, the results of the analysis on the small S100B dataset are not 
adequately powerful to be conclusive. However, these findings highlight the 
importance of future research on this topic in larger datasets.  
Conclusion: Two prognostic models have been constructed which can be used 
for the British TBI patients.  
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1. Introduction 
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1.1. Review of the epidemiology of traumatic brain 
injury and the research question  
Worldwide many people die due to Traumatic Brain Injury (TBI) each year or 
suffer from the resulting neuropsychological disability causing either social or 
individual problems. As a matter of fact, TBI is a silent epidemic [1-7] which 
has been disregarded by policy makers compared with other public health 
challenges such as breast cancer or Acquired Immune Deficiency Syndrome 
(AIDS). However, the annual incidence of brain injury in the United States 
surpasses that of breast cancer or AIDS significantly [1]. It is now the leading 
cause of death and disability among the young generation and anticipated to 
become one of the major causes of mortality by 2020 worldwide [7]. 
1.1.1. Definition  
Based on Medical Heading Subject (MeSH) database, head trauma or 
craniocerebral injury is defined as “a traumatic injury involving the cranium 
and intracranial structures” [8] and described as TBI when it involves brain.  
Standards for Surveillance of Neurotrauma [9] define a case of TBI as 
either:  
1) An occurrence of injury to the head (arising from blunt or penetrating 
trauma or from acceleration –deceleration forces) with at least one of the 
following: 
- observed or self reported alteration of consciousness or amnesia 
due to head trauma 
-  neurologic or neuropsychological changes (determined from 
neurologic and neuropsychological examinations) or diagnosis of skull fracture 
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or intracranial lesions (determined from radiological examination or other 
neurodiagnostic procedures) that can be attributed to the head trauma.  
2)  An occurrence of death resulting from trauma with head injury or 
traumatic brain injury listed on the death certificate, autopsy report, or medical 
examiner‟s report in the sequence of conditions that resulted in death.  
According to the guideline commissioned by National Institute for 
Clinical Excellence (NICE) [10] head injury is defined as “any trauma to the 
head,  other than superficial injuries to the face”.   
 Recently, a new definition of TBI has been proposed by the 
Demographic and Clinical Assessment Working Group of the International and 
Integrity Initiative toward Common Data Elements for Research on Traumatic 
Brian Injury and Psychological Health {Menon,  #303}. The proposed 
definition is: 
 
‘TBI is defined as an alteration in bran function or other evidence of brain 
pathology caused by an external force.’ 
 
The medical term : injury, according to MeSH database, is described as 
“damage inflicted on the body as the direct or indirect result of an external force, with 
or without disruption of structural continuity” [8]. This description suggests that the 
term “brain injury” has association with trauma; hence brain injury and TBI can 
substitute each other in a medical text. In this review, “brain injury” is equated to 
traumatic brain injury when being referred to. Moreover, brain injury patients are a 
subgroup of patients who have head trauma with an evidence for brain damage. Even 
with the current clinical or radiographic diagnostic tools, this distinction is not always 
possible particularly in mild brain injury.  
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1.1.2. Incidence and cost 
In the United States, each year 1.5 million people suffer from TBI of which 
50,000 die, 230,000 are hospitalized and the remaining are discharged home 
[11]. In Europe, the incidence of hospitalization or death is estimated to be 235 
per 100,000 [12]. According to the study of Alan Tennant the incidence rate of 
traumatic brain injury in England was 229.4 in the year 2001-2 and 229.1 for 
the year 2002-3 per 100,000 of general population [13].  
The cost of TBI is classified as either direct or indirect. The direct cost 
amounts to hospitals charges after acute care involving prescribed medicines, 
undertaken procedures or performed rehabilitation strategies and then, further 
out-patient services. The indirect cost is caused by subsequent patient‟s lack of 
productivity, early retirement or sick leave [14]. The total cost related to brain 
injury in 2000 was estimated to be 6$ billion in the United States [15], while 
the exact figure from Europe is unknown [12]. However, in Spain during the 
year 1997, the injuries resulting from traffic crashes imposed 3,397 € to the 
nation [16] which gives an approximate estimation of brain injury cost in a 
European country.  
1.1.3. High risk groups 
Males are at higher risk and age groups of 0 to 4 and 15 to 19 are more prone 
to sustain TBI  than other groups [2]. J David Cassidy and colleagues who 
undertook a best-evidence synthesis on dimensions of mild TBI epidemiology, 
including risk factors reported similar results [17]. Recreational and sporting 
activities [17] and some work-related situations such industrial-type jobs [18] 
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put the individual at a higher risk level as well. In the United States, being 
African-American may act as a risk factor [2]. 
1.1.4. Cause 
The causes of TBI are categorized differently in various studies. Fall, motor 
vehicle –traffic crash, struck by/against an event and assault are conventional 
categories used by most authors with some variations. In 1995, World Health 
Organisation (WHO) proposed a guideline for surveillance of nerurotrauma in 
societies from which the main causes are displayed in  table 1[9]. In the United 
States the most frequent aetiology is fall [2] but in Europe it is said to be motor 
vehicle-crashes [12]. 
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Table 1 External causes of brain injury (drawn from Standards for 
Surveillance of Neurotrauma, ed. D.J. Thurman, Kraus, J.F., Romer, C.J.. 
1995, Geneva: World Health Organisation. [9]) 
1.1.5. Outcome  
Victims of TBI may experience a spectrum of outcome ranging from full 
recovery to death. Those who survive may continue to suffer from various 
degrees of physical or mental disabilities affecting their life and some of them, 
despite being physically fit, may never resume their pre-injury functionality for 
a long time. Mild physical and mental consequences of TBI may be a number 
of complaints such as headache, dizziness, fatigue and difficulty concentrating. 
If a patient demonstrates 3 of these symptoms, he/she would then be diagnosed 
with Post-Concussion Syndrome (PCS) which commonly occurs following 
concussion (a mild form of brain injury but severe enough to result in loss of 
consciousness). The survivors of more severe forms of TBI which result in 
longer periods of loss of consciousness may suffer from more severe disability.  
Mental and physical consequences of TBI do not affect only the 
individual victim. For example, people with TBI may suffer from relationship 
difficulties inside the family. Out of 48 participant couples in Wood RL and his 
colleagues‟ research [19] twenty three (relatively 47%) were separated or 
divorced in the end, meaning that just less than 53% continued their 
partnership. Hawley CA and others [20] reported that the level of stress in 
parents of TBI children was clinically high with the rate of 40%. One third of 
Vehicular and animal transportation: operator or passenger 
Vehicular and animal transportation: pedestrian 
Firearms and other Objects Used as Weapons 
Violence without Use of Firearm or Other Weapons 
Sports/Recreation 
Falls 
Other (Struck by falling object, other specified or known cause of injury, 
Unknown) 
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the parents were found to have poor psychological health. Moreover, 
Montgormery and others [21] observed that 57% of families of children with 
brain injury witnessed behavioural problems in other siblings. With decreased 
amount of time worked and subsequent impact on employment status [13, 18] 
the potential harm of the injury to the family goes beyond psychological 
matters, ending up as an economic burden as well.  
1.1.6. Prognosis  
Prognosis means the prediction of the outcome of the disease and as such it 
would assist the clinicians in having an estimate of the severity. A poor 
prognosis means the clinician should consider the value of more aggressive 
intervention.  
Knowing the prognosis in TBI is important to assist clinicians dealing 
with individual TBI patients, to stratify patients based on the severity of their 
injuries in clinical trials and to perform trauma care benchmarking. Whilst 
overall, advancement in each of these areas can lead to improvement in 
patients‟ outcome, knowing prognosis has a specific advantage in each area. In 
clinical practice, it would assist clinicians in making timely and appropriate 
decisions and also in allocating resources. In clinical trials, knowing the 
prognosis would assist to detect pure effect of the intervention on outcome 
irrespective of the severity and in the recruitment of patients with a truly 
intermediate prognosis. And lastly, the quality of trauma care in a given trauma 
centre can be benchmarked  by comparing the observed prognosis of patients 
cared for in that centre to the expected prognosis at the national level. The 
expected prognosis is calculated by using a model derived from nationawide 
data. 
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Considering the above importance of prognosis in TBI, the research 
question is:  
How can the outcome of a given TBI patient be predicted? 
There are currently two common prognostic tools in TBI to predict the 
outcome: prognostic models and brain injury biomarkers. Prognostic models 
apply commonly measured patient characteristics and provide the probability 
of a given outcome at a certain point in time. Brain injury biomarkers are 
usually serum biomarkers which tend to increase in TBI and also be higher in 
more severe forms of TBI. In the following sections of the introduction, the 
common prognostic models in TBI and the most widely acknowledged brain 
injury biomarker; S100B are discussed.  
1.1.7. Common terms in research into TBI prognosis  
 
Glasgow Coma Scale (GCS) 
 
First introduced by Teasdale et al.  in 1974, this is a scoring system to measure 
the level of consciousness (Table 2). This system is internationally well-
established and ranges from 3 to 15 and is the sum of three subscores assessing 
three domains of eye, verbal and motor response. Later on, in several studies it 
was shown that lower GCS is associated with adverse outcome [22-24]  
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Best verbal response 
Orientated to time, place and person 5 
Appropriate responses but disorientated 4 
Inappropriate responses but coherent words 3 
Incoherent sounds only 2 
No verbal response 1 
 
Best motor response 
Obeys commands 6 
Localise pain 5 
Normal flexion to pain 4 
Abnormal flexion to pain 3 
Extension to pain 2 
No motor response 1 
 
Best eye opening response 
Spontaneous eye opening 4 
Opens eyes to speech 3 
Opens eyes to pain 2 
No eye opening response 1 
Table 2 Glasgow Coma Score is the sum of three types of patient’s 
response score to stimulation: verbal, motor and eye opening.  
 
 
Glasgow Outcome Scale (GOS) 
 
Glasgow Outcome Scale was first introduced by b. Jennet and M. Bond in 
1975 [25]. They categorized the outcome into five groups of death, persistent 
vegetative state, sever disability (conscious but disabled), moderate disability 
(disabled but independent) and good recovery. In 1981 Jennet et al.  proposed 
an extended revised version of the system to enhance its application and 
reliability [26]. In the extendedextended revision of GOS referred to as GOSE, 
each three  last categories are further divided into upper and lower levels 
(Table 3). In 1998, Wilson and others [27] proposed a structured pattern of 
interview to score the outcome of TBI patients based on GOS. 
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GOSE score Performance level 
1 Dead 
2 Vegetative state 
3 Lower sever disability: completely dependant on others 
4 Upper sever disability: dependant on others for some activities 
5 Lower moderate disability: unable to return to work or participate in 
social activities 
6 Upper moderate disability: return to work at reduced capacity, 
reduced participation in social activities 
7 Lower good recovery: good recovery with minor social or mental 
deficits 
8 Upper good recovery 
Table 3 The extended Glasgow Outcome Scale (GOSE)  
1.1.8. Summary 
 
 
 
 
 
 
Traumatic brain injury is a major public health problem and has detrimental 
effects on victims’ lives  due to physical and psychological  morbidity. An 
understanding of prognosis in TBI assists clinicians with timely and appropriate 
decisions and allocation of resources. Also, it is important to understand 
prognosis for benchmarking trauma care quality and clinical trials of new 
intervention. There are currently two common prognostic tools available in the 
literature: brain injury biomarkers and prognostic models.  
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1.2. Prognostic models  
Prognostic models employ a number of patients‟ characteristics such as age, 
GCS, pupillary reactivity, CT findings etc. to predict a given outcome. In this 
section, two internationally known models derived from large cohorts of TBI 
patients plus two models (which have been proposed as well-developed models 
by a systematic review) are introduced.  
Area Under the receiver operator Curve (AUC) is a statistical term to 
measure the model performance (or its predictive strength) and has been stated 
in several places of this section. This concept is further discussed in Paper 1 
(section 2.7.1).  
1.2.1. IMPACT models 
International Mission for Prognosis and Clinical Trial (IMPACT) dataset of 
TBI is the mergence of several previously conducted clinical trials and 
observational studies which in total contains data on more than 9000 TBI 
subjects [28]. Included studies were all from developed world (North America 
and Europe). The initiative started in 2002 targeted at advancing the approach 
in TBI clinical trials and as part of this initiative, the IMPACT models for TBI 
prognosis were published in 2008 [24]. The IMPACT dataset contains severe 
TBI cases as per their admission GCS being 8 or less. Although it contained 
some very few cases with moderate GCS (i,e, GCS of more than 8 but less than 
13),the IMPACT dataset included mainly severe TBI cases. 
Overall 6 prognostic models are proposed by the IMPACT 
collaboration [24]. The core models use age, motor GCS score and pupillary 
reactivity to predict mortality or unfavourable outcome (GOS < 4) at 6 months 
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after sustaining injury. The expanded models use hypoxia, hypotension, the 
Marshall CT classification, traumatic SAH and epidural haematoma in addition 
to the covariates in the core models. The lab models add glucose and 
haemoglobin (Hb) to the covariates included in the expanded models. Models 
are presented in the form of score charts with an online calculator [29].  
From the core models to the lab models and as new covariates are 
added to the models, the performance of the models improves according to 
AUC. The AUCs are reported in various sub-datasets ranging from 0.66 for the 
core model on mortality prediction in the Saphir data (phase III trial of the 
competitive NMDA antagonist DCPP-ene, 1995-1997 [30]) to 0.87 for the 
expanded model on mortality prediction in EBIC data (European Brain Injury 
Consortium survey, 1995) (Saphir and EBIC studies were two of many studies 
pooled into the IMPACT mega dataset [30]).  
The important advantage of the IMPACT models is the large dataset 
from which the models have been derived. Furthermore, the models 
construction complies with many criteria for a well-developed model proposed 
by Perel et al. [31] and Mushkudiani et al [32]. Briefly and apart from the large 
derivation set, the variables used by the models such age, GCS etc.. are readily 
obtainable and the models have been externally validated in another dataset of 
TBI different to the derivation dataset with no significant change in AUC. In 
fact, a high external AUC of 0.83 is obtained for the expanded model for 
mortality prediction when it was run on the CRASH data (section 1.2.2). 
Furthermore, the missing information had been handled appropriately rather 
than omitting the cases with missing values. This is because in the modelling 
procedure, all cases who have a missing value even on one variable are 
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excluded meaning that they in fact do not exist in the data. Imputing the 
missing values with an appropriate strategy is preferable to total loss of 
information [28].  
1.2.2. CRASH models  
The Medical Research Council (MRC) CRASH (Corticosteroid Randomisation 
After Significant Head Injury) study was initially a clinical trial to investigate 
the effect of early administration of methylprednisolone in TBI [33]. The 
dataset of more than 10 000 cases collected in this trial was subsequently used 
to derive prognostic models [23]. The participating hospitals were from various 
countries around the globe with different degrees of contribution to patient 
recruitment. The trial was commenced in 1999 and was terminated in 2004. 
The inclusion criteria were head injury sustained at the age of above 16 with 
admission GCS of 14 or less and clear indication or contraindication for 
corticosteroid administration.  
Overall 6 prognostic models are proposed by the CRASH 
collaboration. Basic models do not contain CT findings and instead use age, 
GCS, pupillary reactivity and major extra cranial injury. However, there are 
also separate models by CRASH which include CT findings in addition to the 
factors in the basic models. Each model (with or without CT) can predict 
mortality or severe disability within 14 days or six months following the injury. 
Moreover, separate models are applicable to low-middle income countries 
versus high-income countries. These models are presented in the tables of odds 
ratios with an online calculator available [34].  
Similar to the IMPACT models, adding more covariates i.e. CT 
findings to the basic models results in improvement in AUC. The AUC of the 
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models ranges from 0.81 for death/severe disability prediction to 0.88 for 
mortality prediction either in high-income or low-income countries.  
The upsides of the CRASH models are almost similar to those of the 
IMPACT models such as easily obtainable variables, external validity and 
handling of missingness with the most important one being the large derivation 
dataset. Moreover, the CRASH models reasonably maintain their predictability 
in the external validation on the IMPACT dataset (a drop from internal AUC of 
0.88 to external AUC 0.77).  
1.2.3. Other models 
Perel et al.[31] performed a systematic review of the literature on the 
prognostic models in TBI and concluded that at the time of the review, there 
were only two models which fulfilled the methodological requirements with 
acceptance external validation: models by Signorini et al. [35] and 
Hukkelhoven et al. [36]. It is not surprising that since this review was 
conducted prior to the introduction of the IMPACT and CRASH models, these 
models are not appraised in Perel‟s work.  
Hukkelhuven et al.  derived a prognostic model on a TBI series from a 
clinical trial in Europe and the North America. The trial was designed to assess 
the effect of Tirilazad Mesylate in TBI and contained over 2,200 cases. Two 
models were introduced to predict mortality or severe disability at 6 months. 
The models employed age, GCS (motor score), pupillary reactivity, hypoxia, 
hypotension, Marshall CT Classification and SAH to make its outcome 
prediction with AUC of 0.78 for mortality prediction and 0.80 for unfavourable 
outcome prediction. These AUCs even increased in the external validation set 
(ranging from 0.83 to 0.89 for various constructed models). The dataset from 
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which the Hukkelhuven‟s models were derived, was later pooled in the 
IMPACT dataset.  
Signorini et al. analysed a dataset of 124 TBI cases all cared in the 
intensive care unit and constructed 6 models (one Baseline model with 5 final 
models). The outcome measure was mortality at 1 year following injury. The 
baseline models contained age, GCS, presence/absence of haematoma on CT 
and pupillary reactivity. The final models contained the covariates in the basic 
model plus ICP measured at various time points e.g. within 24 hours of injury, 
between 24 to 48 hours of injury etc. The AUCs of models ranged from 0.84 
(for the basic model) to 0.9048 for the basic model plus ICP measured between 
24 and 48 hours. The Signorini‟s models are very old dating back to about 20 
years ago (1991).  
1.2.4. Summary  
 
 
Prognostic models are a tool for predicting outcome in TBI. They employ 
patients’ characteristics recorded or known to the clinician and provide the 
probability of an outcome at a certain time point. Currently, there are two 
internationally well-developed prognostic models which have been derived 
from large datasets of TBI: the IMPACT and CRASH prognostic models. The 
development of these models complies with the methodological requirements 
of well-developed models. The factors consistently most associated with 
prognosis are age, GCS, pupillary responses, CT scan findings with 
measures of injury severity and laboratory variables also having value in 
some models 
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1.3. Brain injury biomarkers 
These are chemicals which increase in the blood or CSF following TBI and 
their serum concentration relates to the severity of brain injury and outcome. 
There are many biomarkers proposed in the literature and Table 4 lists some of 
them as compiled by Qurreshi in 2002.  
Obviously the list of some biomarkers proposed  by Qurreshi in 2002 is 
expected to be longer than that in 2002 especially with the new advances in 
better understanding of cellular pathways initiated following TBI. For a 
number of reasons understanding the multifaceted pathogenesis of TBI is 
important. Firstly, it may assist with diagnosis and identifying the severity of 
the damage caused by TBI especially that the advanced imaging modalities are 
not sensitive enough (such as CT to detect diffuse axonal injury) or are not 
widely available due to their high cost (such as MRI). Secondly, knowing these 
cellular and molecular can open up the possibility to investigate therapeutic 
agents to disrupt those pathways which are neurotoxic. It is currently believed 
that the disruption of Blood Brain Barrier (BBB) following trauma can initiate 
immunological responses by activating CNS „resident‟ cells such as microglia 
and astrocytes or by causing the infiltration of the peripheral immune cells 
{Morganti-Kossmann, 2007 #296}. This  subsequently results in 
neuroinflammation. Immune cells react by producing cytokines which can have 
either neuotoxic or neuroprotecitve effects. Interleukin (IL)-1 and  Tumor 
Necrosis Factor (TNF) are some of the cytokines which may have more 
neuroprotecrtive effects. Moreover, it has been found that increased patients 
with severe TBI have increased levels of IL-1, TNF, IL-6, IL-10 in CSF or 
serum and also some cytokines may be significantly higher in those TBI 
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patients with unfavorable outcome such as IL-1 {Chiaretti, 2005 #302}. 
Another expansion in the field of TBI pathogenesis relates to the observation 
that neuronal death following trauma is not always necrotic and it includes 
apoptotic cell death as well {Wang, 2000 #294}. The latter refers to a 
programmed series of events  ultimately causing the cellular death. It is 
currently believed that Calpain proteins are mainly involved in necrotic death 
whereas the apoptotic death is mainly mediated by Caspase 3 {Wang, 2000 
#294}. Siman el al. have shown increased levels of a panel of proteins 
including a calpain-derived protein (alpha-spectrin) in CSF of patients with 
TBI {Siman, 2009 #301}. In the same way, Buki et al. showed that using a 
calpain inhibitor can disrupt the axonal injury pointing to the potential 
pharmacological benefits of understanding the molecules and biomarkers 
involved in the pathogenesis of nervous system in TBI {Buki, 2003 #298}.  
 
Creatinine kinase, brain type 
Glial fibrillary acidic protein 
Lactate dehydrogenase isoenzyme 1 
Myelin basic protein 
Neuron-specific enolase 
S100b protein 
E-selectin 
L-selectin 
Soluble intercellular adhesion molecule-1 
Cleaved tau protein 
Glutamic oxaloacetic transaminase 
Glutamic pyruvate transaminase 
Malate transaminase 
Fructose 1, 6-diphosphate aldolase 
α-hydroxybutyric acid dehydrogenase 
Tumour necrosis factor-α 
Transforming growth factor-β1 
Interleukin-1β 
Interleukin-6 
Interleukin-8 
Interleuin-10 
Interleukin-12 
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Neopterin 
Β2-microglobulin 
Soluble interleukin-2 receptor 
Table 4 Brain injury biomarkers which have been proposed for 
assessment of brain injury severity or prognosis.  
 
Table 5 suggests that a variety of blood markers may have significant 
clinical role in diagnosis or prognosis of brain injury. Niedeggen A et al.  
observed that all TBI patients who have Creatine Kinase-brain type (CK-BB) > 
50 ng/l survive the injury [37]. Mao et al.  demonstrated that serum Myelin 
Basic Protein (MBP) is correlated to extra- and intracranial haematoma and the 
degree of cerebral contusions detected by CT scan [38]. Furthermore, Neuron 
Specific Enolase (NSE) and MPB have higher serum levels in non-survival as 
proposed by Yamazaki Y. et al.  [39]. With regards to cytokines, Gopcevic A. 
et al.  found central venous IL-8 concentration has significant prognostic power 
the same as age and GCS [40]. Similarly, Minambres E. et at. showed the 
correlation of IL-6 arterial and jugular gradient with 6-month GOS [41].  
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Authors Publication year Sample size biomarker outcome Findings 
Nylen et al. [42] 
 
2006 59 Serum-GFAP 1-year GOS - Those with unfavourable 
outcome had higher peak 
GFAP 
- All with GFAP> 15.04 
µg/l died 
Vose et al. [43] 2004 85 Serum S100B, NSE, GFAP 6-month 
GOS 
-S100B was the strongest 
predictor of death 
Pelinka et al.  [44] 2004 92 Serum S100B, GFAP 3-month GOS -S100B had higher power 
for mortality prediction than 
GFAP. 
Niedeggen et al.  [37] 1989 76 Creatine kinase BB (CK-BB) Survival -All with CK-BB> 50 ng/l 
died 
-Those with CK-BB < 25 
ng/l had minimal 
neurological deficits. 
Mao et al.  [38] 1995 112 Serum Myelin Basic 
Protein(MBP) 
CT characteristics - MBP was correlated to the 
volume of extradural 
haematoma, intracranial 
haematoma and the extent 
of the cerebral contusion. 
Yamazaki et al.  [39] 1995 25 Serum Neuron Specific 
Enolase (NSE) and MBP 
Survival -The level of NSE and MBP 
were higher in those who 
died. 
Gopcevic et al.  [40] 2007 20 Central venous plasma IL-8 Survival -IL-8 was significantly 
higher in non-survivors. 
 
Minambres E. et al.  [41] 2003 62 Transcranial IL-6 (arterial and 
jugular gradient) 
6-month GOS -The gradient was higher in 
non-survivals. 
Table 5 Some examples of various brain injury biomarkers used in TBI diagnosis or prognosis.  
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It appears that the most known biomarkers are still S100B, Gilial 
Fibrillary Acidic Protein (GFAP), and Neuron Specific Enolase (NSE). 
PubMed was searched for each of these biomarkers utilizing the MeSh 
(Medical Subject Heading) terms [45] for each marker and brain injury. The 
number of results for some of these were less than 10 published papers namely 
CK-BB, E- and L- selectin, Malate transaminase, α-hydroxybuttyric acid 
dehydrogenase, transforming growth factor-β1, interleukin-1β and 12, 
Neopterin, β2-microglobulin and soluble interleukin-2 receptor. The search for 
S100B retrieved 142 papers which are comparable to those for Myelin basic 
protein (MBP), Neuron-specific Enolase (NSE), and Glial Fibrillary Acidic 
Protein (GFAP). The results for GFAP remarkably outnumbered that for 
S100B at more than 299 publications. However, a review of the titles showed 
that the investigations on GFAP‟s clinical role in brain injury are much less 
than that on S100B (< 30). The main focus of general research into GFAP is at 
molecular level to characterize astrocytic response to injury in vitro and on 
non-human samples. Overall, it appears the amount of literature for S100B is 
substantially more than other biomarkers.  
In the following section, S100B protein as a brain injury biomarker is 
discussed.  
1.3.1. Summary 
 
 
There are several biomarkers of brain injury which have been proposed to be 
associated with outcome in TBI or to be used for outcome prediction. Three 
of the most known of these biomarkers are GFAP, NSE and S100B. However,  
so far,  S100B has received the most attention in the literature.  
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1.4. S100B protein 
S100 proteins are “a family of highly acidic calcium-binding proteins found in 
large concentration in the brain and believed to be glial in origin. They are 
also found in other organs in the body” [46]. It was first introduced in 1965 
when Moore described it as a characteristic protein of the nervous system [46]. 
Rather 0.5% of soluble brain proteins are composed of S100 [46]. This family 
are not exclusively found in nervous system as it was initially thought [47]. It 
is now clear that it is synthesized in normal as well as pathologic or neoplastic 
tissues such as melanoma [48]. 
The S100 protein family comprises at least 25 isomers of which S100B 
is a member (3) with molecular weight of 21 kilo-Dolton (KD) [49]. Other 
prominent members are S100A1 to S100A13 [47, 50]. 
1.4.1. Functions 
S100B protein is found in cytoplasmic compartment [46], as a membrane-
bound molecule [46] or in the extra cellular compartment [47]. In the extra 
cellular compartment it is believed to be secreted by astrocytes, pituitary 
folliculostellate cells and adipocytes in non-pathological situation[47]. For the 
latter to occur, stimulations by a provocative substance such as nor epinephrine 
is needed [47]. Amongst the above aforementioned tissues, brain is the main 
source of knowledge about the extracellular roles of the protein [47]. These 
roles are primarily divided into physiologic and pathologic functions [49]. The 
physiologic (trophic) functions exert their effect when the concentration of 
S100B is at nanomolar levels [47]. Some functions are neurodegeneration [47, 
49], energy metabolism [47] and cytoskeleton modification [49]. At micro 
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molar concentrations, pathologic (toxic) effects [47, 49] of the protein are 
primarily the induction of iNOS in astrocytes [47] which has a fatal impact on 
cells. All of the physiologic and pathologic functions are performed through 
paracrine or autocrine routes [49].  Although in physiologic situations, S100B 
is thought to be released via secretion but after TBI cell membrane discruption 
may be the cause of its release into the extracelluar compartment.  
1.4.2. Effect of age, gender and race 
Gazzolo and others [51] examined these variables in a population of more than 
1000 children who were from 1 month to 15 years old with the mean of 8.4 
years. Of these, 486 were male and the remaining 522 were female and all of 
them were in a healthy clinical condition with no apparent neurologic 
problems. The main observation of this study was higher S100B concentration 
during the first year and in early adolescence (9 to 10 years old) compared to 
other age groups. Table 6 presents the obtained reference intervals at various 
ages during childhood. As seen, the median values in either males or females 
during first year of life and early adolescence are higher than other time 
periods. This report also suggests higher levels of S100B in females. 
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Age at 
sampling,  
years 
(M/F) 
Males (n = 482) Females (n = 522) P
 
value 
Median 25
th
 
 
75th Median 25th 75th 
0–1 
(43/42) 
0.81 0.44 1.93 0.95 0.45 2.24 0.27 
1–2 
(46/40) 
0.72 0.32 1.33 0.77 0.49 1.37 0.35 
2–3 
(52/48) 
0.62 0.39 0.97 0.76 0.59 1.61 <0.05 
3–4 
(52/47) 
0.7 0.32 1.27 0.66 0.37 0.89 0.7 
4–5 
(41/53) 
0.61 0.31 1 0.74 0.44 1.1 0.29 
5–6 
(34/48) 
0.68 0.32 1.24 0.56 0.36 1.1 0.59 
6–7 
(37/49) 
0.6 0.43 0.96 0.86 0.65 1.17 <0.05 
7–8 
(28/39) 
0.9 0.65 0.96 0.9 0.39 0.96 0.77 
8–9 
(35/52) 
1.37 1.34 4.56 1.41 1.03 4.6 0.95 
9–10 
(41/32) 
1.44 0.91 1.75 1.67 1.44 2.03 0.45 
10–12 
(24/18) 
1.45 0.81 2.63 1.74 0.97 2.1 0.71 
11–12 
(16/16) 
0.42 0.39 0.45 0.45 0.41 0.48 0.38 
12–13 
(10/8) 
1.23 1.2 2 1.25 0.96 2.21 0.66 
13–14 
(17/18) 
1.13 0.99 1.89 1.35 1.16 2.23 <0.05 
14–15 
(6/12) 
0.66 0.45 0.72 0.91 0.52 0.97 <0.05 
Total  
1–15 
(482/522) 
0.8 0.44 1.49 0.95 0.58 1.62 <0.05 
Table 6 The effect of gender on S100B concentration at various age 
groups.  
 
Portela‟s group [52] recruited 19 healthy neonate and 15 healthy 
children aged from 4 to 16 and 85 healthy adults from 18 to 70 years old. The 
impact of age was found significant under the age of 20 and non-significant 
afterwards. They found the highest concentration of S100B in the neonates. 
Figure 1 displays the course of serum S100B protein during ageing. As 
depicted, a healthy individual has the highest level of S100B in serum at more 
than 0.4 μg/l after birth. The number is set to drop sharply till the age of 20 
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when its decline rate lessens till the age of 30. After 40, the level tends to 
increase but not significantly. In fact, despite initial sharp decrease of serum 
S100B from nearly 0.4 μg/l to just above 0.1 μg/l during the first twenty years 
of life, the further fluctuations are statistically insignificant. Gazzolo‟s and 
Portela‟s restuls also indicate that S100B in the healthy adult population (i.e. > 
20 years old) is expected to be less than 0.1 μg/l. 
 
Figure 1 Correlation of serum S100B protein concentrations with age 
(from: Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, 
Rotta LN, Silva CT, Busnello JV, Kapczinski F, et al: The serum S100B 
concentration is age dependent. Clin Chem 2002, 48:950-952.). 
 
Abdesselam‟s group [53] compared the S100B concentrations in three 
groups of “black” (n=40), asian (n=44) and caucasian (N=46) healthy 
individuals. They did not find any significant difference between asian (0.11 
µg/l) and black (0.14 µg/l) groups while in the Caucasian the figure was 
significantly lower (0.07 µg/l).  
1.4.3. Proposed clinical roles  
Elevated serum S100B levels have been reported in psychoneurologic diseases 
such as Alzheimer‟s disease, Down‟s syndrome, multiple sclerosis, 
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amyotrophic lateral sclerosis, schizophrenia, depression, cerebral stroke and 
TBI [54]. This biomarker also has prognostic value in melanoma and can help 
to apply an appropriate therapy protocol by detecting metastasis or recurrence 
after treatment [48, 55]. 
There are some reports suggesting that serum S100B levels elevate 
following physical activity compared to values observed before exercise [56-
59]. Moreover the pre-post game difference has been claimed to be 
significantly correlated to the number of headers and trauma events during the 
game such as a football match [58]. However, despite this elevation, the serum 
levels remain within normal range [56]. 
There are some trials on the possible therapeutic roles of S100B after 
brain injury but on animals so far. In the project of Klenddienst‟s group, after 
induced brain injury, the rats received infusion of S100B and consequently 
experienced improved cognitive performance and enhanced hippocampus 
neurogenesis [60]. Nearly the same result had been observed by the same 
scientists in 2004 [61]. 
In the medico legal field, S100B is assumed to have two applications: 
firstly; the identification of the cause of death and secondly; attribution of a 
subsequent disability to brain injury in case of multiple trauma or when such a 
cause and effect relation should be investigated (in judiciary conditions as it is 
sometimes unknown whether the brain injury is the actual source of 
impairment or other elements such as concomitant limb fractures are at play). 
With regards to cause of death, Li and his colleagues published two papers in 
2005 [62, 63]. In both studies 283 autopsy cases were examined within 48 
hours post-mortem. Acute death was defined when survival time was shorter 
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than 6 hours and, in contrast, delayed death happened between 6 hours to 5 
months after injury. S100 immunopositivity revealed that positivity in neurones 
and myelin is more frequent in delayed head injury death and fire fatality while 
in astrocytes, the rate was lower in acute death due to strangulation and 
drowning compared to other subcategories of acute death. The authors also 
reported an inverse relationship of astrocytes S100B positivity with serum 
S100B in acute death. The initial conclusion was the probable usefulness of 
combined analysis of S100B positivity in the brain tissue and serum 
concentrations of the protein for the identification of death resulting from head 
injury, hypoxic and /or ischemic brain damage. In the second paper [63], the 
group observed that serum levels are markedly higher in the right heart and 
subclavian vein after acute death from head injury and asphyxiation due to 
neck compression while mildly to moderately elevated for other blunt and 
sharp instrumental injuries. They also found that serum S100B is lower after 
sub acute than acute death due to head injury. These two studies of Li„s group 
propose an important medico legal role for S100B which is now “a hope on the 
horizon”. 
In the following section, the role of S100B in diagnosis or prognosis of 
TBI has been discussed.  
1.4.4. S100B and TBI  
In this section, the major proposed roles of S100B in various studies are 
discussed. This section is divided into 3 parts of mild brain injury, severe brain 
injury and various severities. This division  is based on GCS (mainly on 
attending or admission to hospital) with GCS < 12 being mild and GCS < 9 
being severe. This grouping of studies simplifies understanding of the different 
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roles of S100B proposed in different studies. At the end, the results of some 
studies in non-TBI serious which can affect the interpretation of S100B role in 
TBI, are also presented.  
Each part of this section is accompanied by a table (Table 7, Table 8 or 
Table 9) which summarises the main findings of studies. Additionally, the table 
contains information on some particular characteristics of each study which is 
helpful in comparing various studies. These characteristics are age, sampling 
time, the time point of outcome assessment, the size of the study and whether 
cases with extracranial injuries were included or excluded (i.e. isolated versus 
non-isolated brain injury). Age is important because of S100B concentration 
overall tends to be higher in children than adults and also it decreases as the 
child ages [51, 52]. Sampling time is important because the elapsed time 
between injury and blood sampling affects the relationship of S100B and 
outcome [64]. Furthermore, S100B serum levels tend to decline in a short 
period of time following their rather immediate surge at the time of injury [65]. 
Regarding the time point of outcome assessment, one may assume that as the 
time passes, a higher proportion of TBI victims who have survived recover. 
Similarly, patients with non-isolated TBI tend to have higher S100B 
concentrations and perhaps worse outcome than those with isolated TBI [66]. 
Lastly, the sample size provides an insight about the power of the study.  
 
Mild brain injury 
 
In this severity group of TBI, S100B can be used to predict the outcome ( PCS, 
GOS or GOSE), or the absence/presence of intracranial pathology determined 
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by CT. The majority of studies tend to report the sensitivity and specificity 
although AUC is a better tool to compare the results across different studies. 
PCS is a collection of signs and symptoms such as headache, dizziness, fatigue 
or difficult concentration which results from head injury severe enough to 
cause loss of consciousness.  
As seen in Table 7, across many papers, sensitivity and specificity do 
not change in the same direction in that when one increases, the other 
decreases. This necessitates a compromise between sensitivity and specificity. 
Thus, it seems investigators prefer more specificity for outcome prediction 
unlike for CT abnormality which a high sensitivity is preferable (as a screening 
or ruling out test). A specific test would enable the therapist not to misdiagnose  
those cases who are prone to develop PCS or GOSE of less than a desirable 
level for the sake of a timely intervention whilst a sensitive test would enable 
ruling out of cases from CT scanning when they are unlikely to benefit from it. 
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Study Number 
of cases 
Children/adults Sampling 
time 
Outcome Outcome 
assessment 
time 
Specificity Sensitivity AUC Isolated Cut-off 
Bazarian et 
al. [67] 
35 10-83 Within 6 
hours 
PCS 3 months 71.4% 56.3% 0.589 no  
Mussach et. 
al [68] 
139 > 20 On 
admission 
CT  50% 100% 0.864 no 0.21 
Savola et al.  
[69] 
172 16-49 Within 6 
hours 
PCS 1 month 93% 27% 0.702 no 0.50 
Morochovic 
et al.  [70] 
102 12-84 Within 6 
hours 
CT  29.8% 83.3%  nop 0.10 
Biberthaler 
et al.  [71] 
1309 > 18 On 
admission 
CT  30% 99%  yes 0.10 
Figueiredo 
et al.  [72] 
50  On 
admission 
CT  20% 100% 0.82 yes 0.10 
Biberthaler 
et al.  [73] 
52  On 
admission 
CT  40.5% 100%  no >0.10 
Muller et 
al.  [74] 
226 > 18 In ED CT  31% 95% 0.73 yes 0.10 
Townend et 
al.  [75] 
112 adults 18-360 
hours 
after 
injury 
GOSE < 
5 
1 month 83% 90% 0.889 no 0.48 
Table 7 Some studies of S100B role in mild TBI (GCS > 12).  
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The AUC for outcome prediction widely ranges from the minimum of 
0.58 [67] to the maximum of 0.88 [75]. This may be explained by differences 
in the type of outcome (being PCS in Bazarian‟s study [67] and GOSE < 5 in 
Townend‟s study [75]) or the time of outcome assessment (being 3 months in 
Bazarian‟s study and 1 month in Towend‟s study) or other factors affecting the 
case-mix such as age. Overall, the Savola‟s study appears to be the most 
powerful study of this type for outcome prediction in mild TBI as the sample 
size is 172 [69]. The authors observed an AUC of 0.702 for PCS one month 
after injury with sensitivity and specificity of respectively 27% and 93%.  
Overall, the AUCs for prediction of intracranial pathology determined 
by CT are higher than those for outcome prediction. The minimum AUC for 
CT pathology prediction is 0.73 (by Muller et al.  [74]) with a maximum AUC 
of 0.86 (by Mussach et al. [68]). The most powerful study of this type is the 
one by Biberthaler et al.  who managed to recruit 1309 mild TBI cases [71]. 
Unfortunately, the AUC is not supplied in this paper but a very high sensitivity 
of 99% with a low specificity of 30% to detect abnormal CT has been obtained. 
The cut-off serum level for this diagnostic performance is 0.10.  
 
Severe brain injury 
 
In severe TBI, S100B has been commonly proposed for the outcome prediction 
(Table 8). The outcome measure can be severe disability (measured by GOS or 
GOSE) or mortality. These studies significantly vary on sampling time and the 
time point of outcome assessment; hence differing results with regards to cut-
offs and AUCs. The sampling time ranges from on admission to some time 
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later even up to 4 days after injury (Plinka‟s study [76]). The outcome 
assessment also ranges from early adverse outcome (i.e. within 12 hours) up to 
1 year following injury.  
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Study Number 
of cases 
Children/adults 
 
Sampling 
time 
Outcome Outcome 
assessment 
time 
Specificity Sensitivity AUC Isolated Cut-off 
Olivercrona 
et al.  [77] 
48 > 15 On 
admission 
GOS < 4 3 month 28% 91.3% 0.585 no 0.32 
Olivercrona 
et al.  [77] 
48 > 15 On 
admission 
Mortality 3 month 95.2% 33.3% 0.687 no 1.67 
Olivercrona 
et al.  [77] 
48 > 15 On 
admission 
GOS < 4 12 month 40% 75% 0.552 no 1 
Olivercrona 
et al.  [77] 
48 > 15 On 
admission 
Mortality 12 month 25 95 0.647 no 1.67 
Vos et al. 
[43] 
85 > 15 On 
admission 
GOS < 4 6 months 59% 88% 0.677 no 1.13 
Vos et al. 
[43] 
85 > 15 On 
admission 
mortality 6 months 41% 100%  no 1.13 
Pelinka et 
al.  [76] 
23  < 12 
hours 
Mortality < 12 hours   0.691 yes 4.42 
Pelinka et 
al.  [76] 
23  13-36 
hours 
mortality Within 13-
36 hours 
  0.802 yes 2.24 
Pelinka et 
al.  [76] 
23  37-60 
hours 
mortality Within 37-
60 hours 
  0.819 yes 2.71 
Table 8 Some studies on S100B role in severe TBI (GCS < 9) (continued)
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Study Number 
of cases 
Children/adults 
 
Sampling 
time 
Outcome Outcome 
assessment 
time 
Specificity Sensitivity AUC Isolated Cut-off 
Pelinka et 
al.  [76] 
23  > 84 
hours 
Mortality > 84 hours   0.971 yes 0.79 
Pelinka et 
al.  [76] 
23  Within 12 
hours 
mortality Within 12 
hours 
  0.692 No 7.99 
Pelinka et 
al.  [76] 
23  Within 
13-36 
hours 
mortality Within 13-
36 hours 
  0.693 No 2.16 
Pelinka et 
al.  [76] 
23  Within 
37-60 
hours 
mortality Within 37-
60 hours 
  0.747 No 0.70 
Pelinka et 
al.  [76] 
23  > 84 
hours 
mortality > 84 hours   0.783 No 1.19 
Mussack 
et al.  [78] 
20  12 hours 
after 
admission 
GOS < 4 A year 
after injury 
70% 77% 0.90 yes 0.59 
Nylen et 
al.  [79] 
59 > 8 Within 2 
days 
GOS< 4 A year 
after injury 
80% 50% 0.69 no 0.55 
Table 8 Some studies on S100B role in severe TBI (GCS < 9) (continued).   
 54 
The study by Olivercrona et al. provides a rough insight about the 
predictive performance of S100B when sampling time is constant but the type 
or the time of outcome is different [77]. As presented in Table 9, AUC of 
S100B tends to be higher for mortality prediction than disability prediction 
(GOS < 4). For example, the authors observed increase of AUC from 0.58 to 
0.68 for mortality versus disability outcome prediction at three months after 
injury. Furthermore, it appears S100B strength for outcome prediction 
decreases as the time for outcome assessment prolongs in that, for instance, 
S100B AUC for disability prediction at three months is 0.585 whereas this is 
0.552 for disability prediction at 12 months. However, the sample size in 
Olivercrona‟s study is small (only 48 cases).  
The study by Plinka et al. provides the opportunity to evaluate the 
effect of sampling time and the presence/absence of extracranial injury on 
S100B predictive strength [76]. With regards to sampling time, it appears the 
later the blood taken, the stronger the predictability. For example, S100B 
measured at less than 12 hours following injury has AUC of 0.691 to predict 
mortality whereas if the sampling is performed after 84 hours, the AUC jumps 
to 0.971. Furthermore, excluding cases with extracranial injuries from the 
analysis led to drop in AUC. This can be observed by comparing AUCs of 
S100B when sampling time is the same but cases with multiple injuries are 
ruled in or out.  
The AUCs across various studies differ with the minimum of 0.552 to 
the maximum of 0.971. Not only factors such as the power of the study (sample 
size), extracranial injuries, sampling time, outcome measure and the time of 
outcome assessment can explain differing AUCs, this can also occur as a result 
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of different case-mix as to age or severity of injuries (including extracranial 
injury). Overall, according to Table 8, the AUC appears to have an average of 
about 0.80 for outcome prediction in severe TBI irrespective of factors 
affecting the sampling time, laboratory method of S100B measurement, 
outcome assessment or case-mix. Moreover, it appears there has to be some 
degree of compromise between sensitivity and specificity in selection of the 
cut-off point as, in outcome prediction, sensitivity and specificity tend to hold 
opposite directions in that if one rises, the other decreases.  
According to the sample size, the most powerful study of the table is 
that by Vos et al.  having recruited 85 cases [43]. Vos el al. observed an AUC 
of 0.677 to predict severe disability 6 months after injury. The blood samples 
were taken on admission and patients with extracranial injury were not 
excluded. The authors reported the cut-off point of 1.13 having a high 
sensitivity of 88% (for severe disability) and 100% (for mortality) with a low 
sensitivity of 59% (for severe disability) and 41% (for mortality).  
 
Various severities  
 
The studies of this type which have included cases with various admission 
GCSs are useful in that a group of TBI patients who talk and are alert on 
admission would deteriorate later on. As such, studies with inclusion of various 
degrees of admission GCS have a higher chance of capturing this group of 
patients and putting them in the same group as those who present with low 
GCS to hospital. Like mild brain injury, S100B in these studies is used for 
detection of intracranial pathology on CT or outcome prediction (Table 9).  
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Study Number 
of cases 
Children/adults Sampling 
time 
Outcome Outcome 
assessment 
time 
Specificity Sensitivity AUC Isolated Cut-off 
Herrmann 
et al.  [80] 
39 >16 Median 
27 hours 
after 
injury 
Neuropsychological 
assessment 
2 weeks 90% 69% 0.81 no 140 
Herrmann 
et al.  [80] 
39 >16 Median 
27 hours 
after 
injury 
Neuropsychological 
assessment 
6 months 88.9% 65% 0.77 no 140 
Honda et 
al.  [81] 
34  1 day CT  100% 27.8% 0.658 no  
Honda et 
al.  [81] 
34  2 day CT  100% 33.3% 0.738 no  
Honda et 
al.  [81] 
34  3 day CT  100% 33.3% 0.689 no  
Bechtel et 
al.  [82] 
152 < 18 Within 6 
hours 
CT  56% 75% 0.67 No 50 
Spinella 
et. at. [83] 
27 < 18 Within 12 
hours of 
injury 
PCPC ≥ 4 Discharge   0.94 No  
Table 9 Some studies on S100B role in TBI with various severities (i.e. with no limitations on GCS).  
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Herrrmam et al.  investigated the effect of the outcome assessment time 
on S100B prognostic strength and observed AUC of 0.81 and 0.77 for 
neuropychological deficit respectively at 2 weeks and 6 months after the injury 
[80]. This may imply that S100B holds less predictive strength for longer term 
outcome prediction. This is in accordance with what Olivercrona et al.  
observed in severe TBI (GCC < 9) [77]. Honda et al.  investigated the effect of 
sampling time on S100B capability to detect abnormal CT and found that the 
second day sampling has a higher AUC than either first day or third day 
samples (AUCs of 0.658 versus 0.738 versus 0.689 respectively from the first, 
second and third day of blood sampling) [81].  
Overall the studies including various severities of GCS are small (i.e. < 
40 cases). However, that by Betchel et al. recruited 152 TBI cases to observe 
AUC of 0.67 (with sensitivity of 75% and specificity of 56%) for detection of 
CT abnormality [82].  
 
Extracranial injury  
 
Some studies have examined the effect of extracranial injury on serum S100B 
concentrations. The importance of this relates to the observation by some 
authors that the brain is not the only source of S100B release into the blood 
stream as other body tissues such as fat tissue can contribute to raised S100B 
serum concentration [66, 84, 85]. There are two types of studies investigating 
this issue: some studies compared S100B serum levels in subjects of trauma 
but sparing TBI with subjects in a healthy control group whilst some other 
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studies compared the serum levels of isolated TBI patients with non-isolated 
cases.  
Unden et al.  discerned that 29% of patients who had uncomplicated 
bone fractures with a negligible likelihood of head injury due to the nature of 
the trauma, had raised S100B (above 0.15 µg/l) [84]. Similarly, Anderson et al.  
compared the S100B concentration in the trauma patients without brain injury 
(based on physical examination and interview) to healthy individuals and 
observed that the maximum S100B concentration in the control group was 
much lower than the minimum S100B contraction in the trauma group (0.13 
versus 0.5 µg/l) [85].  
Savola et al.  performed a more detailed analysis of the effect of 
extracranial injury [66]. They observed the highest S100B concentration was in 
serum of patients who had moderate to severe brain injury with large 
concomitant extracranial injury (median 4.01 versus 0.02 µg/l in the normal 
population). Those patients with isolated moderate to severe brain injury had 
higher S100B concentration to those without brain injury but with large 
extracranial trauma (median 0.94 versus 0.35 µg/l). Furthermore, patients with 
large extracranial injury and without brain injury also had raised S100B but to 
the lesser degree than to those with both large extracranial injury and brain 
injury (0.35 versus 4.01 µg/l). These findings were proven to be statistically 
significant. However, minor extracranial injuries such as soft tissue contusions, 
wounds, sprains, luxations and small fractures tended not to raise S100B. In 
fact, serum S100B concentration in the two groups of minor and large 
extracranial injuries sparing brain injury were significantly different (0.35 
versus 0.07 µg/l). Overall, the findings by Savola. et al. suggest both brain 
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injury and larger extracranial injury can contribute to raise S100B serum 
concentration and cases with non-isolated TBI are expected to have higher 
S100B concentrations than those sustaining isolated TBI.  
1.4.5. Summary  
 
S100B is an isomer of a family of proteins called S100 which are calcium-
binding proteins found in the brain with glial origin. They constitute 5% of 
soluble brain proteins. S100B has positive effects on neuroregeneration, 
metabolism and cytoskeleton at nano molar concentrations with harmful 
effects at micro molar concentrations. S100B serum levels appear higher in 
females than males and also in blacks and Asians than whites. Serum levels 
are maximal in the first year of life when they decrease till the age of 20 to 
reach a plateau of less than 0.1 µg/l for the rest of life.  
S100B rises in several neurological (such as Alzheimer’s disease, 
Down’s syndrome, multiple sclerosis) and non-neurological conditions 
(such as melanoma). Also physical activity can cause its rise in the blood 
without trauma. S100B has been proposed in the forensic medicine to assess 
the cause or nature of the death or disability.  
In mild TBI, S100B can be used for prediction of CT abnormality or 
a certain outcome. For outcome prediction, studies have suggested various 
AUCs ranging from 0.58 to 0.89. Similarly, in severe TBI, S100B predictive 
strength varies across studies with AUCs of 0.58 to 0.90. This diversity in 
AUCs implies differences in sensitivity and specificity too. Overall, it 
appears that sensitivity and specificity of S100B do not follow the same 
direction.  
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1.5. Current issues in TBI prognosis  
1.5.1. Problems with the current prognostic models 
The current prognostic models in TBI suffer from one or more of the following 
disadvantages: the sampling population  being those included in  a clinical trial, 
the time frame being historic and the location as being fromvarious countries. 
Clinical trials can not be  truly representative of the TBI population for which 
the prognostic models need to be  developed. Firstly, the inclusion criteria in 
clinical trials are tailored to serve the very purpose of the trial i.e. assessing the 
efficacy of the intervention. As such, those cases which demonstrate clear 
indication or contraindication for the intervention are excluded from 
recruitment according to the uncertainty principle. This poses a selection bias 
for a prognostic  study. Secondly, some patients may be excluded because of 
the consent issue as to the intervention being administered or not. Further, it is 
important for a prognostic model to take the temporal advances and regional 
differences in brain injury trauma care into account. This means if a model has 
been derived from a historic TBI dataset, it may not necessarily be applicable 
for the current or more recent TBI populations due to introduction of new 
improvements in the trauma care policies bound to occur with the passage of 
time. Similarly, if a model has been developed in a different location, it may 
not necessarily be applicable in every location with differences in care policies. 
Murray et al.  [86] compared some „interventional‟ approaches in TBI 
management across TBI samples from various European countries and 
observed that in some countries such UK or France, victims of TBI have lower 
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chance of direct admission to the neurosurgical centre or to undergo 
intracranial operation than Italy or Spain. Regional differences not only apply 
to care policies but also to the demographic pattern or to the pattern of injury 
severities. Murray et al. compared TBI sample populations in Europe from this 
perspective and demonstrated that TBI victims in UK and France tend to be 
older, less often a vehicle occupant or to sustain major extracranial injury than 
the victims in Italy or France. All of these countries are, in fact, geographically 
near each other and all are grouped in the „high income‟ or „developed‟ 
countries.  
The importance of time and regional differences is even more 
highlighted when the prognostic models are to be used for the trauma care 
benchmarking aimed at providing the relative performance of each trauma care 
centre at a national level. It defines how far (in a positive or a negative 
direction) the quality of care is from the national standard. This comparison is 
accomplished through comparing the prognosis in a trauma centre to the 
standard prognosis at the national level. The prognosis in the national level is 
obtained through prognostic models which are derived from the pooled datasets 
of trauma patients across the country. Conspicuously, using a prognostic model 
in a given country which has been developed in a different country may not be 
necessarily valid for the purpose of benchmarking of trauma care centres.  
The British trauma care is different to that of other countries from either 
Europe or America. Some of these differences include but are not limited to 
transfer policies from the scene to hospital (for example via air or land), the 
skill level of the attending personnel and the initial interventions at scene or 
during the transfer (such as management of life threatening events, intubation, 
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drug administration etc.), admission to the neurosurgical unit (primary, 
secondary or never), adoption of conservative versus interventional approach in 
many clinical scenarios (such as ventilation, ICP monitoring, drug 
administration, operation etc.), discharge policies, community care, patients 
follow-up, rehabilitative strategies etc.  
The CRASH dataset was from a clinical trial study and only 3 studies 
out of 11 studies merged in the IMPACT dataset were observational with the 
rest being clinical trials. Furthermore, the IMPACT dataset is somewhat 
historic in terms of the time of data collection since the most recent sub-dataset 
was Saphir trial which was terminated in 1997. Even, the termination time of 
some sub-datasets go back to 1980s such as UK4 (the UK four centre study as 
finished in 1988) or TCDB (Traumatic Coma Data Bank as finished in 1987). 
With regards to the regional differences in trauma care, this is an issue for both 
the CRASH and the IMPACT models. The CRASH dataset was collected from 
50 countries around the globe and although the originators of the models built 
individual models for developed and developing countries, this distinction can 
not address the country‟s health care expenditure in general or the efficacy of 
trauma care in particular. This is shown in Murray‟s study indicating 
differences in TBI populations as per the demographic pattern, severity pattern 
or the therapeutic approaches across various developed countries even in the 
same European geographical region. This could also be the case for the 
IMPACT dataset which contains cases from various countries mainly in 
Europe and the North America.  
Hukkelhoven‟s models suffer from the same disadvantages as being 
derived from clinical trials, being historic (1991-1994) and regionally diverse 
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(from 15 countries). Signorini‟s model is also historic as its termination dates 
back to 1991. Although the design of this study was observational with no 
regional diversity in the recruitment, the Signorini‟s model is the oldest 
amongst all TBI prognostic models.  
1.5.2. Problems with S100B  
A review of the literature on S100B prognostic role in TBI showed that across 
studies the performance of this biomarker varies significantly. For example, 
Townend et al. achieved a high AUC of 0.88 to predict disability whereas 
Nylen et al. obtained much lower AUC of 0.69 for the same prediction. The 
differences in S100B performance can be explained by differences in case-mix, 
S100B sampling time or laboratory method of measurement and also 
differences in type or time of outcome measure. Different case-mix implies 
different patients‟ characteristics which influence the outcome. For example, if 
a population sample contains significantly older subjects than the other sample, 
the older population may have significantly higher proportion of the adverse 
outcome. However, age is not the only factor which may cause a difference in 
case-mix. Some other important patients‟ characteristics are cause of injury, 
GCS, pupillary reactivity, presence/absence of extracranial injury, various CT 
abnormalities etc. Depending on these factors, one sample may have more 
severe TBIs than the other sample and hence different probability of adverse 
outcome. Furthermore, it appears various laboratory methods of S100B 
measurement vary in their sensitivity/specificity [87] and in the same way the 
time of blood sampling with respect to the time of injury affects the prognostic 
performance of S100B [76]. Lastly, Olivercrona et al. observed that S100B 
may be stronger to predict much shorter- term outcomes (3-month) than 
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outcomes at one year following injury or it is stronger for mortality prediction 
than disability prediction [77]. Unfortunately, studies on S100B are not 
uniform as to the above factors. Therefore, the results differ significantly. As 
such, it is not possible to draw a conclusion on whether or not S100B can be a 
good prognostic factor in TBI.  
1.5.3. Prognostic models versus brain injury biomarkers 
There are currently two available tools to predict the outcome in TBI; brain 
injury biomarkers and prognostic models.  
Brain injury biomarkers can be used by taking a blood sample of the 
patient and then measuring the concentration of the biomarker and relating that 
to the outcome. This relationship can be established through knowing the 
sensitivity and specificity of the biomarker when it is above a certain cut-off. 
This is a familiar tool to clinicians as they commonly used various blood 
markers to associate them with a clinical event such as amylase for acute 
pancreatis, Troponin for myocardial infarction, ALF for liver cancer etc. 
Furthermore, the concept of sensitivity and specificity is well known to 
clinicians and they can appreciate the „degree of uncertainty‟ regarding the 
predictive strength of these biomarkers. On the other hand, prognostic models 
involve a different aspect of medical statistics which is currently novel and 
unfamiliar. The measures to determine the performance of models such as 
AUC are not widely known by doctors and thus the degree of uncertainty can 
be hardly appreciated.  
Prognostic models, however, do not incur measurement of a factor not 
commonly collected in trauma management. From this viewpoint, measuring a 
biomarker can pose extra cost whereas what current prognostic models use for 
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the outcome prediction are factors which are routinely measured during the 
physical examination or are collected for the sake of the patient monitoring 
such as O2 Sat., blood pressure etc.  
The above issues are important regarding the potential practicality and 
popularity of prognostic models versus brain injury biomarkers. However, it 
may be even more important to understand how performance of prognostic 
models and brain injury biomarkers differs in that if one prognostic tool 
significantly outperforms the other, this can influence practicality and 
popularity issues. To the best knowledge of the investigator, no studies so far 
have addressed this problem in one single dataset and comparing various 
studies on the subject of prognostic models versus brain injury biomarkers is 
not reliably conclusive. This is because the highest AUC which has been 
achieved by prognostic models is 0.88 (the CRASH model) and 0.84 (the 
IMPACT model). In the same way, there are studies in the literature which 
have obtained high AUCs of around 0.90 for S100B outcome prediction [75, 
83] beside some other studies which have observed much lower AUC of 0.58 
or 0.69 [77, 79]. This means in some studies S100B competes with prognostic 
models whereas in some other studies prognostic models outperform S100B.  
1.5.4. Combination of prognostic models with biomarkers 
This combination can have two forms: adding a brain injury biomarker to the 
existing prognostic models or adjusting the brain injury biomarker with 
cofounders i.e. other TBI prognosticators. Either of these approaches would 
address the same topic as to whether or not this combination yields a stronger 
predictive tool. Adding biomarkers to prognostic models may enhance the 
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accuracy of models and considering other confounders when using a biomarker 
may enhance the accuracy of the biomarker predictability.  
 
Adding a biomarker to prognostic models  
 
The maximum AUC of currently well-developed models in TBI are 0.88 
(CRASH) and 0.84 (IMPACT) in the derivation dataset which drops to 
respectively 0.77 and 0.80 in external validation. Although these models 
appear promising in terms of not making the prediction at random, it is unclear 
how much accuracy is required for various purposes of prognosis in clinical 
trials, trauma care benchmarking or clinical practice and whether this degree of 
accuracy is acceptable or not. When an ideal model has an AUC of 1, it may be 
argued that these models are far from this ideal. Whilst these models are still 
the best available models for prognosis, there is still scope to improve their 
accuracy by examining various ways to „push‟ their AUC closer to the ideal 
model. Conspicuously, there are still patients who do not meet the predictions 
made by the prognostic models as they may die despite being predicted to 
survive and vice versa.  
One option may be to add other predictors into the models. These 
models contain the core TBI predictors [88] i.e. age, GCS (or motor subscore) 
and pupillary reactivity plus some other covariates such as CT and vital signs. 
However, adding new variables may negatively affect the performance of the 
model in data other than the derivation dataset. This is commonly referred to as 
overfitting: when a model performs very well in the derivation set but 
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significantly drops in performance in different set of data. This may even make 
the model useless when it can not be applied in other TBI series.  
Incorporating a brain injury biomarker to the prognostic models may 
enhance the accuracy of the models without putting the model at risk of 
overfitting. This is because some biomarkers such as S100B have been shown 
to be one of the strongest predictors of outcome in TBI amongst other common 
TBI prognosticators when considered individually and not in combination. Vos 
et al. compared the R
2 
of various TBI predictors and found that S100B was 
stronger to predict poor outcome (GOS < 4) 6 months after TBI than CT and 
GCS. This may indicate that adding S100B to models may result in exclusion 
of other predictors which eventually may lead to a better performing model 
without holding too many covariates and thus the risk of overfitting.  
 
Adjusting the biomarker with other prognosticators 
 
The obvious conclusion from a literature review on S100B role in TBI 
presented in Table 7, Table 8 and Table 9 is contradictory results in that in 
some studies S100B performs very well whereas in other studies the 
performance is not promising. The different results can be explained by 
differences in case-mix, sampling time, laboratory method of S100B 
measurement or the type and time of outcome assessment (being morality, 
severe disability etc.).  
Knowing the reason for this difference in results is important in that it 
may offer a much better prognostic tool than current prognostic models. In fact, 
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some authors have reached very high AUCs for S100B as close to 0.90 [75, 
76].  
1.5.5. Summary  
There are three issues regarding the currently proposed prognostic models 
patient samples are from clinical  trials (both IMPACT and CRASH),  the 
dataset being historic (IMPACT) and places for recruitment being diverse 
(both IMPACT and CRASH). These factors may affect the reliability of models 
in other TBI populations including British cases of TBI. Regarding S100B, 
some studies have reached very high AUCs for outcome prediction which can 
compete with that of prognostic models whereas in some other studies low 
AUCs were found. The differing AUCs across studies can be due to differences 
in case mix, sampling time, laboratory methods of S100B measurement, or 
differences in time or type of outcome measurement. As a result of this 
inconsistency in the literature, it is not possible to decide between a prognostic 
model and S100B which one outperforms the other. This is important since, 
unlike prognostic models, S100B results are easy to interpret although 
prognosis models use routinely measured patients’ characteristics. Trial of the 
combination of S100B with prognostic models may enable a stronger 
prognostic tool than either prognostic models or S100B on their own. This is 
because it is unclear whethe or not the current AUCs of prognostic models are 
adequately high or why in some studies very high AUCs of close to 0. 90 have 
been obtained.  
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1.6. Aim and objectives  
1.6.1. Aim  
The aim of the PhD is to improve our understanding of brain injury prognosis. 
For a number of reasons, this area still requires improvement (section 1.5):  
1.6.2. Objectives  
1. Since, the IMPACT and the CRASH models may not be reliable in a British 
dataset the first objective of the PhD is:  
 
To develop a prognostic tool to predict the survival in TBI applicable to 
the British trauma care.  
 
2. It is important to know which of the two commonly proposed prognostic 
tools i.e. prognostic models and a brain biomarker are more accurate in their 
outcome prediction. Regarding this the second objective of the PhD is:  
 
To ascertain  from a multivariate model and a blood test which one is 
better suited for prognosis in TBI.  
 
3. One way of obtaining more accuracy in TBI prognosis can be combination 
of prognostic models with brain injury biomarkers. This combination can be 
either in the form of adding a biomarker to the prognostic model or 
adjusting  biomarker prognosis with confounders. The former may enhance 
models‟ accuracy without risk of overfitting. Taking account of other TBI 
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prognosticators as confounders may enhance the biomarker predictability as 
some authors have reached AUCs of 0.88 to 0.90 for S100B outcome 
prediction. Thus the third objective of the PhD is: 
 
To determine whether a combination of multivariate models and a blood 
test can significantly improve the prognosis in TBI.  
 
1.6.3. Summary  
In this section the aims and objectives of the PhD are discussed. 
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1.7. Approach, design and the importance of the project 
and the hypothesis formulation  
1.7.1. Design  
 
Observational versus experimental  
 
None of the objectives of the PhD involve intervention as to change the course 
of the disease and as such the design of the study has to be observational.  
 
Cohort versus case-control 
 
It can be assumed that a prognostic tool acts similarly to a diagnostic test to 
diagnose a medical condition. In fact, both of these predict the occurrence of an 
event. Therefore, the appropriate study design has to be cohort. Case-control 
studies only recruit cases with  or without the outcome (or  disease) and are 
generally not suitable for assessment of a diagnostic test or prognosis.  
 
Prospective versus retrospective  
 
Although retrospective data can be used for assessing the prognostic accuracy 
of a model, there are some advantages pertained to prospective research as 
compared to retrospective research. The prospective studies can be designed 
and tailored for the specific purpose of the research right from the beginning 
with regards to many factors such as inclusion/exclusion criteria, data 
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collection, formatting and sampling size. Unfortunately, retrospective data does 
not provide much flexibility regarding these factors as the data collection often 
is part of a different research objective.  
Overall, the best study design for the prognostic analysis is 
observational prospective cohort studies.  
1.7.2. Approach and hypothesis  
The Trauma Audit and Research Network (TARN) is a trauma registry based at 
Salford Royal NHS Foundation Trust, Manchester, UK which receives data on 
trauma patients from participating hospitals across England and Wales [89]. 
TARN is a part of changes recommended by the College of Emergency 
Medicine in trauma management through auditing and researching injury and 
care systems and aims to provide information on the quality of care. The 
trauma patients‟ profiles are submitted to TARN if they reach hospital alive 
after injury and fulfil at least one of the following criteria: 
1. stay at hospital for longer than 3 days 
or 
2. are cared in the Intensive Care (ICU). 
or 
3. have interhospital transfer 
or 
4. die at hospital  
TBI patients are a subgroup of trauma patients whose characteristics are 
stored in TARN. Therefore, TARN can provide a set of TBI cases who are 
from Britain, receive the recent trauma care and are part of an ongoing 
observational initiative. Such dataset can be used to derive a prognostic model 
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which is conventionally a better known prognostic tool than a brain injury 
biomarker. Moreover, the most popular statistical method for model 
construction is logistic regression. This has been shown by the systematic 
reviews on prognostic models in TBI performed by Perel et al.  [31] and 
Mushkudiani et al.  [32]. Regarding this the first and second null hypotheses of 
PhD are:  
1. The probability of survival is not influenced by patients’ 
characteristics in severe TBI.  
2. The logistic regression model does not explain the pattern of 
mortality in severe TBI.  
Furthermore, in 2005 a research study was embarked on at Salford 
Royal NHS Foundation Trust aiming at assessing the strength of S100B to 
predict death or severe disability 3 months following TBI. The setting was the 
hospital ICU to enrol severe TBI cases. The blood samples were obtained 24 
hours (+/- 2 hours) following the injury and the degree of disability was 
assessed by GOS. The investigator joined the research group half way through 
to participate in patient recruitment, data collection and final univariate 
analysis. The study was initially targeted to recruit 100 subjects and the final 
dataset provided the opportunity to perform a multivariate analysis on the data. 
Therefore, it becomes feasible to compare the prognostic strength of a 
biomarker, S100B, to multivariate models on a single dataset and also to assess 
whether or not a combination of the two prognostic tools yields a better 
performance than each tool alone. Therefore, the following null hypotheses are 
formulated tailored to the second and third objective of the PhD:  
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3. Addition of clinicodemographic characteristics of patients 
does not improve the prognostic performance of S100B in 
TBI.  
4. There is no difference between prognostic performance of 
S100B and multivariate models in severe TBI.  
5. There is no difference in prognostic performance between 
multivariate models which do/do not contain S100B as a 
predictor in severe TBI.  
1.7.3. Importance 
Using the TARN data, it is hoped that at the end of PhD, a prognostic model 
has been developed which can be used for prognosis in British TBI individuals 
or series. Furthermore, the performance of prognostic models with that of 
S100B will be compared to provide an insight about which one of these 
prognostic tools may outperform the other. Finally, by trial of combinations of 
prognostic models with brain injury biomarkers, it will be investigated whether 
or not this combination can be an option to improve the predictive strength of 
prognostic models.  
1.7.4. Summary  
The PhD includes two parts: construction of a prognostic model for TBI 
patients using the TARN data and analysing a sample of 100 TBI cases who 
have their S100B serum levels recorded at 24 hr following the injury. The 
latter is aimed at comparing S100B prognostic performance to prognostic 
models or the combination of S100B with other prognosticators. Logistic 
regression will be used as the statistical method.  
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1.8. Study protocol  
The PhD involves the analysis of two TBI datasets: one from TARN with the 
other being the S100B dataset. For the rest of this thesis, the TARN study and 
the S100B study are respectively refer to the analysis, results and the 
interpretation of results as performed on the TARN and S100B TBI datasets.  
AIS codes: various injuries sustained by patients are coded in trauma 
registry using the AIS dictionary [90, 91]. This dictionary allocates a 6 digit 
AIS code to each injury which is followed by a post decimal figure 
representing AIS severity score (briefly severity score or AIS score). AIS 
scores ranges from 1 to 6. For example, a patient with penetrating abdominal 
injury with blood loss of more than 20% by volume receives AIS code and 
severity of 516006.3 (where 516006 is the code and 3 is the severity score).  
ISS: it is the sum of the squared of the three highest AIS scores 
allocated to each patient. It ranges from 1 to 75.  
1.8.1. TARN study  
1. Variables selection: This stage addresses what variables are to be 
investigated in the prognostic analysis. There are many variables proposed for 
TBI prognosis but in the modeling, selection of every proposed prognosticator 
may result in overfitting model and it is advised to base this selection on 
clinical consensus and literature [32] to minimize the number of variables. For 
this study, the variables were selected from those prognostic studies by the 
IMPACT and CRASH plus those suggested by Perel et al.  in their systematic 
review of prognostic models [31]. All these studies have employed multivariate 
analysis and the list of chosen variables are: age [23, 31, 35, 36, 92], cause of 
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injury[92], GCS [23, 31, 35, 36, 92], pupillary reactivity [23, 31, 35, 36, 92], 
Injury Severity Score (ISS) [31, 35], systolic and mean Blood Pressure (BP) 
[31, 36, 92], presence/absence of hypoxia [31, 36, 92], CT findings [23, 31, 35, 
36, 92] and presence/absence of extracranial injury [23]. 
2. Database selection: TARN records the Abbreviated Injury (AIS) code 
and severity for each injury sustained by patients. Thus a given type of injury 
of interest can be retrieved from the TARN registry by selecting the cases that 
have the AIS code related to that very injury. This means that the TBI cases in 
TARN can be selected through brain injury AIS codes. These codes are those 
which come under internal organ under the head section of the AIS dictionary 
[90, 91] plus those AIS codes under the skull which are highly likely to be 
associated with brain injury. These codes pertain to basal skull fracture and not 
simple skull fracture and all have AIS severity of 3 and above (the skull AIS 
codes which are unlikely to be associated with concomitant brain injury all 
have AIS severities of 1 or 2). Furthermore, only recently TARN commenced 
recording pupillary reactivity and as such it is necessary that those cases who 
do not have this variable recorded be excluded from data retrieval. If these 
cases are not excluded, the number of missing information on pupillary 
reactivity would be high making the analysis of this variable impossible. This 
is not desirable since this variable is stated as one of the core TBI 
prognosticators in TBI along with age and GCS [88]. Overall, the selection 
criteria of the data from TARN is either head AIS code under internal organ or 
skull AIS code with AIS severity  ≥ 3 AND pupillary reactivity recorded.  
3. Data preparation: This involves determining the best time point (out of 
at scene and on admission) and also the best sub score of GCS for prognosis 
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and allocating the appropriate Marshall Class to each case. The latter is 
because TARN does not record CT images or reports and thus AIS codes have 
to be used as substitutes to perform this translation.  
4. Univariate analysis: At this stage the linearity of continuous variables 
with outcome and their association with outcome in a univariate analysis are 
addressed. Some of the selected variables are obviously categorical by nature 
namely pupillary reactivity, cause of injury, various CT findings and 
presence/absence of extracranial injury. However, other variables can be taken 
either categorical or continuous. Logistic regression makes an assumption that 
all continuous variables have a linear relationship with logit odds of the 
outcome of interest (referred to as linearity assumption). This implies that if the 
continuous variable does not demonstrate this linearity, it has to be transformed 
to meet this assumption or else be categorized. Furthermore, at this stage it is 
required to run univariate statistical tests (t test or Mann Whitney U test for 
continuous variables and Chi Square test for categorical variables) to assess 
their association with outcome. In the same way, the odds ratio of outcome 
needs to be derived for each variable through logistic regression without 
adjustment for other prognosticators.  
5. Multivariate analysis and model derivation: This stage is the actual 
model construction. It is performed initially with age, GCS, pupillary 
reactivity, ISS and extracranial injury and proceeds with addition of CT 
findings and blood pressure and O2 saturation. Age, GCS, pupillary reactivity 
and extracranial injury are the covariates in the basic CRASH models. Model 
A of IMPACT also contains these covariates apart from extracranial injury 
which is not recorded in IMPACT [92]. We added ISS to this list as the extent 
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of extracranial injury can affect it and thus ISS contains information on 
extracranial injury too. The next step is adding CT features which is the case in 
the CRASH models and IMPACT models. Lastly, addition of blood pressure 
and O2 saturation is based on the order in the IMPACT models.  
6. Internal and external validation: Bootstrapping is used for interval 
validation and the resulting models are run on the IMPACT dataset and a later 
TARN dataset  as the external validation.  
1.8.2. S100B study  
1. Variables selection: this stage is similar to what is done in the literature 
review for the TARN project. However, it further included those variables 
which are not recorded in TARN. The list of selected variables are clinico-
demographic characteristics namely age [23, 24], GCS [23, 24], pupillary 
reactivity [23, 24], cause of injury [92], ISS [31, 92, 93], CT characteristics 
[23, 24, 94], extracranial injury [23], vital signs including mean (BP) [92, 95], 
systolic BP [92, 95], temperature [92, 96], and laboratory measures including 
PH [92, 97], Haemoglobin (Hb)[92, 97], Glucose [92, 97], Platelet (Plt) count 
[92, 97] and prothrombin time (PT) [92, 97] along with O2 saturation (O2 Sat.) 
[92, 96] and Intracranial Pressure (ICP) [35].  
2. Retrospective data collection: the original S100B project contains data 
on age, cause of injury, CT classifications and ISS. However, values of other 
variables are required to be retrospectively recorded with patients identifiers 
(name or hospital number). Some of these data are recorded in the regional 
electronic records (the Electronic Patient Record (EPR) at hospital and also 
ICU for vital signs) and TARN. If the information is not available through 
these sources then the patients‟ case notes are reviewed. For GCS and pupillary 
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reactivity the time point of assessment is on admission whereas for laboratory 
measures and vital signs the closest time point to 24 hours after injury is 
selected. This is when the blood sampling was performed in the original S100B 
study.  
3. Univariate analysis: Chi square test is used for comparing categorical 
variables across the survivals versus non-survivals or those with favourable 
outcome versus those with unfavourable outcome. Mann-Whitney U test or t 
test (depending on the normality of the distribution) is used for continuous 
variables for the same purpose. Similarly, logistic regression is used to derive 
the odds ratio for outcome without adjustment for other factors.  
4. Multivariate analysis and model derivation: two types of multivariate 
analyses are performed. Firstly, the constructed model in the TARN project is 
run in the S100B dataset and its performance is measured as per AUC, 
Nagelkerke R
2
 (section 2.7.2) and classification accuracy. Then the change in 
the performance is measured after adding S100B to this model. Secondly, a 
model is derived with only S100B and its performance is recorded. 
Subsequently those variables which are either found significant in the 
univariate analysis or present in the constructed model of TARN project are 
added to this model to observe the change in performance.  
1.8.3. Summary  
The protocols of the TARN and S100B studies are presented in this section. 
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1.9. Thesis structure  
This PhD thesis is presented in the alternative format (i.e. by publications) as 
opposed to the standard format (which contains sections in the following order: 
introduction/background, methods, results and discussion and future direction). 
The difference is only the location of the materials for each section of the 
standard format in that firstly, they are not presented in the standard sequence 
and secondly, they are interrupted by information from other sections in several 
places. Thus the coherence of a standard thesis is not maintained although the 
information on introduction/background, methods, results and discussion is 
contained in several disparate places.  
This PhD thesis contains 7 papers and all across the thesis these papers 
are referred to base on the number allocated to them (e.g. Paper 1, 2 etc.) 
1.9.1. Relevance of each paper to a standard thesis  
 
Paper 1: Utilisation and Assessment of Prognostic Models Derived Through 
Logistic Regression in Medicine.  
 
This paper covers some background to the concept of predictive models 
discussing ways as to how to use them or how reliable they are to help us with 
the purpose they are built for. This paper also provides an insight about the 
model construction contributing to the methods section.  
 
Paper 2: Predicting Outcome after Severe Traumatic Brain Injury Using the 
Serum S100B Biomarker: Results Using a Single (24h) Time-point [98].  
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This paper provides a portion of the evidence/background leading to 
hypotheses 3 and 4 and also includes partial results with regards to the first 
objective by assessing S100B as a prognostic tool. However, the prognostic 
performance of S100B reported in this paper may be far from ideal to be used. 
The hypothesis 3 addresses the issue that whether accounting for other 
predictive factors would enhance S100B predicative performance. However, 
the question still remains as to, among a brain injury biomarker or a 
multivariate model, which one is the superior prognostic tool. This latter issue 
is addressed in hypothesis 4. This paper is now published in Resuscitation [98].  
 
Paper 3: Comparing Model Performance for Outcome Prediction Using 
Total GCS and Its Components in Traumatic Brain Injury 
 
This paper covers an important step taken to make the appropriate decision 
with regards to methods (step 3 of the TARN study protocol) for the purpose of 
addressing hypotheses 1 and 2. GCS is recorded by TARN in a way that each 
patient potentially can hold records of total GCS and each component i.e. 
motor, eye and verbal at two main time-points of at scene and on admission to 
emergency department. Considering all these combined records together, there 
can be 7 various records for GCS (total, motor, eye, verbal, verbal plus motor, 
motor plus eye and verbal plus eye); each with its own prognostic capability. 
This paper discusses which GCS component and at what time-point of 
measurement is expected to have the best predictive value to be contained in a 
model along with other important predictive factors of outcome in TBI. 
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Paper 4: Using AIS Codes to Classify CT Findings in the Marshal System 
[99] 
 
This paper covers an important portion of the methods (step 3 of the TARN 
study protocol) in PhD to address hypotheses 1 and 2. An algorithm is 
proposed to assign a Marshall CT class to TBI patients based on recorded head 
AIS codes in the dataset or trauma registry. The assumptions, upsides and 
disadvantages of this proposed approach is discussed. This paper is now 
published in BMC Medical Research and Methogology [99].  
 
Paper 5: Prognostic Value of Various Intracranial Pathologies in Traumatic 
Brain Injury  
 
This paper presents an important step with regards to the methods (step 4 and 5 
of the TARN study protocol) employed in PhD and also provides results and 
discussions to refute hypotheses 1 and 2. Based on literature; various CT 
findings have significant prognostic value in TBI. However the question relates 
to the relative influence of each injury such as SAH or contusion on outcome 
when other important factors such as GCS or pupillary reactivity are taken into 
account. This paper compares various proposed CT classifications such as the 
Marshal System or AIS scores and concludes on the strongest intracranial 
pathologies for outcome prediction. The appropriate intracranial pathologies 
proposed in this paper are included in the final prognostic models as presented 
in Paper 6.  
 83 
 
Paper 6: Models of Mortality Probability in Traumatic Brain Injury: Results 
of TARN Modelling  
 
This paper provides the methods, results and the discussion for the PhD with 
regards to hypotheses 1 and 2 and the first objective of PhD is met. Two 
prognostic models are presented which use patients‟ characteristics to make the 
prediction on survival. Refuting the hypotheses 1 and 2 is mainly based on this 
paper.  
 
Paper 7: Comparing the Prognostic Performance of S100B with Multivariate 
Models in Traumatic Brain Injury 
 
This paper includes methods, results and discussion of PhD with respect to 
hypotheses 3, 4 and 5 and to meet the second and third objectives.  
1.9.2. Comparison with a standard thesis  
Each paper, apart from Paper 1, contains sections of introduction, methods, 
results and discussion tailored to the specific objective of that paper. Although 
the objectives of papers may be different to those of the PhD, they are 
important in terms of their relevance to the PhD aim (i.e. improvement of our 
understanding of TBI prognosis). Overall, various sections of a standard thesis 
are presented in the following manner:  
 
Introduction 
This is presented in the introduction section of the PhD thesis and Paper 1.  
 84 
 
Methods 
This is presented in all papers. Additionally, there are two further sections at 
the end of Papers 6 and 7 titled as „Expansion on methods‟ which provide more 
details on the methods used to achieve the five PhD objectives. This material 
was considered overly detailed or irrelevant to standard papers for journal 
publication.  
 
Results 
This is presented in all papers apart from Paper 1. Furthermore, there are some 
results pertained to the TARN project which follow Paper 6 (titled as „Further 
results‟). These were considered overly detailed or irrelevant to a standard 
paper and as such are presented in this way.  
 
Discussion  
This is presented in all papers apart from Paper 1 as each paper discusses the 
limitations, implications of the respective results and their relevance to the 
literature. However, there is also a separate section at the end of the thesis 
which provides further discussion on limitations, implications and comparison 
with the literature in the context of PhD hypotheses, objectives and aim. It is in 
the section that the discussion on how far the PhD objectives are met is given. 
In this section, a summary of the discussion from respective papers is provided 
with respect to limitations, comparison with the literature and 
implications/interpretation of the results in the first paragraph.  
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Future direction 
Apart form Paper 1, each paper presents information related to this. 
Furthermore, there is separate section at the end of PhD which suggests other 
issues to be considered/followed in the future research of TBI prognosis.  
1.9.3. Authors contribution 
At the beginning of each paper, the names of co-authors of that paper are 
provided. Apart from Paper 2, the first author of all papers is the investigator 
(M.M.L.).  
Mehdi Moazzez Lesko (the investigator): the investigator joined an ongoing 
research project on the S100B prognosis to derive its sensitivity and specificity 
for outcome prediction. Then this project was taken further for PhD along with 
TARN project. The investigator contributed to prospective data collection half 
way through. The retrospective data collection (for unrecorded data) was 
performed by the investigator as well. However access to the hospital EPR was 
restricted by the ethics committee and therefore this part was performed by 
F.L., although data retrieval from case notes was done by the investigator 
himself with the help of Health Record Office at the local hospital. Regarding 
the vital signs, the data were delivered in password-secured files via email by 
the IT officer at the local ICU with the patients‟ names as identifiers. All the 
statistical analysis of this study (either the original prospective project or the 
second retrospective part for PhD) was done by the investigator. Regarding the 
TARN project, the investigator performed all the statistical analysis as far as it 
was possible in Statistical Package for Social Sciences (SPSS) or Microsoft 
Excel. However, some parts of the analysis related to fractional polynomial 
analysis (section 7.5.7) were done by Omar Bouamra in SATA. Moreover, the 
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investigator drafted all papers apart form Paper 2 in which only results and 
discussion sections were written by the investigator.  
Omar Bouamra (O.B.): As a statistician, O.B. contributed with 
appropriateness and accuracy of various statistical approaches taken and their 
results and interpretations for both TARN and S100B projects. Specifically, 
O.B. performed all the fractional polynomial analysis in STATA. Accordingly, 
he is the coauthor in all papers except Paper 4.  
Timothy Rainey (T.R.): TR started the patients‟ recruitment of the original 
S100B project. As such, he is the first author of Paper 1 and the co-author of 
Paper 7.  
Tom Jenks (T.J.): TJ is in charge of data retrieval in TARN and contributed to 
data retrieval at various parts of PhD. This particularly was for the analysis 
performed in Papers 3 and 6 and as such he is the co-author of these papers.  
Charmiane Childs (C.C.): As the co-supervisor of PhD and the chief 
investigator of the original ongoing S100B project, C.C. is the main author of 
Paper 2 and for her supervision and contribution to content accuracy, is the 
coauthor of Papers 3, 4, 6 and 7.  
Sarah O’Brien (S.O.B.): As the co-supervisor of PhD, S.O.B is the co-author 
of all papers (apart from Paper 2) for her supervision and feedback on the 
scientific approaches taken and also on the content accuracy and 
communication efficacy with the broader audience.  
Marylyn Woodford (M.W.): M.W. particularly provided advice on the 
allocation of various brain injury AIS codes to Marshall Classes as presented in 
Paper 4. Also M.W. set out the objectives for TARN TBI modeling and 
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provided insight on data retrieval from TARN and thus contributing to Papers 6 
and 3.  
Laura White (L.W.): L.W. performed an in-depth review of the allocation of 
AIS codes to Marshall classes and as such she is the co-author of Paper 4.  
Hester Lingsma (H.L.): From the IMPACT collaboration, H.L. reviewed the 
detailed approach taken in the model construction for its appropriateness and 
provided the relevant comments and suggestions. H.L. is the co-author of Paper 
6.  
Pablo Perel (P.P.): From the CRASH collaboration, P.P. reviewed the detailed 
approach taken in the model construction for its appropriateness and provided 
the relevant comments and feedbacks. P.P. is the coauthor of Paper 6.  
Raphael Sacho (R.S.): RS participated in the first part of S100B project in the 
recruitment and follow-up of a number of patients. Therefore, he is the co-
author of Paper 7.  
Fiona Lecky (F.L.): As the main supervisor of PhD, F.L. initiated this work 
and assisted the investigator with the design and the progress of the work 
throughout the PhD with close supervision and guidance on every part from 
conduct of the studies and adherence to the protocols, to drafting of each paper 
and final thesis compilation. 
It goes without saying that this work was impossible without invaluable 
contribution of every co-author to accomplish each piece of PhD.  
1.9.4. Summary  
The structure of the thesis as the alternative format,  the contribution of each 
paper to the PhD aim and objectives and their relevance to a standard thesis 
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are discussed in this section. The contribution of each author to various papers 
is also provided.   
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2. Paper 1: Utilisation and Assessment of 
Prognostic Models Derived Through Logistic 
Regression in Medicine 
Authors 
 Mehdi Moazzez Lesko  
 Omar Boumra 
 Sarah O‟Brien 
 Fiona Lecky 
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2.1. Abstract  
Over recent years quantifying the probability of the existence or occurrence of 
a medical condition through using various patients‟ characteristics has become 
increasingly common. Logistic regression is the commonly used statistical 
method to make such predictions and its output is called a prognostic model. 
This article is aimed at clinicians with average knowledge of statistics to 
introduce the conceptual framework behind the derivation of a prognostic 
model. Essential statistical concepts to comprehend how a model is used or 
how the accuracy and reliability of a model is assessed are described. To this 
aim, various types of model presentation including tables, scoring systems or 
web-based calculators are also discussed with examples. Similarly, various 
measures (indices) of model performance such as discrimination and 
calibration are described. Finally, it is explained what it is meant by model 
validity or generalisibility. This document can therefore be used to understand 
the various necessary terminologies used in the application of a prognostic 
model.
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2.2. Introduction  
Over recent years quantifying the probability of the existence or occurrence of 
a medical condition through using known demographic, clinical, laboratory or 
other patient‟s characteristics has become increasingly common. An example 
of this is to quantify the probability of the existence of Pulmonary Embolism 
(PE) when a number of observations such as presence/absence of tachycardia, 
haemoptysis or signs and symptoms of Deep Vein Thrombosis (DVT) etc. are 
known [100] or the probability of the occurrence of nausea or vomiting 
following operation when the patient‟s age, duration of surgery or anaesthesia 
are known [101]. To make such predictions, logistic regression is the statistical 
method which is commonly used and its output is called a prognostic model. A 
prognostic model is not expected to perform perfectly and thus there are 
several measures to describe its performance like the performance 
characteristics of a simple clinical or laboratory diagnostic test which is 
described by its sensitivity, specificity, negative and positive predictive value 
etc. Understanding the terms which quantify the performance of a prognostic 
model thus has similar importance to those using them, as understanding these 
aforementioned terms (describing the performance of a simple diagnostic test) 
has to clinicians making diagnoses.  
With increasing use of prognostic models in medicine, this article aims 
to provide an overall introduction to the concept of prognostic models 
constructed through logistic regression, their use and the measures of model 
performance. A substantial knowledge of statistics is not required to 
comprehend the concepts since the essentials of medical statistics required to 
understand logistic regression are first explained in a concise manner herein. 
 92 
This document can be used to understand various necessary terminologies used 
while applying a prognostic model. 
2.3. Essentials of statistics for prognostic models and 
logistic regression  
The value of statistics in medicine is simple to understand. For instance, we 
may wish to know whether or not pulmonary outcome is different in patients 
suffering from Chronic Obstructive Pulmonary Disease (COPD) who take a 
drug, say Salmetrol, to those patients who do not. Ideally, we have to 
investigate all patients with COPD in the „world‟ by giving a drug (Salmetrol) 
to some of them and not to others, in a random fashion and to compare the 
outcome in these two groups. However, this approach is not possible for many 
reasons and thus the statistics assists us to analyse a sample of the population 
of patients with COPD and then to infer what goes on in the real world from 
the analysis of this one sample. 
Statistics is the analysis of the variables and variables are 
objects/characteristics/attributes or „entities‟ which vary and are not constant. 
The parameter is the other term which is alternatively used for the term 
variable. Alternative terms for the term „value‟ are observations, measurements 
or data. The variables can be categorical or continuous.  
Categorical variables vary within certain types/stages of a status or a 
medical condition (such as gender which varies between being male or female 
or the type of breast cancer which can vary among being lobular, ductal or 
mixed). 
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Continuous variables vary by adopting a measured figure. A continuous 
variable is in fact any variable which is not categorical (such as age, weight, 
blood sugar, serum bilirubin etc). However, sometimes continuous variables 
can be converted to categorical variables by defining a certain „cut-off points‟. 
For example, for some reason, a statistician may decide to categorise the 
continuous age as (< 17), (18 to 40), (41-65) and (> 66).  
2.4. Position of prognostic models in statistical analysis 
Statistics in medical science are used for descriptive or analytical purposes.  
In the descriptive form, the average/median and the variability of the 
data are described. In this manner, the variability is described through 
presenting graphs (histogram, box-and-whisker plot or bar chart) or through 
quantifying the frequencies, range, centiles or variance/standard deviation.  
In the analytical form of statistics (Figure 2), two or more groups of 
data are compared or their relation with each other is explored. 
 
Figure 2 A schematic presentation of various common types of analytical 
statistics in medicine.  
 
Comparing the data tells us whether or not the values are 
„meaningfully‟ different in two or more groups. For example, whether or not 
the median of blood cholesterol in a group of patients who had a heart attack is 
Analytical statistics  
Comparison  Relation  
Agreement  Association  Prediction/regression  
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different to those who did not or whether or not the frequency of anaemia in a 
group of male population is different to that in a group of female population. 
Obviously, this „meaningful‟ difference implies that one variable is expected to 
be higher or lower than the other in real life as inferred from the difference in 
the sample. This will be described in more details later (section 2.5).  
Exploring the relation among two or more variables involves one of 
these three aspects: agreement, association or prediction/regression.  
Agreement refers to similarity of the measurements performed by two 
people (inter-rater reliability) or at two time points (intra-rater reliability). One 
example of this is when one wishes to know how Glasgow Coma Scale (GCS) 
scores are similar (i.e. in agreement) if they are measured by two people or by 
one person at separate time points.  
Association means that, among two variables or more, if one variable is 
higher, the other is expected to be higher or lower and thus they are not 
independent. For example, one may be interested to know if the renal clearance 
of Gentamicin is associated with or independent of the renal creatinine 
clearance. In such case, increase or decrease in renal clearance may change the 
serum level of creatinine or these two may be independent.  
Prediction or regression is to estimate the value of one variable when 
the value of one or more other variables are known. This prediction is made 
through models and models are the mathematical equations used to make this 
prediction. The term prognostic model is commonly used to refer to these 
predictive models.  
The are several types of models but the simplest one is a linear 
(univariate) model.  
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2.4.1. Linear models  
The linear model is described by the regression line which is:  
Y = (a × X) + b 
In which, Y is the variable to be predicted (also referred to as 
dependant, outcome or response variable) and X is the variable used to make 
the prediction (also referred to as explanatory variable/factor, independent 
variable/factor, covariate or regressor). a is called the coefficient with b being 
the constant or intercept.  
The above model can be derived through statistical analysis of a sample 
of the population. It allocates actual figures to “a” and “b”. This then enables a 
clinician to calculate the unknown value of Y using the known value of X in 
real life. This formula also shows that X and Y are associated with each other 
i.e. they are not independent. In fact, one way of evaluating the association of 
two variables is to perform the regression in that if a is zero, then it can be 
inferred that there is no association between X and Y.  
2.4.2. Multivariate models  
Multivariate models incorporate more than one variable to predict the value of 
the other variable. Such models are called multivariate models and they take 
the following form:  
Y = (a1 ×X1) + (a2 × X2)…+ b 
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An example of such model is when we want to predict the score of a 
functionality scale called Functional Independence Measure (FIM) total score 
in stroke patients at discharge. This is a scoring system based on some items 
related to motor and cognition functionality which ranges from 18 (total 
dependence or lack of functionality) to 126 (total independence or normal 
functionality). The following model was derived through analysing the data of 
464 stroke patients [102]:  
FIM total score at discharge = - 0. 32 (age) + 0. 80 (FIM 
total score on admission) - 0. 13 (onset to admission 
interval) + 68. 6 
Using the above formula, then the discharge FIM total score can be 
calculated if age, admission FIM total score and the elapsed time between 
onset of symptoms to admission to hospital are known.  
However, the information provided by the above formula is more than 
just a prediction in that:  
 Firstly, if other variables are investigated during the construction of a 
model and they do not appear in the final model, this means those variables are 
not associated with or have no effect on the dependent variable. For example, 
during the construction of the above model to predict FIM, the effect of sex 
and age on FIM was also investigated, but these are not included in the final 
model. It can therefore be concluded that these factors have no effect on FIM. 
Obviously, if the effect of a variable is not considered during the model 
construction, absence of such variable in the model does not necessarily mean 
no additional  effect on the dependant variable. 
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 Secondly, multivariate models take into account the effect of multiple 
variables on a dependent factor collectively. This is usually referred to as 
adjustment with confounders to address the concern that factors may alter the 
effect of each other. An example of this situation is when one is interested to 
know whether or not Body Mass Index (BMI) has any effect on developing a 
cardiac complication following hip fracture in elderly [103]. Here, there are 
other „confounders‟ which may contribute to developing such complication 
such as older age or male sex. Performing a multivariate analysis by taking 
BMI, age and gender into account to predict the occurrence of cardiac 
complication addresses the effect of age and gender on outcome as well. It is 
then stated that the effect of BMI on risk of developing cardiac complication 
following hip fracture is adjusted for age and gender (confounders).  
 Thirdly, in a model which predicts one variable using one or more other 
variables, it can be stated that the predicted variable is associated with the 
predictors or the predictors are risk factors for the predicted variable. For 
example, when the model to predict the cardiac complication in the elderly 
with hip fracture contains age, gender and BMI, it can be stated that age, 
gender and BMI are risk factors for a cardiac event.  
2.5. Position of logistic regression in statistical 
methods 
Logistic regression is a „statistical method‟ used to derive a prognostic model. 
Statistical methods are specified mathematical calculations which can serve the 
purpose of the analysis; being either making a comparison or assessing the 
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relation between two or more variables. Examples of some commonly used 
statistical methods are t test, Chi Square test, Mann Whitney U test etc. 
The idea is firstly, to describe the population sample based on the 
purpose of the analysis and secondly, to determine how certain one can be that 
what is observed in the sample; is going on in the actual population or other 
samples of this population. The degree of certainty with which one can 
generalise what is observed in a sample to the whole population or „the 
meaningfulness‟ of what is observed is referred to as the statistical 
significance.  
There are two ways to investigate and demonstrate the statistical 
significance: estimation and hypothesis testing. Confidence Intervals (CI) are 
commonly used for estimation and the p value is used for hypothesis testing. 
Most statistical methods in medicine address the issue of clinical significance 
through hypothesis testing although often knowing the CI is more informative.  
2.5.1. Estimation and Confidence Intervals 
The Confidence Interval (CI) is presented by two figures between which we can 
be confident the actual value in the population resides with a ‘specified degree 
of certainty’.  This degree of certainty is stated when the CI is reported such as 
97. 5% CI or 95% CI (but 95% CI is the most commonly used). A 95% CI can 
be obtained for the mean, frequency, odds ratio and many other statistically 
descriptive or analytical factors.  
It simply means that if we repeat our sampling 100 times (or take 100 
samples of the population), the value of our interest (be it mean, frequency etc) 
is something between the two given figures 95 times (or in 95 samples of 
population).  This information is very useful simply because by analysing one 
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sample of population, we can estimate what would be observed if we had 100 
samples of population instead of only one. For example, a study found that 
80% of Intravenous Drug (IV) users in a sample of 499 cases detained for 
mandatory rehabilitation were positive for Hepatitis C Virus (HCV). The 95% 
CI from this sample was 76.2-83.6 [104]. This means if the sampling is 
repeated several times from the population of IV drug users under 
rehabilitation, the frequency of being HCV (+) is between 76.2 to 83.6, in 95% 
of the samples.  
CIs can also be used to investigate the association between two 
variables and for this purpose, knowing the CI for the odds ratio is helpful.  If 
this CI does not contain 1 (which demonstrates no association), we can 
conclude that the association between the two variables are statistically 
significant. For example, one may be interested to know if diabetes is 
associated with acute Myocardial Infarction (MI). We can simply obtain the CI 
for the odds ratio of having MI when the patient is diabetic in a dataset which 
contains this information. Shaw. et al. Observed an odds ratio of 1.41 with 
95% CI of 1.26 and 1.57 by analysing a sample of 100,253 patients  [6]. This 
demonstrates a statistically significant association since we can expect the 
presence of the association described by the confidence limits, on 95% of the 
occasions if the sampling of the population is performed repeatedly.  
2.5.2. Hypothesis testing and the p value  
The p value is the probability that what is observed in the sample,  actually 
occurs in the population if the null hypothesis is true. The null hypothesis 
differs according to the purpose of statistical analysis. For example, if the 
purpose is to compare a variable among two or more groups of values, then the 
 100 
null hypothesis is that there is no difference (or the difference is zero). Table 
10 presents some null hypotheses related to various statistical analyses and 
methods. There is a cut-off level for the p value commonly at 5% below which 
the null hypothesis is declared rejected. Thus, when the p value of a statistical 
analysis is less 5%, it is stated that the null hypothesis is refuted.  
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Table 10 Various statistical methods along with their purpose and the hypothesis. 
Purpose of statistical analysis Example of 
statistical method 
Null hypothesis 
Comparison Categorical variable Chi square test The difference between 
frequencies (or proportions) 
is zero 
Continuous variable T test, Mann Whitney 
U test 
The difference between the 
means is zero (t test), the 
difference between the 
medians is zero (Mann 
Whitney U test) 
Relation Agreement - Kappa (κ) test The ratings are independent  
Association Categorical variable Chi Squared Test The difference between 
frequencies (or proportions) 
is zero 
Continuous variable Simple linear 
regression 
The coefficient is zero 
Prediction 
/regression 
Continuous variable Multiple linear 
regression 
The coefficient is zero 
Categorical 
variable 
2 categories Logistic regression The coefficient is zero 
More than two 
categories 
Multinomial 
regression 
The coefficient is zero 
 
 102 
For example, when determining whether the Length Of Stay (LOS) in 
hospital, in trauma patients with and without underlying medical condition is 
different or not, the null hypothesis states that there is no difference. If in a 
sample of trauma patients, we observe a difference between the median LOS in 
patients with underlying medical condition and those without underlying 
medical condition with a p value of, say 3%, we can then say that if there is no 
difference between the LOS in these trauma populations, then there is only 3% 
chance that we observe such a difference in our sample. In other words, the 
type I error of our analysis is only 3%.  
For regression, the null hypothesis is that the coefficient is zero. In 
multiple regressions, i.e. there is more than one covariate; each covariate holds 
a p value related to its coefficient. 
2.5.3.  Logistic regression 
Logistic regression is a statistical method to construct a model to predict a 
categorical variable which has only two categories. Therefore, the outcome 
variable can be the existence (i.e. absence/presence) or occurrence/non 
occurrence of a medical condition such as survival, a postoperative 
complication, having a cancer etc.. The output of the model for a patient with 
given characteristics is loge (odds of what is predicted); for example, loge (odds 
of survival, a postoperative complication, having a cancer, etc.).  
Knowing the odds, calculation of the probability is simple since: 
Odds = probability / (1-probability) 
therefore:  
Probability = odds / (1+ odds) 
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The remaining two sections of this article explain various ways of 
presenting the output of logistic regression and also the indices which are used 
to assess how accurate a model is in its predictions. The output of logistic 
regression can be in two forms: a model (which contains the covariates, 
coefficients and the constant) or the odds ratio for each covariate. If the output 
of a logistic regression is in the form of a model, there are several ways to 
present this.  
2.6. Presentation of the results of logistic regression  
2.6.1. Table  
This is the simplest from of presenting the output of logistic regression 
analysis. The table contains covariates with their related coefficients, odds ratio 
(with or without 95% CI) or p value. If the table only contains the odds ratio, 
then it just provides information on the significance of the effect of each 
covariate on outcome which can be determined by p value or the 95% CI for 
odds ratio. Such table is not helpful to calculate the probability of the outcome 
variable.  
Knowing the coefficients and the constant from the table, the following 
equation can then be obtained:  
Loge(odds of outcome) = (coefficient)1 × (covariate)1 + 
(coefficient)2 × (covariate)2 + (coefficient)3 × (covariate)3 
+ …. + the constant 
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If we call Loge(odds of outcome) as B and the probability of outcome 
as A, the mathematical calculation of the probability of the outcome is as 
follows: 
B = loge (A/ (1-A)) 
e 
B 
= A /(1-A) 
A = e 
B
 / (1+ e 
B
) 
 
Interaction  
 
Two covariates in a model are interacting with each other, when they are 
affecting the degree to which they each influence the outcome (dependent 
variable). This is declared in the model by the originators and is simple to 
mathematically incorporate in the regression equation. In such case, the 
interaction is presented as an „extra‟ covariate which, like other covariates, 
holds an odds ratio and a coefficient. 
Table 11 presents a model which was derived to predict in-hospital 
morality for patients who undergo a vascular surgery [105]. This model 
employs the post-operative values of a number of patients‟ characteristics. In 
this table, the three interactions are in bold and are: between out-of-hours 
surgery and chronic statin therapy and between last mean daily Heart Rate 
(HR) and last mean daily Systolic Blood Pressure (SBP) < 100 or >179 
mmHg’ and between last mean daily HR and  withdrawal of chronic beta-
blocker. These interactions mean that the amount of the effect which, for 
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example, last mean daily HR has on the probability of death would change 
depending on last mean daily SBP or withdrawal of chronic beta-blockers. This 
is simple to mathematically describe as the interactions can be treated as 
individual covariates with their respective coefficients. 
 
Table 11 The model to predict in-hospital mortality following a vascular 
surgery.  
 
Thus the equation obtained from this table to calculate the log e (odds of 
in-hospital death) is as follows:  
log e (odds of in-hospital death) = (Age × 0. 052) + 
((Creatinine > 180 mmol. l-1) × 1. 625) + ((Surgery out of 
hours × no chronic statin therapy) × 2. 113) + (last mean 
daily HR × 0. 017) + ((last mean daily HR × ‘last mean 
daily SBP < 100 or >179 mmHg’) × 0. 019) + ((last mean 
daily HR × withdrawal of chronic beta-blockade) × 0. 017) 
–7. 951 
 
In the above formula, the variables which are of „yes/no type‟ such as 
out-of-hour surgery are 1 when present and are 0 when absent. Therefore, if 
they are absent, their effect on outcome would be zero.  
Covariate  Coefficient  
Age (per one-year increase) 0.052 
Creatinine > 180 mmol.l-1 1.625 
 
Surgery out of hours × no chronic statin 
therapy 
2.113 
 
Last mean daily HR (per beat per minute 
increase) 
0.017 
 
Last mean daily HR × ‘last mean daily 
SBP < 100 or > 
179 mmHg’ 
 
0.019 
 
Last mean daily HR × withdrawal of 
chronic beta-blockade 
0.017 
 
Constant –7.951 
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In the above model, some interactive variables such as out-of-hour 
surgery or withdrawal of chronic beta-blocker are not contained as individual 
covariates in that there is no covariate as out-of-hour surgery or withdrawal of 
chronic beta-blocker separately. This is not always the case in all models. As 
can be seen in this model, Last mean daily HR is contained individually and 
also in interactions with last mean daily SBP and withdrawal of chronic beta-
blockade. 
2.6.2. Scoring system  
In this form of presentation, each covariate receives a score or point and then 
the sum of all scores (called the sum score) is calculated. Each given sum score 
holds an equivalent probability or odds ratio of the outcome. There are several 
ways to obtain the related probability of a sum score. This may be provided in 
a table, presented in a graph, plotted against a line in the monogram or 
calculated through a linear equation.  
 
Example 1: predicting 30-day mortality in patients with ST-elevation MI (TIMI 
risk score): table presentation of the probabilities (Figure 3) 
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Figure 3 The TIMI risk score to predict mortality within 30 days following 
ST-elevation MI (from: Morrow DA, Antman EM, Charlesworth A, 
Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, 
Braunwald E: TIMI Risk Score for ST-Elevation Myocardial Infarction: 
A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation 
: An Intravenous nPA for Treatment of Infarcting Myocardium Early II 
Trial Substudy. Circulation 2000, 102:2031-2037.).  
 
Using this model, a risk score can be calculated which is the sum of 
points given to each particular characteristic presented in the „FRONT‟ table. 
Subsequently, the equivalent odds ratio of death by 30 days can be spotted in 
the „BACK‟ table knowing the calculated risk score [106].  
 
Example 2: the APCHE III prognostic system: the graph presentation of the 
probabilities (Figure 4) 
 
This model was developed by analysing a dataset of 17,440 cases to predict the 
probability of mortality in hospital for patients who are admitted to Intensive 
Care Unit (ICU) due to various medical conditions (APCHE: Acute Physiology 
and Chronic Health Evaluation) [107].  
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Initially, the APACHE III score is calculated which is the sum of points 
allocated to 17 covariates (the sum score). Then the probability of mortality 
related to the calculated sum score can be obtained in Figure 4 based on the 
cause of the admission to the ICU.  
 
Figure 4 The APCHE III prognostic system to predict mortality in ICU 
(from: Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, 
Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A, Harrell FE: 
THE APACHE-III PROGNOSTIC SYSTEM - RISK PREDICTION OF 
HOSPITAL MORTALITY FOR CRITICALLY ILL HOSPITALIZED 
ADULTS. Chest 1991, 100:1619-1636.) 
 
Example 3: calculation of the probability of distant metastasis in renal cell 
carcinoma: a nomogram (Figure 5) 
 
A nomogram is a graphical calculator and in multivariate analysis, it contains 
several scoring lines. Each covariate has a scoring line on which its value can 
be plotted. There is usually three other lines to plot the point given to each 
value, to spot the total points (the sum score) and finally to spot the final 
probability (or odds ratio) of the outcome. Figure 4 presents a „nomogram‟ 
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which can be used to calculate the probability that a patient with renal cell 
carcinoma has a distant metastasis knowing tumour size and symptom 
classification (asymptomatic, local or systemic) [108].  
 
Figure 5 A nomogram to predict distant metastasis in renal cell carcinoma 
(from: Georg CH, Jean-Jacques P, Claudio J, Paul P, Alexandre de La T, 
Laurent S, Gregory V, Jacques T, Luca C, Vincenzo F, et al: Patients with 
distant metastases from renal cell carcinoma can be accurately identified: 
external validation of a new nomogram. BJU International 2008, 101:39-
43.) 
 
Example 4: The IMPACT model for the probability of mortality within 6 
months following severe traumatic brain injury: the linear equation (Figure 6)  
 
In order to make such prediction, first the sum score is calculated using table in 
Figure 6 [24]. 
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Figure 6 The IMPACT model to predict mortality in 6 months following 
severe traumatic brain injury (from: Steyerberg EW, Mushkudiani N, 
Perel P, Butcher I, Lu J, McHugh GS, Murray GD, Marmarou A, Roberts 
I, Habbema JD, Maas AI: Predicting outcome after traumatic brain 
injury: development and international validation of prognostic scores 
based on admission characteristics. PLoS Med 2008, 5:e165; discussion 
e165.)  
 
Then, the probability is calculated using the following equations:  
 
LP = -2. 55 + 0. 275 × sum score 
Probability of mortality within 6 months = 1/ (1+e 
–LP
) 
2.6.3. Web-based calculator 
Oftentimes, an online-calculator is provided which by putting the respective 
value of a number of variables the probability of outcome is given. An example 
of such calculators is the one proposed by Chen. et al.  which predicts the 
probability of caesarean delivery using a number of mother‟s  characteristics 
such as age, height, weight, gestational age, pregnancy weight gain etc [109]. 
This calculator is available at 
http://www.ise.ufl.edu/rmfe/projects/CSPrediction/CSpredictEnscrpited1.htm.  
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2.7. Model Accuracy  
It is ideal that a model makes an absolutely accurate prediction. 
However, this does not happen in reality and therefore there are several 
measures to assess the performance of a model (or how accurate the model‟s 
prediction is). This is similar to a diagnostic test for a disease condition which 
is not always accurate and thus the accuracy of a test is measured through its 
sensitivity, specificity etc. In the same way, accuracy of a model‟s prediction 
can be assessed through several measures. Overall, the performance of a model 
has two dimensions: discrimination and calibration.  
It is first essential that the distinction is made between the predicted 
probability and the observed probability. The predicted probability is the 
probability of the outcome as calculated by the model for a patient with given 
characteristics. The observed probability for a patient with given characteristics 
is the frequency of the outcome among patients who all have those 
characteristics in the dataset. The idea is that two or more patients with the 
same characteristics may have different outcomes observed in real life (and 
thus in the dataset) whereas these two patients have the same probability 
predicted by the model. The observed probability is the proportion of the 
outcome observed in the dataset of patients with a given set of characteristics 
and the predicted probability is the proportion predicted by the model. For 
example, a model may predict the probability of admission to intensive care for 
a severe trauma patient at the age of 50 with underlying heart disease as 60%. 
This means every patient with the above characteristics has 60% chance of ICU 
admission (predicted probability). However, in the dataset from which the 
model has been derived, some patients at the age of 50 and with heart problems 
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may be admitted to ICU and some of them with the same characteristics may 
be never cared in ICU. The observed probability is the frequency of cases with 
these given characteristics who were cared in the ICU.  
2.7.1. Discrimination 
Discrimination is the ability of the model to predict higher probability of 
outcome for the patients who experience the outcome than those who do not 
experience the outcome. In a model with a perfect discriminative performance, 
all patients who experience the outcome at all times have a higher predicted 
probability than the probability predicted for patients who do not experience 
the outcome. However, the perfect performance rarely happens in reality.  
Area Under the Roc Curve (AUC) or C statistics is the measure to 
assess the discriminative performance of the model:  
 
Area Under the Roc Curve (AUC) (C statistics) 
 
This is the probability that in a random pair of patients that one has the 
outcome and the other does not, the patient who experiences the outcome has a 
higher predicted probability by the model than the one without the outcome.  
For example, an ideal model for prediction of death in a disease condition is 
expected to have AUC of 100% (or 1). This means that the predicted 
probability of death for a patient who dies is always (i.e. at 100% of the times) 
higher than the predicted probability of death in a patient who survives.  
Vergouwe et al. stated that in comparing the AUC (or performance) of 
a prognostic model across various population samples, it is important that the 
influence by differences in case-mix and also the value of coefficients taken 
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into account {Vergouwe,  #295}. This means that a large difference between 
performance of a model in the development population compared to the 
external validation population can partially be explained by the differences in 
case-mix or the coefficients and a different AUC does not necessarily reflect a 
different model performance. 
However, this ideal model is rarely achieved in reality and thus the 
AUC is expected to be less than 100%. Nevertheless, if the AUC is more than 
50%, it can be said that at least the prediction is not made by chance. (A 
prediction which is made by chance is like flipping the coin which has 50% 
chance of being either head or tail).  
There is no consensual cut-off for AUC to regard models with AUCs of 
above that cut-off as good discriminative models. However, an AUC of above 
85% may be an indicator of a good discrimination. An example of a prediction 
with this degree of AUC is to predict the breast cancer through mammography 
[110].  
2.7.2. Nagelkerke R2 
This measure is sometimes given to show a model‟s performance. It ranges 
from 0 to 1 (or from 0 to 100%) with 1 indicating the perfect model. 
Nagelkerke R
2
 is sometimes referred to as the equivalent of R
2
 in a linear 
model. Thus understanding R
2
 which is used for a linear model can partially 
help to understand the concept of Nagelkerke R
2
 for a logistic regression 
model. The idea and use of both these measures are the same despite their 
difference in mathematical calculation.  
 
R
2 
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By definition, R2 is the amount of variability in the predicted variable (Y) 
which is explained by the model.  
 
Variability  
 
In the linear regression equation of Y= (a × X) + b, for each value of X, 
there is only one Y value. However, this is not the case in reality (and thus is 
the dataset) in that each value of X can potentially hold several Y values.  
For example, one may wish to predict the Length Of Stay in hospital 
(LOS) from the admission age using a linear model. Obviously each value of 
age can potentially have several different LOS but if a model is derived (where 
the equation will take this form: LOS = (a × age) + b) for each value of 
age there is only one LOS predicted by the model. Thus for each age in the 
dataset, there can be a number of LOSs which are equal to what the model 
predicts and a number of LOSs which are different to this prediction.  
Variability in a set of data is a mathematical calculation which is 
performed through sum of squares and has three types: total sum of squares, 
explained sum of squares and residual sum of square.  
total sum of squares = 
2
1
n
i
i
yy  
explained sum of squares (explained variation) = 
2
1
ˆ
i
i
yy  
residuals sum of squares (unexplained variation)= 
2
1
ˆ
i
ii
yy  
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Where y and y are the observed and predicted values respectively 
(Figure 7). According to this graph, the explained value is the difference 
between the predicted value (the constant line) and the mean of all observed 
values (the dotted line). This is presented as 
_
yy  in the above formula. 
The unexplained value is the difference between the observed value (○) and the 
predicted value (the constant line). This is presented as yy  in the above 
formula.  
 
Figure 7 Explained and unexplained values and variation. The dotted 
vertical line represents the mean of observations.  
 
 
Calculating R
2 
 
R
2
 is calculated using the following formula:  
 R
2
 = 1 – (residuals sum of squares/ total sum of squares) 
or 
R
2
 = 1 – (unexplained variation/ total sum of squares) 
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Similar to AUC, there is no cut-off for R
2
 above which to regard the 
performance of the model acceptable. However, R
2 
is a good measure to 
compare the performance of several models if it is known for every model.  
2.7.3. Calibration (goodness of fit) 
This refers to how close the predicted probability by the model is to the 
observed probability. . This is expressed as how the model fits the data. In an 
ideal model all predicted probabilities are equal to the observed probabilities. 
However, similar to discrimination, this perfect performance is rarely achieved.  
The following measures are used to mathematically describe the 
calibration of a model:  
Negative Predictive Value (NPV): This is the proportion of the patients with 
predicted probability of less than 50% by the model who did not experience the 
outcome.  For example, if the NPV of a model is 80%, there is 80% chance that 
a patient with say 30% predicted probability of death (i.e. any value less than 
50%) did die in reality.  
Positive Predictive Value (PPV): this is the proportion of the patients with 
predicted probability of more than 50% by the model who do experience the 
outcome.  For example, if the PPV of a model is 80%, there is 80% chance for 
a patient with say 60% predicted probability of death (i.e., any value more than 
50%) did die in reality.  
Sensitivity: this is the proportion of the patient with the outcome who hold the 
predicted probability of more than 50% by the model.  For example, if the 
sensitivity of a model is 80% this means the model makes the prediction of 
death of more than 50% for 80% of patients who die.  
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Specificity: this the proportion of the patient without the outcome who hold the 
predicted probability of less than 50% by the model to experience the outcome.  
For example, if the specificity of a model is 80% that means the model makes 
the prediction of no death (i.e. survival) of more than 50% for 80% of patients 
who do not die.  
Accuracy rate (classification accuracy): this is the proportion of the patients 
who are correctly classified by the model.  The correct classification implies 
that if the patient experience the outcome, the predicted probability is more 
than 50% and if the patient does not experience the outcome, the predicted 
probability is then less than 50%.  
 Mathematical calculations of NPV, PPV, sensitivity, specificity and 
accuracy rate can be presented through a 2 ×2 table (similar to a diagnostic 
test) as follow:  
 
Outcome  + - 
+ a b 
- c d 
 
NPV = d / (d + c) 
PPV = a / (a +b) 
Sensitivity = a / (a + c) 
Specificity = d (d + B) 
Accuracy rate = (a + d) / (a + b + c+ d) 
Predicted probability > 50% 
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The concept of these measures for a model is overall similar to a 
diagnostic test. For example, sensitivity of a diagnostic test is the proportion or 
the probability that a patient with the disease has a positive test result. In a 
model, the (+) test result to experience the outcome is when the predicted 
probability is more than 50%. This cut-off of 50% is „by default‟ and it can 
also be set at a figure higher than 50% in which case this would be mentioned 
by the originators of the model.  
2.7.4. Hosmer- Lemeshow goodness of fit test (HL statistics) 
This is a statistical method referred to as „goodness of fit‟ test to assess the 
calibration of a prognostic model. The test provides a p value and if its value is 
less than 5%, it is stated that the model does not fit the data. This reflects that 
the model is not satisfactorily calibrated.  
2.7.5. Brier score (the average quadratic) 
This is the sum of the squared differences between observed probability and 
predicted probability divided by the number of patients. Mathematical 
presentation of this is as follows:  
Brier score = ∑ (observed probability – predicted probability) 2 / n 
Where n is the number of patients.  
A perfect model holds a Brier score of 0 and the worst performing 
model holds a brier score of 1 (100%).  
2.7.6. Calibration plot (Calibration curve) 
This is the plot of observed probability against predicted probability. The 
calibration plot is a valuable tool to assess calibration performance by 
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providing immediate interpretable information across the whole range of 
probability which is from 0 to 1. This means in the calibration plot one can 
observe, for example, the predicted probabilities are closer or more distant to 
the observed probabilities in the higher ranges of probability of outcome than 
lower ranges or vice versa.  
The X axis in the calibration pot is usually predicted probability and the 
Y axis is usually the observed probability. There is line of comparison which 
represents the perfect calibration i.e. observed probability is equal to predicted 
probability at all times (X=Y). In interpretation of a calibration plot, these 
issues should be considered:  
 Overall, how close the predicted probabilities are to observed 
probabilities. This is just the visual presentation of the calibration 
because the mathematical answer to this issue can be obtained through 
HL statistics (section 2.7.4). 
 At what ranges of predicted probabilities (i.e. high, moderate or low 
predicted probability), there is more closeness or more distance from 
the observed probability.  
Figure 8 presents the calibration curves for two models: Admission 
APACHE II (the line) which uses patients characteristics on Admission and 
Worst APACHE II (the dotted line) which uses the worst patients 
characteristics during their stay in ICU to predict mortality [111]. The straight 
line represents the situation in which the models hold the perfect calibration. 
This figure depicts following information about Admission APACHE II model: 
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Figure 8 Calibration curves for the Admission APACHE II score and the 
Worst 24-hour APACHE II score to predict in hospital death (from: 
Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos 
PG, Sirio CA, Murphy DJ, Lotring T, Damiano A, Harrell FE: THE 
APACHE-III PROGNOSTIC SYSTEM - RISK PREDICTION OF 
HOSPITAL MORTALITY FOR CRITICALLY ILL HOSPITALIZED 
ADULTS. Chest 1991, 100:1619-1636.).  
 
 Overall, the predicted probabilities are close to the observed 
probabilities (however, this was shown by the authors of this study 
through HL statistics as well). 
 The best calibration is held with very low (i.e. less than 5%) and 
moderate (i.e. between 35% and 55%) predicted probabilities. This 
means at the these ranges of predicted probability, the difference 
between the observed probability and the predicted probability is 
minimal. The worst calibration is held with low (i.e. between 5% to 
35%) and high (i.e. more than 55%) predicted probabilities. This means 
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at these ranges of predicted probability, the difference between the 
observed probability and the predicted probability is maximal.  
The same information can be obtained for the Worst APACHE II 
model. For example, as depicted, the higher the predicted probability, the more 
distant it is from the observed probability.  
This figure also shows that overall, the predictions made by Admission 
APACHE II model is closer to the observed probability than predictions made 
by the Worst APACHE II model i.e. the admission model has a better 
calibration performance than the worst model.  
2.8. Model’s Generalisability (or validity) 
Model validity refers to the performance of the model in the dataset from 
which the model has been derived (internal validly) or in a separate different 
dataset (external validation). The dataset from which the model is derived is 
called the derivation dataset. The dataset on which the model is validated is 
called internal or external validation dataset. If a model is accurate only in the 
dataset from which it has been derived, then this model is not generalisable i.e. 
is not reliable to be used in settings other than the derivation set. There are 
many reasons why an accurate model on the derivation dataset may not hold 
validity. This may relate to inherent deficiencies of modelling method or the 
design of the study [112]. However, even when a model has been developed 
with vigilant study design and methodology, it is still needed to be examined in 
other settings (or different datasets). 
Internal validity (model reproducibility): this is when the validity of the model 
is examined in a different sample of patients who were not included in the 
derivation dataset just by random [113]. In this manner, the dataset is, for 
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instance, divided into two sub datasets (e.g. 2./3 versus 1/3 of the cases) and 
the derivation is performed in one sample (e.g. on 2./3 of the cases) to obtain 
the indices of performances. Subsequently, the resulting model is run in the 
remaining cases and the performance indices are obtained from this second 
dataset. A model with good internal validation should not demonstrate a huge 
drop in its measures of performance between these two datasets.  
External validation (transportability): this is when the performance of the 
model is investigated in a different dataset of patients which differ to the 
derivation sets in many ways [113]. Based on the type of the difference, there 
are potentially 5 types of external validations: historical, geographic, 
methodological, spectrum and follow-up interval. Failure of a model in any of 
these external validations warns the users of such model in settings which have 
the same type of difference(s) with the derivation set.  
Historical validation: this validation is when the validation dataset is recruited 
from a different calendar time to that from the derivation dataset [113]. The 
importance of such validation relates to the changes in treatment, management 
or health care polices bound to occur over time.  
Geographic validation: this validation is when the validation dataset is 
recruited from a different location (s) which refers to the generalisability of the 
model to a setting in different geographic regions [113]. This type of validation 
would address regional differences of treatment, management or health care 
polices. 
Methodological Validation: this validation is when the validation dataset is 
recruited by a different method [113]. This implies to the differences in 
patients selection or data collection. For example, a dataset of stroke patients 
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may exclude those cases who have had the symptoms less than 24 hours 
whereas in the other sample of stroke patients this exclusion criterion does not 
apply.  
Spectrum validity: this validation is when the validation dataset contains cases 
who, on average, have a different degree of severity or advancement of the 
disease [113]. For example, a dataset may contain brain injury patients who 
attended hospital with GCS of less than 8 in contrast to the other dataset who 
contain brain injury patients with presenting GCS > 12. 
Follow-up interval validity: this validation is when the existent of a condition 
or occurrence of an event pertains to a different period of time in the validation 
dataset to that in the derivation dataset [113]. An example of such validation is 
to assess the performance of a model which predicts the degree of disability of 
stroke patients at discharge from hospital in the other sample of stroke patients 
to predict the same degree of disability at sometime after discharge.  
2.9. Model development  
Beside a good performance, a model has to be well-developed. This means 
construction of a model is much more complicated than performing statistical 
tests such as a Chi Square test. This is because the modelling has to be 
performed through several stages such as careful selection of covariates or data 
preparation for logistic regression. Assessment of the way a presented model 
has been developed is beyond the scope of this article and is similar to critical 
appraisal of a research study. For this purpose, the series of publications in the 
British Medical Journal (BMJ) [114-116] or the quality assessment tool for 
prognostic models proposed by Perel et al.  [31] can be referred to [31]. 
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Musshkudiani et al.  also provided a list of recommendations for constructing 
and validating models which can be used as quality assessment tool [32].  
Briefly, if a model has been derived from a large dataset, is in 
widespread use, has received international acceptance or has been peer-
reviewed prior to its presentation or publication, it may be nearly ensured that 
the model is well-developed. However, cautions should still be taken as to 
various types of external validity. For example, a well-developed model may 
be too old to reflect ongoing changes in patients‟ management. Similarly, a 
model which has been constructed in the developed world may not be good for 
a country which has limited medical facilities or resources.  
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3. Paper 2: Predicting Outcome After Severe 
Traumatic Brain Injury Using the Serum 
S100B Biomarker: Results Using a Single 
(24h) Time-point [98]. 
Authors  
 Timothy Rainey 
 Mehdi Lesko 
 Raphael Sacho 
 Fiona Lecky 
 Charmaine Childs  
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3.1. Abstract  
3.1.1. Background and Objectives 
In recent years, biochemical markers have been employed to predict the 
outcome of patients with traumatic brain injury (TBI). In mild TBI, S100B has 
shown the most promise as a marker of outcome. The objective of this study in 
patients with severe TBI was to: show the range of serum S100B levels during 
the acute phase after trauma: determine if S100B has potential to discriminate 
favorable from unfavorable outcome in patients with similar brain injury 
severity scores and to establish an S100B level „cut-off‟ predictive for death.  
3.1.2. Methods 
All patients with severe TBI, admitted to this neurointensive care unit within 
24 hours of injury were eligible for inclusion in this study. One serum blood 
sample was obtained from each patient at the 24 hours post injury time-point. 
S100B levels were measured using Enzyme-Linked Immunosorbent Assay. 
Injuries were coded using an internationally recognized injury scoring system. 
Three month follow up was undertaken with outcome assessed using the 
Glasgow Outcome Score (GOS). 
3.1.3. Results 
100 patients were recruited. Serum S100B levels ranged from 0.08µg/l to 
12.62µg/l
.
 S100B levels were significantly higher in patients with a GOS of 1 
(death) 2 and 3 (unfavorable outcome) compared with those with GOS 4 and 5 
(good recovery). In this study a cut-off point of 0.53 µg/l has sensitivity of 
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>80% and specificity of 60% to predict unfavorable outcome and 49% to 
predict death.  
3.1.4. Conclusion 
In 100 patients studied with similar brain injury severity scores, serum S100B 
measured at the 24 hour time point after injury is significantly associated with 
outcome but a cut-off 0.53ug/l does not have good prognostic performance.  
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3.2. Introduction  
The severity of brain injury can be assessed in a variety of ways. For the 
paramedic and clinician the best empirical assessment of injury is the degree of 
impaired cerebral function. Here assessment of conscious level using the 
internationally recognised Glasgow Coma Scale (GCS)
 
[117] aids triage, 
prognosis and family counselling. Subsequent assessments of head and other 
body injuries can be made using anatomical scoring systems such as the 
Abbreviated Injury Scale (AIS) [118] and for multiple injuries the Injury 
Severity Score (ISS) [118]. Physiological scoring systems can also be used 
using the revised trauma score (RTS)
 [119]
 and the four elements composing the 
TRISS methodology (Trauma Score and Injury Severity Score) [120]. These 
scoring and survival probability systems are particularly valuable in 
epidemiological studies for assessment of outcome with respect to severity of 
injury.  
In recent years quantitative biochemical markers have been employed 
to diagnose a variety of diseases e.g. creatinine for renal failure [121], troponin 
for myocardial infarction
 
[122] and lipase for pancreatitis [123]. Of the 
calmodulin/troponin C superfamily of calcium binding proteins
 
[50], S100B 
has shown most promise as a biochemical marker of outcome after mild head 
injury [124]. Protein S100B fulfils many of the criteria of an ideal molecular 
serum biomarker for brain damage in this patient group and has proved more 
reliable in predicting outcome compared with other markers such as neuron 
specific enolase [43]. S100B has high specificity for nervous tissue although it 
is recognised that non-nervous tissue such as fat and muscle also release 
protein S100B [125]. Increased levels of S100B are associated with a poor 
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neuropsychological outcome [80, 126]. Consequently, S100B has been 
proposed as a diagnostic and prognostic tool in mild brain injury. It has also 
been used to aid decision making about the need for CT scanning in the 
Emergency Department (ED) [74, 124]. For patients with severe head injury, 
S100B has proved more reliable in predicting outcome compared with other 
markers such Neuron Specific Enolase [43, 78]. However, as blood samples 
have been taken at many different time-points after injury in the various 
published studies, it remains uncertain as to the time-point at which blood 
sample should be taken where S100B levels best reflect the severity of brain 
damage.  
In a recent series of investigations from this Centre, the majority of 
patients with severe TBI admitted to the intensive care unit for medical 
management of their head injury had the same AIS score for the head (AIS 5) 
despite considerable differences in outcome when assessed using conventional 
outcome scores three months after brain damage
 
 [17, 18]. To improve our 
ability to discriminate survivors from non-survivors, the aim of this study was 
to: show the range of serum S100B levels after severe TBI; determine if S100B 
has potential to discriminate favourable from unfavourable outcome in TBI 
patients with the same AIS scores and to establish an S100B level cut off 
predictive for death.  
3.3. Methods 
Research ethics approval was obtained before the study commenced. Patients 
aged ≥16 years with severe head trauma admitted to the intensive care unit 
(ICU) of this large University teaching hospital within 24 hours of injury were 
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eligible for recruitment to the study. Late referrals to ICU (admission ≥24 
hours after injury) were excluded.  
Patients were admitted either as direct referrals from the Emergency 
Department (ED) or as tertiary referrals from ED of other hospitals within the 
Greater Manchester region. All the patients were sedated, intubated, and 
mechanically ventilated and all had an intra or extra-axial lesion on CT, with or 
without systemic trauma. The patients were treated in accordance with local 
neurointensive care guidelines to maintain cerebral perfusion pressure (CPP) at 
60 mmHg or higher and intracranial pressure (ICP) below 20 mmHg. To 
manage raised ICP, patients were positioned 30° head up and received 
sedation, analgesia, neuromuscular blockade and osmotherapy with manitol 
(0.5g/kg) as required. Advanced therapies such as induction of barbiturate 
coma, surgical removal of haematoma, were considered as „second-tier‟ 
therapy when ICP was refractory to first-tier treatments
 
[127].  
3.3.1. Assessment of Injury Severity  
From the patient‟s case notes details of all injuries sustained at the time of the 
accident were noted. Using the AIS directory each injury was assigned a code. 
From the respective codes, a score was given representing the severity of 
trauma in each of seven separate body regions [118]. Briefly, an AIS code 1 
represents minor injury and AIS 5 the most severe of survivable injuries. The 
AIS for the head region includes trauma to the brain and cranium. For an 
assessment of the severity of injuries in all the body regions, the internationally 
recognised Injury Severity Scale (ISS) was used. ISS is calculated by summing 
the squares of three highest AIS severity of scores allocated. However, if there 
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is AIS score 6 among scores allocated, then the ISS of 75 will be automatically 
allocated irerepeticve of other socres.  
3.3.2. Blood sampling  
Blood samples were obtained from each patient at 24h time-point after the 
patient had sustained his/her injury to the head. A single 5 ml blood sample 
was obtained via dwelling arterial cannula. The sample was transported via a 
pneumatic transport system from the ICU to the laboratory. Samples were 
centrifuged (2800 rpm) separated and stored at -70
o
C until batch analysis of 
serum samples (approx 30/batch) was undertaken. Clinical details were 
recorded at the time of sampling. 
3.3.3. Assay 
Stored serum samples were analysed using a one-step immunoassay (enzyme-
linked immunosorbent assay, ELISA; Sangtec 100™ Diasorin, Wokingham 
UK) incorporating S100B antibody coated microtitre plates and tracing 
antibody conjugated with horse radish peroxidase (HRP) and Tetra 
Methylbenzidine (TMB) substrate to give a colour reaction proportional to the 
concentration of S100B in the sample 
3.3.4. Outcome 
Three months after the primary injury was sustained a follow-up assessment 
using the GOS
 
[26] was undertaken by one designated member of the research 
team (RS). Contact was usually made by telephone, speaking either with the 
patient him/herself (when appropriate) or with a relative, identified at the time 
of admission, who had agreed to be contacted in the future for the purpose of 
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outcome assessment. On some occasions patients who remained in the care of 
NHS rehabilitation services at the time of the three month GOS, were assessed 
via discussion with the patient‟s healthcare professional.  
3.3.5. Data collection 
Details of the anatomical distributions of the patients‟ injuries, obtained via the 
medical case notes, were transferred to an Excel™ (Microsoft Corporation) 
database for AIS and ISS scoring by a member of the research team and 
checked by the same Trauma Audit Research Network (TARN) officer 
throughout the study. 
3.3.6. Statistics 
From previous pilot data of nine patients from whom serial S100B samples 
were obtained over the course of the first 5 days after severe TBI, the 24-h 
post-injury time-point was observed to be most promising to detect the point at 
which injury-induced increase in S100B start to fall (Table 12). A continued 
elevation (or absence of a fall) in S100B levels might therefore be expected in 
those patients with the most severe of TBI and is in line with previous 
publications [128]. 
 133 
 
Table 12 Change in S100B serum levels before (range 5-23, median 12.5) 
the 24h after injury time-point and after (range 25-85; median 35h) 24 h. 
(NS: Non-Survivors, S: Survivors) 
 
Comparisons of S100B values in the different categories under 
investigation were made using the Mann-Whitney U-test to compare median 
values. The Receiver Operating Characteristics (ROC) curve to plot sensitivity 
versus 1 – specificity was undertaken using the Statistical Package for the 
Social Sciences (SPSS Inc; Chicago, USA). Each S100B value, in tern, is 
treated as a cut-off and the sensitivity and specificity was determined for each 
S100B value., so allowing for the selection of the optimum cut-off value. 
Where patients have similar AIS (head) scores we predict that a high serum 
protein S100B level, 24 hours after severe TBI, will enable us to discriminate 
between patients who have a good versus a poor outcome three months after 
TBI. A minimum of 96 patients with an AIS for the head of 3 or more are 
needed to achieve 95% power at the 5% significance level to detect a 
difference in poor outcome (GOS 3 or less) of 70% versus 30% for patients 
with a high 24 hour protein S100B level. 
Pilot study patient Serum S100B (μg/l) outcome 
 Before 24 hr time-
point 
After 24hr time-
point 
 
1 1.12 0.73 NS 
2 0.57 0.20 S 
3 1.38 0.82 NS 
4 1.66 1.57 NS 
5 0.50 0.37 S 
6 0.29 0.17 S 
7 0.84 0.22 NS 
8 2.07 3.25 NS 
9 1.19 0.45 S 
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3.4. Results  
One hundred patients (81 male: 19 female) aged 16-86 years (median 31) years 
with TBI were recruited to the study over a period of 25 months (Table 13). All 
patients had sustained severe brain trauma. With the exception of two patients 
only, all injuries to the head scored 4 or 5 (median 5) on the AIS scale 
corresponding with severe brain damage (Table 1). In 53 patients (53%) brain 
injury was the only significant trauma. The remaining 47 patients (47%) had 
additional injuries to the body viscera, bone and soft tissues. In all patients, the 
ISS (representing the sum of all the injuries to head and body) ranged from 9-
50 (median 25), a score corresponding with a classification of severe trauma. 
Thirty one (31%) patients required emergency neurosurgery (Table 1). Of the 
100 patients recruited to the study, 70 patients (70%) survived their injuries 
and 30 (30%) died. All but one of the deaths occurred during the acute period 
after injury (first 5 days). Three months after TBI, GOS ranged from 1-5 
(median 4) (Table 13) 
. 
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Table 13 Characteristics of the 100 study patients 
 
 Number (percentage) 
Gender  
Male/female  81/19 
Age  
Median  31 
Range  16-86 
Highest AIS code   
3 2 
4 37(37%) 
5 61(61%) 
ISS  
Median 25 
Range  9-57 
Multiple injuries  47% 
Emergency neurosurgery  31(31%) 
Outcome  
GOS 1 (death) 30(30%) 
GOS 2 4(4%) 
GOS 3 16(16%) 
GOS 4 29(29%) 
GOS 5 21(21%) 
Unfavourable outcome  50% 
S100B (µg/l)  
Median 0.74 
Range  0.08-12.62 
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The concentration of serum S100B obtained 24 hours after injury 
ranged from 0.08-12.62 (median 0.74) µg/l. In five patients, S100B levels were 
below the limits of detection for the assay. In the 98 patients with the most 
severe brain injury (AIS 4, 5) S100B levels were not significantly different 
between the two AIS categories (Figure 9). However, the p value of 0.06 
inidicates that this finding tends to be significant, should the sample size be 
larger.Table 14 shows S100B levels in patients with and without four key 
conditions: those who required emergency neurosurgery; those patients with 
multiple trauma (as opposed to isolated brain injury only); those who had an 
unfavourable outcome (GOS less than 4) with brain injury severity scored as 4 
and 5 respectively and those patients who died. S100B concentrations were not 
significantly different in patients who underwent emergency neurosurgery 
compared with those who did not. Similarly, the difference in S100B levels in 
patients with multiple trauma compared with the levels in patients with isolated 
brain injury were not significantly different. S100B concentrations (Figure 10) 
were significantly higher in: those with unfavourable versus favourable 
outcome (p=0.00) and those who died versus those who survived (p=0.003, 
Table 14 ). 
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Figure 9 Box and Whisker plot of serum S100B levels (μg/l; open circles) 
in patients with AIS 4 (n=37) and AIS 5 (n=61). Differences between the 
two AIS categories are not significant (p=0.06, Mann-Whitney U-test). 
One extreme outlier (12.62 μg/l) in a patient with AIS 5 has been excluded 
in the figure but the value has been retained for all calculations including 
the median and interquartile range. 
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 Yes NO P value 
N Median 
S100B 
(25
th
 to 75
th
 
centiles) 
N Median 
S100B 
(25
th
 to 75
th
 
centiles) 
Emergency neurosurgery 31 0.83 
(0.47-1.66) 
69 0.73 
(0.39-
1.46) 
0.78 
Multiple injuries 53 0.73 
(0.44-1.74) 
53 0.75 
(0.34-
1.42) * 
0.53 
Unfavourable Outcome 
(GOS < 4) 
47 1.36 
(0.60-2.28) 
50 0.48 
(0.29-
0.94) 
0 
Unfavourable outcome 
(AIS 4) 
14 0.99 
(0.55-2.00) 
23 0.37 
(0.19-
0.53) 
0 
Unfavourable outcome 
(AIS 5) 
35 1.59 
(0.64-2.44) 
26 0.72 
(0.40-
0.98) 
0 
Death 30 1.44 
(0.60-2.32) 
70 0.59 
(0.34-1.20 
0.003 
Death (AIS 4) 6 0.75  
(0.51-1.80) 
31 0.47 
 (0.20-
1.09) 
0.03 
Death (AIS 5) 24 1.61  
(0.65-2.41) 
37 0.75  
(0.45-
1.22) 
0.03 
Table 14 Comparison of serum S100B concentrations (µg/l) in patients who had /did not 
have the following: emergency neurosurgical management, multiple injuries, 
unfavourable outcome (AIS 4, 5) or who died/survived severe TBI. *Patients in this 
category had isolated TBI. Main categories for statistical comparison are emboldened. 
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Figure 10 Scatter plot of serum S100B levels for each GOS score. Patients 
with AIS 3 (*), AIS 4 (○) and AIS 5 (◊). As shown in Figure 9 one outlier, 
12.62 μg/l in a patient with GOS score of 1 is excluded.  
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ROC analysis of these data shows that serum S100B is a significant 
predictor of outcome with an area under the curve (AUC) of 0.77 (CI: 0.68 -
0.86) for prediction of unfavourable outcome (GOS 1, 2 and 3) at 3 months and 
AUC 0.69 (CI: 0.57-0.80) for prediction of death (Figure 11)., The best cut-off 
for S100B (optimizing sensitivity at the cost of lower specificity) is 0.53 µg/l. 
This cut-off provides a sensitivity of 82% with specificity of 60% to predict 
GOS of less than 4 at 3 months. To predict death at three months this cut-off 
has sensitivity of 83% and specificity of 49% 
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Figure 11 Receiver Operating Characteristic (ROC) curve showing plots of sensitivity versus 1-specificty to predict: A, 
unfavorable outcome, assessed at 3 months, at various cut-off levels of serum S100B and B, death at various cut-off levels 
of serum S100B.  
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3.5. Discussion  
In this cohort of 100 patients with severe traumatic brain injury admitted to the 
intensive care unit of our institution, serum S100B levels measured at the 24 
hour time point ranged from 0.08µg/l
 
to 12.62µg/l. Serum levels were 
significantly higher in those patients who, three months after injury, had an 
unfavourable outcome compared with those who had made a good recovery. 
The patients who died also had significantly higher S100B concentrations than 
the survivors. Although there is no significant difference in S100B values 
between AIS categories 4 and 5, within each of these categories S100B levels 
did significantly predict good from a poor outcome. ROC curve analysis 
showed that S100B can be used to predict outcome at 3 months; be it death or 
unfavourable outcome (GOS of 3 or less).  
We chose the cut-off point of 0.53µg/l
 
to optimise sensitivity without 
excessive lowering of specificity. This cut-off has sensitivity greater than 80%, 
meaning that at least 80% of patients who die or have a poor outcome will have 
serum S100B concentrations of >0.53 µg/l
 
at 24 hours post-injury, however the 
specificity for unfavourable outcome and death respectively are 60% and 49%. 
This means that 40% of patients with good outcome and 51% of patients who 
survive will also have “positive” (>0.53µg/l) S100B levels at this time. 
The exact half-life of S100B protein in the blood is still unclear but it is 
thought that it is close to 97 minutes
 
[78]. Although our target time-point for 
blood sampling was 24 hours from TBI, we accepted two hours either side; 22 
to 26 hours on pragmatic grounds. However, the short half life of S100B 
presents a limitation to our study because of the potential change in the levels 
of S100B which might occur between 22 and 24 hours and 24 and 26 hours. 
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Thus, a two hour time gap before or after the target (24h) sampling time may 
lead to variability in S100B concentrations simply due to sample time. 
However, despite the short half-life, S100B serum levels were significantly 
elevated above baseline for up to 3 to 4 days after injury  [22, 23]. The second 
limitation of our study relates to the cohort of patients recruited. All the 
patients recruited to the study were admitted to this neurointensive care unit 
within 24 hours of injury. We cannot be confident, however, that the results we 
have obtained from our centre are generalisable to all neuro-receiving hospitals 
i.e. those with and without specialist neurosurgery teams. It has been shown 
that the provision of early neurosurgical care to TBI patients improves outcome 
(at discharge or 30 days) by comparison to those patients who are not admitted 
to a neurosurgical centre
 
[129]. A future multicentre study may, however, 
provide the results needed to determine if the results we report are 
generalisable to a wider cohort of severe TBI patients. 
Although several previous studies have shown that S100B can predict 
outcome following TBI, unfortunately the cut-offs and their diagnostic 
characteristics differ significantly. For example, Vos et al. suggested an 
admission cut-off of 1.13 µg/l
 
for prediction of unfavourable outcome at 6 
months [43], which is greater than the cut off identified by our study (0.53 
µg/l). However, the diagnostic characteristics are similar (sensitivity 0.88 and 
specificity 0.43). On the other hand, whilst the S100B cut-off from Mussack‟s 
study [78] (0.59µg/l) obtained from samples 12 hours after injury is close to 
our cut-off, specificity is 100% to predict GOS less than 4 at one year
20
 which 
is significantly higher than our specificity of 60%. Similarly, Nylen and 
colleagues investigating S100B on admission report a cut-off of 0.55µg/l. This 
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cut-off provided 100% specificity to predict unfavourable outcome at one year
 
 
[25] and is close to the cut-off of 0.53µg.L
-
which we produced for the 24 hour 
time-point to predict outcome at three months. The prognostic performance of 
S100B to predict outcome might be improved in future studies with more 
consistency in sampling times and follow up intervals. Contrary to our 
expectations we found neither emergency neurosurgery nor multiple trauma 
influenced the performance of this serum biomarker but the type of critical care 
provided (specialist neurosurgical versus general trauma) might, in the future 
be shown to be of importance in influencing patient outcome
 
[129]. 
The time point of 24 hour post-injury is probably more reliable than 
admission serum S100B levels for outcome prediction because the patient has 
already been resuscitated in the emergency department. This obviates the 
effects of tissue perfusion on S100B levels
 
[64]. Similarly, and depending on 
the half-life, the time elapsed from injury to admission to hospital might also 
be expected to influence the serum concentration
 
[78]. 
Although extracranial sources of S100B such as fat, muscle and bone marrow
 
[85]
 
may contribute to S100B levels, minor peripheral injuries do not appear to 
lead to a significant raise S100B levels [66]. This fits with our observations 
that S100B levels were not significantly different in patients with and without 
systemic trauma. It is worth noting here that in this group of patients the 
contribution to the overall ISS due to peripheral trauma was small. 
This study shows that although S100B levels tend to be higher in TBI 
patients with a GOS of less than 4 compared with those patients with a GOS of 
4 or 5, an S100B cut-off of 0.53µg/l is not a reliable prognostic indicator. The 
ROC curves for prediction of death and unfavourable outcome have an AUC of 
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0.67 and 0.75 respectively which is far from ideal to underpin clinical decision 
making. Whilst the cut-off of 0.53µg/l has a sensitivity of more than 80% to 
predict death, the specificity is relatively low (at 60% for prediction of 
unfavourable outcome and 49% for death prediction). This means that serum 
S100B measured 24 hours after injury can reliably detect poor outcome/death 
in more than 80% of cases but 40% of the patients who make a full recovery 
may also have levels above the 0.53µg/l cut-off.  
In conclusion, although serum S100B levels 24 hours after injury are 
significantly correlated with outcome after severe traumatic brain injury, 
S100B may not have a good prognostic performance to guide therapy and 
prognosis. Future research should focus on comparing the prognostic power of 
S100B to other available well-developed prognostic models in traumatic brain 
injury.  
Acknowledgements 
We thank Mrs. Laura White for assistance with AIS coding of injuries and Mr. Omar 
Bouamra for help with statistics. We would like to thank the nurses and doctors of the 
intensive care unit for their help and co-operation with the collection of blood 
samples. 
Conflict of interest 
None declarable 
 146 
4. Paper 3: Comparing Model Performance for 
Outcome Prediction Using Total GCS and Its 
Components in Traumatic Brain Injury 
Authors  
 Mehdi Moazzez Lesko 
 Tom Jenks 
 Sarah J O‟Brien 
 Charmaine Childs 
 Omar Bouamra 
 Maralyn Woodford 
 Fiona Lecky 
 147 
4.1. Abstract  
4.1.1. Introduction 
The Glasgow Coma Scale (GCS) score is used both in clinical practices for 
patient assessment, communication amongst clinicians and in outcome 
prediction models such as TRISS. However in clinical practice and during the 
derivation of prognostic models, it is important to understand which GCS 
subscore- eye, verbal, motor- contributes most to prognosis.  
4.1.2. Objective 
To determine which GCS subscore is best correlated with outcome taking time 
of assessment into account.  
4.1.3. Methods 
Records of patients with brain injury presenting after 1989 were extracted from 
the Trauma Audit and Research Network (TARN) database. Using logistic 
regression, a baseline model was derived with age and Injury Severity Score 
(ISS) as covariates and discharge outcome (survival) as the dependent variable. 
Total GCS, its subscores and their combinations at various time points were 
separately added to the baseline model in order to compare their effect on 
model performance.  
4.1.4. Results 
21,657 cases with brain injury were extracted. The total GCS score at scene 
and its subscore parts had significantly lower predictive power compared with 
those recorded on arrival at Emergency Department (ED) (scene total GCS: 
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AUC: 0.89 (95% CI: 0.89-0.90) and Nagelkerke R
2 
of 0.54, admission total 
GCS: AUC of 0.91(95% CI: 0.91-0.91) and Nagelkerke R
2 
of 0.58). Eye and 
verbal subscores had significantly lower performances compared with total 
GCS, motor subscore and various combinations of GCS subscores. Motor 
subscore and total GCS appeared to have similar predictive performance 
(admission total and motor GCS both had AUC of 0.91(95% CI: 0.91-0.91) 
and Nagelkerke R
2 
of 0.58) 
4.1.5. Conclusion 
GCS on arrival is a significantly better predictor of outcome than that recorded 
at scene. The reason for this is uncertain. Either GCS is recorded more 
accurately at hospital or the effect of intoxication has dissipated by the time of 
arrival at hospital. Motor subscore of GCS is a powerful predictor of outcome 
and contains most of the predictive power of the total score.  
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4.2. Introduction 
The Glasgow Coma Scale (GCS) was first introduced in 1974 to measure the 
depth of unconsciousness in patients with acute brain injury [117]. This scale 
comprises three subscores independently measuring motor response, verbal 
performance and eye opening. Since its introduction, it has been accepted 
internationally in clinical practice as the means to estimate the severity of the 
medical condition or injury affecting the brain. GCS is also used as a predictive 
subscore in prognostic models. These models are developed to assess prognosis 
for a given TBI patient (such as the International Mission for Prognosis and 
Analysis of Clinical Trials (IMPACT) [24] and Corticosteroid Randomisation 
After Significant Head injury (CRASH) models [23]) or to perform 
benchmarking of trauma care systems by trauma registries (TRISS 
methodology) [120].  
There are some disadvantages with the measurement of GCS. It is not 
straightforward to learn [130] and at times it might be impossible to measure 
quickly, which is an issue in emergency situations. Furthermore, the inter-rater 
reliability of total GCS is only moderate as Gill et al.  observed there is a 
probability of 68% that a pair of two GCS scores measured by two observers at 
the same time will differ in one subscore or another [131]. It is also well-
known that assessing the verbal subscore of GCS is not reliable in sedated or 
intubated patients. This is also the case for the motor/eye subscore when 
neuromuscular blockage is used. When using GCS in prognostic models, the 
problem faced by trauma registries is that it is unclear which time point of GCS 
assessment holds better prognostic value. GCS is usually measured both at 
scene (where the injury is incurred) and on admission to the Emergency 
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Departments (ED) and the trauma registries often hold the record at both time 
points.  
Healey et al.  reported that the motor subscore contains the most 
predictive strength of GCS through a careful statistical analysis of a North 
American dataset of general trauma patients [22]. This analysis was performed 
without taking other important prognosticators such as age and extracranial 
injury into account. Ross et al.  reported that the motor subscore may have 
similar diagnostic characteristics to total GCS to identify severe structural brain 
damage [132]. Similarly, Baxt et al.  suggested a Trauma Triage Rule which 
employs the pre-hospital motor subscore of GCS along with other factors such 
as systolic blood pressure or pulse rate to triage major trauma patients [133]. 
However, the latter two studies did not investigate the prognostic performance 
of GCS subscores and they were performed on a North American trauma 
population sample. This is relevant as US trauma patients and care systems 
differ significantly from Europe, both these aspects influencing patient 
outcome and also affecting the GCS/outcome inter-relationship.  
With regards to reports on the similar association of motor subscore and 
total GCS with injury severity, one might argue that measurement of motor 
subscore should suffice. The objectives of this study were twofold: to analyse 
the prognostic power of various GCS subscores in traumatic brain injury 
patients under the British trauma care system taking other important 
prognosticators into account and to investigate which time point of GCS 
measurement (at scene versus on admission to ED) has more prognostic 
strength.  
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4.3. Methods  
A subset of TBI patients presenting to Trauma Audit and Research Network 
(TARN) was studied. TARN is currently the largest trauma registry in Europe 
and receives information on trauma patients from participating hospitals across 
England and Wales and increasingly from other countries in Europe. The 
TARN inclusion criteria are that the injured patient reaches the hospital alive 
and meets either: (I) more than three days stay in hospital, and/or (II) being 
cared in the intensive care, and/or (III) inter-hospital transfer and/or (IV) death 
at any time in hospital. The information is extracted from patients‟ medical 
notes or other available electronic sources by the data collector(s) at the 
participating hospital. Subsequently, TARN staff members code each injury 
sustained using the Abbreviated Injury Scale (AIS) [90]. The final data are 
saved in a main server located on the main campus of the University of 
Manchester. Access to the database is provided by Structured Query Language 
(SQL) server 2000. The inclusion criteria for this study were all TARN patients 
sustaining brain injuries of AIS severity score of 3 or above. Patients with  
head injuries with AIS score 1 and 2 were excluded since these scores refer to 
cases with mild head injuries such as simple or unspecified skull fractures. 
Running the appropriate query in SQL, cases fulfilling the above criteria were 
retrieved from TARN dataset.  
For multivariate analysis, logistic regression was employed and to 
address the linear relationship of continuous variables with log odds of the 
outcome of interest as a requirement for logistic regression [134], fractional 
polynomials transformation was used [135]. In this method, the continuous 
variables are transformed into 1 or more other variables which is referred to as 
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„functional form‟ of the original variables. The transformation is a power 
transformation and the candidates of power are -3, -2, -1, 0, 1, 2, 3 where 0 is 
loge transformation and 1 reflects no transformation (linear). The selection of 
the best transformation(s) is based on when the power candidate(s) yields a 
model with a significant improvement (referred to as „gain‟) in the goodness of 
fit of the model which holds no transformations. Table 15 presents the results 
of fractional polynomials analysis for each covariate. It shows that, for 
instance, age should be transformed into two variables being 
93.0
100
1.0
log
age
e
 and 06.0
100
1.0
3
age  These two 
transformed covariates should be supplied to the model instead of the „true‟ 
age.  
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Variable  Transformation  
Age  
06.0
100
1.0
93.0
100
1.0
log
3
age
age
e
 
ISS s 
64.0
10
17.0
10
2
ISS
ISS  
Scene Scores Total GCS 
05.1
10
GCS
 
Motor GCS 95.1MotorGCS  
Eye GCS 
41.0
1
EyeGCS
 
Verbal GCS 
6.0
1
VerbalGCS
 
Sum of Motor and Eye GCS 82.1log EyeGCSMotorGCSe  
Sum of Motor and Verbal 
GCS 
88.1log VerbalGCSMotorGCSe  
Sum of Verbal and Eye GCS 
45.137
03.0
1
3
EyeGCSVerbalGCS
EyeGCSVerbalGCS  
Admission 
Scores  
Total GCS 
99.0
10
GCS
 
01.1
10
3
GCS  
Motor GCS 
53.0
1
2
MotorGCS
 
66.18
2
MotorGCS  
Eye GCS 
99.6
097log
2
EyeGCS
EyeGCS
e  
Verbal GCS 
57.0
1
VerbalGCS
 
Sum of Motor and Eye GCS 
74.337
37.0
1
3
EyeGCSMotorGCS
EyeGCSMotorGCS
 
Sum of Motor and Verbal 
GCS 
2)(log VerbalGCSMotorGCSe  
Sum of Verbal and Eye GCS 
12.188
3.0
1
3
2
EyeGCSVerablGCS
EyeGCSVerbalGCS
 
Table 15 Fractional Polynominal transformations of variables included in 
the modelling  
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Age and Injury Severity Score (ISS) are covariates with which the GCS 
prognostic strength is adjusted with. Using logistic regression, a baseline model 
was derived with age and ISS as regressors and discharge outcome (survival) 
as the dependent variable. Total GCS, its subscores and their combinations 
were added separately to the baseline model to assess their effect on model 
performance. The various combinations of GCS subscores were the sum of 
motor and eye subscores, motor and verbal subscores and eye and verbal 
subscores. Overall 15 models were constructed (one baseline model, seven 
models with admission GCS, subscores or combination of subscores and seven 
models with scene total GCS, subscores or combination of subscores). Area 
Under the Roc Cure (AUC), classification accuracy, Nagelkerke R
2 
[136] and p 
value of HL statistics were taken as measures of the performance of each 
model. Regarding missing information, all missing total GCS scores were 
imputed with the sum of their subscores in case of lack of availability in the 
dataset. Similarly, if total GCS was recorded as 15 and one or more subscores 
were missing, then the missing subscores(s) were imputed with the full score. 
Apart from this, no other imputation strategies were implemented for missing 
information. The analysis was performed on the complete dataset with no split 
sampling.  
Whilst the fractional polynomials transformations were performed in 
Stata, logistic regression was run in Statistical Package for the Social Sciences 
(SPSS).
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4.4. Result  
Using the inclusion criteria, a dataset of 21,657 TBI cases were extracted 
containing all brain injury records in TARN from January 1988 to April 2008. 
Table 16 presents the clinico-demographic characteristics of the sample 
population. Median age is 34.4 (interquartile range: 20-57) and 73.3% of the 
population are male. The median ISS was 24. The median total GCS was 9 at 
scene with motor, verbal and eye subscores holding respectively medians of 4, 
2, and 2. However, the median total GCS on admission is higher than scene 
score; being 11. Furthermore, the admission motor, verbal and eye subscores 
hold medians of respectively 5, 4, 3. Sixty nine percent of patients survived 
their injuries at discharge. The amount of missing information varied across 
various subscores of GCS and also across the two time points of measurement; 
at scene or on admission. Overall, there are more missing GCS scores at scene 
than on admission.  
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 Median 
(interquartile 
range)/frequency 
(N= 216527) 
Number of 
missing(percentage) 
Age 34.4(20-57) 0 
Male 73.3% 0 
ISS 24(16-29) 0 
Scene GCS   
o Total 
o Motor 
o Verbal 
o Eye 
9(4-14) 9530(44%) 
4(1-6) 9876(45.6%) 
2(1-5) 9867(45.5%) 
2(1-4) 9852(45.4%) 
Admission GCS   
o Total 
o Motor 
o Verbal 
o Eye 
11(6-15) 2677(12.3%) 
5(3-6) 3726(17.2%) 
4(1-5) 3741(17.2%) 
3(1-4) 3721(17.1%) 
Survival 69.4 1(0%) 
Table 16 Patients characteristics and number of missing values for each 
parameter. 
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Adding total GCS, its subscores and various combinations of the 
subscores resulted in a significant decrease of the deviance of the baseline 
model at all times. Also in each model the effect of covariates included in the 
model on outcome was significant i.e. p value < 0.05. Table 17 presents the 
performance of each constructed model per measures of AUC, Nagelkerke R
2
, 
classification accuracy and HL statistic. The baseline model is the model which 
contains only age and ISS and other models are named according to the added 
GCS, subscores or combinations of subscores to the baseline model. Overall 
the baseline model does not have a good performance as per HL statistics and 
adding GCS or subscores does not improve this. However, the performance of 
the baseline model is increased following addition of GCS, subscores or 
combinations of subscores according to AUC, classification accuracy and 
Nagelkerke R
2 
and the AUC increases are statistically significant. Furthermore, 
comparing the admission and scene scores, each model containing admission 
scores outperforms its counterpart model with scene scores in all three 
measures and the AUC differences are statistically significant. For example, 
AUC of the admission „total GCS‟ model is significantly higher than scene 
„total GCS‟ model (confidence intervals: 0.91-0.92 versus 0.89-0.90 
respectively).
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AUC 
(Confidence 
Interval) 
Classification 
accuracy 
Nagelkerke 
R
2 
HL 
statistics 
(P 
value) 
Baseline model 
 
0.84 
(0.83-0.84) 
78% 0.40 50.11 
(0.00) 
Admission 
GCS 
Total GCS 
(N=12127) 
0.91 
(0.91-0.92) 
85% 0.58 62.14 
(0.00) 
Motor 
(N=11781) 
0.91 
(0.91-0.91) 
85% 0.58 48.78 
(0.00) 
Eye 
(N=11805) 
0.89 
(0.89-0.90) 
83% 0.53 46.23 
(0.00) 
Verbal 
(N=11890) 
0.90 
(0.90-0.91) 
84% 0.55 53.12 
(0.00) 
Motor + Eye 
(N=11815) 
0.91 
(0.91-0.91) 
85% 0.58 53.55 
(0.00) 
Motor + 
Verbal 
(N=17993) 
0.91 
(0.91-0.92) 
86% 0.59 46.40 
(0.00) 
Verbal + Eye 
(N=18001) 
0.91 
(0.90-0.91) 
85% 0.57 28.62 
(0.00) 
Scene 
GCS 
Total GCS 
(N=18980) 
0.89 
(0.89-0.90) 
82% 0.54 40.8 
(0.00) 
Motor 
(N=17931) 
0.89 
(0.88-0.90) 
82% 0.54 38.24 
(0.00) 
Eye 
(N=17936) 
0.88 
(0.87-0.88) 
80% 0.50 48.68 
(0.00) 
Verbal 
(N=17916) 
0.88 
(0.88-0.90) 
81% 0.52 59.63 
(0.00) 
Motor + Eye 
(N=11815) 
0.89 
(0.89-0.90) 
82% 0.55 34.56 
(0.00) 
Motor + 
Verbal 
(N=11813) 
0.89 
(0.89-0.90) 
82% 0.55 34.51 
(0.00) 
Verbal + Eye 
(N=11821) 
0.89 
(0.88-0.89) 
81% 0.53 45.02 
(0.00) 
Table 17 Comparison of predicitve models for survival using various GCS 
subscores and their combinations (N: number of cases included in the 
modelling).  
4.5. Discussion  
In this study, we have compared separately the prognostic power of total GCS, 
its subscores and various combinations of its subscores through multivariate 
analysis of a large British dataset of TBI cases. A baseline model was 
constructed with age and ISS and subsequently the improvement in the model 
performance was investigated following addition of GCS, subscores or 
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subscores combinations as per four measures of AUC, classification accuracy, 
Nagelkerke R
2
 and HL statistics. Overall adding GCS, subscores or 
combinations of subscores results in significant improvement of the baseline 
model performance apart from the goodness of fit assessed by the HL statistics. 
Furthermore, it appears that eye and verbal subscores on their own, i.e. with no 
combination with other subscores, hold the least prognostic strength compared 
with total GCS, motor GCS or combination of motor with eye or verbal GCS. 
Similarly, the predictive strength of total GCS, motor GCS and combination of 
eye with verbal subscores or combination of motor with eye subscores appears 
the same.  
4.5.1. Limitations 
We acknowledge a number of limitations. Firstly, for this analysis, an existing 
dataset of TBI patients retrieved from TARN was used. Therefore, the effect of 
local protocols in GCS collection is unclear as to when the condition of the 
patient does not permit measurement of one subscore such as intubation or 
paralysis. In such case, immeasurable subscore might be assigned the lowest 
score or regarded as missing. Furthermore, the record of GCS on admission to 
ED does not clarify whether this has been performed prior to or following 
resuscitation. This depends on each hospital‟s specified polices. In fact, the 
acute course of TBI is unstable in that several events occurring over a short 
time span such as secondary insult or expanding intracranial mass lesion may 
influence the level of consciousness [137]. Post-resuscitation appears to be a 
better time point to collect GCS than admission GCS for predictive purposes as 
in such case the patient is expected to be at least haemodynamically stable. 
Secondly, the GCS predictability was adjusted only with age and ISS. 
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However, pupillary reactivity is also one of the important predictors in TBI but 
was not accounted for in this analysis. This is because recording of pupillary 
reactivity has only recently commenced for TBI submissions in TARN. Had 
pupillary reactivity been included in the modelling procedure, the dataset 
would have then been significantly smaller, yielding less reliable results. 
Furthermore, we compared the prognostic strength of GCS and its subscores in 
several models which are not unified in terms of the number of missing 
information (or the number of TBI cases included). For example, whilst total 
admission GCS was assessed in a model derived from 18980 cases, the scene 
score was assessed in much lower number of TBI cases i.e. 12127. This implies 
that there were a number of cases which were included in the admission model 
but not in the scene model. This is also the case with comparing various 
combinations of subscores. It is unclear how this exclusion would change the 
results.  
4.5.2. Comparison with the literature 
With regards to the  same predictive strength of motor and total GCS, the 
results of our study are consistent with findings by Healey et al. [22]. However, 
in our study, GCS is adjusted with other TBI predictors i.e. age and ISS. 
Moreover, unlike Healey et al. who performed their analysis on general trauma 
patients with no exclusion of intoxication or shock potentially affecting level of 
consciousness, we performed our analysis on a TBI population who all 
sustained documented brain injury determined by AIS codes. Perhaps this also 
explains why the population sample in Healey‟s study consisted of 90% GCS 
score of 15 whereas our dataset contains more varied GCS scores (e.g. median 
admission total GCS: 11 with interquartile range of 6 and 15).  
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Marmarou et al. observed that both enrollment (the time point when the 
patient was enrolled to the study) and pre-enrollment motor GCS have 
significant prognostic effect on outcome in TBI (Marmarou, Lu et al. 2007). 
This finding may be the same as our finding in that earlier GCS (scene GCS) is 
less predictive of survival than later GCS (i.e. admission GCS). The 
explanation for this finding may relate to the completion of resuscitation as 
later time points e.g. on admission or on enrolment to the study are more likely 
to be when the TBI patient has already been resuscitated.  
4.5.3. Implications of the study  
We cannot explain why admission GCS scores have more predictive strength 
than scene scores. It might be due to the effects of alcohol or other drugs, 
which are diminished by the time the patient arrives at hospital. So GCS on 
admission might be more representative of the true level of consciousness 
being caused by the injury per se [138]. Also it might highlight inaccurate 
recording of GCS at scene, which might be due to environmental difficulties or 
skill level of attending personnel. However, whatever the reason for the 
difference in scene and admission GCS predictability, it might have pragmatic 
implications on clinical decisions for therapeutic interventions based on GCS. 
So we suggest that GCS on admission should be taken into account rather than 
GCS at scene.  
We observed that a model which contains total GCS holds similar 
prognostic performance to a model which contains only the motor subscore. 
This suggests that adding eye and verbal subscores to the motor subscore does 
not hold any prognostic value and thus their measurement may not be 
necessary. On the one hand omitting eye and verbal scores  might result in an 
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improvement in the overall inter-rater reliability (between personnel with the 
same level of experience/skill), which is poor for total GCS but better for the 
motor score [131]. Also measuring only motor subscore would be easier to 
teach, learn and implement than total GCS since the error rate of eye and 
verbal GCS is high among unskilled observers compared with skilled ones 
[130]. On the other hand, although GCS scale is designed to measure the depth 
of the unconsciousness, which also relates to the outcome, in practise it is not 
only used for the purpose of prognosis. The results of our study demonstrates a 
possible similar prognostic strength for total and motor GCS but this cannot be 
generalised reliably to other applications of GCS such as day-to-day 
monitoring of patients‟ alertness (as occurs in the intensive care units) or a 
clinical decision on intervention. Further, total GCS with respect to its 
descriptive capability holds more information content compared with motor 
GCS which does not provide any information on eye and verbal response. 
Likewise, each GCS score can be the sum of a varied combination of subscores 
and each combination of subscores might have significantly different mortality 
rates [22]. Therefore, we assume that for each total GCS with a certain motor 
subscores, changes in the eye and verbal subscores would then result in 
different mortality rates. If verbal and eye subscores are not measured, then the 
influence of eye and verbal response on outcome within the group of patients 
with the same motor subscore is ignored. It is considered that the added value 
of the eye and verbal subscores is mainly in trauma patients with more 
moderate degrees of injuries. In our study, age and ISS were taken into account 
as confounders, but the analysis was not performed separately on a subgroup of 
patients with a moderate degree of injury. Overall we believe measurement of 
motor subscore alone, despite being more simple and perhaps more reliable, 
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does not outweigh its disadvantages. Had the motor subscore significantly 
outperformed the total GCS in outcome prediction, omission of eye and verbal 
subscores might have then been suggested in clinical practice.  
The „motor + verbal‟ model has similar predictive performance to „total 
GCS‟ model per AUC and even its performance is higher per Nagelkerke R2. 
This suggests that measuring the eye subscore might not be necessary although 
the advantages and disadvantages of this are similar to measurement of the 
motor score alone, as discussed above. Similarly, the performance of „motor + 
eye‟ model is the same as „total GCS‟ model for admission GCS scores. This 
finding is reassuring in that if measurement of the verbal subscore is not 
possible (for instance due to intubation), then measurement of only motor and 
eye subscores should suffice.  
4.5.4. Future direction  
It is important that the results of our study be validated in a different set of TBI 
cases from different setting (country) and for a different type and time point of 
outcome. The quality of trauma care is one factor which affects the outcome 
and as such has a confounding role. Our dataset was collected from the British 
hospitals with the specified health care policy. Regarding the outcome, 
discharge survival is not the only end target of TBI care and management since 
functionality as close to that prior to the injury is important as well. 
Furthermore, this normal functionality can be achieved in short-term or long-
term.  
4.6. Conclusion  
In a population of TBI patients whose injuries were managed within England in 
Wales over the last 20 years, the total GCS and motor subscore may have 
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similar predictive strength. Furthermore, it appears the eye subscore on its own 
holds less predictive strength than total GCS or various combinations of 
subscores. With regard to admission and scene GCS scores, admission scores 
significantly outperform scene scores for outcome prediction.  
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Codes to Classify CT Features in the 
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5.1. Abstract  
5.1.1. Background  
The purpose of Abbreviated Injury Scale (AIS) is to code various types of 
Traumatic Brain Injuries (TBI) based on their anatomical location and severity. 
The Marshall CT Classification is used to identify those subgroups of brain 
injured patients at higher risk of mortality or deterioration. The purpose of this 
study is to determine whether and how AIS coding can be translated to the 
Marshall Classification  
5.1.2. Methods 
Initially, a Marshall Class was allocated to each AIS codes through cross-
tabulation. This was agreed upon through several discussion meetings with 
experts from both fields (clinicians and AIS coders). Furthermore, in order to 
make this translation possible, some necessary assumptions with regards to 
coding and classification of mass lesions and brain swelling were essential 
which were all approved and made explicit.  
5.1.3. Results 
The proposed method involves two stages: firstly to determine all possible 
Marshall Classes which a given patient can attract based on allocated AIS 
codes; via cross-tabulation and secondly to assign one Marshall Class to each 
patient through an algorithm.  
5.1.4. Conclusion  
This method can be easily programmed in computer softwares and it would 
enable future important TBI research programs using trauma registry data. 
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5.2. Background  
Trauma registries hold records of patients with Traumatic Brain Injury (TBI) 
across a designated region mainly for assessment of trauma care 
centres/systems compared with a national standard e.g. analysing data to 
predict survival probability (observed – expected survival rates). The 
demographic and clinical details of trauma patients are submitted to these 
registries primarily to provide data that will improve clinical outcome for 
trauma patients but they also form a valuable dataset for epidemiological 
studies. The Abbreviated Injury Scale (AIS) [90, 91] was proposed by the 
Association for the Advancement of Automotive Medicine and was designed 
specifically for coding various types of injury and for scoring them based on 
the severity. Using a standard dictionary each entry in a trauma registry dataset 
is assigned a 6-digit AIS code number with a post decimal place representing 
score of severity. The description for each AIS code is contained in the AIS 
dictionary. Each post-decimal score of the injury severity ranges from 1 
(minimal) to 6 (maximal).  
The AIS dictionary is structured by anatomical region of the body such 
as face, neck, abdomen and pelvic contents etc. One section in this dictionary is 
allocated to head trauma, which is subdivided into the whole area (massive 
destruction of cranium and brain, penetrating injury and scalp injury), 
intracranial vessels, cranial nerves (cranial nerves I to XII), internal organs and 
skeletal. This part of the AIS dictionary contains information about the 
anatomical location of the lesion (brain stem, cerebrum and cerebellum), the 
type of the lesion (e.g. haemorrhage, contusion and brain swelling), various 
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subtypes of haemorrhage such as Subarachnoid Haemorrhage (SAH), Subdural 
Haemorrhage (SDH) and the size of the lesion.  
Using the AIS dictionary to describe injuries is probably limited to 
those running trauma registries. It is rarely employed for clinical and 
therapeutic purposes or in data collection for clinical trials because a trained 
coder is needed to code the injuries and also because the description and 
classifications of injuries is more detailed than required for clinical purposes. 
Alternatively, the Marshall Classification of structural brain damage is based 
on CT findings of TBI patients [139]. This system was first introduced in 1991 
and the main aim was to identify those TBI patients at higher risk of 
deterioration or mortality although it has been validated as having predictive 
value for TBI outcome as well [24, 36, 94, 140, 141]. The hierarchy of 
Marshall Classes represents the increasing risk of developing raised ICP 
determined by factors relating to this pathology such as mass lesions or brain 
swelling. This classification challenged the previous perception that patients 
with compressed or absent cisterns who had a good clinical evaluation could be 
treated as if their brain CT is normal [139].  
Understanding the relationship between AIS coding of brain injury and 
the Marshall Classification is important for several reasons. First, the AIS and 
Marshall Classification systems describe slightly different things. The Marshall 
Classification provides the opportunity to identify a subset of TBI patients at 
risk of developing intracranial hypertension. It ignores brain stem and 
cerebellar injuries, which are described in detail in the AIS dictionary. 
Secondly, the Marshall System is focused on closed head injury and was not 
designed for penetrating head injuries, for which there are several AIS codes. 
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Since TBI in trauma registries tends to be coded using the AIS dictionary and 
in clinical settings using the Marshall Classification, it is impossible to 
generate a complete picture of TBI incidence, risk factors and outcome without 
being able to bring these two types of data together.  
Therefore we propose a method for allocating a Marshall Class to the 
AIS codes that are recorded for a given TBI patient. We have assumed that 
each injury description in the AIS dictionary can be used as an alternative to 
the CT reports.  
5.3. Methods  
5.3.1. AIS coding  
Coding of brain injuries in the AIS dictionary is based on anatomical location 
(the brainstem, the cerebellum, the cerebrum and pituitary), the type of injury 
(Table 18), subtypes of haemorrhage (Table 18) and the degree/extent of the 
injury. Some types of injuries relate to certain locations of the brain; these 
being massive destruction (crush) which can affect the whole head or can occur 
in the brain stem, compression and transection exclusively occurring in the 
brain stem and pneumocephalus exclusively occurring in the cerebrum. 
However there are some other types of injuries incurred in more than one 
anatomical location namely ischemia, brain swelling or various subtypes of 
haemorrhage which may occur in the cerebellum or the cerebrum. Similarly, 
penetrating injuries, diffuse axonal injury, contusion, haemorrhage, infarction 
or laceration can be potentially sustained in all parts of the brain which include 
the brain stem, the cerebellum or the cerebrum. The determinants of the 
degree/extent of each injury include multiplicity, being uni/bilateral and 
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midline shift (for contusions) and the volume/diameter (for contusions and 
various subtypes of haemorrhage). The severity of brain swelling in the 
cerebrum is determined by the status of ventricles or the brain stem cisterns - 
either or both may be compressed or absent. Where information is not 
adequately documented, the codes referred to as „Not Further Specified; NFS‟ 
are assigned. Alongside the injuries which fall under the heading  
Penetrating injury 
Diffuse axonal injury  
Contusion 
Haemorrhage 
Brain swelling 
Infarction  
Ischemia 
Pneumocephalus 
Laceration  
Compression  
Massive destruction (crush) 
Transection  
 
Subtypes of haemorrhage 
Epidural 
Intraparenchymal  
Subdural  
Subarachnoid 
Subpial 
Table 18 Descriptions of types of injury and subtypes of haemorrhage in 
the AIS dictionary; update 98 
 
of „internal organ‟ in the head section of the dictionary, there are codes which 
relate to the skeleton and some of them include descriptions of basal skull 
fracture or not simple vault fractures, which should, in fact, be considered as 
traumatic brain injury. Nevertheless, the AIS code 116002, allocated to 
superficial penetrating injury to the head, should be interpreted as not 
accompanied by brain injury. It should be noted that TBI cases may be 
allocated more than one AIS code.  
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5.4. The Marshall Classification  
Table 19 displays the Marshall CT Classification. According to this system, the 
discriminative features are presence/absence of intracranial pathology, 
presence/absence of high or mixed density mass lesions, signs of raised 
intracranial pressure which is status of basal cisterns and midline shift and 
lastly evacuation of mass lesions. In this classification, a high or mixed density 
mass lesion implies contusion or hemorrhage. The extent of the lesion is 
determined by its volume, the cut-off being 25 cc. Moreover, depending on the 
size and surgical evacuation, a lesion can be one of Mashall Classes II, V or 
VI. The higher risk of raised ICP is determined by present, absent or 
compressed basal cisterns and the degree of midline shift – the cut-off point 
being 5mm. These pathologies fall into classes III or IV based on the severity. 
Unlike AIS coding, the Marshall System is mutually exclusive in that a TBI 
case is only allocated to one Marshall Class. 
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Marshall Class   Description  
Class I Diffuse injury I (no visible 
pathology) 
No visible pathology seen 
on CT scan 
Class II Diffuse injury II  Cisterns are present with 
midline shift 0-5 mm 
and/or: lesion densities 
present no high- or 
mixed-density lesion > 25 
cc may include bone 
fragments and foreign 
bodies 
Class III Diffuse injury III 
(swelling) 
Cisterns compressed or 
absent with midline shift 
0-5 mm, no high- or 
mixed-density lesion > 25 
cc 
Class IV Diffuse injury IV (shift) Midline shift > 5 mm, no 
high- or mixed- density 
lesion > 25 cc 
Class V Evacuated mass lesion Any lesion surgically 
evacuated 
Class VI Non-evacuated mass 
lesion 
High- or mixed-density 
lesion > 25 cc, not 
surgically evacuated 
Table 19 The Marshall CT Classification 
5.4.1. Cross-tabulation of AIS codes with Marshall Classes 
As explained above, the Marshall System and the AIS coding hold two 
different approaches to brain injury classification and thus reconciliation 
between the two systems required various assumptions which had to be agreed 
upon from both the clinical and the coding perspective. A number of meetings 
were held with participation of two physicians specialising in emergency 
medicine and neurosurgery and two experts in AIS coding in the UK (from the 
Trauma Audit and Research Network (TARN)) [89] to discuss the most 
appropriate Marshall Class allocated to each AIS code performed through 
cross-tabulation.  Table 20 presents the resulting cross-tabulation based on 
expert consensus where the description for each code can be found in the AIS 
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document. The mapping was decided to be performed initially on AIS 
dictionary; update 98 which is still in widespread use despite the new update 
introduced in 2005. Subsequently, adaptation of this cross-tabulation to suit the 
AIS dictionary; update 2005 was discussed (Table 21). Likewise, the decision 
was made to consider only AIS codes which are either apparently brain injuries 
(such as SAH) or, with a high likelihood, can be regarded to be accompanied 
with brain injury (such as basal skull fractures). However, codes relating to 
unconsciousness were excluded from this cross-tabulation since these codes are 
commonly not used by trauma registries and instead, Glasgow Coma Scale 
(GCS) with the same value for outcome prediction is used to address the level 
of consciousness [120, 142].  
The rational for mapping various AIS codes of brain injury to the 
appropriate Marshall Class particularly regarding the assumptions made for 
brain swelling and mass lesions is provided in the Appnedix.  
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Table 20 Proposed Marshall Class - AIS code combinations based on the 
1998 update of the AIS dictionary
AIS codes  Marshall Class 
113000.6 V/VI 
116004.5 Penetrating injury  
140299.5 Brain stem injury  
140202.5 III 
140204.5 Brain stem injury  
140206.5 Brain stem injury 
140208.5 Brain stem injury 
140210.5 Brain stem injury 
140212.6 Brain stem injury 
140214.6 Brain stem injury 
140216.6 Penetrating injury  
140218.6 Brain stem injury  
140499.3 Cerebellar injury  
140402.3 Cerebellar injury  
140403.3 Cerebellar injury  
140404.4 Cerebellar injury  
140405.5 Cerebellar injury  
140406.5 Cerebellar injury  
140410.4 Cerebellar injury  
140414.4 Cerebellar injury  
140418.4 Cerebellar injury  
140422.5 Cerebellar injury  
140426.4 Cerebellar injury  
140430.4 Cerebellar injury  
140434.5 Cerebellar injury  
140438.4 Cerebellar injury  
140442.4 Cerebellar injury  
140446.5 Cerebellar injury  
140450.3 Cerebellar injury  
140458.3 Cerebellar injury  
140462.3 Cerebellar injury  
140466.3 Cerebellar injury  
140470.3 Cerebellar injury  
140474.4 Cerebellar injury  
140478.5 Penetrating injury 
140699.3 II 
140602.3 II 
140604.3 II 
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Table 20 Proposed Marshall Class - AIS code combinations based on the 
1998 update of the AIS dictionary (continued) 
AIS codes  Marshall Class 
140606.3 II 
140608.4 V/VI 
140610.5 V/VI 
140612.3 II 
140614.3 II 
140616.4 V/VI 
140618.5 V/VI 
140611.3 II 
140620.3 II 
140622.3 II 
140624.4 V/VI 
140626.5 V/VI 
140628.5 II 
140629.4 II 
140630.4 II 
140632.4 II 
140634.5 II 
140636.5 V/VI 
140638.4 II 
140640.4 II 
140642.4 II 
140644.4 II 
140646.5 II 
140648.5 V/VI 
140650.4 II 
140652.4 II 
140654.5 II 
140656.5 V/VI 
140660.3 III 
140662.3 III 
140664.4 III 
140666.5 IV 
140676.3 II 
140678.4 II 
140680.3 II 
140682.3 II 
140684.3 II 
140686.3 II 
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Table 20 Proposed Marshall Class - AIS code combinations based on the 
1998 update of the AIS dictionary (continued)  
 
AIS codes  Marshall Class 
140688.4 II 
140690.5 Penetrating injury  
140799.3 II 
150200.3 I 
150202.3 I 
150204.3 I 
150206.4 I 
150404.3 I 
150406.4 I 
150408.4 I 
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Table 21 Allocating a Marshall Class to AIS code; update 2005 
 
5.4.2. Selection of one Marshall Class 
A TBI patient may receive more than one AIS code whereas each patient 
should receive only one Marshall Class in the Marshall System. In order to 
address this, the decision was made to place all AIS codes which fall under the 
same Marshall Class together as „Equivalent to one Marshall Class‟. In this 
manner, Equivalent to Marshall Class I, II, III, IV or V/VI each respectively 
represents Marshall Classes I, II, III, IV and V/VI. Then an algorithm was 
Code Marshall Class 
140605 II 
140613 II 
140621 II 
140625 II 
140627 II 
140631 II 
140639 II 
140643 II 
140645 II 
140647 II 
140649 II 
140641 V/VI 
140651 II 
140655 V/VI 
140687 II 
140686 II 
140691 Penetrating injury  
140692 Penetrating injury  
140689 II 
140701 I 
140702 I 
140703 I 
140675 II 
140677 II 
140681 II 
140683 II 
140694 II 
140695 II 
140697 II 
140698 II 
150000 I 
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devised to choose one Equivalent to Marshall Class which would be the final 
single Marshall Class mapped. Using of such algorithms for patients who 
sustained multiple brain injuries was proposed by Maas et al.  [94].  
5.5. Results 
5.5.1. The proposed method to allocate a Marshall Class to 
a TBI patient  
This involves two stages: assignment of Equivalent to Marshall Classes and 
then selection of the final Marshall Class.  
 
Stage 1: Assignment of Equivalent to Marshall Classes  
 
Table 22 presents various AIS codes which all come under one similar 
Marshall Class (Equivalent to Marshall Class I, II, and III etc.). According to 
this table, the unclassified codes relating to brain stem, cerebellar and 
penetrating injuries were broken down further into penetrating, brain 
stem/cerebellar codes necessitating addition of two further classes of VII and 
VIII to represent penetrating and the brain stem/cerebellar injuries respectively. 
This has been agreed by the authors of previous guides for using the Marshall 
Classification [140] (personal communication). The other possible options are 
to further split the brain stem/cerebellar injuries into two distinct individual 
Marshall Classes or to merge all penetrating, brain stem and cerebellar codes 
into one class as „unclassified‟. This depends on the research objective. 
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 AIS codes  
Equivalent 
to Marshall 
Class I (no 
visible 
pathology) 
150200,150202,150204,150206, 150404,150406, 
150408 
Equivalent 
to Marshall 
Class II  
140602,140604,140606,140612,140614,140611,140620,140622,140628,140629,140630,140632,140634,140638,140640,140642, 
140644,140646,140650,140652,140654,140684,140688, 140686, 140699, 140676, 140678, 140680, 140682, 140799 
Equivalent 
to Marshall 
Class III 
(swelling) 
140202, 140660, 140662, 140664 
Equivalent 
to Marshall 
Class IV 
(shift) 
140666 
Equivalent 
to Marshall 
Class V/VI 
140608,140610,140616,140618,140624,140626,140636,140648, 
140656, 113000 
Cerebellar/ 
brain stem 
injuries  
140204,140206,140208,140210,140212,140214,140218,140299,140402,140403,140404,140405,140406,140410,140414,140418, 
140422,140426,140430,140434,140438,140442,140446,140450,140458,140462,140466,140470,140474,140499, 
Penetrating 
injury  
140216, 140478, 140690, 116004 
Table 22 Grouping of AIS codes into various ‘Equivalent of Marshall Classes’. 
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Stage 2: Selection of the final Marshall Class 
 
Figure 12 displays an algorithm proposed to select one Equivalent to Marshall 
Class which can be the mapped final Marshall Class for a given patient. This is 
based on the fact that the Marshall Classification is ordinal indicating that, in 
case of multiple injuries, the highest class is the single class allocated to the 
patient. This is reflected in the algorithm. Initially, all penetrating injuries are 
contained in Class VIII. This is the point at which the algorithm stops since the 
Marshall Classification is designed for blunt injuries. At the second step, 
injuries are screened for Equivalent to Marshall Class V which will result in a 
class VI designation in case of surgical evacuation or, otherwise, class V. The 
following steps sequentially take account of Equivalent to Marshall Classes IV, 
III and II. However, prior to searching for Equivalent to Marshall Class II 
leading to allocation of class II, Marshall Class VII is mapped in case of the 
presence of brain stem/cerebellar codes. The algorithm is flexible with the 
position of this step being implemented prior to screening for Equivalent to 
Marshall Class I as displayed in Figure 12 or otherwise being placed following 
exclusion of penetrating codes. In the latter situation, the algorithm begins its 
detection of the single mapped Marshall Class by exclusion of those who have 
sustained penetrating, brain stem or cerebellar injuries.
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Figure 12 Algorithm to derive the Marshall Class from Equivalent to 
Marshall Classes. 
 
Programming the procedure to designate a single Marshall Class to a 
given TBI case for which various AIS codes are recorded is straightforward in 
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computer softwares such as Statistical Package for the Social Sciences (SPSS) 
etc. In the first step, all Equivalent to Marshall Classes are computed as 
nominal variables for each TBI case. Each Equivalent to Marshall Class will 
then be „yes‟ if at least one of the AIS codes allocated to this code (Table 22) is 
present and otherwise such Equivalent to Marshall Class is „no‟. Second, the 
computer has to search all computed Equivalent to Marshall Classes step by 
step in accordance with the algorithm. For example, if a given case has brain 
stem/cerebellar injuries and Equivalent to Marshall Class V/VI with surgical 
evacuation, the Marshall Class VI is allocated.  
5.6. Discussion  
In this study, we have attempted to propose a method to translate the head 
injury AIS codes into the Marshall CT Classification. This involves two steps; 
first to cross-tabulate various AIS codes with the Marshall Classes and 
secondly to select the single Marshall Class allocated to a case of TBI through 
an algorithm. In order to perform this transformation some assumptions had to 
be made..  
5.6.1. Limitations/assumptions  
Although both the Marshall Classification and the AIS dictionary group CT 
features according to their severity, one important difference between the two 
systems relates to their purposes. The main aim of the Marshall Classification 
is to identify those TBI patients who are at higher risk of deterioration or 
mortality, whereas the AIS scoring system is used to classify injuries based on 
their anatomy rather than physiological merits. These different approaches to 
CT classification mean that certain assumptions have to be made when trying 
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to reconcile the two systems. Ideally the two systems would be completely 
interchangeable and no assumptions would be required. Since this is not the 
case an important question is whether or not mapping AIS codes onto the 
Marshall Classification is worthwhile. We believe adoption of the conceptual 
approach we have proposed allays some concerns in that, instead of strictly 
meeting the definition of each Marshall Class, the objective and rational 
surrounding that class are also employed to spot the appropriate AIS codes. A 
disadvantage of the Marshall Classification is that it is not a reliable 
classification to be used in the retrospective research settings in which the 
access to the real CT obtained during acute phase of therapy is often not 
possible in case the Marshall Class is not recorded in the existing dataset.  
The Marshall Classification should be ideally performed by the expert 
who views the CT. However, Marshall Class II, unlike other classes, contains a 
broad range of heterogeneous injury types or severities. Considering the 
different objective of AIS dictionary which is to anatomically classify injury 
severities, mapping AIS codes with Marshall Classes is in fact alike ignoring 
many valuable individual pieces of information by pooling them into one class 
such as class II. This leads to them all being treated similarly in prognostic 
analysis despite potentially having varied individual prognostic merit on their 
own. This defect is substantial when class II contains, for instance, infarction 
beside laceration which are different in nature and perhaps in prognostic 
strength.  
The method proposed in this study is based primarily on the assumption 
that the descriptions in the AIS dictionary can be substitutes for CT reports, but 
this is not always the case. As well as including CT reports, the sources of 
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information to document injury descriptions also encompass MRI, surgery, x-
ray, angiography, post-mortem examinations or clinical diagnosis. 
Nevertheless, it seems reasonable to assume majority, if not all the information 
for AIS coding, is obtained from CT scans since CT is the commonest modality 
for diagnosing structural brain damage for every patient suspected to have 
sustained severe trauma in the developed world and several other developing 
nations.  
 As AIS coding does not rely only on one CT report, the dynamic nature 
of brain injury as to progressing or regressing over time is reflected in AIS 
codes unlike the Marshal Classification. This is because the Marshal 
Classification is collected from CT images/reports at a certain point in time 
(oftentimes on admission) whilst AIS codes contain information after discharge 
or death as well. As such using our algorithm to obtain the Marshal Class with 
AIS codes intermediation would inherit the information on dynamic nature or 
CT findings evolution as well. This poses a problem since evolution of 
structural brain damages per se is a prognostic factor indicating higher chance 
of unfavourable outcome [143]. Servadei et al.  have shown that the worst CT 
classification has more prognostic value than less severe CT classification (s) 
[143]. Consequently, if the Marshal Classification is obtained from AIS codes, 
there may be some overestimation of its negative prognostic role in TBI as 
compared to the Marshal Classification using CT images/reports. This may be 
particularly an issue with patients who sustain more severe brain injuries as 
they are more subject to various means of investigations such as MRI or 
operation.  
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As well as the above fundamental assumption regarding AIS 
descriptions as substitutes for CT reports, there are two other important 
assumptions related to the brain swelling and the mass lesion. Unfortunately 
neither the Marshall Classification nor the AIS dictionary describe precisely 
the severity of brain swelling. The degree of swelling in AIS dictionary is only 
determined by cistern/basal cisterns status whereas the degree of midline shift 
is also an important determining factor. Likewise, although midline shift or 
cisterns status is important in the Marshall Classification of brain swelling, 
other causes of midline shift, such as mass lesion, are disregarded. With respect 
to the size of mass lesions, future research is required to determine the precise 
size cut-offs for categorising such lesions, in spite of the already-known fact 
that larger lesions are associated with poorer outcome [29]. Comparing the cut-
offs, those for subdural and epidural haemorrhage in the AIS dictionary are 
larger than those in the Marshall Classification by 25 cc although this 
difference may be negligible for contusion and intracerebral haemorrhage 
which is only 5 cc. The evidence base for lesion size in both classifications 
appears to be limited, despite claims that the cut-offs are backed by substantial 
experience and are not merely arbitrary [140, 144].  
In Table 20, we assumed that codes indicating hypoxic or ischemic 
brain damage are related to normal CT scan. This may not always be the case 
as some patients may develop brain swelling as a secondary damage to 
hypoxia/hypotension. Whilst our assumption of clear CT for 
hypotension/hypoxia may not be acceptable in our cross-tabulation, we believe 
the algorithm would address this problem. For example, if a patient develops 
brain swelling following hypoxia, then two codes of hypoxia and brain 
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swelling will be allocated. As the injuries are taken through the algorithm, the 
brain swelling Marshal Class of III or IV (depending on the severity) is 
allocated prior to the final step of the algorithm as Marshal Class I (normal 
CT).  
The position of various steps of the algorithm is based on the 
assumption that the Marshal Classification is ordinal in severity. Despite being 
the case from Class I to IV, this is not true for class IV versus class V as 
patients in class IV demonstrate lower likelihood of favourable outcome or 
survival than those in class V [140, 145]. Since the Marshall Classification is 
mutually exclusive, it is conspicuously necessary to prioritise which type of 
injuries is more relevant for allocation of the proper Marshal Class in case of 
multiple brain injuries. Whilst, according to the adverse outcome frequency, 
the brain swelling with compressed cisterns may have to be placed prior to 
mass lesion in the algorithm, we believe the current position of each step is 
more reflective of what occurs in real life of Marshal Classification through 
observing the actual CT. In fact, the current position of various steps of the 
algorithm are according to what has been suggested by Maas et al.  [140]. In 
Maas‟s algorithm, the Marshal Classification was taken as ordinal but still class 
V represented lesser degrees of brain injury than class IV in their subsequent 
prognostic analysis.  
5.6.2. Implication  
The Marshall Classification has prognostic value to make predictions on the 
outcome of TBI patient [24, 36, 94, 140]. AIS coding is also important from 
prognostic viewpoint [146] but the severity scores (ranging from 3 to 6 in TBI) 
encompass a wide variety of different injuries that the relationship of the score 
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and CT findings can not be easily made particularly in clinical settings where 
the AIS dictionary is not a familiar tool. Hence, it is important for trauma 
registries to ` avoid exclusive reliance on AIS coding for the sake of better 
communication with the clinical audience. As the Marshall Classification holds 
comparable prognostic value to age, GCS, pupillary reactivity, SAH etc. [24, 
36] and trauma registries commonly do not have record of this classification, 
the translation of AIS codes to the Marshall system opens up the possibility for 
multivariate prognostic analysis of large series of TBI subjects saved in trauma 
registries. In fact, the internationally known IMPACT prognostic models [24] 
in TBI employ the Marshall Classification for outcome prediction and using 
our proposed translation not only permits running the IMPACT models in 
trauma registries, derivation of new prognostic models including the Marshall 
Classification becomes feasible. Furthermore, as other TBI series accrued in 
clinical studies (observational or clinical trials) often do not have AIS coding, 
our proposed translation facilitates mergence of datasets from trauma registries 
and clinical studies to conduct more powerful studies or performance of 
comparative analysis across datasets when data recording is not uniform.  
5.6.3. Future direction 
The design of the algorithm is such that at the end of the allocation, there must 
be no cases left with no Marshall Class assigned. We ran our algorithm in a 
dataset of 802 TBI cases from the Trauma Audit Research and Network 
(TARN) and noticed that there were no cases left with no Marshall Class 
allocated (unpublished data). However, we acknowledge that our proposed 
allocation still requires three possible forms of validation in the future. First, it 
is yet to be determined how accurate our method is when the Marshall 
 188 
Classification is performed using the AIS codes. In this manner, AIS codes are 
applied as substitutes for CT reports and in case all the assumptions are 
followed, 100% accuracy should be met. The second form of validation is 
when the allocation is performed with actual CT images at hand. In this 
manner, the allocations are compared across two groups. In one group, the 
classification is done through observing the CT and in the other group the 
Marshall Class is obtained following assignments of AIS coding and 
subsequently using our proposed cross-tabulation and algorithm. This form of 
validation is not expected to yield 100% accuracy and it examines how strong 
the assumptions are. The third form of validation is to compare the Marshall 
Classification at certain time point with that collected from AIS codes obtained 
from any available source including CT, MRI, operation notes etc. This form 
of validation would examine the influence of multiple sources of information 
or the temporal effect of events on the cross-tabulation and algorithm.  
5.7. Conclusion  
Using robust assumptions, we have proposed a method to allocate a single 
Marshall Class to a patient whose AIS codes are available, such as in trauma 
registries. This would enable future important TBI research programs.  
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5.8. Appendix: description of AIS codes to the Marshall 
Classes cross-tabulation 
AIS codes outside cerebrum or unrelated to raised ICP 
 
The Marshall Classification enables categorising a subset of TBI patients at 
risk of developing intracranial hypertention. Therefore injuries sustained in the 
brain stem and cerebellum is ignored. However, there are many codes 
describing the injuries in these two anatomical locations in the AIS dictionary. 
Almost all these codes do not have a Marshall Class equivalent. Bearing this in 
mind, we differentiated other non cerebral injuries relating to the brain stem or 
cerebellum by grouping them as „brain stem injury‟ or „cerebellar injury‟ 
without allocating a Marshall Class. The exception is AIS code 140202, which 
identifies the brain stem compression and thus corresponds to the Marshall 
Class III which involves compressed or absent cisterns. Moreover, the Marshall 
System is not designed for penetrating injuries [139] for which there are 
several AIS codes. Therefore, we grouped all such AIS codes as “penetrating 
injury” with no Marshall Class allocated. However, a penetrating injury AIS 
code related to the brain stem or cerebellum should still be grouped as 
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penetrating injury rather than a cerebellar or brain stem injury. This is because 
penetrating and blunt brain injuries pathophysilogically differ.  
Similarly, a number of AIS codes representing cerebral injuries are not 
directly related to raised intracranial pressure. These include massive 
destruction of both cranium and brain (crush), infarction, intraventricular 
haemorrhage, ischemia, pneumocephalus, laceration and pituitary injury. Such 
injuries are best mapped to the Marshall Class II since they do not indicate a 
normal CT (i.e. Marshall Class I) nor do they indicate brain swelling or mass 
lesions (i.e. Marshall Classes III and above). However, crush injury should be 
mapped to the most severe Marshall Class i.e. Class VI because of the very 
severe nature of this injury.  
 
Not Further Specified (NF)S AIS codes 
 
In allocating the appropriate Marshall Class to the cerebral AIS codes, we 
assumed that NFS injuries are minimally severe injuries of their type as is 
always the case in the dictionary. For example, the code 140999 which 
represents cerebral NFS was allocated to Marshall Class II, which represents 
the least severe brain injury in the Marshall Classification.  
 
Brain swelling 
 
Although, in the Marshall Classification, only class III is declared as „brain 
swelling‟ by Marshall et al. , class IV also contains this pathology. This is 
because midline shift, which denotes class IV, can be caused by brain swelling 
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as well. Thus, there are two Marshall Classes of III and IV indicating brain 
swelling, which are distinguished by compressed/absent cisterns for class III 
and midline shift of more than 5mm for class IV. However, in AIS coding the 
degree of the brain swelling is determined by the status of ventricles/cisterns 
being normal, compressed or absent. Therefore, the highest degree of brain 
swelling in AIS dictionary, i.e. absent cisterns, actually falls in the Marshall 
Class that indicates the lowest degree of brain swelling (class III) with no 
equivalent AIS code for Marshall Class IV. This inability in the AIS dictionary 
to distinguish between Marshall Classes III and IV poses a problem. The 
decision is whether or not to pool all AIS codes of brain swelling into Marshall 
Class III and to leave Class IV blank or to allocate AIS codes of mild and 
moderate brain swelling to Marshall Class III and AIS codes for severe 
swelling to Class IV. We selected the second option assuming that Marshall 
Classes III and IV represent mild and severe brain swelling respectively, 
irrespective of the criteria of the severity.  
 
Mass lesions  
 
There are several separate AIS codes for two kinds of mass lesions; contusion 
and haemorrhage. There are also several severity groups (small, moderate and 
large, massive or extensive) into which these lesions can fall depending on the 
size as ascertained by AIS severity scores. Furthermore, the cut-offs for this 
classification based on size are different in the AIS dictionary and the Marshall 
Classification. Whilst the Marshall Classification uses the simple cut-off of 
25cc regardless of type and location, those used in the AIS dictionary vary by 
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the type, anatomical location and, at times, by age of the patient. For instance, 
a single contusion in the cerebrum is small when < 30 cc, large when between 
30 cc and 50 cc and is extensive when > 50 cc (The cut-offs for the size-wise 
grouping of intracerebral haemorrhage, epidural or subdural hematoma are 
receptively 30cc, 50cc and 50cc.) 
Regarding the size of high density mass lesions, a problem exists on the 
cut-off or criteria to distinguish small from large lesions being different in the 
AIS dictionary and the Marshall Classification. Therefore the assumption was 
made that small haemorrhage and contusion (unilateral or bilateral), SAH and 
Subpial haemorrhage correspond to the Marshall Class II with all other large, 
massive or extensive mass lesions coming under class VI.  
 
Skull fractures  
 
Codes indicating several skeletal fractures (basal skull fracture or not simple 
vault fractures) were all placed in Marshall Class I, which is described as no 
intracranial pathology.  
5.8.1. AIS 2005 
Adapting our proposed mapping for the 2005 update is simple since we know 
that the update to the head section involves changes in a number of AIS scores 
and the addition of some new codes. None of the old AIS codes, which have 
undergone changes in their severity score, are affected in terms of their mapped 
Marshall Class. However, for new AIS codes,  represents the most appropriate 
Marshall Class mapped. Some of the new AIS codes have arisen because some 
of the old AIS codes have been further sub-divided to specify the injuries in 
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more detail. Overall these criteria do not affect the mapping proposed in  for 
each particular injury. For example, in the 2005 AIS dictionary, the severity of 
Diffuse Axonal Injury (DAI) is further qualified by whether or not it is 
confined to white matter/basal ganglia or involves the corpus callusom. No 
matter which is the case, the equivalent Marshall Class II, as allocated in , still 
holds. Nevertheless, there are 3 new codes (140701, 140702 and 140703) that 
describe the hypoxic or ischemic brain damage which occurs due to systemic 
hypoxia, hypotension or shock. Since these causes of brain damage are not 
directly related to head trauma, we can infer that the head CT of such patients 
should be clear which indicates Marshall Class I (no visible pathology).  
Acknowledgment  
We would like to acknowledge the help of Prof. Andrew Maas from the 
IMPACT collaboration in discussion of the methods used to arrive at our final 
algorithm. This work is supported by the funding from the Trauma Audit and 
Research Network (TARN) and Overseas Research Students (ORS) Award 
Scheme, University of Manchester. 
 194 
6. Paper 5: Prognostic Value of Various 
Intracranial Pathologies in Traumatic Brain 
Injury 
Authors 
 Mehdi Moazzez Lesko 
 Omar Bouamra 
 Sarah O‟Brien 
 Fiona Lecky 
 195 
6.1. Abstract  
6.1.1. Introduction 
Various diagnosed intracranial pathologies in Traumatic Brain Injury (TBI) can 
help to predict patients‟ outcome. These pathologies can be categorised using 
the Marshal Classification or the Abbreviated Injury Score (AIS) dictionary or 
can be described through traditional descriptive terms referring to the type of 
injury such as Subarachnoid Haemorrhage (SAH), Subdural Haemorrhage 
(SDH), Epidural Haemorrhage (EDH) etc.  
6.1.2. Objective  
To assess the prognostic value of AIS scores, the Marshall Classification and 
various intracranial pathologies in TBI.  
6.1.3. Method 
A dataset of 802 TBI patients in the Trauma Audit and Research Network 
(TARN) database was analysed using logistic regression. Initially reference 
models were constructed with age, Glasgow Coma Scale (GCS), pupillary 
reactivity, Injury Severity Score (ISS), cause of injury and presence/absence of 
extracranial injury as predictors and survival at discharge as outcome. 
Subsequently, AIS score, the Marshall Classification and various intracranial 
pathologies such as haemorrahge, SAH or brain swelling were added to assess 
the relative predictive strength of each variable and also to assess the 
improvement in the predictive performance of the models.  
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6.1.4. Results 
 Various AIS scores or Marshal Classes did not appear to significantly affect 
the outcome. Among traditional descriptive terms, only brain stem injury and 
brain swelling significantly influenced outcome (odds ratios for survival: 0.17 
(95% CI: 0.08-0.40) and 0.48 (95% CI: 0.29-0.80) respectively). Neither 
haemorrhage nor its subtypes such as SAH, SDH, and EDH were significantly 
associated with outcome. Adding AIS scores, the Marshall Classification and 
various intracranial pathologies to the prognostic models resulted in almost 
equal increase in the predictive performance of baseline models. 
6.1.5. Conclusion 
In this relatively recent dataset, the significant effect of brain swelling and 
brain stem injury on outcome in comparison to injuries such as SAH suggests 
the need to improve therapeutic approaches to patients who have sustained 
these injuries. 
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6.2. Introduction  
Traumatic Brain Injury (TBI) can cause various types of intracranial 
pathologies. It may lead to contusion, haemorrhage or diffuse axonal injury 
(including brain swelling). With regards to predicting outcome, the presence of 
structural damage indicates poorer outcome compared with a normal CT [147]. 
There are several traditional terms such as intracranial haemorrhage, 
Subarachnoid Haemorrhage (SAH), Epidural Haemorrhage (EDH), Subdural 
Haemorrhage (SDH), brain swelling to describe the structural brain damage. 
The association of these pathologies such as intracranial haemorrhage [93], 
SAH [24, 36, 92, 140, 148-152], SDH [92, 94, 153], EDH [24, 92, 94, 140, 
148] and brain swelling [94, 143, 149] with outcome has been shown in the 
TBI literature.  
Abbreviated Injury Scale (AIS) dictionary is a document which codes 
various intracranial injuries sustained due to TBI. The injuries are coded based 
on anatomical location of the lesion (brain stem, cerebrum and cerebellum), the 
type of the lesion (e.g. haemorrhage, contusion and brain swelling), various 
subtypes of haemorrhage such as SAH, SDH and the size/degree of the 
pathology. Each AIS code is equivalent to a particular injury description and is 
followed by a figure as one post-decimal place ranging from 1 (the minimal 
severity) to 6 (the maximal severity). The post-decimal point is referred to as 
AIS severity score. For example, an SDH less than 50cc in an adult receives 
AIS code of 140652 which has severity score of 4. This is presented as 
140652.4 
Furthermore, the Marshal Classification of CT findings in TBI is first 
introduced in 1991 and is used to have a more accurate predictive assessment 
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of TBI patients who sustained intracranial hypertension by considering those 
injuries which are causes of, or somehow related to, raised ICP [139]. Since 
this classification is based on the degree of brain swelling or the extent of mass 
lesion, it disregards physiological characteristics and anatomical distribution of 
injuries in that, for example, contusion, SDH or EDH are all considered as 
mass lesions. Some studies have shown this classification can also be applied 
to predict the outcome in TBI [24, 36, 92, 94, 140, 143]. 
The Trauma Audit and Research Network (TARN) [89], based in the 
UK, is a trauma registry which receives detailed information on severe trauma 
patients mainly from trauma receiving hospitals in England and Wales. TARN 
has embarked on a project to construct prognostic models applicable to a subset 
of trauma patients who have sustained brain injury using a dataset which 
includes cases submitted after September 2005. This provides an opportunity to 
assess the predictive performance of various intracranial pathologies due to 
TBI. The studies on this issue so far have been conducted on older datasets 
which do not take account of temporal advances and improvements in trauma 
care systems [24, 36, 92-94, 140, 143, 148-153]. The objective of this study is 
twofold: to determine the relative prognostic strength of various AIS severity 
scores of brain injury and the Marshall Classification and to determine which 
intracranial pathologies are more important for outcome prediction in TBI 
using a more recent dataset.  
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6.3. Methods  
6.3.1. Patients included  
TARN holds the anonymous record of each TBI patient with various AIS codes 
and scores. The criteria for submission to TARN are that the patient arrives at 
hospital alive and fulfils one of the following criteria: (I) more than three days 
stay in hospital, (II) being nursed in the intensive care unit, (III) inter-hospital 
transfer or (IV) death at any time point in hospital. If a given patient meets the 
criteria, trained coders then code the sustained injuries using the AIS 
dictionary. The criteria to retrieve TBI cases from TARN general trauma 
registry  were AIS severity score of brain injury 3 or more (AIS codes under 
the „Internal Organ‟ in the head section of the dictionary, update 98 [90]) OR 
AIS cods related to basal and compound/depressed/open skull fracture AND 
availability of pupillary reactivity at any time point in TARN dataset. The 
reason for the availability of pupillary reactivity as a criterion was that many 
well-conducted studies have shown the importance of this variable for outcome 
prediction in TBI [23, 24, 36, 92, 93, 137] and it has only been recorded in 
TARN recently i.e. from September 2005 onward. The outcome measure for 
the analysis was survival at discharge and where applicable, the time point of 
measurement of covariates was on admission. 
6.3.2. Differentiation of various intracranial pathologies  
To investigate the predictive importance of AIS scores, the decision was made 
to choose the highest AIS score in case the patient had more than one AIS code 
assigned (34.4% of patient had more than 2 AIS codes/severity score assigned). 
Furthermore, AIS codes were classified according to what is presented in table 
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23. This classification exclusively describes type, subtypes and location and 
disregards the extent/degree of injuries as determined by size, volume or other 
parameters in the AIS dictionary. Injury types include contusion, haemorrhage 
and brain swelling with EDH, SAH and intracranial haemorrhage as subtypes 
of haemorrhage only if they are sustained in the cerebrum (i.e. not in the brain 
stem or cerebellum). These are intracranial pathologies which have been found 
by the International Mission for Prognosis And Clinical Trial Design 
(IMPACT) [28, 92, 94] to significantly affect the outcome in TBI. Moreover, 
there are other injury types sustained in the cerebrum which are not contained 
in  table 23 in order not to make the classification overly detailed and thus 
complicated. Some examples of these codes are infarction, ischemia or diffuse 
axonal injury. Furthermore, should the haemorrhage or contusion be sustained 
in the brain stem or cerebellum, in table 23 , this is classified under the brain 
stem and cerebellar injuries and not the cerebral injury.  
 
Table 23 Traditional terms to describe intracranial pathologies in TBI 
 
 
In the same way, AIS codes were differentiated according to the 
Marshall Classification [139]. An algorithm was applied which enabled a 
Marshall Class to be allocated to each patient depending on the brain injuries 
described by AIS dictionary. This algorithm adds two additional classes to the 
original Marshall Classification to represent penetrating and brain 
Cerebral contusion 
Cerebral brain swelling 
Cerebral haemorrhage  
Cerebral EDH 
Cerebral SDH 
Cerebral SAH 
Brain stem injury 
Cerebellar injury 
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stem/cerebellar injuries as classes VII and VIII respectively. However, since in 
TARN, the distinction between classes V and VI can not be reliably made, 
these two classes were merged together in this analysis (class V represents 
evacuated mass lesion versus class VI representing non-evacuated mass 
lesion).  
6.3.3. Examination of prognostic value of AIS severity 
scores and various intracranial pathologies  
Initially the significance of the association of the brain injury AIS severity 
scores and various intracranial pathologies 
with survival at discharge was investigated using Chi Square test. Then two 
models were constructed. One model included age, GCS, pupillary reactivity, 
Injury Severity Score (ISS) (model A) and the other model included the same 
covariates except that ISS was replaced with presence/absence of major 
extracranial injury (i.e. extracranial AIS severity score > 3) and the cause of 
injury (model B). The reason for this replacement was that ISS and extracranial 
injury could not be contained in the same model due to multicolinearity effect. 
Following replacement of ISS with extracranial injury, the cause of injury 
became significant. The admission values were selected for GCS and pupillary 
reactivity and all missing information on these covariates were replaced firstly 
with observations en-route or, secondly, at scene. These models were named as 
“the baseline models A and B”.  
Subsequently, brain injury AIS severity scores and various intracranial 
pathologies were added separately to each model A and B firstly to observe the 
significance of effect of each variable on outcome in the model and secondly to 
observe the changes in the model performance according to the significance of 
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the decrease in the deviance or increase in Area Under the Roc Curve (AUC) 
and Nagelkerke R
2
 [136]. Due to insufficient cases with AIS score 6 (only 6 
cases in the whole dataset), this score was merged with AIS score 5. Various 
intracranial pathologies as presented in table 23 were supplied to the models 
altogether (i.e. not individually) only if they were found significant in the 
univariate analysis. However, we observed that some pathologies such as 
various types of haemorrhage were not significant in our models unlike the 
literature. This was thought likely to be due to the given combination of 
intracranial pathologies in table 23. Therefore, various combinations were 
investigated by merging/omitting various pathologies. This was performed 
based on the literature and the results of our multivariate analysis. We 
differentiated numerically each combination (i.e. combinations 1A to 5A and 
1B to 3B where A and B represent models A and B).  
6.4. Results  
The results are presented in 3 sections to cover: the univariate analysis, the 
significance of each variable in the multivariate models and lastly their added 
value to the performance of the models.  
6.4.1. Patients characteristics and the univariate analysis 
The clinicodemographic characteristics of the population studied are shown in 
Table 24. The dataset comprised 802 TBI cases. The median age was 39 and 
males constituted 75.2% of the population. The commonest causes of injury 
were Road Traffic Collisions (RTC) and falls. The majority of cases (51.1%) 
had severe TBI i.e. GCS < 9 recorded on admission to the emergency 
department. Most cases (68.6%) had normal pupillary reactivity followed by 
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neither reactive at 16.5%. The median ISS was 25 and the frequency of major 
extracranial injury was 14.5% as determined by extracranial AIS score > 3. 
 
Table 24 Clinicodemographic characteristics of the population sample 
studied. 
 
Table 25 demonstrates the frequency of each AIS score, Marshall Class 
and various intracranial pathologies along with the results of univariate 
Covariate Median 
(interquartile 
range) 
Frequency 
(percentage) 
Age 39 
(22-58) 
 
Gender Male - 603 
(75.2%) 
Female - 199 
(24.8%) 
Cause of injury RTC - 314 
(39.2%) 
Fall - 313 
(39.0%) 
Assaults - 143 
(17.8%) 
Others - 32 
(4%) 
GCS(categorical) Mild (13-15) - 278 
(35.8%) 
Moderate (9-12) - 99 
(12.7%) 
Severe (3-8) - 399 
(51.5%) 
Pupillary reactivity Normal - 446 
(68.6%) 
Abnormal-both 
reactive 
- 69 
(10.2%) 
Abnormal-only one 
reactive 
- 28 
(4.3%) 
Neither reactive - 107 
(16.5%) 
ISS 25 
(16-29) 
 
Extracranial injury (cut-off: AIS=4) - 116 
(14.5%) 
Survival - 599 
(74.7%) 
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analysis. Most cases had the highest AIS score of 4 (39.4%) and only 6 cases 
were recorded with the highest AIS of 6. Likewise, haemorrhage (of any type) 
was present in 76.4% of cases with SDH the most frequent type of 
haemorrhage (22.1%) followed by SAH (18.6%). Similarly, 8.9% and 5.1% of 
cases had brain stem and cerebellar injury respectively (of any kind such as 
haemorrhage or contusion). Nevertheless, non-hemorrhagic brain injuries such 
as contusion and swelling were present in 39.9% and 34.2% of the patients 
respectively. When using the Marshal CT Classification, the most frequent 
pathology is class II (50.5%) followed by class V/VI (20.7%) and III (10.6%). 
All covariates including AIS scores and the Marshal Classification were 
significantly associated with survival apart from contusion and SDH. Therefore 
contusion and SDH were not investigated further in the multivariate analyses. 
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Table 25 Frequency of various AIS score, Marshall Classes and 
intracranial pathologies. The p value represents the significance of 
association with survival at discharge. 
Covariate Frequency 
(percentage) 
Odds ratio for 
survival 
(CI) 
p value 
by Chi 
square 
test 
Highest AIS 
scores 
3 189 
(23.6%) 
 < 0.005 
4 316 
(39.4%) 
0.73 
(0.42-1.27) 
5 291 
(36.2%) 
0.15 
(0.09-0.25) 
6 6 
(0.7%) 
0.02 
(0.00-0.22) 
Cerebral contusion 320 
(39.9%) 
1.25 
(0.90-1.74) 
0.18 
Cerebral brain swelling 275 
(34.2%) 
0.31 
(0.22-0.43) 
< 0.005 
Cerebral haemorrhage 533 
(66.5%) 
0.61 
(0.42-0.87) 
< 0.005 
Cerebral EDH 95 
(11.8%) 
2.85 
(1.49-5.45) 
< 0.005 
Cerebral SDH 178 
(22.1%) 
1.17 
(0.79-1.73) 
0.43 
Cerebral SAH 149 
(18.6%) 
0.56 
(0.38-0.82) 
< 0.005 
Brain stem injury 72 
(8.9%) 
0.08 
(0.04-0.14) 
< 0.005 
Cerebellar injury 41 
(5.1%) 
0.30 
(0.16-0.56) 
< 0.005 
Marshal 
Classification 
I 65 
(8.1%) 
 < 0.005 
II 405 
(50.5%) 
1.17 
(0.54-2.50) 
III 85 
(10.6%) 
0.39 
(0.17-0.90) 
IV 74 
(9.2%) 
0.19 
(0.08-0.44) 
V/VI 166 
(20.7%) 
0.160 
(0.08-0.35) 
Brain 
stem/cerebellar 
injury 
4 
(0.5%) 
0.05 
(0.005-0.57) 
Penetrating 
injury 
3 
(0.4%) 
0.32 
(0.03-3.92) 
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6.4.2. The significance of each variable in the model  
Table 26 and Table 27 show the effect of AIS scores, the Marshall 
Classification and intracranial pathologies on outcome (survival at discharge) 
using multivariate analysis. The combination 1A and 1B were the ones 
presented in  tabel 23 (except for contusion and SDH which were not 
significant in the univariate analysis). In model A (Table 26), AIS score 4 was 
not significantly associated with outcome whereas AIS score 5/6 were 
marginally significant (<0.1 but > 0.05).  Regarding the Marshal Classification, 
no Marshal Class showed significant association with outcome although the 
Marshall Class II was marginally significant (p = 0.06). Moreover, among all 
intracranial pathologies, only brain stem injury was significantly associated 
with discharge survival whereas brain swelling and cerebellar injury were 
marginally significant (p = 0.08 and 0.09 respectively).  
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Table 26 Prognosis associated with AIS scores, the Marshall Classification and intracranial pathologies in the multivariate model A (*: p 
< 0.005, **: p < 0.05) 
 Baseline model A Model A + AIS scores Model A + Marshal 
Classification 
Model A + combination 
1A 
Model A 
 
Age 0.96 
(0.95-0.97)** 
0.96 
(0.95-0.97)** 
0.95 
(0.94-0.96)** 
0.95 
(0.94-097)** 
GCS Mild - - - - 
Moderate 0.41 
(0.20-0.82)* 
0.40 
(0.20-0.81)* 
0.37 
(0.18-0.77)** 
0.40 
(0.19-0.82)* 
Severe 0.22 
(0.12-0.39)** 
0.22 
(0.12-0.41)** 
0.22 
(0.12-0.41)** 
0.23 
(0.12-0.43)** 
Pupillary reactivity Normal - 
 
- - - 
Abnormal-both reactive 0.40 
(0.21-0.74)** 
0.40 
(0.21-0.75)** 
0.37 
(0.19-0.71)** 
0.40 
(0.21-0.76)** 
Abnormal-only one 
reactive 
0.28 
(0.12-0.65)** 
0.26 
(0.11-0.60)** 
0.26 
(0.11-0.61)** 
0.26 
(0.11-0.61)** 
Neither reactive 0.04 
(0.02-0.09)** 
0.05 
(0.03-0.09)** 
0.05 
(0.02-0.1)** 
0.05 
(0.02-0.10)** 
ISS 0.18 
(0.10-0.33)** 
0.29 
(0.15-0.56)** 
0.26 
(0.14-0.5)** 
0.27 
(0.14-0.51)** 
AIS 3 - 
 
- - - 
4 - 1.28 
(0.63-2.60) 
- - 
5/6 - 0.52 
(0.25-1.08) 
- - 
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Table 26 Prognosis associated with AIS scores, the Marshall Classification and intracranial pathologies in the multivariate model A (*: p 
< 0.005, **: p < 0.05) (continued)
  Baseline model A Model A + AIS scores Model A + Marshal 
Classification 
Model A + combination 
1A 
Marshal Class I - 
 
- - - 
II - - 2.70 
(0.97-7.5) 
- 
III - - 0.1 
(0.31-3.16) 
- 
IV - - 0.70 
(0.22-2.21) 
- 
V/VI - - 0.74 
(0.26-2.12) 
- 
Brain stem/cerebellar injury - - 0.39 
(0.00-42.11) 
- 
Penetrating injury - - 1.2 
(0.02-82.91) 
- 
Combination 1A Brain swelling - - - 0.64 
(0.38-1.05) 
EDH - - - 1.80 
(0.76-4.28) 
SAH - - - 0.22 
(0.10-0.50) 
Brain stem injury - - - 0.45 
(0.18-1.14)** 
Cerebellar injury - - - 0.94 
(0.52-1.69) 
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In model B (Table 27), no significant association between AIS score 4 
and outcome was observed whereas this association was significant for score 
5/6. Unlike model A, Marshal Classes IV and V/VI demonstrated significant 
effects on outcome. Moreover, among intracranial pathologies, only brain 
swelling and brain stem injury significantly influenced survival at discharge in 
model B. 
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Table 27 Prognosis associated with AIS scores, the Marshall Classification and various intracranial pathologies in the multivariate 
model B (*: p < 0.05, **: p < 0.005)
 Baseline model B Model B + AIS scores Model B + Marshal 
Classification 
Model B + combination 
1B 
Model B 
Age 0.96 
(0.95-0.97)** 
0.96 
(0.95-0.97)** 
0.96 
(0.94-0.97)** 
0.96 
(0.95-0.97)** 
GCS Mild - 
 
- - - 
Moderate 0.39 
(0.19-0.80)* 
0.37 
(0.18-0.76)** 
0.34 
(0.16-0.72)** 
0.39 
(0.18-0.81)* 
Severe 0.18 
(0.10-0.32)** 
0.23 
(0.12-0.42)** 
0.22 
(0.12-0.42)** 
0.22 
(0.12-0.41)** 
Pupillary reactivity Normal - - - - 
Abnormal-both reactive 0.40 
(0.21-0.74)** 
0.40 
(0.21-0.77)** 
0.38 
(0.2-0.75)** 
0.40 
(0.21-0.76)** 
Abnormal-only one 
reactive 
0.21 
(0.09-0.49)** 
0.23 
(0.10-0.55)** 
0.23 
(0.09-0.56)** 
0.21 
(0.09-0.50)** 
Neither reactive 0.03 
(0.02-0.07)** 
0.04 
(0.02-0.07)** 
0.04 
(0.02-0.08)** 
0.04 
(0.02-0.08)** 
Extracranial injury 0.22 
(0.12-0.40)** 
0.21 
(0.11-0.39)** 
0.18 
(0.10-0.35)** 
0.24 
(0.13-0.44)** 
Cause of injury RTC - 
 
- - - 
Fall 0.60 
(0.34-1.05)* 
0.64 
(0.36-1.17) 
0.71 
(0.39-1.3) 
0.60 
(0.33-1.10) 
Assaults 1.71 
(0.77-3.82) 
1.91 
(0.83-4.42) 
2.09 
(0.90-4.85) 
1.80 
(0.78-4.15) 
Others 1.01 
(0.29-3.55) 
1.11 
(0.31-3.98) 
0.97 
(0.25-3.77) 
0.98 
(0.27-3.52) 
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Table 27 Prognosis associated with AIS scores, the Marshall Classification and various intracranial pathologies in the multivariate 
model B (*: p < 0.05, **: p < 0.005) (continued)
  Baseline model B Model B + AIS scores Model B + Marshal 
Classification 
Model B + combination 
1B 
AIS 3 -  
 
- - 
4 - 0.85 
(0.41-1.75) 
- - 
5/6 - 0.23 
(0.11-0.46)** 
- - 
Marshal Class I - 
 
- - - 
II - - 1.85 
(0.64-5.36) 
- 
III - - 0.7 
(0.23-0.49) 
- 
IV - - 0.26 
(0.08-0.86)* 
- 
V/VI - - 0.33 
(0.11-0.99)* 
- 
Brain stem/cerebellar injury - - 0.24 
(0.00-39.06) 
- 
Penetrating injury - - 0.11 
(0.00-4.46) 
- 
Combination 1B Brain swelling - - - 0.48 
(0.29-0.80)** 
EDH - - - 1.67 
(0.70-4.01) 
SAH - - - 1.00 
(0.56-1.81) 
Brain stem injury - - - 0.17 
(0.08-0.40)** 
Cerebellar injury - - - 0.50 
(0.20-1.35) 
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Since in the analysis of types of hemorrhage, none showed significant 
association with outcome in neither model A nor B despite this being observed 
in other studies [24, 36, 92-94, 140, 143, 148-153], other combinations of 
intracranial pathologies were investigated. These combinations were based on 
(1) hemorrhage commonly thought to be  predictive of adverse outcome in TBI 
from a clinical viewpoint, underpinned by literature [23, 93], (2) brain stem 
being a significant predictor in both models A and B, (3) brain swelling being a 
significant predictor in model B and marginally significant in model A and (4) 
cerebellar injury being marginally significant in model A. Table 28 presents 
various combinations of intracranial pathologies, created according to the 
above observations. All combinations, which were formed based on the results 
of model A (i.e. combinations 2A, 3A, 4A, 5A), contained brain stem injury as 
this variable was significant in model A. The different combinations for model 
A related to the presence/absence of marginally significant covariates (brain 
swelling and cerebellar injury) and the clinically important variable: 
hemorrhage. Further, combinations 2B and 3B were originated based on the 
results of model B. Both combinations contain the significant covariates of 
model B (brain stem injury and brain swelling). The only difference of these 
two combinations related to presence or absence of hemorrhage i.e. 
hemorrhage is included in combination 2B but not in the combination 3B. 
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Table 28 Categories within combinations of various intracranial 
pathologies (+: present, -: not present) 
 
Following the trial of these various combinations of intracranial 
pathologies, it was observed that, in model A, brain stem injury remained 
significant in all combinations, with haemorrhage never being significantly 
associated with outcome. Furthermore, in combinations where the brain 
swelling and the cerebellar injury were present i.e. combination 2A (brain stem 
injury, cerebellar injury and brain swelling) and combination 3A (combination 
2A plus haemorrhage i.e. brain stem injury, cerebellar injury, brain swelling 
and haemorrhage), these covariates showed a marginally significant association 
with discharge survival. Similarly, in model B, the brain stem injury and the 
brain swelling were significantly associated with outcome in both 
combinations whilst haemorrhage demonstrated no significant association in 
combination 2B (brain stem injury, brain swelling and haemorrhage). We also 
added each intracranial pathology individually i.e. without combining with 
other intracranial pathologies and observed the same results.  
 Combination Brain stem 
injury 
Cerebellar 
injury 
Brain 
swelling 
Hemorrhage 
Based on 
results from 
model A 
Combination 
2A 
+ + + + 
Combination 
3A 
+ + + - 
Combination 
4A 
+ - - + 
Combination 
5A 
+ - - - 
Based on 
results from 
Model B 
Combination 
2B 
+ - + + 
Combination 
3B 
+ - + - 
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6.4.3. Added value of each variable to the model 
performance  
Table 29 shows the added value of AIS scores, the Marshall Classification and 
various intracranial pathologies to models A and B. The AUC and Nagelkerke 
R
2 of the models A and B prior to and following addition of each new variable 
(AIS scores, Marshall Classification or intracranial pathologies) are presented. 
The baseline models A and B had AUC and Nagelkerke R
2 
of respectively 0.91 
and 0.57. Addition of AIS scores and the Marshall Classification to model A 
resulted in a significant decrease in the deviance of the model along with 
increase in AUC from 0.91 to 0.92. Further, addition of various intracranial 
pathologies to this model demonstrated similar increase in AUC. In terms of 
Nagelkerke R
2
, the degree of increase varied. Similar to model A, both AIS and 
the Marshall Classification significantly decreased the deviance of model B 
whilst increasing AUC from 0.91 to 0.92. Moreover, adding various 
intracranial pathologies to this model resulted in the same increase of AUC as 
to AIS score or the Marshall Classification, apart from the combination 1B 
which raised AUC slightly higher as to 0.93. Similar to model A, the increase 
in Nagelkerke R
2 
varied.  
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Table 29 The added value of AIS scores, the Marshall Classification and various intracranial pathologies to the performance of models 
to predict survival at discharge.
 AUC Decrease in 
deviance 
 (p value) 
Nagelkerke R
2
  AUC Decrease in 
deviance  
(p value) 
Nagelkerke R
2
 
Baseline model 
A 
0.91 
(0.89-0.93) 
- 0.57 Baseline model 
B 
0.9 
(0.88-0.93) 
- 0.57 
AIS 0.92 
(0.89-0.94) 
<0.001 0.58 AIS 0.92 
(0.90-0.94) 
<0.001 0.61 
Marshal 
Classification 
0.92 
(0.90-0.94) 
<0.001 0.60 Marshal 
Classification 
0.92 
(0.90-0.94) 
<0.001 0.62 
Combination 1A 0.92 
(0.90-0.94) 
- 0.60 Combination 1B 0.93 
(0.90-0.95) 
-  
Combination 2A 0.92 
(0.90-0.94) 
 0.60 Combination 2B 0.92 
(0.90-0.94) 
- 0.61 
Combination 3A 0.92 
(0.90-0.94) 
 0.60 Combination 3B 0.92 
(0.90-0.94) 
<0.001 0.61 
Combination 4A 0.92 
(0.90-0.94) 
 0.59 
Combination 5A 0.92 
(0.90-0.94) 
<0.001 0.59 
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6.5. Discussion 
In this study, the predictive power of AIS severity scores, the Marshal 
Classification and various traditionally descriptive intracranial pathologies has 
been investigated. Using a subset of TBI patients submitted to TARN, two 
reference prognostic models to predict the discharge survival were constructed 
with important TBI prognosticators namely age, GCS, pupillary reactivity, ISS, 
cause of injury and extracranial injury as covariates. Then the association of 
each classification system (AIS severity score or the Marshall Classification) or 
descriptive pathology with outcome and also its contribution to the 
performance of the reference models were assessed in univariate and logistic 
regression analyses respectively. AIS score 5/6 appears to have a significant 
effect on outcome with AIS score 3 as the reference. Regarding the Marshal 
Classification, various Marshal Classes do not appear to have significant 
influence on outcome prediction in model A with only classes V and V/VI 
being significant in model B. Moreover, haemorrhage does not seem to be 
important although brain swelling and brain stem injuries (of any kind 
including haemorrhage and contusion) may be the important predictors of 
outcome among all structural damages. This analysis shows that including 
these classifications or intracranial pathologies slightly enhances the predictive 
power of baseline prognostic models as per AUC and Nagelkerke R
2
.  
6.5.1. Implications of the study 
Although various AIS scores on univariate analysis have odds ratios of less 
than one for survival, which decreases in line with the increase of the score, 
this effect seems not to be maintained in multivariate analysis. This is because 
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score 4 does not hold significant association with outcome despite score 5 
being significantly more predictive of death than score 3. This implies that the 
prognostic difference between AIS scores 3 and 4 is not significant. We cannot 
explain this finding because both scores contain various types and severities of 
injuries. However, it is possible that some injuries which are coded 3 should be 
perhaps placed under AIS score 4 or vice versa.  
The Marshall Classification does not appear to be a reliable classifier 
for TBI patients based on their probable outcome. Although, addition of the 
Marshal Class to the baseline predictive models improved the performance, 
this does not add anything to the notion that structural brain damage (of any 
kind) is an indicator of a worse outcome than no intracranial pathology [147]. 
A reliable classification should be able to effectively provide relative predictive 
strength for each category of pathological findings which can be referred to as 
the capability of the classification system to score each individual category for 
outcome prediction. The Marshall Classification appears to fail in this matter in 
our analysis. However, we believe our results do not undermine the validity of 
the Marshall Classification for descriptive purposes or to indentify those TBI 
cases who are at high risk of developing raised ICP. In fact, not only this 
classification has not been proposed from the prognosis viewpoint, it may still 
be appropriate as a CT classification. This is because we used AIS codes to 
assign one Marshall Class to a TBI case in our data. AIS coding, however, 
employs the information not only from CT reports but also any source which 
can provide information on intracranial pathology (such as MRI, operation 
notes, clinical diagnosis etc.). Thus, according to results, one may assume this 
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classification is not good for categorising intracranial pathologies but valid for 
pathologies observed by CT.  
This study in part permitted us to assess the prognostic importance of 
the type and anatomical location of brain damage following TBI. Contusion 
appears not to have a negative prognostic value because it does not influence 
the survival status. This is also the case for haemorrhage, when it is used in 
multivariate analysis. However, brain swelling still seems to be an important 
factor for outcome prediction. Regarding the location of the lesion, it appears 
that the most important location is the brain stem with no importance for 
cerebellar and cerebral lesions apart from brain swelling. These findings may 
have some therapeutic implications as there is currently no definitive or 
appropriate therapy/intervention for brain stem injury. Although this finding 
appears intuitive for clinicians involved in treating these patients, this poor 
prognosis is observed in comparison with other factors influencing the 
outcome. This means victims of brain stem injury still have a chance of 
survival since the brain stem injury is only one factor for calculating the 
probability of outcome in our prognostic models. Furthermore, the negative 
effect of brain swelling on outcome compared with haemorrhage or other 
injuries may imply the current therapeutic strategies are not sufficient for 
averting  the poor outcome. This is highlighted further as our dataset is current 
and so modern therapeutic approaches have been taken into account. It is 
important to note that lack of significance for traumatic cerebral haemorrhage 
does not indicate the full efficiency of existing therapeutic approaches to 
intracranial pathologies. There are still many patients who sustain traumatic 
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cerebral haemorrhage and do not survive or subsequently end up with severe 
disability. 
6.5.2. Comparison with the literature 
Gennarelli et al.reported a non-linear relationship between AIS scores and 
mortality in that mortality consistently decreases as AIS score increased 
especially for scores 3 and above [144]. In our study, we observed that for AIS 
scores of brain injury, although there may be a decrease in the odds ratio of 
survival as AIS score increases (model B), the effect of score 4 on outcome is 
not significant as compared to score 3. Two important differences between our 
study and Gennarelli‟s may indicate more reliable results in our study. Firstly, 
we performed a multivariate analysis taking other important predictors into 
account where this was not performed in Gennarelli‟s study. It might be that 
the additional prognosis of AIS 4 versus 3 is covered by inclusion of GCS and 
pupillary reactivity in the models as GCS and the pupillary reactivity are more 
likely to be low/abnormal as AIS increases. Secondly, our analysis was 
exclusively performed on a subgroup of head AIS scores whereas Gennarelli‟s 
study is about AIS scores from all body regions.  
The association of the Marshall Classification with outcome has been 
investigated in a number of other studies [24, 36, 92, 94, 140, 143]. Maas el. al. 
demonstrated that classes V and VI had a lower mortality rates than class IV 
but they observed that overall the Marshal Classification has reasonable 
discriminative power (AUC= 0.669) [140]. This appears similar to our finding 
that adding the Marshal Classification to the predictive models would improve 
the performance. No adjustment for confounders was made in this study. 
Moreover, Servadei et al.  performed a univariate analysis on the outcome 
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predictability of the Marshal Classification with a similar result to our 
univariate analysis [143]. Among the studies which performed a multivariate 
analysis, the Marshal Classification was reported as a significant prognosticator 
when this classification was not used in its original form [24, 36, 92]. Apart 
from classes V and VI in these studies, various other Marshal classes were 
merged together such as class III merged with class IV [24, 92] or class I 
merged with class II [36]. We did not perform such mergence as we intended 
to use the Marshall Classification in its original form although mergence of 
classes V and VI was unavoidable due to lack of reliable information. One 
study found significant influence of each Marshall Class on outcome with only 
merging classes V and VI following adjustment with age, motor GCS and 
pupillary reactivity [94]. However, in this study the reference category was 
class II whereas in ours class I was the reference category.  
The difference in severity of TBI may explain the difference of our 
findings with regards to haemorrhage, SAH and EDH with many other studies 
consistently reporting the predictive significance of haemorrhage [93], SAH 
[24, 36, 92, 140, 148-152], or EDH [24, 92, 94, 140, 148]. For example, 
Fearnside et al.  observed a significant prognostic importance for SAH by 
multivariate analysis of a dataset in which all patients had GCS of 8 or less 
whereas in our dataset 35.8% of patients had mild GCS (i.e. >12) [149]. 
Similarly, Azian et al.  excluded those cases without intracranial haemorrhage 
and reported the significant predictive strength of SAH and EDH [148]. It may 
be that haemorrhage, SAH or EDH is a less important predictor of outcome in 
patients with less severe TBI unlike those who sustained more serious injuries. 
However, one important strength of our research is that our dataset is much 
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more recent than those used in other such studies. Moreover, the other 
explanation of the different results may relate to using AIS codes which rely 
also on MRI, operation notes or even mere clinical diagnosis and not only CT 
images. Regarding this, it is important to consider our study as a prognostic 
analysis of intracranial pathologies and not merely CT findings. As such, 
although it somewhat gives prognostic insight about various CT finding as they 
count in AIS coding, we believe the results of our study are more relevant for 
clinical decision makings with regards to the ultimate patient‟s diagnosis rather 
than only CT findings.  
6.5.3. Limitations  
Although our dataset contains severe cases of trauma per TARN submission 
criteria, our study may be considered to suffer from strong selection bias. This 
is because death is one criterion to be included into the TARN trauma registry 
(a bias towards inclusion of patients who die). Whilst this can potentially pose 
a bias, in our analyzed dataset only 5 cases stayed at hospital for less than 3 
days and of these only 3 cases died. We can assume that the remaining 2 who 
survived entered the dataset due to either intensive care or inter-hospital 
transfer (the other two criteria for submission to TARN). This also highlights 
that majority of cases in the data (99.37%) sustained brain injuries severe 
enough to stay at hospital for longer than 3 days. As such, it can be assumed 
that the inclusion criteria for this study is longer than 3 days stay at hospital 
since 99.37% of cases entered the dataset because of this criterion. One may, 
however, consider a selection bias towards excluding those cases who sustain 
intracranial pathology but not severe enough for more than 3 days in-hospital 
care and they do not enter the registry since they survive. Whilst this is an issue 
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with our current dataset, we believe the number of such cases must not be high 
to pose a significant bias to our study. In fact, the analyzed dataset is more 
representative of TBI victims who sustain intracranial pathologies as 35.8% of 
cases had admission mild GCS (i.e. > 13). This subgroup of patients represents 
those patients who „talk and die‟. Overall, the survival rate in our data is close 
to the average survival rate in other severe TBI populations (70%). We believe 
although the selection bias is an issue with our analysis, it is not strong to 
significantly undermine the results.  
The other limitation of our study is that we classified various 
intracranial pathologies described by AIS codes according to the Marshall 
Classification [99]. This classification was designed to identify risk of raised 
ICP based on CT image whereas AIS coding is performed from any source of 
information including MRI, operating notes etc.. Whilst AIS coding mostly 
relies on CT reports, the effect of other sources of information on the Marshall 
Classification obtained with AIS intermediation is unclear [99]. Furthermore, 
AIS coding is reflective of the dynamic nature of the brain injury as it employs 
multiple sources complied over time whereas the Marshall Classification is 
from a certain point in time (oftentimes on admission). Servadei et al.  
demonstrated that the evolution of intracranial pathologies per se is a TBI 
prognosticator [143]. The temporal change of brain injury is consequently 
inherited in the Marshall Classification when obtained from AIS descriptions 
but not when obtained from observing the actual CT image. Overall, there may 
be some overestimation of negative prognostic strength of the Marshall System 
when it is performed via AIS coders.  
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In this study, the highest AIS score was taken as a single variable for 
the analysis of association with outcome. However, patients may sustain 
multiple intracranial injuries and thus attract many AIS codes for each injury, 
especially if the brain injury is of severe type. Thus choosing only one AIS 
score out of several severity scores allocated might not be appropriate. This is 
an area for future research to determine how the predictive strength of 
intracranial injuries changes in the event of multiple intracranial injuries. It is 
still unclear which patient is at higher risk of experiencing unfavourable 
outcome, for instance, if one of them has multiple injuries with severity of 3 
and the other has one brain injury scored as 4. 
In this study, the original hypothesis was that prognostic analysis of 
combinations 1A or B would enable us to propose a reliable classification with 
significant prognostic value. However, apart from the brain stem injury and 
brain swelling, all other intracranial pathologies appeared non-significant in 
this analysis. Although this finding adds valuable information to the current 
literature with respect to the relative efficiency of therapeutic approaches to 
each intracranial pathology, at this stage we can not propose a classification 
apart from using the common conventional terms such as SAH, EDH, SDH etc.  
6.5.4. Future direction  
As some TBI patients, especially those who sustain severe injuries, 
have a high chance of multiple types of injury, the future research on 
development of a classification of intracranial pathologies for prognostic 
purposes should examine the impact of the number of intracranial injuries. 
Other important factors might be the anatomical location because of the 
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importance of brain stem injury, types of injury because of the importance of 
brain swelling and also the extent or severity of each injury.  
The results of our study still require further validation in a different 
series of TBI. This particularly relates to the follow-up interval with regards to 
the outcome assessment and also the type of outcome (disability versus 
survival). Whilst in this study, the endpoint of outcome was discharge survival 
(well-recognised in prognostic analysis of trauma registries data [22, 120, 129, 
142, 154]), this analysis should be replicated for disability and also long term 
outcome such as 6 months following injury.  
6.6. Conclusion  
Within a subset of severe TBI patients, not all AIS scores or  Marshall Classes  
have prognostic significance when taken into account along with 
clinicodemographic prognostic factors. This suggests AIS scores and the 
Marshall Classification may not be appropriate to classify intracranial 
pathologies. The significant association of brain swelling and brain stem injury 
implies the need to improve therapeutic approaches to those patients who have 
sustained these injuries. Furthermore, development of any new classification 
which can be employed for predictive purposes entails considerations given to  
the type, location; extent and multiplicity of injuries prioritising which one of 
these factors are of more importance.  
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7.1. Abstract 
7.1.1. Background 
Prognostic models in traumatic brain injury (TBI) are employed to design 
clinical trials, to assess/compare trauma care systems and to adjust trauma care 
for an individual patient. The current available prognostic models are rather old 
(the IMPACT models) or derived from non-homogenous datasets in terms of 
the trauma care delivered (the CRASH models).  
7.1.2. Aim 
To construct prognostic models to predict outcome in recent UK TBI patients.  
7.1.3. Method 
Records of patients with brain injury since January 2005 were extracted from 
the Trauma Audit and Research Network (TARN) database. TARN holds the 
records of patients with severe injuries i.e. longer than 3 days stay at hospital, 
inter-hospital transfer, critical care in hospital or death. Following a literature 
review, the variables age, cause of injury, GCS, pupillary reactivity, Injury 
Severity Score (ISS), CT classifications and various intracranial pathologies, 
systolic and mean blood pressure, hypoxia and the presence of extracranial 
injury were tested with survival at discharge as outcome. Variables with no 
significant correlation on univariate analysis were excluded. Stepwise logistic 
regression analysis was performed.  
7.1.4. Results  
Two models were derived on 802 patients with significant brain injury (models 
A and B). Age, GCS, pupillary reactivity, hypoxia and brain stem injury are 
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significant predictors in both. However, model A contains ISS in contrast to 
model B with the presence of brain swelling, cause of injury and major 
extracranial injury. Both models have high predictive performance (Model A; 
Area Under the ROC Curve (AUC) =0.92 (95% CI: 0.90-0.95), Nagelkerke R
2
: 
0.62 and HL test: P value = 0.20, Model B; AUC = 0.93 (95% CI: 0.91-0.95), 
Nagelkerke R
2
: 064 and HL test: P value= 0.19).  
7.1.5. Conclusion  
We have developed two prognostic models applicable to UK patients recently 
hospitalised after traumatic brain injury. 
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7.2. Introduction  
Traumatic Brain injury (TBI) is a global public health issue and is the cause of 
a substantial number of deaths and disabilities each year [155]. Tackling the 
problem involves devising and implementation of several preventive measures 
ranging from legislations on speed limit and seat belt for primary and 
secondary prevention [156] to the provision of the appropriate acute trauma 
care and rehabilitative strategies as tertiary prevention to avert the negative 
consequences of brain damage when it has already occurred. To this aim, 
prognosis is one of the several factors which can potentially help clinicians 
with decision making. Further, availability of a prognostic tool would assist 
trauma registries to benchmark local care systems by comparing their 
performance to a national standard performance. It has been suggested that 
accurate prognostic tools can also improve patient selection in trials of new 
interventions in TBI [157]. 
It is well-established that prognostication of TBI can not be based on a 
single clinical measure. For example, although in general, brain-injured 
patients with low or moderate Glasgow Coma Scale (GCS) are more prone to 
unfavourable outcome but a significant proportion of these patients can have a 
reasonable outcome with appropriate care [158]. Similarly, many patients with 
admission GCS scores of more 14 or 15 may deteriorate to experience 
unfavourable outcome [158]. This is because the prognosis in TBI depends on 
several clinical factors such as age, level of consciousness, pupillary reactivity 
or  Computed Tomography (CT) features [92]. The interaction among these 
factors is such that the effect of one factor on outcome may be influenced or 
eliminated in the presence or absence of the other. To address this complex 
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interaction, prognostic models have been employed to construct a tool which 
provides the probability of various outcome measures for a given victim of 
TBI over time taking multiple predictors into account.  
In two recent systematic reviews, Perel. et al.  [31] and Mushkudiani et 
al.  [159] observed that the literature contains numerous TBI prognostic models 
but many of these models are methodologically flawed in that the derivation 
samples are too small to provide powerful results, the models are not externally 
validated and some studies lack measures of model performance. These are 
important considerations with regards to the reliability of the presented 
prognostic models. However, there are currently two large initiatives which 
have constructed accurate and reliable prognostic models available online; 
these projects being International Mission for Prognosis and Analysis of 
Clinical Trials (IMPACT) [28] and Corticosteroid Randomization After 
Significant Head injury (CRASH) studies [23, 24].  
The derivation of the CRASH and IMPACT models from clinical trials 
can pose a selection bias as only cases who met the inclusion criteria for the 
sake of given intervention were contained in the dataset. Furthermore, it is 
important that prognostic analysis is accounted for as an ongoing procedure in 
updated and contemporary TBI series [88]. As such, the IMPACT models may 
be considered somewhat historic. Similarly, the regional diversity in trauma 
care should be taken into account as countries exercise different policies with 
regards to many factors which can affect the outcome such as pre-hospital care, 
intervention versus conservative approach or provision of neuro-intensive care 
[86]. The Trauma Audit and Research Network (TARN) is a trauma registry 
based in the University Of Manchester, UK which holds records of trauma 
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patients admitted to participating hospitals across England and Wales [89]. 
Therefore, the TARN dataset contains cases who were cared under the British 
trauma care system whereas the British data in either CRASH or the IMPACT 
prognostic studies were merged with data from other parts of the world with 
different trauma care policy than that in Britain.  
With regards to the importance of regional and temporal differences in 
trauma care and the importance of observational studies for prognostic 
analysis, the objective of our study is to construct a prognostic model by using 
TBI cases from TARN which can be reliably applied to TBI outcome 
prediction in the UK. 
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7.3. Methods 
To obtain a well-developed prognostic model, the quality assessment tool 
proposed in Perel‟s systematic review was used as a guide [31]. Briefly, the 
internal validity of a model involves adequate rationale to include clearly-
defined predictors, employment of appropriate imputation strategies for 
missing information, performance of an adequate strategy to construct the 
model, appropriate management of interactions, appropriate management of 
continuous variables and lastly the inclusion of 10 outcome events per variable. 
Moreover, the derivation sample should be adequately described and the model 
should be presented with confidence intervals along with measures of 
discrimination and calibration. A well-developed model is also expected to 
sustain its performance in data different to the derivation dataset.  
7.3.1. Selection of predictors and population sample 
The predictors were selected based on the literature review; these being age 
[23, 31, 35, 36, 92], cause of injury [92], GCS [23, 31, 35, 36, 92], pupillary 
reactivity [23, 31, 35, 36, 92], Injury Severity Score (ISS) [31, 35], systolic and 
mean blood pressure [31, 36, 92], presence/absence of hypoxia [31, 36, 92], CT 
findings [23, 31, 35, 36, 92] and presence/absence of extracranial injury [23]. 
The dataset was selected from TARN. The criteria for submission to TARN are 
more than three days stay at hospital, reception of intensive care, inter-hospital 
transfer for specialist care or death due to injury after admission. Hospitals 
submit data to TARN via a web based data collection system. Trained coders at 
TARN would then code the injuries of each trauma case using the Abbreviated 
Injury Scale (AIS) dictionary (currently update 1998) [90]. The inclusion 
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criteria for this study were head AIS codes under the „internal organ‟ [90, 91] 
which held severity score of 3 or above including basal and 
compound/depressed/open skull fracture and availability of pupillary reactivity 
at any time point of trauma care in TARN. The latter criterion arose as 
pupillary reactivity has been shown to be correlated with outcome in the 
IMPACT and CRASH models and TARN commenced recording this variable 
only recently i.e. from September 2005 onward. The outcome measure for the 
analysis was survival at discharge and where applicable, the time point of 
measurement of variables was on arrival at the first hospital (such as for GCS, 
pupillary reactivity, blood pressure etc.).  
7.3.2. Univariate analysis 
The correlation of each covariate with survival was assessed utilizing Mann 
Whitney U test for continuous variables and Chi square test for categorical 
variables with p < 0.05 indicating significance. Age and ISS were considered 
continuous with cause of injury, pupillary reactivity, presence/absence of 
hypoxia (O2 saturation < 90 mmHg), CT findings and the presence/absence of 
extracranial injury as categorical variables. However, GCS, systolic and mean 
blood pressures were assessed both categorically and continuously. GCS was 
categorized into mild i.e. GCS 13 -15, moderate i.e. GCS 9-12 and severe i.e. 
GCS scores of < 9. The cut-offs for systolic blood pressure were 120 mmHg 
and 150 mmHg categorizing that into low blood pressure (<120 mmHg), 
normotension (120-150 mmHg) and hypertension (>150 mmHg) [95]. These 
were the cut-offs proposed by the IMPACT group which are the 25
th
 and 75
th
 
centiles of systolic blood pressure in their data and were observed to have 
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significant influence on outomce in the multivariate anslsyis. Similarly, the cut-
offs of 85 and 110 mmHg were used for mean blood pressure [95]. 
 The descriptions of AIS codes available from AIS dictionary were used 
as “substitutes” for CT findings. This variable was categorized according to the 
Marshal CT Classification [99]. Descriptions of AIS codes were also grouped 
based on commonly-used descriptive terms namely contusion, brain swelling, 
intracranial haemorrhage, Epidural Haemorrhage (EDH), Subdural 
Haemorrhage (SDH), Subarachnoid Haemorrhage (SAH), brain stem injury 
and cerebellar injury. In this manner, if the contusion or haemorrhage occurred 
in the brain stem or cerebellum, it was grouped as the brain stem or cerebellar 
injury. Moreover, we examined the association of each head AIS severity score 
(ranging from minimal 1 to maximal 6) to the outcome. 
To address the linear relationship of continuous variables with loge 
(odds of survival) as a requirement for logistic regression analysis (commonly 
referred to as linearity assumption) [134], fractional polynomials functions of 
continuous variables were employed [135]. Briefly, in this method, power 
transformation(s) of the variable is selected out of the power candidates of -3, -
2, -1, 0, 1, 2, 3 where 0 is loge transformation. The fractional polynomial 
analyses showed that whilst age can be included in the model without any 
transformations; GCS, ISS, systolic and mean blood pressure require 
transformation to correct their non-linear relationship. This simply implies that, 
for instance instead of the crude GCS or ISS values, the following 
transformations are required to be made prior to addition to the model: 
76.0
1
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GCS , 02.110
1
log
1
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e
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7.3.3. Model derivation  
Based on univariate analyses and with the significant level of 5%, the 
covariates identified suitable for inclusion in the modelling procedure were: 
age, cause of injury, GCS (continuous/categorical), pupillary reactivity, ISS, 
extracranial injury, systolic blood pressure (categorical), mean blood pressure 
(categorical), hypoxia, brain swelling, intracranial haemorrhage, EPH, SAH, 
brain stem injury, cerebellar injury and the Marshal Classification. Forward 
stepwise logistic regression was used “manually”. Initially a model was 
constructed with age, GCS, pupillary reactivity, ISS and extracranial injury and 
subsequently other variables (CT finding, systolic and mean blood pressure and 
presence/absence of hypoxia) were added. Age, GCS, pupillary reactivity and 
extracranial injury are the covariates in the basic CRASH models. Model A of 
IMPACT also contains these covariates apart from extracranial injury which is 
not recorded in IMPACT [92]. We added ISS to this list as the extent of 
extracranial injury can affect it and thus ISS contains information on 
extracranial injury too. The next step was adding CT features which is the case 
in the CRASH models and the IMPACT model B. Lastly, addition of blood 
pressure and hypoxia was based on the order in the IMPACT model C. Each 
step involved addition of the next variable and evaluation of the new model in 
terms of the decrease in the deviance, the multicolinearity effect with other 
covariates and improvement in the models performance. If the decrease in the 
deviance compared to the model of the previous step was not significant, the 
variable was excluded from the rest of the modelling. In case of 
multicolinearity effect; the modelling procedure was branched with two 
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„parallel‟ models to avoid containment of variables with this effect in the same 
model.  
During the modelling procedure, it was observed that categorical GCS 
is similar to its continuous form in terms of the added predictive value to the 
model and thus, the modelling was continued with categorical GCS due to its 
simplicity to use as compared to complicated fractional polynomials 
transformations. Likewise, two types of classification of pupillary reactivity 
were tested in terms of the predictive value in the model (4 categories: normal, 
abnormal both eyes reactive, only one eye reactive and bilaterally unreactive 
versus 3 categories: both eyes reactive, only one eye reactive and bilaterally 
unreactive). It was observed that the prognostic strength is better when this 
variable is used with 4 categories rather than with 3 categories. 
Neither systolic nor mean blood pressure demonstrated significant 
effect on outcome when they included in the same model. However, when 
systolic and mean blood pressures were tested in the separate models. 
Furthermore, it was observed that between hypertension and low blood 
pressure only low blood pressure demonstrated significant association with 
outcome when normotension was the reference category. Thus the 
hypertension category was merged with the normotension category leaving 
these variables with only two categories of normotension (including 
hypertension) versus low blood pressure. Moreover, as the model with mean 
blood pressure did not show acceptable goodness of fit as per HL statistics (i.e. 
p value < 0.05), the model with systolic blood pressure was selected.  
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7.3.4. Interactions 
This happens when the effect of one covariate on outcome is influenced by the 
presence of the other covariate. Based on the literature, these interactions were 
investigated: age with cause of injury [160], systolic blood pressure with 
hypoxia [95] and mean blood pressure with present/absent hypoxia [95].  
7.3.5. Imputation  
In multivariate analyses, every case with one missing value is discarded as if it 
does not exist in the dataset. Proper „guess‟ on missing values in a dataset is 
superior to such loss of cases. In this study, all the univariate analyses were 
performed without imputation where in the multivariate analysis, the missing 
information was sequentially imputed with values recorded en route or at 
scene. However, this strategy failed to fill some missing values on systolic 
blood pressure and presence/absence of hypoxia. Therefore, the remaining 
unrecorded data on these variables were all placed into a separate category as 
„missing‟. 
7.3.6. Model validation 
For the external validation, the final models were run on a different TBI dataset 
from TARN (from May 2008 to April 2010) and also the IMPACT dataset.  
Fractional polynomials transformation was performed in Stata and all 
other univariate analyses, model derivation and validation procedure were 
performed in Statistical Package for the Social Sciences (SPSS version 15).  
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7.4. Results  
The inclusion criteria retrieved 802 TBI cases from the TARN trauma dataset. 
The admission date of all cases was from September 2005 (which was the start 
date of recording pupillary reactivity in TARN) until April 2008 (with only one 
case recorded in April). However, there were some occasional records on 
pupillary reactivity prior to start date of recording pupillary reactivity in TARN 
which included in this analysis (127 (15.8%) cases in total).  
Table 30 compares the characteristics of patients whose profiles were 
submitted to TARN after September 2005 and were included in the modelling 
procedure to those who were excluded during the same period. The reason for 
this exclusion was lack of information on pupillary reactivity on every time 
point of measurement in TARN. As seen, the figures related to admission GCS 
and ISS are equal or close in both groups. Similarly, although male percentage 
and survival rate in included cases are different from those in excluded cases; 
this is not statistically significant (p > 0.05). The included dataset, however, 
seems to consist of significantly younger patients than the excluded dataset.
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Table 30 Comparison of demographic and injury characteristics of cases 
which were excluded from the model derivation to those included (i.e. 
submissions to TARN after September 2005) (brakets: 75% interquatile 
range). 
 
Table 31 shows the clinicodemographic characteristics of the 
population sample and the results of univariate analysis. The median age is 39 
with interqaurtile range of 22 to 58 with significant correlation with outcome. 
Males constitute 75.2% of the population with no influence of gender on 
outcome. The majority of the study population (91.9%) are recorded as being 
British with 40% missing information on this variable. No correlation is 
observed between nationality and outcome. Median GCS is 13 (interquartile 
range: 5-15) and the frequency of mild, moderate and severe GCS categories 
Variable 
Excluded submissions 
(1558) 
Included 
submissions 
(675) 
p 
value 
Age 
43.4 
(25.8-67.4) 
38.2 
(23.1-56.5) 
0.01 
Male 71.1% 74.6% 0.20 
Admission overall 
GCS 
12 
(6-14) 
11 
(4-14) 
0.09 
ISS 
25 
(17-30) 
25 
(17-30) 
- 
Survival rate 72.8 73.8 0.72 
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are 35.8%, 12.7% and 51.4% respectively. GCS is significantly correlated with 
outcome both continuously and categorically. Most patients have pupillary 
reactivity recorded as brisk-brisk (68.6%) followed by bilaterally no reaction 
(16.5%). Additionally, the effect of pupillary reactivity on outcome prediction 
is observed to be significant. The patients‟ ISS scores has a median value of 25 
(interquartile range: 16-29) with significant correlation with outcome. 14.5% of 
patients have concomitant extracranial injury as determined by extracranial 
AIS score of 4 or above. This significantly subjects the patient to a lower 
likelihood of survival. 
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Table 31 Clinicodemographic characteristics of population sample and results of univariate analysis *The p value indicates the 
correlation of all categories of covariate with outcome and not only one category. 
 
Covariate Median 
(interquartile 
range) 
Frequency 
(percentage) 
Odds ratio for 
survival 
p value by Man Whitney U test/Chi square 
test 
Age 39 
(22-58) 
 0.98 
(0.98-0.99) 
0.00 
Gender Male  603 
(75.2%) 
 0.75 
Female  199 
(24.8%) 
0.94 
(0.65-1.36) 
Nationality British  442 
(91.9%) 
 0.24* 
European  15 
(3.1%) 
2.10 
(0.47-9.46) 
Others  24 
(4.9%) 
1.22 
(0.45-3.37) 
Cause of 
injury 
RTC  314 
39.2%) 
 0.00 
fall  313(39.0%) 0.93 
(0.66-1.32) 
Assaults  143(17.8%) 2.662 
(1.53-4.62) 
others  32(4%) 1.369 
(0.57-3.28) 
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Table 31 Clinicodemographic characteristics of population sample and results of univariate analysis *The p value indicates the 
correlation of all categories of covariate with outcome and not only one category. (continued) 
 
Covariate Median 
(interquartile range) 
Frequency 
(percentage) 
Odds ratio for 
survival 
p value by Man 
Whitney U 
test/Chi square 
test 
GCS(categorical) Mild  278 
(35.8%) 
 0.00 
Moderate  99 
(12.7%) 
0.35 
(0.19-0.66) 
Severe  399 
(51.4%) 
0.08 
(0.05-0.12) 
Pupillary reactivity Brisk-brisk  446 
(68.6%) 
 0.00* 
Sluggish-sluggish  53 
(8.1%) 
0.21 
(0.11-0.41) 
Brisk-sluggish  16 
(2.4%) 
0.17 
(0.06-0.49) 
None-brisk  16 
(2.4%) 
1.52 
(0.20-11.79) 
None-sluggish  12 
(1.8%) 
0.02 
(0.00-0.10) 
None-none  107 
(16.5%) 
0.03 
(0.02-0.05) 
ISS 25 (16-29)  0.93 
(0.92-0.94) 
0.00 
Extracranial injury (cut-off: AIS score =4)  116 
(14.5%) 
0.51 
(0.37-0.71) 
0.00 
Survival  599 
(74.7%) 
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With regards to physiological measures (Table 32), the median systolic 
and mean blood pressure are 136.5 (interquartile range: 120-75) and 145 
(interquartile range: 126-160) respectively. According to systolic blood 
pressure, 40.4% of cases are normotensive with 29.1% and 26.1% remaining 
records of hypertension and low blood pressure respectively. However, per 
mean arterial blood pressure, majority of cases are hypertensive at 82.3% with 
only 8.1% and 3.7% records of normotension and hypotension respectively. 
Neither systolic nor mean blood pressure have any influence on outcome 
prediction when used continuously whereas this influence is significant 
categorically. Furthermore, 6.5% patients are hypoxic with a significantly 
higher chance of death compared to non-hypoxic patients.  
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Table 32 Vital signs of the population studied and results of univariate analysis. 
 
 
Covariate Median 
(interquartile range) 
Frequency 
(percentage) 
Odds ratio for 
survival 
p value by Man 
Whitney U 
test/Chi square 
test 
Systolic blood pressure 136.5 
(120-75) 
 1.008 
(1.00-1.01) 
0.4 
Systolic blood pressure 
(categorical) 
Hypotension 
(< 120 mmHg) 
 209 
(26.1%) 
0.37 
(0.25-0.56) 
0.00 
Normtension 
(120-150 mmHg) 
 324 
(40.4%) 
 
Hypertension 
(> 150 mmHg) 
 233 
(29.1%) 
0.41 
(0.27-0.62) 
Mean blood pressure(continuous) 145 
(125-160) 
 1.01 
(1.00-1.01) 
0.37 
Mean blood pressure 
(categorical) 
Hypotension 
(< 85 mmHg) 
 30 
(3.7%) 
0.11 
(0.04-0.31) 
0.00 
Normtension 
(85 – 110 mmHg) 
 65 
(8.1%) 
 
Hypertension 
(> 110 mmHg) 
 660 
(82.3%) 
1.73 
(1-2.99) 
Hypoxia (O2 Saturation < 90 mmHg)  51 
(6.5%) 
0.17 
(0.09-0.31) 
0.00 
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With regards to AIS scores, the Marshall Classification and various 
intracranial pathologies (Table 33), most cases have the highest brain injury 
AIS score of 4 at 39.4% and only 6 cases are recorded with the highest AIS of 
6. Likewise, intracranial haemorrhage (of any type) constitutes 76.4% of cases 
with SDH being the most frequent type of haemorrhage (22.1%) followed by 
SAH (18.6%). Similarly, 8.9% and 5.1% of cases have brain stem and 
cerebellar injury respectively (of any kind such as haemorrhage or contusion). 
Nevertheless, non-hemorrhagic brain injuries such as contusion and swelling 
comprise 39.9% and 34.2% of the sample population respectively. Regarding, 
the Marshal CT classification, the most frequent class is class II (50.5%) 
followed by class V/VI (20.7%). The Marshal Classification, various AIS 
scores and CT findings are significantly correlated with survival apart from 
contusion and SDH. 
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Table 33 AIS score, CT findings and the Marshal Class of the population studied and results of the univariate analysis 
Covariate Frequency (percentage) Odds ratio for 
survival 
p value by Man Whitney U 
test/Chi square test 
Highest AIS scores 3 189 
(23.6%) 
 0.00 
 
4 316 
(39.4%) 
0.73 
(0.42-1.27) 
5 291 
(36.2%) 
0.15 
(0.09-0.25) 
6 6 
(0.7%) 
0.02 
(0.00-0.22) 
Contusion 320 
(39.9%) 
1.25 
(0.90-1.74) 
0.18 
Brain swelling 275 
(34. 2%) 
0.31 
(0.22-0.43) 
0.00 
Intracranial haemorrhage 613 
(76.4%) 
0.55 
(0.36-0.83) 
0.00 
Epidural haemorrhage 95 
(11.8%) 
2.85 
(1.49-5.45) 
0.00 
Subdural haemorrhage 178 
(22.1%) 
1.17 
(0.79-1.74) 
0.43 
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Table 33 AIS score, CT findings and the Marshal Class of the population studied and results of the univariate analysis (continured) 
 
Covariate Frequency (percentage) Odds ratio for 
survival 
p value by Man Whitney U 
test/Chi square test 
SAH 149 
(18.6%) 
0.56 
(0.38-0.82) 
0.00 
Brain stem injury 72 
(8.9%) 
0.08 
(0.04-0.14) 
0.00 
Cerebellar injury 41 
(5.1%) 
0.30 
(0.16-0.56) 
0.00 
The Marshal CT 
classification 
I 65 
(8.1%) 
 0.00 
II 405 
(50.5%) 
1.17 
(0.54-2.50) 
III 85 
(10.6%) 
0.39 
(0.17-0.90) 
IV 74 
(9.2%) 
0.19 
(0.08-0.44) 
V/VI 166 
(20.7%) 
0.160 
(0.08-0.35) 
Brain stem/cerebellar injury 4 
(0.5%) 
0.05 
(0.005-0.57) 
Penetrating injury 3 
(0.4%) 
0.32 
(0.03-3.92) 
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7.4.1. Proposed models  
Table 34 (a: model A, b: model B) presents two models derived from the 
dataset. Each model is presented with the covariates, their odds ratios (plus 
confidence intervals), the significance level of the effect on outcome and the 
constant. The reason for the construction of two models is mainly related to the 
correlation of ISS and extracranial injury observed in the correlation matrix 
during the model construction. This implies that these two covariates can not 
be contained in the same model due to multicolinearity effect. Furthermore, it 
was observed that in the multivariate analysis the cut-off point of AIS severity 
score ≥ 3 for the presence of extracranial injury does not yield significant 
correlation with outcome. Nevertheless, when this cut-off was increased to 
extracranial AIS severity score ≥ 4, the significance level of this correlation 
decreased to less than 5%. The other difference between model A and model B 
relates to the predictive power of cause of injury and brain swelling which, 
unlike in model A, has importance in model B. 
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 Coefficient Odds 
ratio 
95. 0% C. I 
for odds ratio 
Sig.  
Age -0.05 0.95 0.94 0.96 < 0.005 
GCS mild      
moderate -0.86 0.42 0.21 0.87 0.02 
severe -1.42 0.24 0.13 0.44 < 0.005 
Pupillary 
reactivity 
Normal      
Abnormal-both 
reactive 
-0.98 0.38 0.2 0.72 < 0.005 
Only one 
reactive 
-1.27 0.28 0.12 0.68 < 0.005 
None reactive -2.87 0.06 0.03 0.11 < 0.005 
 -1.36 0.26 0.14 0.47 < 0.005 
Brain stem injury -1.71 0.18 0.08 0.39 < 0.005 
Hypoxia Yes -1.31 0.27 0.13 0.57 < 0.005 
Missing -0.5 0.61 0.27 1.36 0.225 
Systolic 
blood 
pressure 
Normotension      
low blood 
pressure  
-0.63 0.53 0.31 0.91 0.02 
Missing -0.77 0.46 0.1 2.17 0.329 
Constant 5.63     
Table 34 (a) results of multivariate analysis of outcome prediction: model 
A 
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 Coefficient Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Sig.  
Age -0.04 0.96 0.94 0.98 <0.005 
GCS mild     <0.005 
moderate -0.99 0.37 0.17 0.79 0.01 
severe -1.42 0.24 0.13 0.46 <0.005 
Pupillary 
reactivity 
Normal     <0.005 
Abnormal-
both reactive 
-1.01 0.36 0.18 0.71 <0.005 
Only one 
reactive 
-1.54 0.21 0.08 0.54 <0.005 
None 
reactive 
-3.13 0.04 0.02 0.09 <0.005 
Injury 
cause  
RTC     0.37 
Fall  0.83 2.31 0.56 9.43 0.24 
Assaults  -1.02 0.36 0.05 2.57 0.31 
Others  0.76 2.14 0.04 114.99 0.71 
Table 34 (b) results of multivariate analysis of outcome prediction: model 
B
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 Coefficient Odds 
ratio 
95. 0% C. I. 
for odds 
ratio 
Sig.  
Extracranial injury -1.26 0.28 0.15 0.55 <0.005 
Brain stem injury -1.85 0.16 0.07 0.35 <0.005 
Brain swelling -0.89 0.41 0.24 0.7 <0.005 
Hypoxia Yes -1.42 0.24 0.11 0.54 <0.005 
Missing -0.38 0.68 0.30 1.54 0.36 
Systolic 
blood 
pressure 
Normotension      
low blood 
prusse  
-0.60 0.55 0.31 0.97 0.04 
Missing -0.71 0.49 0.10 2.48 0.39 
Interaction 
of age and 
injury 
cause 
Age and RTC      
Age and fall -0.02 0.98 0.95 1 0.05 
Age and assault 0.04 1.05 0.99 1.10 0.08 
Age and others -0.02 0.98 0.90 1.07 0.69 
Constant 5.99     
Table 34 (b) results of multivariate analysis of outcome prediction: model 
B (continued) 
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7.4.2. Models performance  
Table 35 shows various dimensions of models performances in the derivation 
dataset and two external datasets from IMPACT and TARN. The two models 
have approximately similar figures on every measure of performance in the 
derivation set. The commonly used measure of performance, i.e. AUC, is 0.92 
(95% CI: 0.90-0.95) for model A and AUC = 0.93 (0.91-0.95) for model B in 
the prediction set. With regards to calibration, HL test of model A and B had a 
p value of 0.20 and 0.19 respectively. The TARN external dataset contains TBI 
cases from May 2008 till May 2010 with the same inclusion criteria as those 
for the derivation set although the AUC of model A remains the same in the 
TARN external validation set, the AUC of model B drops from 0.93 to 0.82. 
However, it was not possible to run model A in the IMPACT data as ISS was 
not recorded by IMPACT and thus model B was run for survival and 
favourable outcome prediction (Glasgow Outcome Scale (GOS) ≥ 4). The 
AUC of model B drops from 0.93 to 0.68 and 0.69 respectively for survival 
and favourable outcome prediction in the IMAPCT external dataset.  
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Table 35 Performance of models A and B across various measures of performance (n: number of cases).
 Model A Model B 
Prediction set 
(n=802) 
External 
validation set 
from TARN 
(n=990) 
Prediction set 
(n=802) 
External 
validation set 
from TARN 
(n=792) 
External validation set from the 
IMPACT 
(n=5476) 
survival favourable outcome 
Positive 
predictive value 
68.5% 91.5% 68.5% 90.4% 18.6% 39.8% 
Negative 
predicative value 
94.5% 73.1% 94% 85% 56.6% 28.1% 
Sensitivity 80.8% 94.6% 79.4% 99.3% 73.2% 77.1% 
Specificity 89.8% 64.6% 89.8% 25.3% 11.8% 7.1% 
Classification 
accuracy 
87.9% 89.1% 87.5% 90.1% 24.3% 38.2% 
HL statistics (p 
value) 
0.20  0.19    
Brier score 0.09 0.02 0.08 0.1   
AUC 0.92 
(0.90-0.95) 
0.92 
(0.89-0.94) 
0.93 
(0.91-0.95) 
0.82 
(0.78-.0.86) 
0.68 
(0.67-0.70) 
0.69 
(0.68-0.70) 
Nagelkerke R
2
 0.62  0.64    
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Figure 13 and Figure 14 show the Receiving Operating Curve (ROC) 
curve of respectively model A and B. For model A, the decrease in AUC in the 
TARN external dataset as compared to that in the derivation set is slight 
(constant line versus dashed line). This is also the case for model B as depicted 
by Figure 14. However, the decline is relatively huge in IMPACT data for 
either survival or favourable outcome prediction.  
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Figure 13 ROC curves of model A 
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Figure 14 ROC curves of model B  
 
Figure 15, Figure 16 and Figure 17 show the degree of agreement 
between the predicted probability of survival made by the models and the 
probability observed (calibration plot) (Figure 15: the derivation set, Figure 16: 
the TARN external validation set, Figure 17: the IMPACT external validation 
set). The line reflects the ideal situation in which every prediction is equal to 
the observed probability. As seen, the dispersion from such ideal situation is 
reasonable for both models A and B in either the derivation set or the TARN 
external validation set. However, the calibration appears poor at some points in 
the IMPACT external validation set. We compared the IMPACT dataset with 
the derivation dataset across various patients characteristics and observed that 
the two datasets are significantly different as per every covariate in the model 
such as age, GCS, pupillary reactivity etc. apart from the survival rate. 
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Figure 15 Calibration plot of Models A (○) and B ( ) in the TARN 
derivation dataset 
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Figure 16 Calibration plot of Models A (○) and B ( ) in the TARN external 
validation dataset. 
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Figure 17 Calibration plot of Model AB(○: favourable outcome prediction, 
: survival prediction) in the IMPACT external validation dataset. 
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7.5. Discussion  
Two predictive models of survival to discharge (model A and B) have been 
developed in this study utilizing a recent dataset of severe TBI patients, the 
majority whom received their trauma care in the UK. These two models share 
the covariates: age, GCS, pupillary reactivity, hypoxia and brain stem injury. 
However, model A contains ISS in contrast to model B which includes 
extracranial injury, brain swelling, cause of injury and its interaction with age 
instead. The discrimination powers (AUCs) are 0.92 (95% CI: 0.90-0.95) for 
model A and 0.93 (0.91-0.95) for model B. Both models have acceptable 
calibration per HL test (p value > 0.05). In addition to good performances of 
these models in terms of their discrimination and calibration, the derivation 
method applied in this study conforms to the criteria for a well-developed 
model in TBI [31, 159].  
7.5.1. Limitations  
We performed a selection bias analysis to compare the characteristics of 
patients who were excluded from the modelling due to lack of information on 
their pupillary reactivity to those who were included in the modelling. To this 
aim, the characteristics of 675 (84.2%) of cases in the dataset (included cases) 
who were submitted to TARN from September 2005 to Aril 2008 were 
compared to 1558 TBI cases who were not included in the dataset (excluded 
cases) during the same time period. It was observed that, these two groups do 
not hold statistically significant differences with respect to their gender, 
admission GCS, ISS and survival rate whereas it appears the excluded cases 
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are older than the included cases (43.4 versus 38.2). However, this difference 
between the ages, although being statistically significant, may not be clinically 
significant  
One of the limitations of this study relates to the population sample 
which can not be a truly representative of all TBI patients. This is because the 
sample was extracted from TARN which requires certain submission criteria 
for a given trauma patient such as longer of 3 days stay at hospital or admission 
to intensive care unite. However, although the presented prognostic models are 
not applicable to every TBI patient, it may be easy to ascertain the possible 
applicability to a given TBI patient since the prediction of long stay at hospital 
or transfer to ICU can often be made on admission based on initial clinical 
situation or CT findings.  
The further limitation of this study may be the inclusion of children in 
the analysis (7.5% were less than the age of 15). It has been shown the effect of 
age on outcome in TBI may be different in adults and children in that 
increasing age in children renders a better functionality than in adults [161]. In 
our models, age holds an odds ratio of less than one for survival and as age 
increases, the odds ratio decreases irrespective of the age value representing 
childhood or adulthood. This may suggest that the models presented here are 
best used for adult patients since the majority of the derivation dataset 
comprised adults (median: 39 with interquartile range of 22 to 58). However, it 
is unclear whether or not, despite the differences in functional measures, the 
trends in mortality due to TBI differ in children and adults as well.  
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7.5.2. Comparison with the literature  
The AUCs of our models are higher than those of the IMPACT and CRASH 
models which have AUCs of respectively 0.87 and 0.88. This may primarily 
relate to the differences of characteristics between the IMPACT and CRASH 
datasets to that in this study. In the IMPACT dataset, the majority of patients 
had severe head injury (GCS<9), and no mild brain injuries were included. 
This results in a smaller spread of baseline risks which automatically decreases 
the AUC. Moreover, the outcome prediction in the IMPACT study was long 
term (6 months mortality and unfavourable outcome). The CRASH study 
recruited cases with a lower degree of severity with the inclusion criteria of 
presenting GCS of < 15 on arrival at hospital within 8 hours of injury. 
However, the time point for survival as the outcome measure in our study 
(discharge) is similar to that of the CRASH study (14 days or earlier).  
With regards to application of prognostic models to benchmark the 
trauma care, we believe our TBI models are better than the IMPACT and 
CRASH models for this purpose. This is because the IMPACT and CRASH 
models were derived from clinical trials and hence are less likely to be a good 
representative of the trauma care recipients than data saved in trauma registers. 
On the other hand, for the purpose of stratification of TBI severity in trials, the 
CRASH and IMPACT models are better options as our models have been 
derived from an ongoing observational project. Furthermore, if one wishes to 
apply a prognostic model in a clinical setting, this may depend on the specific 
purpose of such use. Our models predict the discharge survival which is useful 
to provide insight on the acute care of TBI victims. During the acute course 
management, one important strategy can be the provision of neuro-intensive 
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care which has been shown to improve the outcome in TBI [129]. Using our 
models may facilitate balancing decisions on admission/transfer to neuro-
intensive care against appropriate allocation of such resources. On the other 
hand, the IMAPCT and CRASH models can be used to long-term outcome 
prediction which, despite having value during acute care, there are of unique 
value for decisions on delivery of chronic care such as rehabilitative or 
community care.  
Although ISS is contained in none of the CRASH and IMPACT 
prognostic models, it is one of the covariates which is contained in prognostic 
models for general trauma patients such as the TRISS [120] and TARN models 
[142]. Apart from our TBI model A, this variables is also included in the 
Signorini‟s model [93] of TBI prognosis which was reported as one of the best-
developed models in the literature by the Perel‟s  systematic review [31]. The 
ISS partially reflects the effect of extracranial injury on outcome in TBI and is 
calculated by summing the square of three highest AIS severity scores in 
different body regions. Thus extracranial injuries which are severe enough to 
attract high AIS severity scores in multiple trauma would affect ISS and thus 
indirectly the outcome in a model which contains ISS. This may explain why 
ISS and extracranial injury can not be contained in the same model as like our 
model A, Signorini‟s TBI model which included ISS, did not contain 
extracranial injury either.  
7.5.3. Implications of the study  
Among the two models, the advantage of one model over the other mainly 
depends on the purpose of using a prognostic model since both have similar 
performances. In a setting where access to trained coders for coding the 
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injuries are not available, model B may be a better option as it does not involve 
calculation of fractional polynomial transformation of ISS 
 (                                   ). On the other hand, trauma registries may opt for 
model A which contains less covariates to run specifically where missing 
values are an issue. Conspicuously, the selection of the appropriate model in a 
retrospectively accrued TBI dataset depends on the availability of values on 
each covariate used by the model.  
We examined the importance of various intracranial pathologies from 
the literature in our modelling procedure and found that only brain stem injury 
(as in either model A or B) and brain swelling (as in model B) are significant. 
Although we based this piece of analysis on observations by other studies 
about prognostic strength of CT, unfortunately, we did not have access to the 
actual CT images in our registry and thus descriptions to brain injury AIS 
codes in the dictionary were used as substitutes for CT reports. However, CT is 
not the only source for AIS coding as the coding can be done based on the 
results of MRI, operational notes and etc. Therefore, whilst majority of 
information for AIS coding is obtained from CT reports, caution should be 
taken with regards to using the term „CT‟ abnormality to refer to brain stem 
injury and brain swelling in our models. As such, it is important to note the 
diagnosis of these pathologies in our models should not exclusively depend on 
CT and it can be according to MRI results, intracranial operation or even 
merely clinical basis. Consequently, using the term „intracranial pathology‟ is 
preferable to „CT finding‟ when referring to these pathologies in our models.  
We have no certain explanation as to why cause of injury and brain 
swelling lose their significance if the extracranial injury in Model B is replaced 
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with ISS in model A. This may, however, imply that extracranial injury, injury 
causes and brain swelling contains the same predictive strength as ISS does on 
its own since the performances of the two models do not significantly differ. 
Considering that extracranial injury influences ISS, it can be assumed that each 
ISS value represents partly extracranial injury with the remaining part being 
dependent on intracranial injury. Therefore, in reality, this „intracranial‟ part of 
ISS may be equivalent to cause of injury and brain swelling in its predictive 
strength. This may lead to the conclusion that due to the direct possible effect 
of brain swelling on ISS, there must be some degree of correlation between 
cause of injury and the type of intracranial injury sustained which would affect 
AIS coding and subsequently ISS [94].  
We have externally validated our models on two other TBI datasets 
from TARN and the IMPACT collaboration. Our models performance seems 
promising in the TARN dataset which is from a different time periods but 
otherwise with the same inclusion criteria (historical validation) [113]. This 
implies the models are valid for trauma benchmarking in Britain. However, the 
external validation in the IMPACT dataset does not appear satisfactory despite 
AUCs still being far above the cut-off of random guess (0.50). This may be due 
to different case-mix or time point of outcome prediction which is long term in 
IMPACT (6 months). The other explanation may be that our derivation dataset 
is more up to date.  
Trauma registries use prognostic models derived for general trauma 
patients including patients with traumatic brain injury to benchmark trauma 
care systems. The most well-known of these prognostic models are the TRISS 
methodology [120] but they are several other models tailored for different 
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subsets of patients such as intubated patients [154], patients with penetrating 
injury [120] or children [162]. TARN has also developed its own model of 
prognosis to suit the UK trauma population [142]. Benchmarking of neuro-
trauma care may have to be performed separately from benchmarking general 
trauma care through models derived from TBI populations. Furthermore, all 
commonly used general trauma models do not contain pupillary reactivity 
which in both models A and B holds a large effect on outcome (for example, 
the category of „both absent‟ holds the largest coefficient in both models and 
other categories of pupillary reactivity also have high coefficients compared to 
coefficients of other covariates). In fact, pupillary reactivity is the only 
covariate which is included in the TBI models (such as our proposed TBI 
models and also the CRASH and the IMPACT models) but is excluded in 
models for general trauma patients. Furthermore, bearing in mind that GCS not 
always suggests brain injury (as its impairment may be due to intoxication or 
secondary brain damage following hypoxia or hypotension), abnormal 
pupillary reactivity is the clinical finding which amongst the factors included in 
either general trauma or TBI prognostic models, may be the most indicative of 
underlying brain damage. This suggests that recording the pupillary reactivity 
for all victims of TBI must be declared mandatory in trauma registries 
including TARN.  
7.5.4. Future directions 
Beside the historic external validation which was performed on a TARN TBI 
dataset from a different time period, the proposed models still require further 
external validation to examine their „universal‟ generalisibiity. Ideally, a 
prognostic model should hold geographic validation (on datasets from different 
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localities), methodological validation (on datasets with a different study design 
or method of data collection), spectrum validation (on datasets with different 
severity of injuries) and follow-up interval validation (on datasets with 
different time point of outcome assessment) [113]. Although one may consider 
the performance of our models unsatisfactory in the IMPACT dataset to rule 
out various aspects of their external validity such as  methodological, spectrum 
or follow-up interval, this drop of performance can be due to our contemporary 
derivation dataset as compared to the IMPACT data or different case-mix and 
thus our models still have to be run in other recent TBI series to examine their 
validity.  
In this study, the coefficient of each regressor is provided which, if 
presented on a web-calculator could assist clinicians in quantifying the 
probability of survival for a TBI patient with given characteristics. 
Nevertheless, the safety of prognostic models in predicting the outcome for an 
individual patient is a controversial topic and requires further investigation. On 
the one hand, provision of this model may lead to withdrawal of active therapy 
to a patient with a poor predicted prognosis. On the other hand, with growing 
consensus on the various components of TBI management such as intubation 
or use of osmotic diuretics, the concern over the negative effect of models 
prognosis on appropriate therapy may be allayed especially if probability of 
outcome is considered along with other factors influencing TBI management. 
In fact, senior doctors often make predictions on the potential outcome of 
individual TBI patients and the role of prognostic models here may be solely to 
quantify this prediction. 
 266 
The models presented in this study are used to predict survival at 
discharge. However, TBI management which includes therapeutic measures 
followed by rehabilitative schemes should target full recovery to the same level 
of physical and mental health as prior to the occurrence of injury and not only 
survival. Regarding this, in TBI management, knowledge on the probability of 
survival is not the only required factor in terms of prognosis since it is also 
important to know the risk of disability in survivals. Derivation of models to 
assist with prediction on outcomes apart from survival on a dataset from more 
homogeneous trauma care systems/policies is a matter of future research.  
7.5.5. Conclusion  
Two well-constructed prognostic models have been derived and internally 
validated which can be used to predict the survival of severe TBI patients 
based on simple clinical characteristics particularly applicable to British trauma 
care system.  
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7.6 Expansion on methods 
The main stages of model development as presented in the paper were 
covariates selection, dataset selection, selection bias analysis, univariate 
analysis, model derivation (i.e. manual stepwise logistic regression), 
imputation of missing information and model validation (internal and external). 
Some further details about performance of these steps follow. Moreover, not all 
of these stages were performed independently or in the above-mentioned 
sequence. For example, the imputation of missing information was performed 
during the model derivation.  
7.5.6. Dataset selection  
This was performed in two steps  
 
Step I 
 
The format of recording data in TARN is such that each hospital holds a 
distinct `submission to TARN. This means if a patient has been transferred 
from the first admitting hospital to a second hospital or further to a third 
hospital, he/she holds a number of TARN submissions equal to the number of 
attended hospital (assuming all attended hospitals submit data to TARN as 
otherwise the attended non TARN hospital is missing). Therefore, TARN saves 
information of submissions and not cases. In this first step of dataset selections, 
all submissions which met the criteria (i.e. brain injury AIS score of 3 or more 
plus basal and compound/depressed/open skull fracture AND also availability 
of pupillary reactivity at any time point (at scene, en route, at Emergency 
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Department (ED))) were extracted from the TARN „mother‟ dataset through 
running the appropriate syntax in Microsoft SQL Server. This procedure 
returned 1009 submissions.  
 
Step II 
 
This step involved firstly matching all submissions which belonged to one 
patient (case) and then to exclude those patients who did not have submission 
either from the first attended hospital or the last hospital from which the patient 
was discharged. The first submission was required for the record of admission 
variables such as GCS, pupillary reactivity, blood pressure etc. and the last 
submission was required for the record of the discharge survival. After 
matching procedure, there were 735 cases which had not been transferred and 
thus information on admission and discharge was available. Of the remaining 
274 transferred cases, only 67 cases had all the information available which 
meant 207 (274 - 67) cases did not have information from either the first 
hospital or the last hospital. To sum up, the final dataset contained 802 cases of 
TBI.  
7.5.7. Univariate analysis  
This stage involved the following analyses: 
Describing the distribution of each variable: the one-sample Kolmogorov-
Smirnov test was used to test whether the values of continuous variables were 
normally distributed or not. The p value of this test for all continuous variables 
was less than 0.05 (i.e. indicating non-normal distribution) and thus the median 
and the interqaurtile range were calculated to describe the distribution of each 
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covariate. For categorical variables, the frequency of each category was 
calculated.  
Describing distribution of each variable in survivors and non survivors: the 
Mann Whitney U test was used for this purpose to compare the median and 
IQR of continuous variables and Chi Squared test was used for categorical 
variables. The logistic regression was also run to calculate the unadjusted odds 
ratio for survival for each covariate.  
Fractional polynomial analysis: this was performed to assess the linear 
relationship of the continuous covariates with loge (odds of outcome) 
and, in case of non-linearity, to identify the appropriate power transformations. 
This refers to the linearity assumption by the logistic regression. If the 
continuous variable does not demonstrate this linearity (between the variable 
and loge (odds of outcome)), then it has to be categorised or 
transformed. Fractional polynomial transformation is the power transformation 
of variables out of 7 power candidates of -3, -2, -1, 0, 1, 2, 3. [135]. This 
method is used to transform those continuous variables which do not meet the 
linearity assumption. Fractional polynomial analysis has to be performed in 
Stata since SPSS does not have this feature. The output of this analysis in Stata 
can be used not only to assess various transformations of the variable but also 
to assess the linearity assumption in the first place. The output of Stata shows a 
table containing three models: the linear model, the first degree model, and the 
second degree model. The linear model includes the continuous variable as it is 
(i.e. with no transformations or power transformation 1). The first degree 
model includes the variable with only one power transformation and the second 
degree model is with 2 power transformations. Based on the changes in the 
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deviance, one model has to be selected which demonstrates what power 
transformations should be used. Selection of the model is based on the 
significance of „gain‟ in the deviance as compared to the previous model. For 
example, if the change (or gain) in the deviance is significant in the first degree 
model as to the linear model (the model at the previous stage), then this means 
one power transformation should be applied to meet the linearity assumption. 
The power transformation is presented for each model derived in Stata. 
However, the final transformation(s) is the power transformation as suggested 
by the selected model plus/minus a constant which is provided separately by 
Stata. This implies that the formula to transform the continuous variable takes a 
different form to merely being a power transformation. For example, the GCS 
transformation takes the following form:. 
76.0
1
10
2
GCS  
02.1
10
1
log
1
10
2
GCS
GCS
e
 
The above formula clearly show that the power transformation is not 
the only mathematical calculation. For example, the first formula contained a 
constant (-0.76) alongside the power transformation of 2.  
Examples of the type of tables given by Stata to select the model of 
transformation presented later in this section with respect to each continuous 
variable analysed (Table 36 , Table 39, Table 41, Table 42 and Table 43).   
Furthermore, there is a way to visualise the results of Fractional 
polynomial analysis in a graph. This graph is drawn to assess how close the 
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observed probabilities were to the predicted probability for various values of 
the continuous variables (a discussion on predicted versus observed probablity 
is presented in Paper 1; section 2.7). For this purpose, the logistic regression is 
run on the dataset with the transformation indentified by fractional polynomials 
as covariates and the survival as outcome. The calculated predicted probability 
for each case in the dataset was saved (SPSS has this feature to save this 
probability in front of each case included in the data). The observed probability 
is also calculated for each value of the continuous variable. For example 
various cases with the same age of 23 may experience different outcomes as 
one may die and the other may survive. As such, the observed probability for 
each value of age is the frequency of cases who experience the outcome. The 
final graph can be drawn with x axis being the continuous variable and y axis 
being the probability. In this section, various examples of this type of graph are 
presented with respect to each continuous variable analysed. (Figure 18, Figure 
19, Figure 20, Figure 21, Figure 22, Figure 23, Figure 24, Figure 25 and Figure 
26). The constant line represents the predicted probability with circles (○) 
standing for the observed probability. It is expected that the circles (i.e. the 
predicted probabilities obtained through fractional polynomial transformation) 
follow the line (observed probability). This will be referred to as whether these 
two follow the same pattern or not. The image which shows the pattern of the 
predicted and observed probabilities visualises whether or not the fractional 
polynomial transformation meets the linearity assumption satisfactorily. A 
perfect transformation is when the predicted and observed probabilities (y axis) 
follow absolutely the same pattern as the continuous variable changes (x axis).  
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For sake of presentation, the y axis of the graph was scaled using the 
logit of the observed/predicted probability (i.e. Log (probability/(1- 
probability)). This, however, caused a problem when the probability was 1 or 
0. In order to rectify this problem, the frequency of the cases who were all dead 
or all alive were taken into account by using the following formula: 0.5 – 
frequency/ frequency. This calculation is referred to as „correction for the 
frequency‟.  
 
Age  
 
Table 36 shows the results of fractional polynomial analysis for age. According 
to this table, the linear model had p value of 0.00. This significant p value for 
the linear model indicates there is no need for transformation or the age meets 
the linearity assumption as it is. Figure 18 and Figure 19 demonstrate the plot 
of predicted and observed probability against age (with no transformations) 
before and after correction for the frequency. Overall, predicted and observed 
probability followed the same pattern apart from some cases who were less 
than the age of 20 or around the age of 60 which this has been corrected in 
Figure 20 following the correction for frequency. 
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Table 36 Comparison of models of fractional polynomial transformations 
for age  
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Figure 18 The plot of age against predicted and observed probability 
without transformation before correction for the frequency. 
 
 df Deviance Gain P Powers 
Not in the 
model 
0 907.437    
Linear 1 882.981 0.000 0.000 1 
First degree 2 879.814 3.167 0.075 3 
Second 
degree 
4 878.215 4.766 0.450 -2 3 
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After correction for frequency 
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Figure 19 The plot of age against predicted and observed probability 
without transformation after correction for the frequency.  
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Cause of injury  
 
TARN does not hold a distinct variable with this name. Instead it has two other 
variables with the names of „mechanism of injury‟ and „level of intent‟ which 
were used to generate the cause of injury in this study. Categories included 
under level of intent in TARN were: non-intentional, alleged assault, suspected 
child abuse, suspected self-harm, sports, suspected high risk behaviour, 
alleged intent (non-assault) and others. Injury mechanism included vehicle 
incident/collision, fall more than 2 meters, fall less than 2 meters, shooting, 
stabbing, blast, blow, and burn, skeletal/organ/vessel destruction and others.  
The categories to include in the cause of injury were selected from the 
IMPACT study which contained RTC, work-related, assault, sports/recreation 
and others. There were two major differences between TARN formatting of 
cause of injury and that in IMPACT. This related to work-related injuries 
which are not recorded in TARN but recorded in IMPACT and „fall‟ which is 
recorded in TARN but not in IMPACT. Thus, the final categories to be 
included as cause of injuries were RTC, fall, assaults, sports and others (work-
related was discarded from the IMPACT categorisation and instead fall from 
the TARN categorisation was added).  
With the above modified IMPACT categorization, a strategy was 
required to allocate a cause of injury (out of RTC, fall, assaults, sports and 
others) to each case of TBI in the dataset from the information available on 
“injury mechanism” and “injury intent”. Table 37 demonstrates the cross-
tabulation of „injury intent‟ with „injury mechanism‟. The strategy to allocate 
an injury cause to each case based on this cross-tabulation was decided as 
follows:  
 286 
 
Table 37 The cross-tabulation of injury mechanism and injury intent. 
 
All patients who have their level of intent recorded as sports should go 
under „sports‟ regardless of their injury mechanism. Similarly, all patients who 
have their injury mechanism recorded as assault or level of intent as assault 
should go under „assault. This means, for instance, if the patient has RTC under 
injury mechanism and assault under injury intent, assault was allocated 
irrespective of RTC as injury mechanism (there were overall 3 cases with this 
combination). With regards to RTC (as a cause of injury), as seen in Table 37, 
there were 321 cases with this injury mechanism. Of these, 3 were assault and 
4 were sports with remaining 314 being “others” under injury intent. To 
exclude the assaults and sports patients, RTC needed to be defined as when 
injury mechanism is RTC and level of intent is “others”. This was because 
patients with injury intent of assault or sports were respectively allocated to 
assault and sports. The same thing applies for falls. Table 38 summarises how 
each category of cause of injury were defined from injury mechanism and 
injury intent.  
 Injury Mechanism Total 
RTC Fall assault others 
Injury 
Intent 
assault 3 11 97 3 114 
sports 4 8 0 2 14 
others 314 313 29 18 674 
Total 321 332 126 23 802 
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Table 38 Allocation of injury cause based on injury mechanism and level 
of intent.  
 
GCS 
 
The IMPACT models use motor GCS instead of total GCS whereas the 
CRASH models use total GCS. The analysis presented in Paper 3 was 
performed to assess whether total GCS is preferable or its motor component. 
The results demonstrated that these two do not have a significant difference in 
outcome prediction. Furthermore, in the TARN dataset, the admission GCS 
score had only 26 missing values where this was much more for motor GCS 
(246 missing cases). Regarding this and the same predictive strength of total 
GCS to motor GCS, the decision was made to include the total GCS rather than 
motor GCS in the modelling.  
Total GCS was treated as both continuous and categorical. With the 
cut-offs of 12 and 9 (inclusive), this variable was categorised into three 
categories of mild, moderate and severe brain injury. For the continuous form, 
Table 39 shows the result of its fractional polynomials transformation. 
According to this table, the second degree model provided significant gain in 
the deviance (as determined by the P value) compared to the first degree and 
the linear model. The column representing gain is in fact the subtraction of the 
Cause of injury Definition 
RTC 
injury mechanism = RTC AND level of 
intent = others 
Fall 
injury mechanism = Fall AND level of 
intent = others 
Assault 
injury intent = assault OR level of intent = 
assault 
Sports Level of intent = sports 
Others 
remaining cases 
 
 
 288 
deviance of the respective model from the previous model. The output of 
STATA contained the following transformations for GCS: 
76.0
1
10
2
GCS
 and 
02.1
10
1
log
1
10
2
GCS
GCS
e
. Figure 20 shows the 
observed and predicted probabilities follow reasonably similar patterns with 
these transformations.  
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Table 39. Comparison of models of fractional polynomial transformations 
for GCS.  
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Figure 20 The plot of predicted and observed probability of survival 
without correction for the frequency.  
 df Deviance Gain P Powers 
Not in the 
model 
0 876.751    
Linear 1 704.556 0.000 0.000 1 
First 
degree 
2 684.970 19.586 0.000 0 
Second 
degree 
4 650.716 53.839 0.000 -2 -2 
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Pupillary reactivity.  
 
TARN records pupillary reactivity for each individual right and left eye as 
brisk, sluggish, absent or otherwise missing. A new variable was created which 
combined the records of each eye. Table 40 shows the frequency of each 
category following combining the right and left eye recordings. Chi square test 
for this pupillary reactivity categorisation demonstrated a significant difference 
between survivors and non-survivors (P < 0.0005). 
Table 40. Frequency of various categories of pupillary reactivity after 
combination of right and left eyes in survivals and non-survivals.  
 
ISS 
 
The Injury Severity Score (ISS) is a measure on an ordinal scale of anatomical 
severity of injury. It is the sum of the squared of the 3 highest AIS severity 
scores allocated to the patient. Table 41 shows the results of fractional 
polynomial analysis. According to this table, the first degree model is the best 
model since it provided a significant gain over the linear model. The formula 
for this presentation as given in the STATA output was                  . 
Figure 21 demonstrates the plot of ISS with observed and predicted 
probability without correction for frequency. According to this graph, some 
ISS values (just below 20) have similar observed probabilities whereas their 
predicted probabilities differ. However, this is not the case after the correction 
91.0
10
log
ISS
e
 Total  Survival  Non-survival  
Brisk-brisk 446(55.6%) 405(82.5%) 41(25.8%) 
Sluggish-sluggish 53(6.6%) 36(7.3%) 17(10.7%) 
Brisk-sluggish 16(2%) 10(2%) 6(3.8%) 
None-brisk 16(2%) 15(3.1%) 1(0.6%) 
None-sluggish 12(1.5%) 2(0.4%) 10(6.3%) 
None-none 107(13.3%) 23(4.7%) 84(52.8%) 
Missing  152(19%) - - 
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for frequency was performed as depicted in Figure 20. According to this figure, 
observed and predicted probabilities follow almost the same pattern in an 
acceptable way. 
 
Table 41 Comparison of models of fractional polynomial transformations 
for ISS.  
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Figure 21 The plot of predicted and observed probability of survival 
before correction for the frequency. 
 
 df Deviance Gain P Powers 
Not in the 
model 
0 907.437    
Linear 1 802.639 0.000 0.000 1 
First 
degree 
2 794.982 7.657 0.006 0 
Second 
degree 
4 793.691 8.948 0.524 -2 -1 
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After correction for frequency 
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Figure 22 The plot of predicted and observed probability of survival after 
correction for frequency.  
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Extracranial injury  
 
In TARN, AIS codes and severities are not recorded together under the 
same variables. This means there are a number of variables representing AIS 
codes with some others representing severity scores. AIS codes are saved under 
C (C1 to C21) with AIS severities under S (S1 to S21). For example, if a 
patient receives AIS codes and scores of 7164006.3 and 630299.2, he/she holds 
C1 and C2 (AIS codes) recorded as 7164006 and 630299 with S1 and S2 
(severity scores) recoded as 3 and 2. The ending number of C and S is used to 
match the AIS code with the severity score. As in the above example, C2 and 
S2 represent 630299.2.  
To create the variable representing the extracranial injury, a new 
nominal variable was created to count the number of cases with extracranial 
injury AIS codes, whose AIS score was above 3. To do this, the syntax was 
used which first searched C1 to C21 to spot extracranial AIS codes and then 
subsequently checked the matched AIS score (i.e. S1 to S21) for scores above 
3.  
Using this cut-off, the frequency of extracranial injury was 277 
(34.5%).  
 
Systolic blood pressure  
 
This variable was treated both continuously and categorically with the cut-offs 
for categorisation being 120 and 150 from the IMPACT [95]. Table 42 displays 
the results of fractional polynomial analysis of systolic blood pressure. As 
seen, the second degree model provides the highest significant gain in deviance 
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as compared to the linear model. The formula for the transformation in the 
output of STATA was 731.0
1
100
1
SysBP
SysBP  and 
229.0
1
100
ln
1
100
2
SysBPSysBP
SysBP . Figure 23 and Figure 24 
display the plot of systolic blood pressure with observed and predicted 
probabilities respectively before and after correction for the frequently. Even 
after the correction for the frequency (Figure 24), the patters of distribution of 
the predicted and the observed probabilities do not appear to be satisfactorily 
the same.  
 
 df Deviance Gain P  Powers 
Not in 
model 
0 555.333    
Linear 1 546.005 0.000 0.000 1 
First 
degree 
2 518.632 27.373 0.000 -2 
Second 
degree 
4 496.449 49.556 0.000 -1  -1 
Table 42 Comparison of models of fractional polynomial transformations 
for systolic blood pressure.  
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Figure 23 Plot of predicted and observed probability of survival for 
systolic blood pressure before correction for frequency.  
 
 
 
After correction for frequency 
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Figure 24 Plot of predicted and observed probability of survival for 
systolic blood pressure after correction for frequency.  
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Mean blood pressure  
 
This variable was also treated both continuously and categorically with the cut-
offs for categorisation being 85 and 110 from the IMAPCT [95]. Table 43 
displays the results of fractional polynomials analysis of mean blood pressure. 
According to this analysis, the second degree model held the best gain 
according to the p value in the deviance as compared to the linear model. The 
formula for the transformation in the output of the STATA was 
981.0
100
333.0
1
MeanBP
MeanBP  and 
386.0
100
333.0
ln
100
333.0
2
MeanBPMeanBP
MeanBP . Figure 25 and 
Figure 26 show the plot of mean blood pressure with predicted and observed 
probability of survival. Similar to  systolic blood pressure, even after correction 
for the frequency, the patters of distribution of the predicted and the observed 
probabilities do not appear to be satisfactorily the same. Furthermore, mean 
blood pressure demonstrated a significant association with outcome by logistic 
regression whereas Mann Witney U test did not find any significant difference 
in mean blood pressure between survivors and non-survivors. 
 
Table 43 Comparison of models of fractional polynomial transformations 
for mean blood pressure.  
 df Deviance Gain P  Powers 
Not in 
model 
0 544.192    
Linear 1 538.157 0.000 0.014 1 
First degree 2 520.952 17.206 0.000 -2 
Second 
degree 
4 511.815 26.342 0.010 0.5  0.5 
 
 297 
Before correction for frequecny
(one extreme value of blood pressure of 0 with 
odds of death of -23 was excluded) 
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Figure 25 Plot of predicted and observed probability of daeth for mean 
blood pressure before correction for frequency.  
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odds of death of -23 was excluded) 
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Figure 26 Plot of predicted and observed probability of daeth for mean 
blood pressure after correction for frequency.  
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AIS scores, the Marshall Classification and various intracranial pathologies  
 
AIS severity scores are saved in TARN under S1 to S21. Moreover, 34.4% of 
cases had more than 3 brain injury AIS codes/scores allocated to them. Due to 
this, a syntax was written to search all brain injury AIS scores for the highest 
one.  
TARN does not have record of CT images/reports and thus AIS 
descriptions in the AIS dictionary were used for the Marshall Class allocation. 
The method applied is presented in Paper 4.  
Similarly, AIS codes were used to define various types of intracranial 
pathologies. The pathologies investigated are presented in Paper 5 (cerebral 
contusion, cerebral brain swelling, cerebral haemorrhage, cerebral EDH, 
cerebral SAH, brain stem injury and cerebellar injury). Table 44 provides AIS 
codes allocated to each intracranial pathology. Apart from SAH, all injuries 
have more than one code  which represents taking severity of injury based 
on size or being unilateral versus bilateral into account. However, haemorrhage 
(Not Specified: NS) encompasses cases with unknown type of cerebral 
haemorrhage or intracerebral haemorrhage. Furthermore, the brain stem and 
cerebellar injuries encompass various types of injuries including contusion, 
haemorrhage, infarction etc.  
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Table 44 Various AIS codes allocated to each intracranial pathology.  
Brain injury AIS codes 
Contusion 140204,140402,140403,140404,140405,140602,140604,140606,140608,140610,140612,140614, 
140616,140618,140611,140620,140622, 140624,140626 
 
Brain swelling 140662, 140664, 140666, 40660, 140628 
 
Epidural 
haemorrhage 
140414,140418,140422,140630,140632,140634,140636 
 
Subdural 
haemorrhage 
140438,140442,140446,140650,140652,140654,140656 
 
SAH 140684 
 
Haemorrhage 
(Not  
Specified: NS) 
140629, 
140638,140640,140642,140644,140646,140648,140678,140686 
 
Penetrating 
injury 
140216, 140478, 140690 
Brain stem 
injury 
140202,140204,140206,140208,140210,140212,140214,140216, 
140218,140299 
 
Cerebellum 
injury 
140402,140403,140404,140405,140406,140410,140414,140418,140422,140426,140430,140434,140438, 
140442,140446,140450,140458,140462,140466,140470,140474,140478,140499 
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7.5.8. Model derivation  
The overall stages of model derivation are described in the Paper 6. What 
follows is more detailed explanation of the modelling procedure. In order to 
avoid confusion with the „stepwise‟ logistic regression, each step is referred to 
as „level‟. In each level one model or more were derived for the purpose of that 
very level and the observations obtained during performance of that level are 
provided. The model(s) derived is (are) presented in the Appendix labelled 
according to the relevant level.  
Some levels involved adding of new variable(s) to the model derived at 
the previous level and observing the significance of change in the model 
deviance, in AUC and in the p value of the HL statistics. Multicolinearity 
among variables was also examined in the correlation matrix given by the 
output of SPSS at each level to avoid containment of two variables with this 
effect in the same model (multicolinearity effect: when two variables included 
in the same model are associated with each other. This should not occur and 
one of the two variables should be excluded from the model. SPSS output 
contains a table with the name of the Correlation Matrix which gives the 
degree of the associations among all the variables included.). Furthermore, 
based on the literature, the interaction between variables was specified in the 
SPSS syntax and the significance of the interaction was examined in the model 
output. In order for a variable to stay in the model, that variable had to decrease 
the deviance significantly and demonstrated significant association with 
survival with an acceptable significance and direction of odds ratio. Failure to 
meet any of these three requirements resulted in the removal of the variable.  
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It should be noted that although in the Paper 6 the imputation is 
described as a separate stage for the sake of presentation suitable for a journal 
article, this was in fact performed during model derivation. Furthermore, model 
derivation is a „try and error‟ procedure with regards to how a covariate may be 
included in the model (i.e. continuous or categorical, if categorical with 
what/how many categories), the order in which variables are included (i.e. 
which one is the first, the second, and the last) and the order of the levels of 
modelling. Although an overall strategy of model derivation was decided prior 
to modelling, however, „adaptations‟ were necessary due to the given 
observations obtained during the progress of the procedure. This section 
describes what prospectively occurred during the levels of the modelling. A 
perspective on the approach taken below in terms of efficiency and 
effectiveness is given in the main thesis discussion.  
The model derivation was performed over 15 levels and   table 45 
presents the title of each level along with the main observation(s) obtained at 
that very level. The title of the level somewhat shows the main aim of that level 
which is based on either the observation(s) on the previous level or the 
progress of the modelling procedure by adding/considering new variables. In 
fact  Table 45 can reflect on the inherent „try and error‟ nature of modelling by 
demonstrating the lack of a clear coherence in the procedure. This is because 
some levels could have been done prior or following to their current position or 
some repetitions could have been avoided. For example, following performing 
8 levels, the various cut-offs for extracranial injury (extracranial AIS severity 
score) were explored. This level could have been done at a much earlier level 
such as level 3. The current position of this level then resulted in reconstruction 
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of all models which had been derived up to level VIII (i.e. unnecessary 
repetition in retrospect). The following section supplies the way the model 
derivation was performed with respect to Table 45. Table 57 situated after this 
explanation provides main points and decisions of the modelling procedure 
important for understanding the way the final models were proposed and the 
levels which addressed these points.  
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 Table 45 Various levels of model derivation 
 
Level Title Observation(s) 
I Automatic stepwise modelling of age, 
continuous GCS, pupillary reactivity, ISS 
and extracranial injury 
 One of GCS transformations was 
discarded by SPSS which was not 
acceptable. 
II Manual stepwise modelling of age, 
continuous GCS, pupillary reactivity, ISS 
and extracranial injury 
 Pupillary reactivity: absent-brisk 
had odds ratio of above one for 
survival (not acceptable) 
 ISS and extracranial injury can not 
be included in the same model due 
to multicolinearity effect. 
III New categorisation of pupillary 
reactivity/decision to employ ISS or 
extracranial injury 
 Pupillary reactivity with three 
categories of both reactive, only 
one reactive and none reactive is 
better. 
 Extracranial injury (extracranial 
AIS score > 2) did not have a 
significant association with 
outcome in the model. 
IV Model IIIA including categorical GCS (12 
categories) 
 GCS scores of 9, 4 and 3 had odds 
ratio of above one for survival (not 
acceptable) 
V Model of level IIIA including new 
categorisation of GCS (3 categories) 
 GCS with 3 categories had 
significant association with 
outcome. 
VI Testing the value of cause of injury  Cause of injury is significant only 
when GCS is continuous. 
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  Table 45 Various levels of model derivation (continued)   
Level Title Observation(s) 
VIII Trial of the new categorisation of 
extracranial injury 
 Extracranial injury (extracranial 
AIS > 3) can be included in the 
model without ISS (with GCS either 
continuous or categorical). 
IX Imputation of missing GCS and pupillary 
reactivity 
 All missing GCSs were imputed 
with en-route and then at scene 
scores without significant changes 
in the model performance. 
 All missing pupillary reactivities  
were imputed with en-route and 
then at scene scores without 
significant changes in the model 
performance. 
 
X Inclusion of intracranial pathology  AIS scores were not selected as not 
all of them demonstrated significant 
association with outcome. 
 The Marshall Classification was not 
selected as not all classes 
demonstrated significant association 
with outcome. 
 SAH, EDH and haemorrhage did 
not show significant association 
with outcome. 
 Brain swelling and brain stem injury 
demonstrated significant association 
with outcome. 
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Table 45 Various levels of models derivation (continued). 
Level Title Observation(s) 
XII Adding systolic blood pressure, mean blood 
pressure and hypoxia 
 Neither systolic blood pressure nor 
mean blood pressure were significantly 
associated with outcome (with 195 
missing cases in total) 
 Hypoxia was significantly associated 
with outcome. 
XIII Analysis of missingness/imputation of mean 
and systolic blood pressure and hypoxia 
 On univariate analysis, cases with 
missing systolic blood pressure tended 
to be younger, have lower GCS, more 
frequency of brain stem injury and 
lower survival rate. 
 On multivariate analysis, age and 
cause of injury significantly affected 
the missingness of systolic blood 
pressure. 
 On univariate analysis, cases with 
missing mean blood pressure tended to 
be younger, have lower GCS, lower 
frequency of extracranial injury and 
brain stem injury and lower survival 
rate. 
 On multivariate analysis, only age had 
significant effect on missingness of 
mean blood pressure. 
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 Table 45 Various levels of model derivation  (continued)  
Level Title Observation(s) 
XIII 
(continued from the previous page) 
Analysis of missingness/imputation of mean 
and systolic blood pressure and hypoxia 
 On univariate analysis, cases with 
missing O2 Sat. tended to have lower 
GCS, higher frequency of extracranial 
injury and brain stem injury and 
lower survival rate. 
 On multivariate analysis, only GCS 
had a significant effect on 
missingness of O2 Sat.. 
 All missing cases with systolic or 
mean blood pressure or O2 Sat. were 
placed in a separate category as 
missing. 
XIV Trial of systolic and mean blood pressure 
individually/2 versus 3 categories 
 Hypertension (either as per systolic or 
mean) was not significantly 
associated with outcome. 
 The model with mean blood pressure 
did not show acceptable goodness of 
fit. 
XV Assessment of interactions  Among possible interactions of age 
with cause of injury and systolic 
blood pressure with hypoxia, only age 
with cause of injury was significant. 
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7.5.9. Level I: Automatic stepwise modelling of age, 
continuous GCS, pupillary reactivity, ISS and extracranial 
injury 
We selected the variables from the literature that have the most consensus for 
being of higher prognostic value in TBI. At this first level age, continuous 
GCS, pupillary reactivity, ISS and extracranial injury were included in the 
automatic stepwise logistic regression. Pupillary reactivity had 6 categories of 
brisk-brisk, brisk-sluggish, sluggish-sluggish, sluggish –none, brisk-none, 
none-none. GCS was in its continuous form with two fractional polynomials 
transformation of 76.0
1
10
2
GCS
and 
02.1
10
1
log
1
10
2
GCS
GCS
e
. Similarly, ISS was 
transformed into                                           . These variables are included in the 
basic IMPACT/CRASH models. However, ISS is not present in these models 
but is in another well-developed model [93]. 
The final model discarded one of the GCS transformations during the 
automatic procedure whereas practically if one transformation is discarded, the 
other should not be retained. However, the „automatic‟ nature of this level 
offered no control to keep both transformations in the model. Thus the next 
level was performed to run logistic regression in the „manual stepwise‟ method.  
7.5.10. Level II: manual stepwise modelling  
At this level, a model was initially derived with age (step 1 model). 
Subsequently four further models were derived by adding continuous GCS 
91.0
10
log
ISS
e
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(two fractional polynomial transformations) to “model step 1” to construct 
„model step 2‟. Similarly pupillary reactivity (with 6 categories) was added to 
„model step 2‟ to construct „model step 3‟. This process was continued by 
adding ISS and extracranial injury to the models constructed at the previous 
steps (Table 46). The deviance of each constructed model at each step was 
spotted in the SPSS output and the significance of the difference of the drop in 
the deviance as compared to the deviance of the model in the previous step was 
assessed through Chi square test with one degree of freedom. To do this the 
online Chi square calculator was used [163]. From this level onward all logistic 
regressions were run with the „enter‟ method of SPSS (i.e. not stepwise).  
Table 46 lists the deviance of each model, the difference of this 
deviance with the model at the previous step and the significance of the 
difference (p value). As seen, adding each covariate to models resulted in a 
significant decrease in the deviance indicating that the covariate should be 
retained in the model. In this „manual‟ stepwise procedure, two fractional 
polynomials transformations of GCS were supplied to the model together 
whereas in the automatic form, the computer supplied them separately.  
The final resulting model demonstrated that the odds ratio of the pupil 
category: absent-brisk did not have a reasonable direction for survival (it was 
more than one) (Appendix: level II model). Furthermore, ISS and extracranial 
injury were correlated in the correlation matrix indicating that these two 
variables can not be retained in the same model.  
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Table 46 Changes in the deviance in the manual stepwise modelling at 
level II. 
 
7.5.11. Level III: new categorisation of pupillary 
reactivity/decision to employ ISS or extracranial injury  
As one category of pupillary reactivity in model II did not have a reasonable 
direction for its odds ratio of survival, pupillary reactivity was categorised 
differently as both reactive, only one reactive and none reactive. Furthermore, 
since at the previous level, ISS and extracranial injury were correlated, at this 
level, two models were constructed: model IIIA with age, continuous GCS 
(fractional polynomials transformations), pupillary reactivity (with new 
categorisation), ISS (fractional polynomials transformation) and model IIIB 
with age, continuous GCS (fractional polynomials transformations), pupillary 
reactivity (with new categorisation) and extracranial injury.  
In model IIIA (age, continuous GCS, pupillary reactivity, (3 categories) 
and ISS) all covariates were significantly correlated with outcome including 
pupillary reactivity with new categorisation and also ISS. However, in model 
 
 
deviance difference P value of the 
difference 
Step 1: Age 883.069 -  
Step 2 : Age +GCS 565.905 317.164 <0.005 
Step 3: Age +GCS +Pupillary reactivity 411.731 154.174 <0.005 
Step 4: Age +GCS +Pupillary reactivity 
+ ISS 
397.587 14.144 <0.005 
Step 5: Age +GCS +Pupillary reactivity 
+ ISS + Extracranial Injury 
392.310 5.277 0.0216 
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IIIB, extracranial injury (extracranial AIS severity score > 2) did not hold a 
significant association with outcome. The AUC of models IIIA and IIIB were 
respectively 0.91 and 0.90 with p value of HL statistics being 0.83 and 0.45.  
7.5.12. Level IV: model IIIA including categorical GCS 
Since GCS was correlated with outcome both in the continuous and categorical 
form, model IIIA was reconstructed this time with GCS included categorically 
with each GCS score counted as one individual category (thus 13 categories). 
The reference category was GCS 15.  
The resulting model (i.e. model IV) demonstrated that firstly, only GCS 
scores 14, 12, 10 and 7 held a significant effect on outcome and secondly, GCS 
score of 9, 4 and 3 had odds ratios of above one for survival whilst this was 
expected to be less than one. Therefore, in the next level, GCS was categorised 
into mild, moderate and severe GCS with the cut offs as 9 and 12.  
7.5.13. Level V: model of level IIIA including new 
categorisation of GCS 
GCS was categorised into mild (GCS < 12), moderate (12-9) and severe (< 9). 
Subsequently model IV was reconstructed with this new categorisation of 
GCS.  
The resulting model (model V) showed that all three categories of GCS 
had significant association with outcome with an acceptable direction for odds 
ratios (i.e. the odds ratios were less than one and decreasing as GCS became 
lower). The AUC of this model was 0.908 with P value of HL statistics being 
0.93.  
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7.5.14. Level VI: testing the value of cause of injury  
The cause of injury was added to models IIIA (with continuous GCS) and V 
(with categorical GCS) with RTC as the reference category. This resulted in a 
significant decrease in the deviance of the model IIIA (with continuous GCS) 
but no significant decrease was observed in model V (with categorical GCS). 
However, the sports category in model VIA has an “astronomical” value 
(81656351.28) for odds ratio. This was attributed to the small number of cases 
in this category (only 14 cases in the whole dataset). Therefore, the „sports 
category‟ was merged with the „others‟ category and the model was run again. 
The resulting model (model VIA) demonstrated that all included covariates 
(i.e. age, continuous GCS, pupillary reactivity (with 3 categories), ISS and 
cause of injury) had significant association with outcome with acceptable 
directions for odds ratios. The AUC of this model was 0.916 with p value of 
0.55 for HL statistics.  
7.5.15. Level VII: trial of the new categorisation of pupillary 
reactivity 
It was felt that the pupillary reactivity could be better described using further 
information available from the database of abnormal both reactive. New 
categorisation of pupillary reactivity as normal (brisk-brisk), abnormal-both 
reactive (brisk-sluggish or sluggish-sluggish), only one reactive (none-sluggish 
or none-brisk) and none reactive (none-none) were tested on models level VIA 
(age, continuous GCS, pupillary reactivity, ISS and injury cause) and level V 
(age, categorical GCS, pupillary reactivity and ISS). With the new 
categorisation of pupillary reactivity two models were constructed: model 
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VIIA from model VIA and model VIIB from model V. It was observed that 
this new categorisation of pupillary reactivity (i.e. with 4 categories) is better 
than the previous one (i.e. with three categories) since AUC of models VIA 
and V respectively increased from 0.916 to 0.922 and from 0.908 to 0.914. The 
p value of HL statistics for models VIIA and VIIB were respectively 0.549 and 
0.572 in both models, Furthermore, pupillary reactivity still held its significant 
association with outcome.  
So far two models were constructed. Both models shared age, GCS, 
pupillary reactivity and ISS. The differences were: GCS being continuous in 
model VIIA but categorical in model VIIB and cause of injury being present in 
model VIIA but absent in model VIIB. This meant when GCS was categorical, 
cause of injury was not significant.  
7.5.16. Level VIII: Trial of the new categorisation of 
extracranial injury  
So far it was observed that the extracranial injury with the extracranial AIS cut-
off of 3 can not be held in the same model with ISS and also it does not hold a 
significant effect on outcome in a model which does not contain ISS. It was 
thought these observations may be different if the cut-off for extracranial AIS 
increases to 4 (inclusive). Level VIII was performed to assess this. The 
frequency of extracranial injury based on this new cut-off was 116 (14.5%). 
Up to this stage, several models were constructed and the following 
issues were explored: the importance of ISS versus extracranial injury, various 
categorisations of pupillary reactivity, continuous versus categorical GCS and 
the importance of cause of injury. These issues required to be considered in the 
conduct of this level. To assess this new cut-off of extracranial injury 
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(extracranial AIS severity score > 3), it was firstly assessed whether or not this 
new cut-off would enable extracranial injury to be included in the same model 
with ISS. Thus this variable was added to model IIIA (age, continuous GCS, 
pupillary reactivity (4 categories) and ISS). Since this model contained 
continuous GCS, the addition of extracranial injury to model IIIA was also 
tested with categorical GCS (i.e. three categories). The resulting models did not 
have a significant decrease in the deviance indicating that extracranial injury 
still can not be held in a model with ISS. Secondly, it was examined that 
whether or not extracranial injury with this new cut-off would have a 
significant association with outcome if the model does not contain ISS. For this 
purpose, model IIIB (age, GCS and pupillary reactivity) was reconstructed 
twice once with continuous GCS and then with categorical GCS. It was 
observed that in both resulting models, the deviance significantly decreased 
and also extracranial injury demonstrated a significant association with 
outcome. Thirdly, the value of cause of injury was tested by adding this 
variable to the newly-constructed models IIIB. It was observed that cause of 
injury significantly decreased the deviance of both models and also held a 
significant association with outcome (models VIIIA and VIIIB). The AUC of 
models VIIIA and VIIIB were respectively 0.917 and 0.910 and HL statistics 
of both models had a significant p value.  
7.5.17. Level IX: Imputation of missing GCS and pupillary 
reactivity  
Four models were constructed so far. Model VIIB (age, categorical GCS, 
pupillary reactivity and ISS) was deemed better than VIIA model (age, 
continuous GCS, pupillary reactivity, ISS and cause of injury) because its AUC 
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is only slightly lower (0.914 versus 0.922) but has simpler classification of 
GCS by not using fractional polynomials making the model user-friendly. For 
the same reason, Model VIIIB (age, categorical GCS, pupillary reactivity, 
extracranial injury and cause of injury) was deemed better than model VIIIA 
(age, continuous GCS, pupillary reactivity, extracranial injury and cause of 
injury) despite having only slightly a lower AUC (0.917 versus 0.920). 
Therefore, models VIIB and VIIIA were chosen to proceed with imputation of 
missing data and further levels of models derivation. So far all the logistic 
regression models were run on complete cases which amounted to 645 cases. 
The excluded cases had missing information of either GCS or pupillary 
reactivity.  
The imputation strategies for GCS was firstly to sum motor, eye and 
verbal components if they were available as there were occasions when the 
GCS components were recorded but total GCS was missing; Secondly, to 
impute the remaining missing information with en route and then at scene GCS 
recordings and thirdly to identify patients who had been intubated by weighing 
within GCS similar to TARN general trauma predictive models [142]. There 
were overall 26 cases with missing total GCS. The first step resulted in 
imputation of one case. Imputing with the en route records resulted in the 
reduction of missing cases to 23. Subsequently, all the remaining missing 
GCSs were imputed with scene scores with no missing value left for the last 
step of imputation strategy. The model was not rerun at this stage because 21 
of the missing GCS cases also had missing pupillary response. Following the 
imputation of GCS, missing pupillary reactivities were imputed. The 
imputation was performed on uncombined pupillary reactivity (i.e. separately 
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for the left and right eye) and with 6 categories. The adopted imputation 
strategy for each eye was as follow: firstly, if one eye was missing and the 
other was recorded, the missing eye was regarded as normal. This was initially 
performed for all admission, en route and at-scene records of pupillary 
reactivity. Table 47 presents the number of missing pupils prior to and 
following this first step of imputation. Secondly, the missing admission pupils 
were imputed with en route records. This decreased the missingness of both 
right and left eye from 122 to 108. Thirdly, the missing information on each 
eye was imputed with at-scene records. This final step decreased the number of 
missing information to 0 for each eye. Following the imputation, the syntax to 
combine the pupillary reactivity of each eye was run again.  
Table 48 compares the performance of the models prior to and 
following the imputation of missing GCS and pupillary reactivity. As seen, the 
change in AUC is negligible for both models (drops of 0.003 and 0.007 
respectively for models VIIB and VIIIB). Even the p value of HL statistics in 
model VIIIB became more distant from the significant level when it was 0.063 
before imputation and 0.547 after imputation.  
 
Table 47 Frequency of missing information on pupillary reactivity for 
each eye prior to and following the first step of imputation 
Site of record Left eye Right eye 
 Before 
imputation  
After 
imputation  
Before 
imputation  
After 
imputation  
Admission 136 122 138 122 
En rout 761 761 762 761 
At scene 484 473 477 473 
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Table 48 Comparison of performances of models VIIB and VIIIA before 
and after imputation of GCS and pupillary reactivity.  
7.5.18. Level X: Inclusion of intracranial pathologies   
The results of the level X and the following level (Level XI: adjustment to 
model X) are presented and discussed in Paper 5. In this paper, the baseline 
models A and B in the paper were models IXA (model VIIB after imputation 
of GCS and pupillary reactivity) and IXB (model VIIIB after imputation of 
GCS and pupillary reactivity) in the actual modelling procedure. Then AIS 
scores (i.e. 3, 4, and 5/6), the Marshal Classification and various intracranial 
pathologies (i.e. including brain swelling, intracranial haemorrhage, EDH, 
SAH, brain stem injury and the cerebellar injury) were added separately to 
each model. This resulted in the construction of 6 models. However, these 6 
models were named with the prefix „X‟ in the staged approach discussed here. 
Their equivalent naming is presented in Table 49 (plus the equivalent naming 
of baseline models). The Appendix does not repeat these 8 models given in 
Paper 5.  
Model Before imputation After imputation 
Number of 
cases 
AUC HL test Number of 
cases 
AUC HL test 
Level 
VIIB 
650 0.914 
(0.889-0.940) 
0.573 802 0.911 
(0.888-0.934) 
0.658 
Level 
VIIIA 
650 0.917 
(0.891-0.943) 
0.063 802 0.908 
(0.884-0.932) 
0.547 
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Table 49 The name of each model presented in the paper with the 
equivalent name in the actual procedure model construction. 
Name of the model in the paper Name in the modelling procedure 
Baseline model A Model IXA 
Model A + AIS scores Model XA1 
Model A + Marshal Classification Model XA2 
Model A + combination 1A Model XA3 
Baseline model B Model IXB 
Model B + AIS scores Model XB1 
Model B+ Marshal Classification Model XB2 
Model B + combination 1B Model XB3 
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This level and the following level (level XI) assess the prognostic value 
of AIS scores, the Marshall Classifications and various intracranial 
pathologies. However, these levels were performed within the modelling 
procedure and thus the „appropriate‟ models among the resulting models 
required to be selected to proceed with the modelling. The selection of the most 
appropriate classification/intracranial pathologies was based on AUC and the 
significance of the association of each type of brain injury with outcome.  
All models of XA1 to XA3 had the same AUC. However, model XA1 
was not selected because in this model, none of AIS scores i.e. scores 4 and 5/6 
held significant association with outcome. Similarly, model XA2 was not 
selected because among all 6 categories of the Marshall Classification, only 
class II was associated with outcome with marginal significance. Among 
models XB1 to XB3, model XB1 was not selected since in this model AIS 
score 4 did not hold significant association with outcome. Similarly, model 
XB3 was not selected since among all 6 categories of the Marshal 
Classification included in this model, only classes IV and V/VI (merged) were 
significantly associated with outcome. Overall models XA3 and XB3 were 
selected for further analysis i.e. trial of various combinations of intracranial 
pathologies at level XI.  
7.5.19. Level XI: Adjustments to model X 
At this level, six models were constructed. The rational for various 
combinations of intracranial pathologies and the AUC of constructed models is 
presented in Paper 5. Briefly, this was based on the haemorrhage being 
significantly associated with outcome from either clinical or evidence 
viewpoint and brain swelling, brain stem injury and cerebellar injury being 
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marginally (0.05 < p value < 0.10) or significantly associated with outcome in 
models constructed at the previous level. However, since in Paper 5 the odds 
ratios and significance (p values) are not given, the Appendix, unlike level X, 
contains all models at this level. Table 50 lists the equivalent name of each 
model in the modelling procedure to that in the Paper 5.  
  
Name of the model in the paper  Name in the modelling procedure  
combination 2A  Model XIA1 
combination 3A Model XIA2 
combination 4A Model XIA3 
combination 5A Model XIA4 
combination 2B Model XIB1 
combination 3B Model XIB2 
Table 50 The name of each model presented in the paper with the 
equivalent name in the actual procedure of TBI prognosis model 
construction.  
 
After the analysis of the model performance, models XIA4 and XIB2 
were selected; these being the models in which all intracranial pathologies 
described held significant association with outcome. The reason for this 
selection was that, apart from model XIA4, in none of the models XIA1 to 
XIA4, all intracranial pathologies included held significant association with 
outcome. All these models had equal AUCs. Similarly among models XIB1 
and XIB2, model XIB2 was selected because unlike model XIB1, all 
intracranial pathologies included were significantly associated with outcome.  
7.5.20. Level XII: Adding systolic blood pressure, mean 
blood pressure and hypoxia 
Systolic blood pressure (categorical), mean blood pressure (categorical) and 
hypoxia (categorical) were added to models XIA4 and XIB2 altogether. 
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Systolic and mean blood pressures were not used continuously, since firstly 
although they were associated with outcome by logistic regression on 
univariate analysis, this is not supported by Mann Whitney U test. Secondly, 
the plot of predicted and observed probabilities against the fractional 
polynomials transformation of both variables did not demonstrate that these 
two probabilities would follow the same pattern of distribution in an acceptable 
way (Figure 24 and Figure 26).  
In the resulting models (models XIIA and XIIB), it was observed that 
neither systolic blood pressure nor mean blood pressure were significantly 
associated with outcome with normotension as the reference category. 
However, hypoxia demonstrated a significant association with outcome. The 
logistic regression was run on 607 cases.  
7.5.21. Level XIII: missingness analysis/imputation of 
missing mean and systolic blood pressure and hypoxia  
At the previous level, only hypoxia turned out to be significant in the 
multivariate models. However, the analysis was run only on 607 cases since the 
remaining 195 cases had missing information on hypoxia, mean or systolic 
blood pressure. Thus it was thought that if the missing cases are included in the 
modelling, the results might change. This level was performed to include all 
cases in the analysis of hypoxia and blood pressure following imputation of 
missing values. However, unlike GCS and pupillary reactivity, imputing 
missing values with en route and scene scores did not result in imputation of all 
missingness for mean blood pressure, systolic blood pressure and hypoxia. 
Thus an analysis was performed to assess what variables could affect the 
missingness for each of the above 3 variables. This analysis provides the 
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answer as to whether or not if some variables changes in the dataset, the 
missingness would change. For example, it may that if the patient ages, the 
chance of missingness of hypoxia decreases. This analysis is important with 
regards to „multiple imputation‟ as a method to impute missing values based on 
the existing data. By multiple imputation the missingness is predicted from the 
values of other none-missing variables. To perform this statistical method, it is 
first necessary to know if other variables can affect the missingness of the 
variable of interest.  
 
Systolic blood pressure  
 
There were overall 36 cases with missing systolic blood pressure. Replacing 
missing admission scores with en route and scene values resulted in the 
reduction of missing information to 31 and 21 respectively. Subsequently, an 
analysis was performed to assess the effect of other variables on the systolic 
blood pressure missingness. These „other‟ variables were decided to be those 
which had been included in the models so far. Initially, the characteristics of 
population with missing systolic blood pressure were compared with those who 
had this variable recorded. Chi square test was run for categorical variables 
(extracranial injury, injury cause, brain stem haemorrhage, brain swelling and 
survival rate) with Mann Whitney U test for the continuous variables (age, 
GCS and ISS). Also logistic regression was run with age, GCS, ISS, 
extracranial injury, brain stem haemorrhage, brain swelling and survival as 
covariates and systolic blood pressure missingness as outcome. This latter 
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multivariate analysis would show the effect of each variable on the missingness 
of systolic blood pressure.  
Table 51 demonstrates the comparison of the two populations of 
missing and non-missing systolic blood pressure. It appears those subjects with 
missing systolic blood pressure tended to be younger, have lower GCS and 
more frequency of brain stem injury and lower survival rate (these are the 
variables with significant p values). Similarly, the missingness was 
significantly associated with pupillary reactivity per univariate analysis (p 
value = 0.015). Table 52 demonstrates the results of logistic regression 
analysis. As seen, only age and cause of injury (assault) were significantly 
associated with missingness in the multivariate analysis. This means there were 
only two variables which can predict the missingness of systolic blood 
pressure. Due to this small number of „predictors of missingness‟ in the data, 
multiple imputation was deemed inappropriate. Therefore, following 
imputation of missing systolic blood pressure with en route and scene scores 
the decision was made to group all the missing values as a separate category. 
Subsequently, the continuous systolic blood pressure was categorised into low 
blood pressure (< 119), normotension (120-150), hypertension (> 151) and 
missing. 
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Table 51 Comparing characteristics with missing systolic blood pressure 
with those without missing systolic blood pressure.  
 
Table 52 Logistic regression analysis to predict systolic blood pressure 
missingness.  
 Missing 
(n= 21) 
Available 
(n=781) 
P value 
age 26 39 0.016 
GCS 3 13 0.001 
Pupillary 
reactivity 
Normal 0.9 99.1 0.015 
Abnormal-
both 
reactive 
2.9 97.1 
Only one 
reactive 
3.6 96.4 
Neither 
reactive 
5.6 94.4 
ISS 29 25 0.196 
Extracranial   0.063 
Injury 
cause 
RTC 3.2 96.8 0.544 
Falls 1.6 98.4 
Assault 3.5 96.5 
Others 3.1 96.9 
Brain stem injury 23.8 1 0.016 
Swelling 38.1   0.710 
Survival rate 38.1 75.7 0.00 
 
 Sig.  odds ratio 
Age .002 .929 
GCS .710 .965 
Pupillary reactivity Normal .238  
Abnormal-both reactive .112 4.702 
Only one reactive .116 8.656 
None reactive .083 6.866 
ISS .485 .975 
Extracranial injury .942 1.086 
Brain stem injury .787 1.250 
Brain swelling .385 .547 
Cause of injury RTC .224  
Fall .114 3.834 
Assaults .041 5.250 
Others .998 .000 
survival .383 .433 
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Mean blood pressure  
 
The dataset contained 47 cases with missing mean blood pressure (this variable 
was calculated from systolic and diastolic blood pressure and since there were 
already 36 missing systolic blood pressure, 11 cases with missing diastolic 
blood pressure rendered in total 47 cases with missingness on mean blood 
pressure). Initially, scene and en route mean blood pressure (in the continuous 
from) was calculated from respective scene and en route systolic and diastolic 
blood pressure. Then the missing admission mean blood pressure (continuous) 
was imputed first with en route and then with scene values. This resulted in the 
decrease of missingness to 43 and 32 respectively. Then the analysis was 
performed to compare the characteristics of the population with missing mean 
blood pressure to that with non-missing mean blood pressure. This comparison 
was made on age, GCS, pupillary reactivity, ISS, extracranial injury, cause of 
injury, brain stem injury, brain swelling and survival rate using Chi square and 
Mann Whitney U test. Similarly, logistic regression was run with these 
variables and the missingness as the outcome.  
Table 53 demonstrates that the population with missing mean blood 
pressure was significantly younger, had lower GCS, had higher frequency of 
extracranial injury, brain stem injury and survival rate. Moreover, it appeared 
by univariate analysis, pupillary reactivity also affected the missingness (p 
value = 0.003). According to the multivariate analysis, only age had a 
significant effect on the missingness of mean blood pressure (Table 54). As 
such, multiple imputation was deemed inappropriate. Subsequently and 
following the imputation of missing mean blood pressure with en route and 
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scene records, the remaining missingness was categorised in a separate 
category. Thus, mean blood pressure was re-categorised as hypotension (< 84 
mmHg), normotension (85-110 mmHg), hypertension (> 111 mmHg) and 
missing. 
 
Table 53 Comparing characteristics of cases with missing mean blood 
pressure to those without missing mean blood pressure. 
 Missing 
(n=32) 
Available 
(n=770) 
P value 
age 26 39 0.002 
GCS 3 13 0.00 
Pupillary 
reactivity 
Normal 1.3 98.7 0.003 
Abnormal-
both reactive 
2.9 97.1 
Only one 
reactive 
7.1 92.9 
Neither 
reactive 
7.5 92.5 
ISS 27.5 25 0.092 
Extracranial 37.5 13.5 0.00 
Injury 
cause 
RTC 8 92 0.224 
Falls 4.5 95.5 
Assault 4.2 95.8 
Others 6.3 93.8 
Brain stem injury 25 8.3 0.001 
Swelling 31.3 34.4 0.712 
Survival rate 37.5 76.2 0.00 
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Table 54 Logistic regression analysis to predict missingness of mean blood 
pressure.  
 Sig.  odds ratio 
Age .000 .923 
GCS .768 .973 
Pupillary reactivity Normal .244  
Abnormal-both 
reactive 
.163 3.743 
Only one reactive .246 4.900 
None reactive .052 7.668 
ISS .204 .955 
Extracranial injury .343 2.627 
Brain stem injury .220 2.440 
Brain swelling .299 .510 
Cause of injury RTC .551  
Fall .351 2.033 
Assaults .152 2.865 
Others .998 .000 
survival .476 .519 
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O2 sat. (hypoxia) 
 
There were overall 114 cases with O2 saturation recording missing. The 
strategy of imputation was similar to other variables which was replacing the 
missing information initially with en route and then scene records. 
Replacement with en route values resulted in 108 cases with missing O2 Sat. 
Further replacement of missing values with scene values resulted in 78 missing 
cases. An analysis was carried out to compare the characteristics of the 
population with missing O2 Sat. to that with recorded (available) hypoxia. 
Similarly, logistic regression was run to assess the association of each variable 
with missingness on O2 Sat.  
According to Table 55, patients with missing O2 Sat. tended to have 
lower GCS, larger frequency of major extracranial injury and brain stem injury 
and a lower survival rate. Furthermore the effect of pupillary reactivity on 
missingness was significant accordingly. Moreover, according to Table 56 
which demonstrates missingness in a multivariate analysis, only GCS had a 
significant association with missing O2 Sat. Therefore, similar to mean and 
systolic blood pressure, following the imputation of missing O2 Sat. with en 
route and scene values, this variable was re-categorised as hypoxia (O2 sat < 
90%), non-hypoxia and missing without using multiple imputation.  
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Table 55 Comparing characteristics of cases with missing O2 sat. to those 
without missing O2 Sat.  
 
Table 56 Logistic regression analysis to predict missingness of O2 sat.  
 Missing O2 Sat.  
(n=78) 
Available O2 Sat.  
(n=723) 
P value 
Age 36 39 0.081 
GCS 7 13 0.00 
Pupillary 
reactivity 
Normal 7.8 92.2 0.005 
Abnormal-
both 
reactive 
8.5 91.5 
Only one 
reactive 
12.8 87.2 
None 
reactive 
18 82 
ISS 26 25 0.067 
Extracranial 28.2 13 0.00 
Cause of 
injury 
RTC 11.8 88.2 0.307 
Fall 8.9 91.1 
Assaults 8.4 91.6 
Others 3.1 96.9 
Bran stem injury 17.9 8 0.004 
Swelling 35.9 34.1 0.753 
Survival rate 59 76.4 0.001 
 
 Sig.  odds ratio 
Age .112 .988 
GCS .017 .908 
Pupillary reactivity Normal .523  
Abnormal-both reactive .492 .711 
Only one reactive .632 1.334 
None reactive .293 .584 
ISS .967 .999 
Extracranial injury .566 1.363 
Brain stem injury .396 1.461 
Brain swelling .544 .823 
Cause of injury RTC .477  
Fall .182 1.638 
Assaults .382 1.430 
Others .592 .567 
Survival .694 .845 
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7.5.22. Level XIV: trial of systolic and mean blood pressure 
individually/2 versus 3 categories 
This level was performed to assess the importance of blood pressure on the 
complete data. It was initially necessary to assess the effect of hypoxia on the 
deviance of the models prior to inclusion of blood pressures. This was because 
hypoxia was a significant predictor at level XII where neither systolic nor mean 
blood pressures were significant. Furthermore, since there were two types of 
models to be run (models with suffix A and models with suffix B), this level 
was divided into two sections. At each section, systolic and mean blood 
pressure were added separately as these variables are apparently correlated 
with each other (multicolinearity effect). This means if systolic blood pressure 
changes, mean blood pressure would change as well. It is the pre-requisite for 
logistic regression that all the variables included should not affect each other in 
that if one variable changes, all others remain constant.  
 
Models XIVA  
 
Model XIVA1 (model XIA4 + hypoxia)  
 
Adding hypoxia to model XIA4 resulted in a significant decrease in the 
deviance of model XIA4 (495.663 versus 481.898, P < 0.005). Furthermore, 
hypoxia showed a significant association with outcome. AUC of the resulting 
model was 0.932. 
  
Model XIVA2 (model XIVA1 + mean blood pressure with 3 categories) 
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Adding mean blood pressure resulted in a significant decrease in the deviance 
of model XIVA1 (From 481.898 to 468.188, p < 0.0005). The category low 
blood pressure demonstrated a significant association with outcome with no 
significant association for the hypertension category. The AUC of the resulting 
model was 0.927.  
 
Model XIVA3 (model XIVA1 + mean blood pressure with 2 categories) 
 
Categories of hypertension and normotension were merged together leaving 
mean blood pressure with only 2 categories of hypotension versus no-
hypotension plus one category of missing information. This resulted in a 
significant decrease in the deviance of model XIVA1 (from 481.898 to 
468.333, p value < 0.0005). Furthermore, hypotension was significantly 
associated with outcome and AUC of the model was observed to be 0.927.  
 
Model XIVA4 (model XIVA1 + systolic blood pressure with 3 categories) 
 
Adding systolic blood pressure resulted in a significant decrease in the 
deviance of the model (from 481.898 to 476.259, p < 0.0005). Category: low 
blood pressure demonstrated a p value of close to significance (0.057) and 
AUC of the resulting model was 0.924.  
 
Model XIVA5 (model XIVA1 + systolic blood pressure with 2 categories) 
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Categories of hypertension and normotension were merged together leaving 
systolic blood pressure with only 2 categories of low blood pressure versus no-
low blood pressure plus one category of missing information. This resulted in a 
significant decrease in the deviance of model XIVA1 (from 481.898 to 
476.318, p value < 0.0005). Furthermore, Hypotension was significantly 
associated with outcome and AUC of the model was 0.924.  
 
Selection of the best model among Models type A 
 
Overall models with blood pressure (models XIVA2-5) were better than the 
model without blood pressure (model XIVA1) in terms of the effect on the 
deviance. This was because adding blood pressure (systolic or mean, with 2 or 
3 categories) resulted in a significant decrease in the deviance. Among models 
with mean blood pressure (models XIVA2 and XIVA3), the model with 2 
categories of mean BP is better since the category hypertension has no 
association with outcome in model XIVA2. Furthermore, among models with 
systolic BP, the model with 2 categories of systolic BP (model XIVA5) is 
selected as the category: hypertension has no association with outcome (model 
XIVA4). Lastly, among models XIVA3 and XIVA5, model XIVA5 was 
selected as the HL statistics of the other was observed to have a p value of less 
than 0.05 (0.111 versus 0.048 for model XIVA5). 
 
Models XIVB 
 
Model XIVB1 (model XIB2 + hypoxia) 
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Adding hypoxia to model XIB2 resulted in a significant decrease in the 
deviance (478.725 versus 465.888, p value < 0.005). Moreover, the association 
of hypoxia with outcome was significant and the AUC of the model was 0.928. 
 
Model XIVB2 (model XIVB1 + mean blood pressure with 3 categories) 
 
Adding mean blood pressure resulted in a significant decrease in the deviance 
of the model (from 481.898 to 451.936, p < 0.0005). The category hypotension 
demonstrated a significant association with outcome. However, the association 
of hypertension was not significant. The AUC of this model was AUC = 0.932.  
 
Model XIVB3 (model XIVB1 + mean blood pressure with 2 categories) 
 
Categories of hypertension and normotension were merged together leaving 
mean blood pressure with only 2 categories of hypotension versus no-
hypotension plus one category of missing information. This resulted in a 
significant decrease in the deviance of model XVB1 (from 481.898 451.940, p 
value < 0.0005). Furthermore the hypotension category was significantly 
associated with outcome. The AUC of the model was 0.932.  
 
Model XIVB4 (model XIVB1 + systolic blood pressure with 3 categories) 
 
Adding systolic blood pressure resulted in a significant decrease in the 
deviance of the model (from 481.898 to 461.154, p < 0.0005). None of systolic 
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blood pressure categories (neither hypotension nor hypertension) demonstrated 
significant association with outcome. The AUC of the model was 0.930.  
 
Model XIVB5 (model XIVB1 + systolic blood pressure with 2 categories) 
 
Categories of hypertension and normotension were merged together leaving 
systolic blood pressure with only 2 categories of low blood pressure  versus no-
low blood pressure plus one category of missing information. This resulted in a 
significant decrease in the deviance of model XIVB1 (from 481.898 to 
461.349, p value < 0.0005). The hypotension category significantly associated 
with outcome and the mode had an AUC of 0.929.  
 
Selection of the best model among models XVB1-5 
 
Overall models with blood pressure (models XIVB2-5) are better than the 
model without blood pressure (model XIVB1). This is because adding blood 
pressure (systolic or mean, with 2 or 3 categories) resulted in a significant 
decrease in the deviance. Among models with mean blood pressure (models 
XIVB2 and XIVB3), the model with 2 categories of mean BP is better since 
the category hypertension has no association with outcome in model XIVB2. 
Furthermore, among models with systolic BP, the model with 2 categories of 
systolic BP (model XIVB5) is selected as the categories hypertension and 
hypotension have no association with outcome in model XIVB4. Lastly, among 
models XIVB3 and XIVB5 (systolic versus mean blood pressure), model 
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XVB5 was selected as this model contains systolic blood pressure which is also 
included in model XIVA5.  
7.5.23. Level XV: assessment of interactions 
According to the literature, there are two interactions which needed to be 
investigated in the so-far-constructed models (models XVA5 and XVB5): 
interaction of age with cause of injury [160] and interaction of systolic blood 
pressure with hypoxia [96]. Each syntax of models XIVA5 and XIVB5 was run 
again with declaration of the aforementioned interactions.  
 
Model XVA1(model XIVA5 plus interaction of hypoxia and low blood pressure) 
 
Adding the interaction of hypoxia with hypotension resulted in a significant 
decrease in the deviance of the model from 476.318 to 470.917 (p value < 
0.005). Furthermore, among the interaction of various categories of hypoxia 
(yes, no and missing) with various categories of systolic blood pressure 
(normotension, hypotension and missing), only the interaction of missing 
hypoxia with hypotension appeared significant. This appeared to be not 
clinically significant. Thus, this interaction was not included in the model. The 
AUC of this model was 0.925 (0.903-0.946).  
 
Model XVB1 (model XIVB5 plus interaction of age and cause of injury and 
interaction of hypoxia and systolic blood pressure) 
 
Following addition of the above interactions to the model, the deviance of the 
model XIV5 significantly decreased from 461.349 to 446.764 (p value < 
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0.005). Furthermore, among interactions of various categories only interaction 
of age and fall was significant with no significant interaction between hypoxia 
and systolic blood pressure.  
 
Model XVB2 (model XIVB5 without interaction of hypoxia and systolic blood 
pressure) 
 
At this stage, model XIVB5 was run only with interaction of age and cause of 
injury. It was observed that the deviance of model XIVB5 significantly 
decreased from 461.349 to 451.830 (p value < 0.005). Age demonstrated a 
significant interaction with fall. The AUC of this model was 0.931.  
7.5.24. Main points and decisions in model derivation 
Table 57 presents the main points/decisions which were made during the 
modelling procedure based on the observations obtained at each level/model. 
This table assists with clarification of the „hidden‟ coherence of the modelling 
procedure. 
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Table 57 Main points/decisions made during the model derivation with their respective levels and models.  
 
Main point/decision Relevant levels Involved models 
Pupillary reactivity with 4 
categories: normal, abnormal 
both reactive, only one reactive, 
none reactive 
II, III, VII II, IIIA, IIIB, VIIA, VIIB 
Categorical GCS rather than 
continuous GCS 
IX VIIA, VIIB, VIIIA, VIIIB 
Categorical GCS with 3 
categories rather than 13 
categories 
IV, V IIIA, IV, V 
ISS and extracranial injury not 
to be in the same model 
II, VII II, IIIA,IIIB, VIIIA, VIIIB, 
Cause of injury in the model 
with extracranial injury but not 
with ISS 
VI, VIII IIIA, V, VIA, IIIB, VIIIA, VIIIB 
Cut-off for extracranial injury 
AIS severity score 4 and not 3 
VIII IIIA, IIIB, VIIIA, VIIIB 
Only hypotension important 
(hypertension merged with 
normotension) 
XIV XIVA2, XIVA3, XIVA4, XIVA5, XIVB2, XIVB3, XIVB4, 
XIVB5 
Why systolic blood pressure 
and not mean blood pressure 
XIV XIVA2, XIVA3, XIVA4, XIVA5, XIVB2, XIVB3, XIVB4, 
XIVB5 
Only brain stem injury and 
brain swelling as important 
intracranial injuries 
X, XI IXA, XA1, XA2, 
XA3,IXB,XB1,XB2,XB3,XIA1,XIA2,XIA3,XIA4,XIB1,XIB2 
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7.5.25. Calibration plot/Brier Score  
To draw the calibration plot, survival probability of each individual as 
predicted by the model (predicted probability) was saved. The predicted 
probabilities were then divided into bands with intervals of 0.1. The mean 
predicted probability and the observed probability were calculated within each 
band. Then, the scatter plot of the mean predicted probability and the mean 
observed probability were drawn in Excel.  
The brier score is not given in the SPSS output of logistic regression 
and thus this index was calculated by creating the appropriate syntax using the 
following formula (section 2.7):  
∑ (observed probability – predicted probability) 2 / n 
7.5.26. External validation  
The IMPACT dataset of TBI was sent through email by HL. It included 11023 
cases. Firstly, the IMPACT dataset was „prepared‟ for the validation according 
to the variables and their format in the TARN models. Secondly, since the 
IMPACT dataset contained missing information, an analysis was performed to 
compare the characteristics of patients with full variables recorded to those 
with one or more missingness. Thirdly, the characteristics of the TARN and the 
IPMACT were compared across various variables included in the TARN 
models. Fourthly, the TARN model B was run on the IMPACT data. The 
validation of TARN model A was deemed not feasible since the IMPACT 
dataset did not contain record of ISS.  
 
Preparation of the IMPACT dataset  
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This involved adjustments for the different format of recording of pupillary 
reactivity and cause of injury in the IMPACT dataset to that in the TARN 
dataset and the lack of extracranial injury and brain stem injury in the IMPACT 
dataset.  
In TARN TBI models, pupillary reactivity contains four categories 
(normal-both reactive, abnormal-both reactive, only one reactive, none 
reactive) whereas in IMPACT, the pupillary reactivity contain three categories 
(reacting, one reacting and neither reactivity). In order to alleviate this 
mismatched format of pupillary reactivity, the categories of normal and 
abnormal-both reactive were merged into „both reacting‟ in the TARN dataset.  
Furthermore, cause of injury in IMPACT holds 11 categories (Table 
58) whereas the TARN models contain only 4 categorises. Following the 
advice of a TARN member of staff (TJ), the equivalent category of cause of 
injury in TARN models was defined for each category in IMPACT. This is 
presented in Table 58. This mapping was based on the closest possible 
equivalent injury cause among RTC, assault, fall or others to that in the 
IMPACT classification. However, one may argue that the „bike/skate ect.‟ 
should have been considered as RTC whereas in this mapping it is considered 
as others. In TARN data recording, RTC is recorded when vehicle incidence or 
a collision occurs. However, in the IMPACT dataset it was not clear what 
percentage of cases with „bike/skate etc‟ as their cause of injury sustained their 
injury following collision and not skating.  
 
 339 
 
Table 58 The mapping of categories of injury cause in IMPACT to TARN.  
 
There are two variables in the TARN models which were not recorded 
in IMPACT; these being extracranial injury and brain swelling. In order to 
rectify this problem, extracranial surgery and Marshal Class III in IMPACT 
were used as proxies respectively for extracranial injury and brain swelling.  
 
IMPACT missingness 
 
The IMPACT dataset supplied to TARN had complete data on pupillary 
reactivity, hypoxia and systolic blood pressure. However, there was a number 
of missing information on other variables presented in Table 59. In total, 5542 
cases had a missing value on one variable or the other. Thus only 5481 cases 
remained with all the data available. Chi square test was run to assess the 
significance of the difference between the complete cases and those with one or 
more missing values on GCS, cause of injury and extracranial surgery. 
 
Table 59 The number of missing information in the IPMPACT dataset.  
 
Variable  Missingness  
GCS 3230 (58.2%) 
Cause of injury 17(0.3%) 
Extracranial surgery  3090 (55.7%) 
 
IMPACT classification TARN model classification 
Motor/vehicle occupant RTC 
Pedestrian RTC 
Motor/pedestrian/RTA/ other RTC 
Motorbike/Moped RTC 
Assault Assault 
domestic/fall Fall 
fall/alcohol Fall 
work-related Others 
Sports Others 
bike/skate ect. Others 
Other Others 
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Comparison of the TARN and the IMPACT datasets  
 
This was performed after merging the TARN and the IMPAT dataset in SPSS 
and across age, GCS, pupillary reactivity, cause of injury, extracranial 
surgery/injury, brain swelling and hypoxia using Mann Whitney U test for 
continuous variables (age) and Chi square test for categorical variables (GCS, 
pupillary reactivity, cause of injury, extracranial surgery/injury, Marshall Class 
III/brain swelling and hypoxia).  
 
Running of TARN model B on the IMPACT dataset  
 
This was performed on the merged TARN and IMPACT dataset. Since 
IMPACT holds the record on favourable versus unfavourable outcome, model 
B was also run for prediction of favourable outcome. The logistic regression 
was run on the complete cases of IMPACT dataset i.e. with no imputation.  
 
External validation in TARN dataset  
 
For this purpose, the derived models were run on another dataset of TBI cases 
from TARN which contained submissions from May 2010 till May 2010. Both 
internal and external datasets had the same inclusion criteria. First the two 
datasets (prediction and the external validation sets) were compared across 
various patients‟ characteristics.  
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7.6. Further results 
The results of univariate analysis, final derived models and their validation are 
presented in Paper 6 (Table 31, Table 32, Table 33, Table 34 and Table 35). 
What follows is the further results of the univariate analysis and the external 
validation.  
Table 60 presents the frequency/median of each variable across the 
groups of survivals and non-survivals. The significance of the differences are 
presented in Paper 6 (Table 31, Table 32 and Table 33). 
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 Variable Survival Non-survivals 
Median 
 
Frequency 
(percentage) 
Median 
 
Frequency 
(percentage) 
Age 40 
 
 49  
Gender Male  452 
(75%) 
 151 
(25%) 
Female  
 
147 
(73.9%) 
 52 
(26.1%) 
Nationality British  
 
334 
(75.6%) 
 108 
(24.4%) 
European  
 
13 
(86.7%) 
 2 
(13.3%) 
Others  
 
19 
(79.9%) 
 5 
(20.8%) 
Cause of 
injury 
RTC  
 
227 
(72.3%) 
 87 
(27.7%) 
Fall  
 
222 
(70.9%) 
 91 
(29.1%) 
Assaults  
 
125 
(87.4%) 
 18 
(12.6%) 
Others  
 
25 
(78.1%) 
 7 
(21.9%) 
GCS (continuous) 12 
 
 6  
GCS 
(categorical) 
Mild  377 
(92.2%) 
 32 
(7.8%)_ 
Moderate  
 
84 
(81.6%) 
 19 
(18.4%) 
Severe  
 
138 
(47.6%) 
 152 
(52.4%) 
Pupillary 
reactivity 
Brisk-brisk  
 
405 
(82.5%) 
 41 
(25.8%) 
Sluggish-
sluggish 
 
 
36 
(7.3%) 
 17 
(10.7%) 
Brisk-brisk  
 
10 
(2%) 
 6 
(3.6%) 
None-brisk  
. 
15 
(3.1%) 
 1 
(0.6%) 
None-sluggish  
 
2 
(0.4%) 
 10 
(6.3%) 
None-none  
 
23 
(4.7%) 
 84 
(52.8%) 
Table 60 The frequency/median of various variables across survivals and 
non-survivals (continued)
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Variable Survival Non-survivals 
 Median 
 
Frequency 
(percentage) 
Median 
 
Frequency 
(percentage) 
Extracranial injury (AIS > 2)  
 
546 
(91.2%) 
 140 
(69%) 
Extracranial injury (AIS > 3)  
 
   
Systolic blood pressure 
(continuous) 
138  129  
Systolic 
blood 
pressure 
(categorical) 
low bllod 
pressure (< 120 
mmHg) 
 
 
142 
(67.9%) 
 67 
(32.1%) 
Normotension 
(120-150 mmHg) 
 290 
(85%) 
 51 
(15%) 
Hypertension (> 
150 mmHg) 
 151 
(69.9%) 
 65 
(30.1%) 
Mean blood pressure 
(continuous) 
145.68  135.8  
Mean blood 
pressure 
(categorical) 
Hypotension  
(< 85 mmHg) 
 6 
(20%) 
 24 
(80%) 
Normotension 
(85-110 mmHg) 
 47 
(69.1%) 
 21 
(30.9%) 
Hypertension 
 (> 110 mmHg) 
 522 
(79.5%) 
 135 
(20.5%) 
Hypoxia 98 
 
 93S  
Highest AIS 
score 
3  
 
21 
(11.1%) 
 168 
(88.9%) 
4  
 
46 
(14.6%) 
 270 
(85.4%) 
5  
 
131 
(45%) 
 160 
(55%) 
6  
 
5 
(83.3%) 
 1 
(16.7%) 
Contusion  
 
247 
(77.2%) 
 73 
(22.8%) 
Intracranial haemorrhage  
 
443 
(72.3%) 
 170 
(27.7%) 
EDH  
 
84 
(88.4%) 
 11 
(11.6%) 
SDH  
 
137 
(77%) 
 41 
(23%) 
SAH  
 
97 
(65.1%) 
 52 
(34.9%) 
Table 60 The frequency/median of various variables across survivals and 
non-survivals (continued)
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Variable Survival Non-survivals 
 Median 
 
Frequency 
(percentage) 
Median 
 
Frequency 
(percentage) 
Marshal 
Classification 
I  
 
56 
(86.2%) 
 9 
(13.8%) 
II  
 
356 
(87.9%) 
 49 
(12.1%) 
III  
 
60 
(70.6%) 
 25 
(29.4%) 
IV  
 
40 
(54.1%) 
 34 
(45.9%) 
V/VI  
 
84 
(50.6%) 
 82 
(49.4%) 
Brain 
stem/cerebellar 
injury 
 1 
(25%) 
 3 
(75%) 
Penetrating 
injury 
 2 
(66.7%) 
 1 
(33.3%) 
Table 60 The frequency/median of various variables across survivals and 
non-survivals (continued).   
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Table 61 presents the comparison between those cases in the IMPACT 
dataset which had one or more missing value (excluded cases) and those which 
had all the data available. As seen the differences are significant across all 
variables (age, GCS, pupillary reactivity, cause of injury, brain swelling) 
except extracranial surgery, hypoxia and systolic blood pressure (hypoxia 
showed a marginal difference i.e. p value < 0.10 and more than 0.05). 
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Table 61 Comparison of the cases which had all data recorded (included) 
to those cases which had one or more missing value across various 
variables in IMPACT. 
 
 Excluded cases 
(5542) 
Included cases 
(5481) 
p value 
Age 32 
(22-48) 
30 
(21-43) 
0.00 
GCS Mild 1.8% 
(100) 
6.9% 
(378) 
0.00 
Moderate 6% 
(333) 
10.7% 
(585) 
Severe 34% 
(1883) 
82.4 
(4514) 
Missing 58.2% 
(3230) 
- 
Pupillary 
reactivity 
Both reacting 64.5% 
(3575) 
68.7% 
(3765) 
0.00 
One reacting 16.4% 
(915) 
12.1% 
(660) 
Neither 
reacting 
19.1% 
(1059) 
19.2% 
(1052) 
Cause of 
injury 
RTC 57.3% 
(3176) 
63.2% 
(3459) 
0.00 
Assault 5.2% 
(289) 
7.7% 
(423) 
Fall 22.6% 
(1251) 
17.5% 
(959) 
Others 14.7% 
(813) 
11.6% 
(636) 
Missing 0.3% 
(17) 
- 
Extracranial 
surgery 
yes 8.7% 
(481) 
20.2% 
(1105) 
0.543 
Missing 55.7% 
(3090) 
- 
Brain swelling 17.5% 
(972) 
21.9% 
(1197) 
0.00 
Systolic 
blood 
pressure 
Hypotension 49% 
(1291) 
51% 
(1344) 
0.418 
Normotension 49.9% 
(4185) 
50.1% 
(4202) 
Hypoxia 22.4% 
(1243) 
21.1% 
(1153) 
0.083 
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Table 62 presents the comparison between the IMPACT and the TARN 
datasets. According to this table, the differences between all variables (age, 
GCS, pupillary reactivity, cause of injury, extracranial injury, brain swelling, 
hypoxia and systolic blood pressure) are significant as per the p values apart 
from survival rates. The IMPACT dataset appears to contain slightly younger 
population of TBI cases. Furthermore, based on GCS, the TARN dataset 
included less severe cases since 35.8% of cases were recorded as mild GCS in 
contrast to this being 6.1% in IMPACT. This is also the case for pupillary 
reactivity as more cases in TARN dataset had both reactive pupils (79.2% 
versus 66.6%). Furthermore, according to hypoxia, the cases in IMPACT 
appear to have been more physiologically disturbed than those in the TARN 
dataset.
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Table 62 Comparison of the IMPACT and the TARN datasets across 
various variables included in the TARN model B.  
 The IMPACT 
dataset 
The TARN 
dataset 
P 
value 
Age 31 
(22-46) 
39 
(22-58) 
<0.005 
GCS Mild 478 
(6.1%) 
278 
(35.8%) 
<0.005 
Moderate 918 
(11.8%) 
99 
(12.7%) 
Severe 6397 
(82.1%) 
399 
(51.7%) 
Pupillary 
reactivity 
Both reacting 7340 
(66.6%) 
515 
(79.2%) 
<0.005 
One reacting 1572 
(14.3%) 
28 
(4.3%) 
Neither 
reacting 
2111 
(19.2%) 
107 
(16.5%) 
Cause of injury RTC 6949 
(58.8%) 
314 
(39.2%) 
<0.005 
Assault 2353 
(8.7%) 
313 
(39.0%) 
Fall 1025 
(19.9%) 
143 
(17.8%) 
Others 1481 
(12.5%) 
32 
(4%) 
Extracranial injury 1702 
(19.5%) 
116 
(14.5%) 
<0.005 
Brain swelling 2169 
(19.7%) 
275 
(34.3%) 
<0.005 
Hypoxia 2396 
(21.7%) 
51 
(6.5%) 
<0.005 
Systolic blood 
pressure 
Hypotension 2635 
(92.5%) 
215 
(7.5%) 
<0.005 
Normotension 8387 
(93.7%) 
566 
(6.3%) 
Survival 8149 
(73.9%) 
599 
(74.7%) 
0.635 
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Table 63 presents the differences between the TARN internal 
(derivation) dataset and the TARN external dataset. The two datasets appear 
significantly different across every variable apart from ISS as per the p values.  
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Table 63 Comparing characteristics of patients between the TARN 
internal and external datasets.  
 Internal TARN 
dataset 
External TARN 
dataset 
P value  
Age 39 
(22-58) 
43.9 
(24.2-67) 
<0.005 
GCS Mild 278 
(35.8%) 
758 
(57%) 
0.021 
Moderate 99 
(12.7%) 
159 
(12%) 
Severe 399 
(51.7%) 
412 
(31%) 
Pupillary 
reactivity 
Normal 541 
(67.5%) 
821 
(80.7%) 
<0.005 
Abnormal-both 
reactive 
94 
(11.7%) 
17 
(1.7%) 
Only one reactive 39 
(4.9%) 
51 
(5%) 
None reactive. 128 
(16%) 
128 
(12.6%) 
Cause of 
injury 
RTC 314 
(39.2%) 
448 
(40%) 
<0.005 
Assault 313 
(39.0%) 
1 
(0.1%) 
Fall 143 
(17.8%) 
664 
(59.3%) 
Others 32 
(4%) 
6 
(0.5%) 
ISS 25 
(16-29) 
25 
(16-29) 
0.452 
Extracranial injury 116 
(14.5%) 
123 
(8.9%) 
<0.005 
Brain swelling 275 
(34.3%) 
415 
(29.9%) 
0.034 
Brain stem injury  92 
(6.6%) 
0.045 
Hypoxia 51 
(6.5%) 
59 
(4.7%) 
<0.005 
Systolic 
blood 
pressure 
Hypotension 215 
(7.5%) 
304 
(22.5%) 
<0.005 
Normotension 566 
(6.3%) 
1050 
(77.5%) 
<0.005 
Survival 599 
(74.7%) 
1113 
(80.2%) 
<0.005 
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8.1. Abstract 
8.1.1. Introduction  
There are currently two prognostic tools available for predicting outcome in 
Traumatic Brain Injury (TBI). The first involves prognostic models combining 
clinico-demographic characteristics of patients for outcome prediction, whilst 
the second employs serum brain injury biomarkers. S100B is a widely-
acknowledged biomarker of brain injury.  
8.1.2. Objective 
To identify which method has better prognostic strength and explore how 
combining these methods might improve the prognostic strength.  
8.1.3. Methods 
We analysed data from 100 TBI patients, all of whom were admitted to the 
intensive care unit and had arterial S100B levels recorded at 24-hours after 
injury. TBI prognostic models A and B, constructed in Trauma Audit and 
Research Network (TARN), were run on the dataset and then S100B was 
added as an independent predictor to each model. Furthermore, another model 
was developed containing only S100B and subsequently, other important TBI 
predictors were added to assess their ability to enhance the predictive power of 
this model. The outcome measures were survival and favourable outcome at 
three months. 
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8.1.4. Results 
 Among all the prognostic variables (including age, cause of injury, GCS, 
pupillary reactivity, Injury Severity Score (ISS) and CT features); S100B has 
the highest predictive strength on multivariate analysis. No difference between 
performance of prognostic models or S100B in isolation is observed. Addition 
of S100B to the prognostic models improves the performance (e.g. Area Under 
the roc Curve (AUC), R
2
 Nagelkerke and classification accuracy of TARN 
model A to predict survival increase respectively from 0.64, 0.10 and 71% to 
0.72, 0.20 and 74.7%). Similarly, the predictive power of S100B increases by 
adding other predictors to S100B (e.g. AUC (0.69 versus 0.78), R
2
 Nagelkerke 
(0.15 versus 0.30) and classification accuracy (73% versus 77%) for survival 
prediction).  
8.1.5. Conclusion 
S100B appears to be the strongest prognostic variable in TBI. A better 
prognostic tool than those which are currently available may be a combination 
of both clinic-demographic predictors with S100B. 
 354 
8.2. Introduction  
Outcome prediction in Traumatic Brain Injury (TBI) is one of the many factors 
taken into account by clinicians for the provision of acute and rehabilitative 
care to the sufferers. The prediction is made based on the relationship between 
the outcome and indicators of injury severity and should provide the likelihood 
of an individual patient experiencing various types of outcomes such as 
survival versus death. There are currently two prognostic tools available to 
make such prediction: serum biomarkers of brain injury that relate to outcome 
or prognostic models that incorporate various clinico-demographic factors 
(routinely measured characteristics such age, Glasgow Coma Scale (GCS), 
pupillary reactivity, Computed Tomography (CT features) etc.) to calculate the 
probability of a given outcome. So far several biomarkers have been proposed 
which show higher concentrations in blood of those TBI patients experiencing 
an unfavourable outcome [164]. However measurement of S100B is one of the 
brain injury biomarkers which has received more attention. This astroglial 
protein [47] has been demonstrated to be associated with outcome in TBI [43, 
69, 75, 78, 80, 83, 98, 126, 128, 165, 166].  
The association of S100B with outcome has prompted the researchers 
to determine serum cut-off levels, which can be used as a „diagnostic‟ test for a 
given outcome of interest such as survival or disability. We have recently 
reported our study on the effectiveness of serum S100B measured 24-hours 
after injury to predict unfavourable outcome i.e. Glasgow Outcome Scale 
(GOS < 4) or death at 3-months after injury in a subset of TBI patients who 
were all admitted in the Intensive Care Unit (ICU) at Salford Royal NHS 
Hospital, UK [98]. In this study, S100B levels above the cut-off point 0.53 µg/l
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had a sensitivity of 82% and 83% to respectively predict unfavourable outcome 
and mortality. However, the specificity was moderate at 60% for unfavourable 
outcome and 49% for mortality (Area Under the Roc Curve (AUC) for 
unfavourable outcome prediction: 0.77, AUC for mortality prediction: 0.69). 
Vos et al.  also found similar results in a cohort of severe TBI patients, the cut 
off of 1.13 µg/l being higher as an earlier admission sample [43]. They 
reported an AUC of 67.7 to predict poor outcome 6 months after severe TBI. 
Similarly, other cut-offs for TBI outcome prediction has been suggested by 
other researchers [69, 75, 76, 78, 167]. It may be that considering other TBI 
prognosticators such as age or GCS would enhance the prognostic power of 
S100B.
 
Prognostic models are often constructed through logistic regression run 
on large datasets of TBI cases which hold information on various clinico-
demographic characteristics or laboratory measurements. A “model” refers to 
an equation which calculates the probability of a given outcome by summing 
scores attributed to each predictor found to be important in the multivariate 
analysis. Thus the prognostic models are in fact equations providing the 
probability of outcome using given patient‟s characteristics. Two important 
such models proposed for international application are the International 
Mission for Prognosis and Analysis of Clinical Trials (IMPACT) models [24] 
and the Corticosteroid Randomisation After Significant Head injury (CRASH) 
[23]. The IMPACT model is presented in a user friendly fashion in that it 
attributes a score to each important prognosticator and then the probability of 
death or unfavourable outcome at the time point of 6 months can be calculated. 
The CRASH model is pertinent to low and middle income countries as the data 
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from TBI patients in these nations are contained in the derivation dataset and 
separate models applicable to these nations have been presented. An online 
calculator for either of these models is available [29, 34]. Similar to these 
international models, the Trauma Audit and Research Network (TARN) [89] 
has proposed its own TBI models (models A and B) suitable for the British 
trauma population at a national level [168].  
Due to the limited literature on comparing prognostic models with brain 
injury biomarkers, it is still unclear which TBI prognostic tool (a brain 
biomarker or a prognostic model) is superior. Whilst prognostic models appear 
to have received more popularity than biomarkers (and S100B) in their 
applicability, the AUC of these models may still not be adequate for clinical 
purposes. For example, the highest AUC of the IMPACT models is 0.87. 
Comparing this AUC with a more familiar diagnostic tool such as 
mammography for breast cancer diagnosis which has AUC of about 0.85 [110], 
may indicate prognostic models are still required to improve in their 
performance. However, there are studies which have obtained very high AUCs 
of close to 0.90 [75, 78] for S100B unlike some other studies on S100B which 
found much lower AUCs of less than 0.70 [76, 79]. This can be due to the 
difference in case-mix across studies which per se highlights the importance of 
considering other TBI outcome predictors in assessing S100B prognostic 
strength. In fact, this is the point where prognostic modelling through 
multivariate analysis meets research into S100B. 
The overall objective of this study is threefold: to compare the 
performance of these two prognostic tools (prognostic models and a brain 
injury biomarker), to investigate how adding S100B to TBI prognostic models 
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improves their performance and to investigate how combinations of S100B 
with other predictors may improve the predictive strength of S100B.  
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8.3. Methods 
8.3.1. Data collection 
For the purpose of this study, we used an available dataset from a study of 100 
TBI patients conducted previously. The study dataset had been accrued 
prospectively to assess the prognostic performance of S100B on its own in a 
univariate analysis. Patients, who had been admitted within 24 hours after the 
injury, were recruited from ICU at Salford Royal Hosptial, UK. The dataset 
contained information on gender, age, Injury severity Score (ISS), cause of 
injury, Computed Tomography (CT) descriptions, serum S100B levels and 
outcome as measured by GOS at 3 months following injury. Serum blood 
samples had been taken at 24 hours after the injury time and were analysed 
using a one-step immunoassay (enzyme-linked immunosorbant assay, ELIZA; 
Sangtec 100
TM
 Diasorin, Wokingham, UK) [98]. 
The inclusion criteria were all TBI patient admitted to Hope ICU who 
were older than 16 years old {Rainey, 2009 #210}. Exclusion criteria were all 
patients who arrived at ICU more than 24 hours after their injury and in case 
the consent was not performed. After obtaining the blood sample at 24 hours 
following the injury, the legally acceptable relative was consented as the 
patient was still unconscious. Had the patient died meanwhile then the relative 
would not be approached. Three months later the patient or the consenting 
relative were contacted to assess the patient's outcome. Prior to this contact, the 
casenote of the patient was reviewed to ascertain if the patient had died during 
his stay at hospital. All patients were at home at 3 months after their injury, had 
they been still alive.  
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Important predictors of outcome in TBI were selected following a 
literature review: clinico-demographic characteristics namely age [23, 24], 
GCS [23, 24], pupillary reactivity [23, 24], cause of injury [92], ISS [31, 92, 
93], CT features [23, 24, 94], extracranial injury [23], vital signs including 
mean Blood Pressure (BP) [92, 95], systolic BP [92, 95], temperature [92, 96], 
and laboratory measures including PH [92, 97], Haemoglobin (Hb) [92, 97], 
Glucose [92, 97], Platelet (Plt) count [92, 97] and Prothrombin Time (PT) [92, 
97] along with O2 saturation (O2 Sat.) [92, 96] and Intracranial Pressure (ICP) 
[35]. Although some of these variables were available in the dataset, a search 
of patients‟ records was needed to fill the gaps. Ethical approval for this was 
obtained from the Salford and Trafford Research Ethics Committee (reference 
05/Q1404/157(amendment 2007)). The potential sources for this extra 
information were case notes, regional electronic records of patients (either the 
hospital Electronic Patient Record (EPR) or ICU) and TARN, which is a 
trauma registry based at Salford Royal NHS Hospital, UK. The time point for 
measurement of clinico-demographic characteristics was admission records 
(GCS and pupillary reactivity). For vitals signs, laboratory values, O2 Sat. and 
ICP, the nearest observation to 24 hours after injury was used. The time point 
of 24 hours post injury was when the blood sample was taken for S100B assay 
in the original study. 
8.3.2. Univariate analysis 
The effect of each covariate on survival and favourable outcome was assessed 
using Mann Whitney U test for continuous variables and Chi square test for 
categorical variables with the significant level of 5%. Unlike some variables 
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which were clearly categorical, e.g. pupillary reactivity, the decision to use 
other variables categorically or continuously was based on whether or not there 
was a linear relationship with log odds of survival or favourable outcome 
(linearity assumption). This was a preliminary requirement for the multivariate 
statistical analysis selected for this study i.e. logistic regression [134]. 
Fractional polynomials analysis [135] was applied to assess continuous 
variable linearity. If there was no linearity, the relevant variable was then used 
categorically with the best cut-offs adopted from the literature. Subsequently 
the significance of association with outcome was tested on the dataset by Chi 
square test. If the variable demonstrated significant association in its 
continuous form with no linearity with log odds of outcome, trials of various 
cut-offs were performed to obtain the categorical significance as well.  
8.3.3. Multivariate analysis 
The performance of TARN TBI prognostic models (models A and B) [168] 
was assessed on the study dataset since these models are suitable for our 
dataset in that all cases have received British trauma care and were nursed in 
the ICU. Overall 7 models were constructed. Model A without S100B and 
model B without S100B were constructed using the covariates from TARN TBI 
models A or B through logistic regression. Following the derivation of these 
models, S100B was added to each model to construct two further models 
(model A with S100B and model B with S100B). Similarly, a model was derived 
only including S100B (S100B model). Subsequently, predictors from TARN 
TBI models A and B and those variables which were found significant per 
univariate analysis but not contained in the TARN models were added to the 
S100B model. This resulted in construction of two more models: expanded 
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S100B model A and expanded S100B model B. Each model was run twice; once 
for survival prediction and once for favourable outcome prediction.  
The performance of each model was assessed using three measures i.e. 
AUC, Nagelkerke R
2
 [136] and classification accuracy. Then for each research 
objective, the performance of pairs of models was compared for each measure 
of performance. The pair of models compared are presented in Table 64. For 
example, the performance of the model A without S100B was compared with 
the model A with S100B per three measures of performance to address the 
research objective as to the value of adding S100B to a TBI prognostic model. 
The difference between each measure of performance was considered high (or 
clinically significant) if it was more than 0.05 for AUC and Nagelkerke R
2
 and 
more than 10% for classification accuracy. These cut-offs were arbitrary and 
were chosen in order not to take small increases in performance measures into 
account.  
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Table 64 Various pairs of models compared according to research 
objectives. Each model was run twice; once for survival prediction and 
once for favourable outcome prediction.  
 
Models A and B (with and without S100B) were derived through 
logistic regression (enter method) in Statistical Package for the Social Sciences 
(SPSS) 15 for windows. However, the expanded S100B models A and B were 
derived through stepwise method.  
Objective  Models compared  
Comparing performance of S100B 
with multivariate prognostic models  
 Model A without S100B versus 
S100B model 
 Model B without S100B versus 
S100B model  
Assessing the added value of S100B 
to prognostic models 
 Model A without S100B versus 
model A with S100B 
 Model B without S100B versus 
model B with S100B  
Assessing S100B performance after 
adjustment with other predictors (the 
added value of other prognosticators 
to S100B) 
 S100B model versus expanded 
S100B model A 
 S100B model versus expanded 
S100B model B  
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8.4. Results  
Table 65 presents the results of the univariate analyses for clinico-demographic 
characteristics and S100B (median/frequency, odds ratio and significance of 
association with survival or favourable outcome). The dataset contains 100 TBI 
patients with median age of 31 and male to female ratio of 81/19. Neither age 
nor sex is significantly associated with survival or favourable outcome. 
However, GCS is significantly associated with either outcome (i.e. survival and 
favourable outcome) both continuously and categorically when the cut-off for 
categorization is 9 (i.e. severe versus non-severe brain injury). Nevertheless, 
GCS with the cut-offs of 9 and 12 (i.e. severe versus moderate versus mild 
brain injury) does not demonstrate significant association with outcome. The 
other variables which are significantly associated with survival are ISS (in its 
categorical form) and S100B. For favourable outcome, apart from continuous 
and categorical GCS, age and S100B are significant. 
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Table 65 Clinicodemographic characteristics of the study patients. *Despite the significant P value, the CI for odds ratio 
does include 1 which implies a non-significant association. The reason for this discrepancy is that odds ratios were obtained 
through logistic regression whereas the P value was derived through Mann Whitney U test. 
 Median or 
Frequency (%) 
Odds ratio 
 
P value 
(Survival) 
P value 
(Favourable 
outcome) Survival Favourable 
outcome 
Age 31 0.99 
(0.97-1.02) 
0.96 
(0.94-0.98) 
0.45 <0.001 
Male/female 81%/19% 1.95 
(0.69-5.48) 
1.48 
(0.54-4.06) 
0.2 0.44 
GCS Continuous 8 1.14 
(0.98-1.33) 
1.14 
(1.01-1.29) 
0.02* 0.02 
Categorical Cut-
offs 9 
and 12 
mild 17%   0.11 0.11 
moderate 19% 0.71 
(0.10-4.86) 
1.18 
(0.29-4.73) 
severe 54% 0.27 
(0.05-1.29) 
0.47 
(0.15-1.45) 
Cut-off 9 (Severe GCS) 54% 0.32 
(0.11-0.97) 
0.43 
(0.18-1.03) 
0.03 0.05 
Pupillary reactivity Both reacting 53%   0.25 0.09 
Only one reacting 6% 0.26 
(0.05-1.48) 
0.12 
(0.01-1.11) 
Neither reacting 16% 1.13 
(0.27-470) 
1.01 
(0.32-3.20) 
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Table 65 Clinicodemographic characteristics of the study patients. *Despite the significant P value, the CI for odds ratio does include 1 
which implies a non-significant association. The reason for this discrepancy is that odds ratios were obtained through logistic regression 
whereas the P value was derived through Mann Whitney U test. 
 Median or 
Frequency (%) 
Odds ratio 
 
P value 
(Survival) 
P value 
(Favourable 
outcome) Survival Favourable 
outcome 
Cause of 
injury 
RTC 43%   0.47 0.15 
Fall 42% 0.62 
(0.24-1.57) 
0.79 
(0.33-1.85) 
Assault 11% 1.55 
(0.29-8.29) 
4.71 
(0.91-24.42) 
Sports 4% 0.34 
(0.03-2.74) 
 
1.05 
(0.13-8.13) 
ISS Continuous 25 1.00 
(0.94-1.05) 
1.00 
(0.95-1.05) 
0.74 0.85 
Categorical 3-24 27%   0.01 0.26 
25-
75 
73% 0.21 
(0.06-0.77) 
0.60 
(0.24-1.47) 
Extracranial injury 5% 1.83 
(0.66-5.12) 
2.25 
(0.91-5.54) 
0.24 0.07 
S100B 0.7 0.49 
(0.30-0.80) 
0.21 
(0.10-0.44) 
<0.005 <0.005 
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Table 66 presents the results of univariate analysis for various CT findings. 
Among all CT features only the presence of compressed cisterns is 
significantly associated with survival. Similarly, for favourable outcome 
prediction, only the presence of mass lesion is significantly associated with 
outcome. 
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  Median or 
Frequency 
(%) 
Odds ratio 
 
P value 
(Survival) 
P value 
(Favourable 
outcome) Survival Favourable outcome 
Marshal CT 
classification 
II 6%   0.45 0.08 
V 33% 0.62 
(0.06-6.17) 
0.87 
(0.14-5.51) 
VI 61% 0.38 
(0.04-3.48) 
0.35 
(0.06-2.04) 
Mass lesion 89% 0.21 
(0.02-1.69 
0.19 
(0.04-0.93) 
0.1 0.02 
Haemorrhage 94%  0.18 
(0.02-1.63 
0.1 0.09 
Contusion 42% 0.76 
(0.32-1.804) 
0.61 
(0.27-1.35) 
0.54 0.22 
Table 66 CT findings of the population studied.  
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 Median or 
Frequency 
(%) 
Odds ratio 
 
P value 
(Survival) 
P value 
(Favourable outcome) 
Survival Favourable outcome 
SAH 26% 0.95 
(0.36-2.51) 
0.81 
(0.33-1.99) 
0.92 0.65 
SDH 43% 0.452 
(0.19-1.08) 
0.48 
(0.21-1.06) 
0.07 0.07 
EDH 20% 0.57 
(0.20-1.58) 
0.78 
(0.29-2.08) 
0.27 0.62 
Brain swelling 15% 0.83 
(0.26-2.69) 
1.17 
(0.39-3.51) 
0.76 0.78 
Midline shift 22% 0.69 
(0.253-
1.87) 
0.79 
(0.31-2.05) 
0.46 0.63 
Compressed Cisterns 6% 0.19 
(0.03-1.11) 
0.18 
(0.02-1.63) 
0.04 0.09 
Table 66 CT findings of the population studied. (continued) 
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Table 67 (Page 370, Page 371, Page 372 and Page 373) presents the 
results of univariate analyses for vital signs and laboratory measurements. 
Among all the variables (mean and systolic BP, temperature, PH, Hb, Glucose, 
Plt count, PT, hypoxia and ICP), only ICP in both categorical and continuous 
form holds a significant relationship with survival but is unrelated to 
favourable outcome. 
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 Median or 
Frequency% 
Odds ratio 
 
P value  
(Survival) 
P value 
(Favourable 
Outcome) Survival Favourable outcome 
Mean BP [95] Hypotensive (< 85 
mmHg) 
31% 1.5 
(0.40-2.76) 
2.69 
(1.09-6.65) 
0.82 0.1 
Normotensive (85-110 
mmHg) 
49%   
Hypertensive (> 110 
mmHg) 
14% 2.04 
(0.21-
20.05) 
1.82 
(0.31-10.58) 
Systolic BP [95] Hypotensive (< 120 
mmHg) 
57% 0.59 
(0.22-1.57) 
0.99 
(0.40-2.44) 
0.48 0.19 
Normotensive (120-150 
mmHg) 
31%  - 
Hypertensive (> 150 
mmHg) 
6% 1.19 
(0.28-4.98) 
0.33 
(0.09-1.18) 
Temperature [35] Normothermia 55%   0.2 0.08 
Hyperthermia (> 38) 19% 0.42 
(0.11-1.63) 
0.38 
(0.13-1.16) 
PH Continuous 7.4 0.23 
(0.00-
56.99) 
2.19 
(0.01-489.22) 
0.6 0.78 
categorical
§
 normal 34%     
Alkalosis (> 7.45) 24% 0.69 
(0.23-2.11) 
1.33 
(0.47-3.79) 
0.518 0.594 
Table 67 Vital signs and laboratory measurements of the study patients. The citations refer to the literature where the cut-
offs were obtained. 
§ 
There were no cases recorded as acidosis (PH < 7.35). 
 371 
 
 Median or 
Frequency
% 
Odds ratio 
 
Survival Favourable 
outcome 
Survival Favourable 
outcome 
Hb Continuous 99.5 1.01 
(0.99-1.03) 
1.00 
(0.98-1.02) 
0.41 0.87 
Categorical Anemia (< 135 mmg/dl in 
makes and < 116 mmg/dl in 
females) [169] 
88% 0.40 
(0.07-2.10) 
0.44 
(0.08-2.51) 
0.26 0.34 
normal 6%   
Glucose Continuous 6.7 1.02 
(0.96-1.08) 
1.00 
(0.96-1.05) 
0.97 0.32 
Categorical Cut-offs of 
2.5 and 11 
[170, 171] 
Hypoglycaemia -   0.84 0.34 
Normoglycemia 88%   
Hyperglycaemia 6% 0.84 
(0.14-4.87) 
0.44 
(0.08-2.51) 
Table 67 Vital signs and laboratory measurements of the study patients. The citations refer to the literature where the cut-
offs were obtained. 
§ 
There were no cases recorded as acidosis (PH < 7.35). (continued)
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 Median or 
Frequenc
y% 
Odds ratio 
 
Survival Favourable outcome 
Survival Favourable outcome 
Glucose 
(Continued 
from  the 
previous 
page)  
Categorical  Cut-off 
of 6 
[97] 
Hypoglycaemia 28%   0.085 0.278 
Hyperglycaemia 66% 1.17 
(0.45-
3.05) 
0.61 
(0.25-1.50) 
Plt Continuous 150 1.00 
(0.99-
1.01) 
1.00 
(0.99-1.00) 
0.46 0.97 
Categorical Cut-offs 
of 100 
and 450 
[172] ¥ 
Thrombocytopeni
a 
16% 2.11 
(0.70-
6.39) 
1.500 
(0.51-4.43) 
0.18 0.46 
Normal 78%   
Cut-off 
of 200 
[97] 
thrombocytopenia 74% 1.35 
(0.44-
4.17) 
0.69 
(0.26-1.88) 
0.6 0.52 
normal 20%   
Table 67 Vital signs and laboratory measurements of the study patients. The citations refer to the literature where the cut-
offs were obtained. 
§ 
There were no cases recorded as acidosis (PH < 7.35).¥: there were no cases with thrombosis (i.e. Plt 
count > 450) (continued)
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 Median or 
Frequency% 
Odds ratio 
 
Survival Favourable outcome 
Survival Favourable outcome 
PT 17.7 0.91 
(0.75-
1.11) 
1.02 
(0.86-1.22) 
0.36 0.8 
Hypoxia 0   - - 
ICP Continuous 13 0.91 
(0.85-
0.97) 
0.94 
(0.89-0.99) 
<0.005 0.06 
Categorical Normal 67%   <0.005 0.08 
Increased (> 
20 mmHg) 
[35] 
19% 0.22 
(0.08-
060) 
0.43 
(0.17-1.11) 
Table 67 Vital signs and laboratory measurements of the study patients. The citations refer to the literature where the cut-
offs were obtained.(continued) 
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8.4.1. Importance of prognosticators in multivariate 
models 
Table 68 (Page 375 and Page 376) and Table 69 (Page 377 and Page 378) 
display the odds ratios along with the significance of association on each 
covariate with survival (Table 68 ) and favourable outcome (Table 69 ) in the 
models which were constructed.  
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Table 68 Odds ratios and significance of relationships of each covariate in various models investigated for survival and 
favourable outcome prediction. The numbers in the parentheses are 95% confidence intervals. The significant associations 
are starred (*: marginally significant i.e. p value <0.10 but >0.05, **: significant i.e. p value < 0.05, ***: p value < 0.005).  
 Model A 
without 
S100B 
Model A with 
S100B 
Model B 
without 
S100B 
Model B with 
S100B 
S100B 
Model 
Expanded 
S100B model 
(A) 
Expanded 
S100B model 
(B) 
Survival 
Age 0.99 
(0.96-1.01) 
1.01 
(0.98-1.04) 
0.99 
(0.95-1.02) 
1.01 
(0.97-1.06) 
  1.01 
(0.97-1.06) 
Severe GCS 0.33 
(0.09-1.27) 
0.42 
(0.11-1.69) 
0.32 
(0.08-1.28) 
0.42 
(0.10-1.74) 
   
Pupillary 
reactivity 
Both 
reactive 
       
Only one 
reactive 
0.44 
(0.11-1.75) 
0.46 
(0.17-2.01) 
0.4 
(0.10-1.66) 
0.42 
(0.09-1.97) 
 0.43 
(0.10-1.94) 
0.35 
(0.07-1.66) 
Neither 
reactive 
0.98 
(0.32-2.94) 
1.65 
(0.47-5.76) 
0.98 
(0.31-3.06) 
1.73 
(0.47-6.37) 
 1.92 
(0.50-7.28) 
2.12 
(0.55-8.11) 
ISS 0.49 
(0.10-2.31) 
0.88 
(0.18-4.30) 
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 Model A 
without 
S100B 
Model A 
with S100B 
Model B 
without 
S100B 
Model B with S100B S100B 
Model 
Expanded 
S100B model 
(A) 
Expanded 
S100B model 
(B) 
Survival 
Cause of 
injury 
RTC        
Fall   0.47 
(0.05-4.46) 
0.7 
(0.06-8.19) 
  0.8 
(0.07-9.83) 
Assault   0.64 
(0.00-235) 
1.34 
(0.003-581) 
  0.61 
(0.001-255.) 
Sports   0.03 
(0.00->10 
3
) 
<0.005 
(0.00->10
3
) 
  0.003 
(0.00->103) 
Interaction 
of cause of 
injury and 
age 
RTC        
Fall   1.01 
(0.96-1.07) 
0.99 
(0.94-1.05) 
  0.99 
(0.93-1.05) 
Assault   1.03 
(0.86-1.23) 
0.99 
(0.83-1.20) 
  1.02 
(0.84-1.22) 
Sports   1.11 
(0.44-2.8) 
1.19 
(0.47-2.98) 
  1.22 
(0.48-3.08) 
Brain swelling   0.63 
(0.17-2.28) 
0.69 
(0.17-2.87) 
  1.22 
(0.48-3.01) 
Increased ICP      0.29** 
(0.09-0.88) 
 
Compressed cisterns      0.08 
(0.01-0.59)** 
0.1 
(0.01-0.67)** 
S100B  0.44 
(0.25-0.80)** 
 0.39 
(0.21-0.73)** 
0.49 
(0.30-0.80)*** 
0.42 
(0.24-0.75)*** 
0.34 
(0.18-0.66)*** 
Table 68 Odds ratios and significance of relationships of each covariate in various models investigated for survival and 
favourable outcome prediction. The numbers in the parentheses are 95% confidence intervals. The significant associations 
are starred (*: marginally significant i.e. p value <0.10 but >0.05, **: significant i.e. p value < 0.05, ***: p value < 0.005). 
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Table 69 Odds ratios and significance of relationships of each covariate in various models investigated for survival and 
favourable outcome prediction. The numbers in parantheses are confidence intervals. The significant associations are 
starred (*: marginally significant i.e. p value <0.10 but >0.05, **: significant i.e. p value < 0.05, ***: p value < 0.005) 
(continued) 
 Model A 
without S100B 
Model A with 
S100B 
Model B 
without S100B 
Model B with 
S100B 
S100B 
model 
Expanded 
S100B model 
(A) 
Expanded 
S100B model 
(B) 
Favourable outcome 
Age 0.95 
(0.93-0.98)*** 
0.97 
(0.94-0.10)** 
0.94 
(0.89-0.98)** 
0.95 
(0.89-1.01)* 
 0.97 
(0.94-0.98)** 
0.95 
(0.89-1.01)* 
Severe GCS 0.33 
(0.10-1.10)* 
0.37 
(0.09-1.48) 
0.28 
(0.07-1.08)* 
0.32 
(0.07-1.51) 
 0.37 
(0.09-1.49) 
0.32 
(0.07-1.52) 
Pupillary 
reactivity 
Both reactive        
Only one reactive 0.11 
(0.01-1.00)** 
0.1 
(0.01-0.94)** 
0.07 
(0.007-0.79)** 
0.06 
(0.004-0.79)** 
 0.1 
(0.01-0.94)** 
0.06 
(0.004-0.79)** 
Neither reactive 0.61 
(0.21-1.75) 
1.14 
(0.33-3.95) 
0.63 
(0.21-1.95) 
1.26 
(0.32-5.05) 
 1.15 
(0.33-3.98) 
1.27 
(0.32-5.05) 
ISS 0.41 
(0.09-1.93) 
0.81 
(0.15-4.45) 
     
Cause of 
injury 
 
 
RTC  
 
      
Fall   0.48 
(0.04-5.14) 
0.41 
(0.02-7.35) 
  0.41 
(0.02-7.31) 
Assault   0.18 
(0.00-104.82) 
0.31 
(0.00-296.42) 
  0.33 
(0.00-294.278) 
Sports   0.02 
(0.00->10 
3
) 
<0.005 
(0.00->10 
3
) 
  0.001 
(0.00->10 
3
) 
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Table 69 Odds ratios and significance of relationships of each covariate in various models investigated for survival and 
favourable outcome prediction. The numbers in parantheses are confidence intervals. The significant associations are 
starred (*: marginally significant i.e. p value <0.10 but >0.05, **: significant i.e. p value < 0.05, ***: p value < 0.005) 
(continued).  
 Model A 
without 
S100B 
Model A with 
S100B 
Model B 
without S100B 
Model B with 
S100B 
S100B 
model 
Expanded 
S100B 
model (A) 
Expanded 
S100B model 
(B) 
Favourable outcome  
Interactio
n of cause 
of injury 
and age 
RTC        
Fall   1.03 
(0.97-1.10) 
1.03 
(0.95-1.11) 
  1.03 
(0.95-1.11) 
Assaul
t 
  1.12 
(0.91-1.38) 
1.1 
(0.88-1.36) 
  1.09 
(0.88-1.36) 
Sports   1.15 
(0.46-2.88) 
1.32 
(0.53-3.30) 
  1.32 
(0.53-3.30) 
Brain swelling   0.83 
(0.23-3.07) 
0.91 
(0.21-4.08) 
   
Mass lesion        
S100B  0.22 
(0.10-0.49)*** 
 0.18 
(0.07-0.45)*** 
0.21 
(0.10-0.44)*** 
0.21 
(0.10-0.48)*** 
0.18 
(0.07-0.45)*** 
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Models A and B with and without S100B: The blank cells related to 
these models in Table 68 and Table 69 are those variables which are not 
contained in the respective TARN TBI model. In both models A and B none of 
the covariates show significant associations with survival status and this still 
holds after S100B was added, whilst S100B is the only significant predictor in 
both models. Also adding S100B to these models resulted in a significant 
decrease in the deviance according to Chi square test. For  favourable outcome 
prediction (Table 69), only pupillary reactivity competes with S100B in models 
A and B holding a statistically significant association. Age also appears 
significant in model A without S100B, Model A with S100B and model B 
without S100B but this is marginal in model B with S100B (5% < p value < 
10%). The other marginally important factor is severe GCS in models without 
S100B.  
S100B model and expanded S100B models A and B: Construction of 
expanded S100B models A and B was with the inclusion of covariates from the 
TARN TBI models A and B along with those predictors found significant in 
univariate analysis (Table 65 and Table 67); being presence/absence of 
compressed cisterns and ICP for survival and presence/absence of mass lesion 
for favourable outcome. The blank cells are those variables which were absent 
in TARN TBI models A and B, lack significance in univariate analysis or 
discarded during stepwise logistic regression. As seen, S100B on its own has a 
significant influence on outcome be it survival or favourable outcome and 
addition of other factors to S100B models does not change the significance of 
this influence. Amongst those covariates displayed for survival prediction, 
S100B is followed by compressed cisterns (in both expanded S100B models A 
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and B) and then increased ICP (in the expanded S100B model A). For 
prediction of favourable outcome, S100B still holds its dominant significance 
with pupillary reactivity as the second best predictor followed by age 
(significant in expanded S100B model A but marginally significant in 
expanded S100B model B).  
8.4.2.  Models performance  
Table 70  presents the measures of performance of each model to compare the 
constructed models for survival or favourable outcome prediction. As seen, per 
AUC or R
2
 Nagelkerke the worst performing models are those which do not 
include combinations of S100B with other TBI predictors (model A without 
S100B, model B without S100B and S100B model). According to this table, 
also the best models appear to be expanded S100B models A and B (S100B 
plus one or two other predictors). 
 381 
 
Table 70 Various measures of performance for each constructed model 
(survival).  
.
 Classification 
accuracy 
AUC Nagelkerke 
R2 
HL 
statistics 
Survival 
Model A without S100B 71% 0.64 
(0.52-0.76) 
0.10 0.18 
Model A with S100B 74.7% 0.72 
(0.61-0.83) 
0.20 0.56 
Model B without S100B 70% 0.66 
(0.55-0.76) 
0.11 0.33 
Model B with S100B 75% 0.77 
(0.67-0.87) 
0.25 0.54 
S100B 73% 0.69 
(0.57-0.80) 
0.15 0.15 
Expanded S100B model 
(A) 
77% 0.78 
(0.66-0.88) 
0.30 0.59 
Expanded S100B model 
(B) 
77% 0.79 
(0.70-0.89) 
0.30 0.42 
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Table 70 Various measures of performance for each constructed model 
(favourable outcome).  
 
Comparing the performance of S100B model with model A without S100B 
and model B without S100B (the first objective of the study): This can address 
the question as to which prognostic tool among S100B or a prognostic model is 
better. Figure 27 and Figure 28 show the ROC curves of these models to 
respectively predict survival and favourable outcome. According to the graphs, 
 Classification 
accuracy 
AUC Nagelkerke 
R2 
HL 
statistics 
Favourable outcome 
Model A without S100B 67% 0.76 
(0.67-0.85) 
0.27 0.24 
Model A with S100B 76% 0.84 
(0.76-0.92) 
0.46 0.25 
Model B without S100B 70% 0.78 
(0.70-0.87) 
0.11 0.85 
Model B with S100B 77% 0.86 
(0.79-0.94) 
0.52 0.94 
S100B 67% 0.77 
(0.68-0.86) 
0.32 0.02 
Expanded S100B model 
(A) 
76% 0.84 
(0.76-0.91) 
0.46 0.73 
Expanded S100B model 
(B) 
77% 0.87 
(0.80-0.94) 
0.52 0.95 
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the differences in AUCs do not appear significant (the constant line versus the 
dashed lines).  
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Figure 27 The ROC curves of models A and B without S100B and S100B 
model for survival prediction 
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Figure 28 The ROC curves of models A and B without S100B and S100B 
model for favourable outcome prediction. 
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 Table 71 provides the differences in models performance across various 
measures (for example: AUC of S100B model minus AUC of model A without 
S100B = 73% - 71% = 2% for survival prediction). According to this table, 
AUC of S100B model does not appear to be highly different to that from 
models A and B without S100B to predict either survival or favourable 
outcome (the difference less than our clinical significance of 0.05). This is also 
the case for Nagelkerke R
2 
showing
 
a difference of less than 0.05 and also for 
classification accuracy showing a difference of less than 10%.  
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Table 71 The performance of S100B model versus models A and B without 
S100B (the figures demonstrate the difference in the respective measure of 
performance across the compared models) 
 
Changes in the performance of models A and B following the addition of 
S100B (the second objective of the study): This would address the added value 
of S100B to prognostic models. Figure 29 and Figure 30 show the ROCs 
curves of models to respectively predict survival and favourable outcome. 
According to graphs, adding S100B model to models A and B results in 
increase of AUC (thin lines versus the thick lines).  
 Classification 
accuracy 
AUC R
2 
Nagelkerke 
Survival 
S100B versus 
model A without 
S100B 
2% 0.05 0.05 
S100B versus 
model B without 
S100B 
3% 0.03 0.04 
Favourable outcome 
S100B versus 
model A without 
S100B 
0 0.01 0.05 
S100B versus 
model B without 
S100B 
3% 0.01 0.21 
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Figure 29 The ROC curves of models A and B with and without S100B for 
survival outcome prediction.  
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Figure 30 The ROC curves of models A and B with and without S100B for 
favourable outcome prediction.
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Table 72 provides the differences in the performance of models prior 
and following addition of S100B. According to this table, the increases in 
model‟s AUC are clinically significant; being 0.08 for model A after adding 
S100B to predict survival or favourable outcome and also for model B to 
predict favourable outcome. For survival prediction, the increase in AUC of 
model B is even greater still at 0.11. Similarly, the increases in Nagelkerke R
2 
with S100B are high in both models A and B for either outcome prediction. 
With regards to classification accuracy, this index of performance increases 
after addition of S100B, although the degree of increase is varied and not close 
to the clinical significance (i.e. an increase of 10%) at all times.  
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Table 72 Comparing the performance of Models A and B with and without 
S100B (the figures demonstrate the difference in the respective measure of 
performance across the models compared) 
 
Changes in the performance of the S100B model following 
construction of expanded S100B model A or B (the third objective of the 
 Classification 
accuracy 
AUC R
2 
Nagelkerke 
Survival 
Model A without 
S100B versus 
Model A with 
S100B 
3.7% 0.08 0. 10 
Model B without 
S100B versus 
Model B with 
S100B 
5% 0.11 0.14 
Favourable outcome 
Model A without 
S100B versus 
Model A with 
S100B 
9% 0.08 0.19 
Model B without 
S100B versus 
Model B with 
S100B 
7% 0.08 0.41 
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study): This should be considered to assess how the prognostic strength of 
S100B would improve after other TBI prognosticators are taken into account. 
Figure 31 and Figure 32 demonstrate the ROC curves of these models for 
respectively survival and favourable outcome prediction. It can be observed 
that the AUC of S100B model appears to rise following addition of other TBI 
prognosticators (the dot line versus the constant lines). 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
1-Specificity 
S
e
n
s
it
iv
it
y
 
S100B model Expanded S100B model A Expanded S100B model B 
 
Figure 31 The ROC curves of S100B model and expanded S100B models A 
and B for survival prediction.  
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Figure 32 The ROC curves of S100B model and expanded S100B models A 
and B for favourable outcome prediction. 
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Table 73 gives the differences in model performance following adding 
other variables to the S100B model. The AUC of S100B model increases by 
0.09 and 0.07 respectively following construction of expanded S100B model A 
for survival and favourable outcome prediction. This increase is also of similar 
magnitude for expanded S100B model B at 0.1 for both types of outcome 
prediction. Similarly, Nagelkerke R
2 
 increases by 0.15 and 0.14 in expanded 
S100B model A respectively for survival and favourable outcome prediction and 
this increase is still significant for the expanded S100B model B being 0.14 and 
0.20. However, the change in classification accuracy for survival prediction is 
low (less than our clinical significance of 10%) in both expanded models 
whereas this is high for favourable outcome prediction. 
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Table 73 The performance of S100B versus expanded S100B model A and 
B (the figures demonstrate the difference in the respective measure of 
performance across compared modesl).  
 Classification 
accuracy 
AUC R
2 
Nagelkerke 
Survival 
S100B model 
versus expanded 
S100B model A 
4% 0.09 0.15 
S100B model 
versus expanded 
S100B model B 
4% 0.10 0.15 
Favourable outcome 
S100B model 
versus expanded 
S100B model A 
9% 0.07 0.06 
S100B model 
versus expanded 
S100B model B 
10% 0.10 0.20 
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8.5. Discussion  
In this study, the two common prognostic tools (prognostic models and 
a brain injury biomarker) in TBI were compared in a multivariate analysis by 
constructing two types of models: prognostic models containing a composite of 
important clinical prognosticators and a model which only contains S100B. 
The results show that these two prognostic tools do not differ in their 
performance per AUC, Nagelkerke R
2 
and classification accuracy. However, 
following addition of S100B to TBI prognostic models (TARN TBI models A 
and B), the performance of the models improve per AUC and Nagelkerke R
2
. 
Furthermore, taking other important TBI prognosticators into account along 
with S100B in a prognostic model improves the S100B prognostic strength. In 
all models which contain S100B and other predictors, S100B appears to be the 
most reliable predictor, showing a significant effect on outcome at all times.  
8.5.1. Limitations  
Our series suggests that including S100B with two or three other 
important TBI prognosticators would provide a stronger prognostic tool than 
either alone. It was hoped that the results of the multivariate analysis of the 
S100B dataset would provide the precise information on the relative prognostic 
importance of each variable contained in the models. However, in this study 
the findings for survival prediction are significantly different to that for 
favourable outcome prediction and also to the literature [23, 24, 31, 92]. For 
example, only compressed cisterns (as in expanded models A and B) and the 
increased ICP (as in expanded S100B model A) were found to be significant, 
with all other variables being insignificant. For favourable outcome prediction, 
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despite pupillary reactivity being present in all constructed models for outcome 
prediction with age being present in 5 out of 7 models, compressed cisterns and 
increased ICP were never found to be significant. Overall, our results can not 
suggest the most important TBI prognosticators to be included in a „small‟ 
prognostic model. This is because of the differences of our results regarding 
most important prognosticators between the two types of outcome and also 
because of the differences of the results with the literature which suggests 
important prognostic strength for age, GCS and pupillary reactivity. However, 
we believe our data suggest that S100B combined with 1 or 2 predictors out of  
age, pupillary reactivity and GCS is able to provide a strong prognostic tool in 
that these three variables are shared by currently well-developed prognostic 
models i.e. CRASH and IMPACT models.  
 
Sample size  
 
It should be noted that the objective of our study was not to construct a 
prognostic tool which could be reliably reproduced in other population of TBI 
cases. We performed a comparative analysis of various models in our dataset 
of 100 cases to investigate which of the current prognostic tools might be a 
stronger predictor of outcome and due to the small population sample the 
characteristics of the final models are not reliable. However, despite the small 
dataset, we believe our findings are valuable for comparing the performance of 
the various models with each other. The comparisons were made, firstly, across 
three measures of model performance i.e. AUC, Nagelkerke R
2
 and 
classification accuracy, secondly, on more than one pair of models and thirdly, 
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for the prediction of more than one type of outcome i.e. survival and 
favourable outcome. From all these aspects the results of comparisons are 
consistent. However, the number of cases prevents model differences being 
statistically as well as clinically significant hence the overlaps in AUC 
confidence intervals (Table 70).  
Furthermore, although the increase in classification accuracy is not 
close to the our cut-off of clinical significance (i.e. > 10%) at all times, the 
clinically significant changes in AUC or Nagelkerke R
2
 would support the 
study findings. For example, although adding S100B to models A and B or 
adding other TBI predictors to S100B model does not yield an increase of 10% 
in classification accuracy for survival prediction, the increases in AUC and 
Nagelkerke R
2
 are large enough to be considered clinically significant per the 
cut-off of 0.05. In fact, AUC and Nagelkerke R
2
 are more reliable to compare 
competing models in that if a model holds higher AUC and Nagelkerke R
2
, this 
model holds a better performance even if the classification accuracy is not 
different.  
8.5.2. Comparison with the literature  
With regards to the combination of a brain injury biomarker with other TBI 
prognosticators to obtain a more reliable predictive power, the results of our 
study are consistent with other studies. Diminopoulou et al.  observed that a 
prognostic model which contains age, GCS and S100B performs better than 
one without S100B [165]. Similarly, Vos et al.  constructed a prognostic model 
which only contained clinical characteristics namely GCS and CT Marshal 
Classification [139] and demonstrated the improvement in the model 
performance following adding S100B, Glial Fibriliary Protein Acidic Protein 
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(GFAP) and Neuron Specific Protein (NSP) [43]. The two latter serum proteins 
have been shown in some studies to be raised in TBI which, similar to S100B, 
may have prognostic value as well. However, we observed a stronger 
predictive power can be obtained with only S100B in combination with other 
predictors routinely measured. To the best of our knowledge, no researchers 
have, so far, attempted to compare the two current prognostic tools (proposed 
prognostic models versus brain injury biomarkers), in terms of their relative 
predictive strength. This is an important comparison since we found no 
significant difference in the performance of these two current prognostic tools. 
This goes against the conclusion by many authors that S100B may not hold 
enough prognostic strength in TBI [67, 77, 82, 98, 173]. Should other 
prognosticators be taken into account, S100B could be a good tool perhaps 
even superior to current multivariate models.  
8.5.3. Implications of the study  
It is currently acknowledged that the most reliable of the available TBI 
prognostic models are those developed from the CRASH and the IMPACT 
datasets. Both of these models have been derived from a large cohort of TBI 
cases ( > 10,000 cases). Conspicuously, collection of such large numbers of 
TBI cases occurs over a long period of time and requires devotion of a huge 
amount of funding and resources. We observed that S100B on its own has the 
same prognostic strength as the prognostic models when identification of its 
prognostic characteristics in a univariate analysis does not entail accruing a 
large dataset. For instance, the pilot study in our centre demonstrated that a 
dataset of 100 TBI patients should suffice to investigate the prognostic 
characteristics of S100B. One may argue that collection and recording of data 
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from TBI cases may also occur within ongoing procedures such as in trauma 
registries. However, it is unclear how often a TBI prognostic model requires 
updating to take account of improved trauma care policies, new advances in 
management and therapeutic approaches. The time frame to update a 
prognostic model may also not provide an adequate number of TBI cases for 
construction of a reliable prognostic model. The major advantage of prognostic 
models over S100B appears to be the value of each covariate in the model 
being easily obtainable in the clinical notes because they are routinely 
measured. However, measuring S100B serum level is currently not a part of 
routine clinical practice but should its use increase, cost would decrease. In 
fact, the costly research into developing a prognostic model which uses 
commonly measured clinical data should be contrasted with the possible lower 
cost of measuring S100B in every TBI patient which can be included as a part 
of routine blood sampling.  
Among all constructed models, expanded S100B models A and B are 
the best per three measures of performance (AUC, Nagelkerke R
2
 and 
classification accuracy). These two models, apart from S100B, include only 1 
or 2 other covariates. This may imply that combination of S100B with 1 or 2 
other TBI prognosticators could provide a stronger prognostic tool than either 
multivariate models without S100B or S100B in isolation.  
In this study, we investigated the effect of many important prognostic 
factors (ranging from demographic and clinical observations to CT findings, 
vital signs and laboratory measures) and observed that S100B shows a 
significant effect on outcome in all models which contain this covariate. This is 
not the case with other predictors. This finding suggests an important clinical 
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implication in that S100B could be the most reliable factor among other 
measures such as GCS, pupillary reactivity or even ICP to monitor the course 
of brain injury [65].  
8.5.4. Future direction  
We embarked on the current project on the basis of limited literature on 
comparing prognostic models and brain injury biomarkers. As such, it is 
important to establish which prognostic tool is better and whether or not the 
combination of the two would be a better option. Whilst examining this 
requires a large dataset of TBI cases, we decided to first analyse the relatively 
small TBI data available to us. In this small sample, prognostic models do not 
appear significantly different to S100B. Similarly, their combinations either by 
adding S100B to prognostic models or considering one or two other TBI 
prognosticators along with S100B may be a better option. However, these 
results have to be validated in a larger TBI series. Similarly, we believe the 
idea of S100B (or brain injury biomarkers) versus prognostic models needs to 
be considered and taken forward in investigation on accurate prognosis in TBI. 
Had the results obtained on our small sample of S100B data been different 
(such as no significant improvement of performance in combination of S100B 
and prognostic models), then future research on this would appear less 
important. However, comparing prognostic models with biomarkers or 
assessing their combinations is a problem in medicine in general [174] and in 
TBI prognosis in particular [88]. This is because multivariate analysis requires 
much large datasets which are costly and time consuming to accrue for S100B. 
It is stated that the adequate sample size for modelling should include 500 
subjects [159].  
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8.6. Conclusion 
A comparisons of performance of the two currently used prognostic tools in 
TBI; a) multivariate prognostic models and b) laboratory biomarkers (in this 
study S100B) was shown to have an equivalent performance. However, S100B 
individually has the strongest influence on outcome. A future prognostic model 
which may perform better to predict outcome would be one which combines 
the S100B laboratory biomarker with a minimum of 1 to 2 TBI clinical-
demographic prognostic factors. This, however, requires to be examined in a 
larger cohort of TBI cases.  
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8.7. Expansion on methods  
8.7.1. Data collation/missing information  
Due to the retrospective collation of some patients‟ data, strategies were 
implemented to minimise the amount of missing information particularly on 
clinico-demographic values. Whilst the values for age, cause of injury, CT 
features and ISS were available in the original study dataset, information on 
GCS and pupillary reactivity was obtained from case notes, Electronic Patient 
Records (EPR) and TARN. These sources were not uniform in data recording 
in that, for example, admission GCS might have been available in TARN when 
missing in EPR. Therefore, for clinico-demographic data, all sources were 
searched for the following time points: - at scene of injury, en route and on 
admission to the first hospital (in case of transfer) and subsequently at the 
earliest time point following admission to ICU (the observations could be 
recorded by either clinicians or the nursing staff). Subsequently, missing 
admission values were imputed with en route, at scene and finally from the 
earliest time point following admission to ICU. However, this strategy still 
yielded 10% and 15% missing values on GCS and pupillary reactivity 
respectively. Similarly, with the patients‟ identifiers, the EPR was searched for 
laboratory values. This resulted in 42%, 7%, 6%, 6%, 6%, 7% missing values 
respectively on PH, Glucose, Hb, Plt count and PT. There was no limitation for 
the length of elapsed time on either side of 24-hours (earlier or later) to spot the 
closest measurement; had the information been missing at this exact time point. 
However, if the difference between the closest time of recording was more than 
24 hours different to the time point of 24 hours following the injury, the value 
 402 
was then counted as missing. Since all patients were enrolled from the ICU, it 
was possible to access the observations on their vital signs along with O2 Sat. 
and ICP electronically recorded every 10 minutes during the ICU stay. There 
were only 74% cases with their temperature recorded [175] (38% rectal 
temperature and 36% brain temperature) which means 26% cases with missing 
information on this variable (rectal temperature was imputed with brain 
temperature). However, the amount of missing data was far lower for systolic 
blood pressure, mean blood pressure and ICP retrospectively at 6%, 6%, and 
8%. 
 
8.7.2. Data preparation/continuous versus categorical  
 
Clinicodemographic variables 
 
Fractional polynomials analysis showed that whilst age held linear relationship 
with logarithmic odds of both types of outcome, this is not the case for ISS and 
continuous GCS. Nonetheless, unlike ISS, GCS presented a significant 
association with both outcome measures of favourable outcome or survival in 
the continuous form by Mann Whitney U test. Therefore, for GCS, initially 
cut-offs of 9 and 12 were used to categorise this variable into mild, moderate 
and severe GCS. However, this categorisation resulted in no significant 
relationship with outcome by Chi square test and thus mild and moderate 
categories were merged together to group GCS values into severe (GCS < 9) 
and not severe (GCS ≥ 9) which yielded a significant association. On the one 
hand, GCS was significantly associated with outcome continuously but could 
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not be used in the multivariate model without transformation and on the other 
hand, its categorical form with 3 categories did not show significant association 
with outcome as per Chi square test. Since transformation of continuous GCS 
by means of fractional polynomials was expected to yield complicated 
mathematical calculations on a small sample size of only 100 cases, the 
decision was made to use GCS categorically rather than continuously. 
Regarding ISS, initially, cut-offs points of 8, 15. 24, 40 and 75 were used 
[176]. Nonetheless, due to small sample of cases within each range of ISS: 9 to 
15 (only one case) and ISS: 41 to 75 (only seven cases) with no case recorded 
as ISS less than 8, ISS: 9-15 was pooled into ISS: 16-24 with ISS: 41-75 
merged with ISS: 25-40. Therefore, ISS was left with two categories of 3 to 24 
and 25-75. Further, for identification of cases with extracranial injury, 
extracranial AIS scores > 2 were used as the criterion.  
 
S100B  
 
S100B showed a linear relationship with either survival or favourable outcome 
as per fractional polynomials analysis and therefore was analysed only 
continuously.  
 
CT features 
 
CT reports of patients were available from the original dataset and therefore 
using these reports the appropriate Marshal Class using the algorithm 
suggested by Maas et al. [94] were allocated to each case. However, Marshal 
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Class IV was merged with the Marshal Class V because there were only one 
case with Marshal Class IV. Furthermore, other traditional descriptive terms 
for structural brain damage proposed by literature were also applied as nominal 
(yes/no) variables; being brain swelling, mass lesion, midline shift, cisterns, 
SAH, SDH, EDH, haemorrhage and contusion..  
 
Vital signs, O2 Sat. and ICP 
 
Cut-off points of 120 and 150 were used to categorise systolic blood pressure 
into hypotension, normtension and hypertension with 85 and 110 for mean 
blood pressure as proposed in the IMPACT study [95]. Furthermore, 
temperature values were first grouped into hypothermia (< 35 ° C; based on 
IMPACT [96]), normothermia (> 35 ° C but < 38 ° C) and hyperthermia (> 38 
° C; based on Signorini‟s study [35]) and since there was only one case within 
the hypothermic group, this was merged with normothermia. Furthermore, 
there were no cases with hypoxia recorded in the dataset. Consequently, 
hypoxia was discarded at this early stage from further analysis. Regarding ICP, 
fractional polynomials analysis did not prove a linear relationship with 
outcome. However, it was observed this variable holds significant correlation 
with survival in its continuous form. Using the cut-offs of 20, 30 and 40 as 
suggested by Signorini et al.  [35] to categorise ICP into mildly, moderately or 
severely raised ICP did not affect this significance. Using this categorisation, 
there were no cases within the severely increased group with only 6 cases in 
the moderately increased group. Because of this, all severities of raised ICP 
were merged into one group to have only two categories as raised ICP versus 
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normal ICP. The results demonstrated that both categorisations (either with 
four categories or with two categories) were significantly associated with 
survival but not favourable outcome. In the modelling procedure, ICP with two 
categories was included.  
 
Laboratory values 
 
Although the effect of PH, Hb, glucose, Plt count and PT on outcome are 
expected to flatten in the normal range values, in the IMPACT dataset, these 
parameters demonstrate a linear relationship with outcome with no obvious 
threshold point. Therefore, all laboratory measures were also continuously 
assessed along with their categorical form. For PH, cut-offs of 7.35 and 7.45 
were used to categorise PH values into acidosis, normal and alkalosis. 
Nevertheless, there were only 4 cases with acidosis and thus these cases were 
included in the normal group. For Hb, the upper and lower normal limits were 
employed to categorise this variable. The cut-offs  were different per gender 
(normal range: males: 135-180 mg/dl and females: 115-160 mg/dl) [169]. 
Using this categorisation, the dataset contained only one male case with Hb of 
above 181 which was then included in the normal range group resulting in the 
dataset containing no case with high Hb. Similarly, the upper and lower limits 
of 2.5 mmol/dl and 11 mmol/dl [171] [170] were used to recode glucose values 
into hypoglycaemia, normoglycemia and hyperglycaemia. Along with this 
categorisation, the cut-off of 6 mmol/dl as observed in the IMAPACT study 
[97] as the changing point in the trend of the influence of glucose on outcome 
was also tested. Additionally, since a similar change in the trend was observed 
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by the IMPACT for the Plt count at the value of 200 × 10
3 
[97], this value was 
used to categorise Plt count into thrombocytopenic versus normal group. 
However, along with this categorisation, Plt count was also categorised using 
the cut-offs of 100 and 450 which conventionally groups the values into 
thrombocytopenia, normal and thrombocytosis [172, 177]. Regarding PT, using 
9 min. and 12 min. as the upper and lower limits of normal range yielded no 
cases within the normal and below-the-normal-range groups and thus this 
variable was only continuously analysed. 
The performance of TARN TBI prognostic models (models A and B) 
[168] was assessed on the study dataset. Adaptations of these models to the 
dataset in this study included using GCS with two categories (severe and non-
severe GCS), using pupillary reactivity with three categories (normal, only one 
reactive and both reactive) and omission of hypoxia, brain stem injury and 
extracranial injury due to the small number of cases with each of these 
observations (there were no cases recorded with hypoxia or brain stem injury 
and there were only 5 cases recorded with extracranial injury which all 
survived till 3 months after injury and only one experienced unfavourable 
outcome).    
8.7.3. Handling missing information  
All the remaining missing information were imputed with multiple imputation 
strategy in Stata.  
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9. Discussion
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In this PhD, tow prognostic models have been constructed and the prognostic 
strength of S100B has been compared with prognostic models and also the 
prognostic strength of combination of these two tools has been examined. 
These next few pages summarise the approach and results in each project.  
 
TARN project  
 
The TARN TBI dataset (n=802) was used for the model derivation. Initially, 
the data were retrieved from TARN based on head AIS codes under internal 
organ in the AIS dictionary plus those skull AIS codes with AIS severity of 3 
or above. Those submissions which did not have their pupillary reactivity 
recorded at any time point were not selected.  
Further TBI data were retrieved from TARN with the same inclusion 
criteria irrespective of pupillary reactivity being recorded or not (n= 21657). 
Then the prognostic strength of various time points of GCS measurement and 
also various sub scores were compared in a multivariate analysis (i.e. following 
adjustment with age and ISS). The results demonstrated that total GCS and the 
motor subscore hold the similar prognostic power with admission 
scores/subscores being stronger than scene scores/subscores. This implied that 
in the modelling admission GCS/motor score may be better than scene 
GCS/motor score and since the number of missing information of motor 
subscore was much higher than that of total GCS in the derivation dataset (167 
versus 26), the admission total GCS was used in the subsequent modelling 
procedure.  
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Parallel to the above analysis, a method was devised to translate the 
brain injury AIS codes to the Marshall Classification facilitating allocation of a 
Marshall Class when AIS codes are at hand. Initially a cross-tabulation was 
devised which was agreed upon from both clinical and AIS coding viewpoints. 
Furthermore, an algorithm was proposed which can allocate one single 
Marshall Class to a TBI patient in a trauma registry who has various AIS codes 
of brain injury recorded. Following this, the cross-tabulation and algorithm 
were programmed in SPSS and thus a Marshall Class was assigned to each 
case in the derivation dataset.  
Subsequently, the univariate analysis was performed using Mann 
Whitney U test for continuous variables i.e. age, GCS, ISS, systolic and mean 
blood pressures and Chi Square test for categorical variables i.e. GCS, gender, 
nationality, cause of injury, extracranial injury, systolic and mean blood 
pressure, hypoxia, various AIS severity scores, the Marshall Classification and 
various intracranial pathologies (T test was never used since none of the 
continuous variables were found normally distributed by one-sample 
Kolmogorov-smirnov test). The univariate analysis demonstrated all variables 
significantly associated with outcome apart from gender, nationality, contusion 
and SDH. Therefore, these variables were excluded from the modelling. 
Furthermore, fractional polynomial analysis was performed to assess the 
assumption of linearity for logistic regression. This analysis demonstrated that 
age has a linear relationship with logit odds of survival and thus can be 
included in the model as „it is‟ (i.e. with no transformation or categorisation). 
However, for other variables the power transformations were required.  
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Following the univariate analyses, logistic regression was run on the 
TARN dataset. First age, GCS, pupillary reactivity, ISS and extracranial injury 
were supplied to one single model with automatic regression. However, it was 
observed that the automatic regression discarded one of the two fractional 
polynomial transformations of GCS. This was not acceptable. Thus this stage 
was run again „manually‟ in that each variable was supplied to the model at 
separate stages. Furthermore, it was observed that extracranial injury is 
significantly associated with outcome when firstly, the cut-off is extracranial 
AIS severity score of 4 and above (and not 3) and secondly, when it is not 
included in the model which contains ISS. This resulted in branching the 
modelling procedure with two parallel models one model including ISS and 
excluding  extracranial injury and the other excluding ISS but including 
extracranial injury. Additionally, it was observed that cause of injury is 
significant only in the model which contains extracranial injury.  
During the modelling procedure, the prognostic value of various AIS 
severities (3, 4 and 5/6), the Marshall Classification and various intracranial 
pathologies were assessed. It was observed that whilst adding the AIS severity 
and the Marshall Classification improves the prognostic strength of 
multivariate models, these may not be accurate in grouping injuries based on 
prognostic merit. This is because not all AIS severities or Marshall Classes 
demonstrated significant association with outcome. Regarding various 
intracranial pathologies namely haemorrhage, SAH, EDH, brain swelling, brain 
stem injury and cerebellar injury, only the brain stem injury and brain swelling 
were significantly associated with outcome. Several models were constructed 
to perform this piece of analysis. However, only those models in which all 
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intracranial pathologies were significant were chosen for the modelling 
procedure. These are two models: one only containing the brain stem injury 
and the other containing the brain stem injury along with the brain swelling.  
The prognostic value of hypoxia, mean and systolic blood pressures 
were also examined. It was discerned that whilst hypoxia is significantly 
associated with outcome, hypertension (as per either mean blood pressure (i.e. 
> 110 mmHg) or systolic blood pressure (i.e. > 150 mmHg) was never 
significant. Thus only hypotension versus normotension (including 
hypertension) was considered. Finally, between systolic and mean blood 
pressure, systolic blood pressure was selected since these two variables could 
not be included in the same model (as they lost their significance) and also the 
model with mean blood pressure did not demonstrate acceptable calibration as 
per HL statistics.  
There were overall 26, 136 and 138 missing cases with admission GCS, 
left and right pupillary reactivity respectively. This missingness was filled with 
the en route and then the scene records which left the dataset with no missing 
values of these variables. However, for hypoxia and systolic blood pressure 
(each with 36 and 114 missing cases), this strategy failed to fill all the missing 
values and thus the cases with missingness were all grouped in a different 
category as „missing‟. 
In the end two models were derived: model A and B. Both models 
contain age, GCS, pupillary reactivity, the brain stem injury, hypoxia and low 
blood pressure. However, model A contains ISS which is absent in model B 
whereas model B contains cause of injury, extracranial injury and brain 
swelling instead. The performance of these models is presented across various 
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indices. They have AUCs of 0.92 (C.I.: 0.90-0.95) and 0.93 (C.I.: 0.91-0.95) 
respectively for models A and B. Model A was externally validated on a 
different serious of TBI from TARN and maintained its performance as per 
AUC (0.92). Model B also demonstrated reasonably good performance in the 
same external dataset (AUC: 0.82). However, the drop in AUC for model B as 
it was re-run in the IMPACT data was somewhat huge (AUC: 0.68 for survival 
prediction and 0.69 for favourable outcome prediction at 6 months). From 
various aspects the proposed models can be considered well-developed 
regarding the strategies taken during the model derivation. 
 
S100B project 
 
The analysis of the first prospective S100B project which the investigator 
contributed to its completion, demonstrated that S100B, 24 hours after injury, 
has a high sensitivity to predict unfavourable outcome or death (more than 
80%) but its specificity is somewhat low (60% for unfavourable outcome and 
49% for death).  
With regards to the second part of S100B project, initially, the patients‟ 
case notes, EPR and TARN were searched for the variables which were not 
recorded in the original S100B study. In fact, the first S100B project only had 
records of age, cause of injury, CT findings and ISS. Subsequently, the 
association of each TBI prognosticator with outcome was assessed with the 
outcome (survival and favourable outcome at 3 months). The TARN TBI 
models A and B derived in the other part of PhD were run on the S100B 
dataset of 100 cases and their performance was compared with the model 
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which included only S100B. The performance was compared across various 
measures namely AUC, Nagelkerke R
2
 and classification accuracy. In order not 
to consider small differences in these indices, the differences of more than 0.05 
were considered „clinically‟ significant for AUC and Nagelkerke R2. Similarly, 
the difference of more than 10% was considered clinically significant for 
classification accuracy.  
The results demonstrated that, particularly as per AUC, the difference 
between performance of prognostic models and S100B is not clinically or 
statistically important. Regarding the importance of combinations of S100B 
with prognostic models, S100B was added to TARN models A and B to 
evaluate their change in performance. It was observed that this addition results 
in clinically significant increase in the models performance as per AUC and R
2
 
Nagelkerke. However 95% confidence intervals for AUCs overlapped 
implying inability to show the statistical significance. Similarly, those TBI 
prognosticators which were present in either model A or B or were found 
significant in the univariate analysis were added to the S100B model. 
Following to this, a clinically significant improvement in performance was 
observed as per AUC and Nagelkerke R
2
. However, this improvement was not 
statistically significant.  
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9.1. Limitations  
9.1.1. TARN project 
Summary from the respective papers  
Some limitations of this project have been already discussed in Papers 3, 4, 5 
and 6.  
Paper 3: in the analysis of prognostic value of various GCS subscores 
and the admission scores/subscores versus the scene scores/subscores, it was 
unclear that whether the immeasurable values (i.e. due to intoxication or 
intubation) were assigned as missing (i.e. leaving it blank during data entry) or 
were received the lowest GCS subscore based on the local hospital policy. This 
implies that some lowest GCS subscores in the analysis might represent 
missing values unlike the GCS criteria for the lowest subscore. Similarly, in 
this analysis the adjustment was performed with age and ISS although 
pupillary reactivity is an important confounder too. Furthermore, the definition 
of „admission to the emergency department‟ (the record which was taken from 
TARN as representing admission GCS) varies across hospital in terms of being 
prior to or following resuscitation. This is important as it has been suggested 
that post-resuscitation values may be better for prognostic analysis [137].  
Paper 4: regarding the method which was proposed to assign a 
Marshall Class to a case of TBI in trauma registries, this suffers from some 
limitations as to AIS scores being substitutes to CT reports and the assumptions 
made about the mass lesion and brain swelling. The source of information for 
AIS coding is not only CT and can be MRI or operational notes as well. This 
indicates the dynamic nature of brain injury which is inherited in AIS coding 
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but not the Marshall Classification which is obtained via direct observation of 
CT image. Furthermore, the cut-offs for sizewise categorisations of mass 
lesions in AIS dictionary are different to that in the Marshall Classification. In 
the same way, the criteria to assess the degree of brain swelling are different in 
the two systems (being midline shift and cisterns status in Marshall 
Classification versus only the status of cisterns in the AIS dictionary).  
Paper 5: using AIS codes as substitutes to CT reports is also a 
limitation for the prognostic analysis of various intracranial pathologies in this 
paper as the CT findings/classifications from the literature were used as a basis 
for this analysis. Moreover, brain injury AIS codes are commonly multiple and 
taking only the highest code to assess the prognostic value of AIS scores may 
not be an appropriate approach.  
Paper 6: regarding the proposed final TBI models, the derivation 
dataset may not be a true representative of severe TBI according to TARN 
inclusion criteria. Even within the TARN context and according to the 
selection bias analysis, the derivation dataset was slightly younger than 
excluded TBI cases due to lack of pupillary reactivity recorded. Furthermore, 
children were not excluded from the multivariate analysis although it is thought 
the course of TBI differs in children versus adults.  
 
****** 
The approach taken in model derivation may be „holistic‟. This applies to the 
involvement in overly detailed observations which may not only lack 
importance with regards to their enhancement in the model performance; they 
may in fact disturb the model performance in other populations of TBI. This 
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overly detailed approach in modelling may be reflected in the difference 
between AUC of levels IIIÁ and VIIIB models and the final TARN models A 
and B which is only 0.01 (for model A) and 0.02 (for model B). Despite this 
slight difference, we still proceeded with the modelling since at the very early 
level it was unclear how far the performance of the model(s) would increase. 
This slight degree of difference occurs when levels IIIA and VIIIB models 
respectively contain only 4 or 5 variables (age, GCS, pupillary reactivity and 
ISS in level IIIA model and age, GCS, pupillary reactivity, extracranial injury 
and cause of injury in level VIIIB model) whereas TARN model A contains 
only 3 more variables (brain stem injury, hypoxia and systolic blood pressure) 
and TARN model B contains only 4 more variables (brain swelling, brain stem 
injury, hypoxia and systolic blood pressure). However, although in terms of 
AUC the difference between models IIIA to final models is small, it is unclear 
whether or not this degree of difference is in fact unimportant in the clinical 
context. For example, the AUC of mammography to diagnose breast cancer is 
statistically high (85%) [110] whereas this diagnostic tool has much less value 
in the diagnosis of breast cancer than other tools such as Fine Needle 
Aspiration (FNA) or biopsy. Furthermore, models A and B contain extra 
variables than model IIIA which puts emphasis on the prognostic value of these 
extra variables such as CT findings, hypoxia or hypotension. This is important 
especially with regards to tertiary preventive measures to consider 
interventions to treat CT abnormalities, hypoxia or hypotension in TBI 
patients. However, if the models are to be used to assess and compare the 
quality of care, this degree of difference in AUC may be negligible and models 
IIIA or IIIB may sufficiently serve the purpose.  
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Our series of TBI cases may not be representative of severe TBI cases 
to refute the hypotheses 1 and 2. Although according to TARN inclusion 
criteria, only the profile of those trauma patients who sustained severe injuries 
are submitted to TARN, comparing our dataset of TBI to the IMPACT dataset 
demonstrates that the severity of TBI in TARN is less as per GCS and pupillary 
reactivity. For example, 19.2% of cases in the IMPACT dataset had neither 
reactive pupils whereas this figure was significantly lower in the TARN data at 
16.5%. Even if one wishes to consider severe brain injury as GCS ≤ 8, 35.8% 
of our sample sustained mild brain injury (i.e. admission GCS 15, 14 or 13). 
However, the cases in our dataset had severe injuries enough to stay at hospital 
for more than 3 days or to receive ICU care (or to fulfil other criteria of TARN 
submission reflecting severe injuries). Similarly, all cases had one or more 
head AIS code representative of either intracranial pathology or 
compressed/depressed/open skull fracture.  
One other limitation of the models relate to survival being assessed at 
discharge rather than assessing this at a certain point in time such as 30 days 
after injury. A time-fixed outcome assessment has two important advantages 
over discharge outcome. Firstly, it is well-known that as time passes, the 
probability of death decreases after TBI. As such, varied length of time of 
outcome assessment plays a confounding role as it influences what the 
prognostic models predict which is the probability of survival. Secondly, there 
is a bias to consider some patients with severe TBI who are discharged from 
hospital but end up in rehabilitative centers and subsequently die there. These 
patients are in fact non-survivors of TBI but have been discharged because of 
the severity of injury being deemed unresponsive to any therapeutic 
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intervention. The bias is that this group of patients with severe injuries are 
considered as alive whereas they have not survived their severe injuries.  
 
It is an obvious disadvantage of TARN TBI model B that its 
performance significantly drops in the IMPACT external TBI population and 
one may consider that the same observation would have been observed, had the 
IMPACT had ISS records to externally validate model A (model A was not 
validated on the IMPACT data since ISS was not recorded). The reason for this 
poor external performance may be either significant difference of case-mix 
between the IMPACT and the TARN dataset or the inherent lack of 
transportability in TARN models. The IMPACT dataset pooled various 
datasets from observational and clinical trial studies conducted in varied 
geographical regions (across Europe and the North America) and the endpoint 
of outcome measure was at 6-months after the injury. The IMPACT dataset 
also contained more severe cases of TBI as per GCS and pupillary reactivity. 
Moreover, TARN models hold historic validation as there is not a significant 
drop in performance across various indices where the models are validated in a 
TARN TBI series from a different time period as to the derivation set. 
Similarly, the decrease in performance in the IMPACT dataset does not reflect 
our failure in constructing models suitable for the British trauma care system. 
So far, it is clear that the external performance of the models may be less than 
some IMPACT and CRASH TBI models in terms of some types of 
transportability related to geography, methodology, spectrum and fellow-up 
interval (Paper 1, section 2.8).  
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Handling the continuous variables is one aspect of model development. 
We applied fractional polynomial transformation to address the linearity 
between the continuous variables and the logit odds of survival. During the 
modelling procedure we decided to discard continuous GCS (due to the same 
performance of the model with continuous GCS to the model with categorical 
GCS). Using categorical GCS with three categories of mild, moderate and 
severe may not be an appropriate approach since in this way GCS is not treated 
as a continuous entity. For example, two patients with different GCSs of 4 and 
8 are both put in the same category as severe GCS whereas GCS 8 and 4 are 
numerically different and thus may have different prognostic values. It may be 
that using other methods to address the linearity of GCS with logit odds of 
survival such as spline functions [178] be superior than fractional polynomials 
especially if the resulting model is expected to sustain its performance in other 
external datasets. Although, it is unclear which method to address linearity is 
better from the statistical point of view, using complicated mathematical 
formula proposed by fractional polynomials does not have clinical appeal.  
There are some downsides related to TBI models A and B compared to 
the CRASH and the IMPACT models. First and the utmost is the large 
population sample in which the CRASH and IMPACT models have been 
derived. The CRASH dataset contained more than 2000 TBI cases from high 
income countries and more than 7000 cases from the low to middle income 
courtiers. The IMPACT dataset contained 8509 cases (all from high income 
countries). However, our sample size in TARN was still large enough for 
derivation of a model as the number of patients with the outcome (i.e. 
survivals) was more than 10 times the number of predictors. Furthermore, both 
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the CRASH and the IMPACT models, unlike the proposed model in PhD, do 
not experience a huge drop in performance as per AUC (the IMPACT models 
were validated in the CRASH dataset and vice versa). The other upside of the 
IMPACT and the CRASH models over the TARN models may be related to 
the amount of human resources and expertise devoted to the development of 
such models.  
The derivation of prognostic models on the TARN TBI data was based 
on the argument that the IMPACT and CRASH models may not be valid for 
the British trauma care system. Therefore, one may argue that at the beginning 
these models should have been run on a sample of TBI cases in TARN to 
demonstrate whether or not the models actually lack the validity. Whilst this is 
a clearly missed step in the approach taken in this PhD, the IMPACT group 
have run their model on a subset of TBI cases from TARN and have observed 
an AUCs of between 0.80 and 0.85 for various IMPACT models. Despite this 
degree of performance is much higher than the random guess (i.e. AUC of 
0.50) but there is still scope to obtain a better performance closer to 1. 
Furthermore, this degree of performance is lower than that of the TARN 
general trauma model used for benchmarking of trauma care (Ps07 model; 
AUC = 0.94) [142]. Unfortunately, the CRASH model has not been run on the 
TARN data so far. However, it is not likely that the results of such analysis 
would have changed the procedure to construct a prognostic model for the 
British TBI population. This is because the performance of the CRASH models 
as per AUC dropped when externally validated. In fact, the maximal external 
AUC of the various CRASH models is 0.77. This is much lower than the AUC 
of the TARN general trauma model (AUC = 0.94) [142]. It is not likely that the 
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external validation of the CRASH models would increase in a TARN dataset to 
become close to the current AUC of the Ps07 model. Even in the internal 
validation, the highest AUC of the CRASH models is far below that of the 
Ps07 model (being 0.87). These issues are important with regards to the trauma 
benchmarking since the models used for this purpose overall have much higher 
AUCs than what has been obtained by the IMPACT and CRASH. Whilst from 
clinical perspective the AUCs by the IMPACT and CRASH appear acceptable, 
they are not suitable to offer a national standard which the local trauma care 
can be compared to (given the current TARN model performance for general 
trauma).  
In the same way, the validation of the TARN general trauma model in a 
subset of TBI cases was not performed in this PhD prior to embarking on the 
modeling. This is important since if general trauma models maintain their 
performance in TBI patients, then construction of models specifically designed 
for TBI patients may not be necessary. However, despite in the actual approach 
taken in this PhD, the general trauma models were not validated in the TBI 
dataset (s), the Ps07 model was once run in the derivation dataset of TBI 
models A and B (n=802) following the modeling procedure having been 
already completed. The results demonstrated that the AUC of this model 
underwent a drop in performance from 0.94 to 0.85. This can justify the 
derivation of prognostic models for TBI patients different to those built for 
general trauma patients.  
Although, for the objective of PhD, the prospective study design was 
preferable (as discussed in section 1.7.1), the PhD by design is retrospective. 
This in itself poses problems on those parts of study relevant to the protocol 
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and data collection. Whilst a prospective study offers the possibility that the 
investigator tailors the protocol and data collection to the research objective, in 
a retrospective study only the existing data is analysed. In TARN project, it 
was not possible to assess the prognostic value of some variables such Hb [24], 
temperature [92] or ICP [35] whereas these might have been possible to record 
in a prospective design. In fact, some limitations in TARN project could have 
been eliminated, had the study been prospective such as less strong selection 
bias as per the inclusion criteria and assessing the prognostic value of various 
CT findings.  
9.1.2. S100B project  
Summary from the respective papers  
Some limitations of this project have been discussed in papers 2 and 7 so far.  
Paper 2: there are issues with the blood sampling at 24 hours which 
was merely based on pragmatic reasons and not evidence. However, the patient 
is expected to be more stabilised at this time point than admission. In the same 
way, the flexibility of 2 hours on either side of 24 hours following the injury is 
important as the half life of S100B is thought to be around 2 hours and as such 
significant changes in blood levels can be expected for example from 24 hours 
to 26 hours after injury (a gap of 2 hours in the sampling time which is close to 
the half life).  
Paper 7: the main limitation is the sample size which, despite being 
large enough for the univariate analysis of S100B prognosis, does not offer 
powerful results for the multivariate analysis in refuting the hypotheses 3, 4, 
and 5 (type II error). Similarly, due to this small sample, it was also not 
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possible to suggest which TBI prognosticators can be considered along with 
S100B to predict the outcome in TBI.  
 
****** 
 
For a number of reasons further caution should be taken in 
interpretation of the results of the study having recruited only adult cases. 
Apart from the possible different trajectories of brain injury in children and 
adults, S100B concentration also tends to be higher in healthy children than 
adults. It has been shown that as age increases, S100B serum levels decreases 
up to the age of 20 following which it plateaus [52]. Also, Geyer et al., in a 
sample of 148 children with mild TBI observed that serum levels decrease up 
to the age of 8 followed by an increase [179]. However, it is yet unclear how 
the serum levels of S100B differ in children versus adults following TBI and 
how this possible difference could affect the prognostic strength of S100B. 
Furthermore, S100B is a protein which is synthesized in astroglial cells and 
then reaches the blood stream after passing the blood brain barrier. The 
disposal of this protein is thought to be through renal excretion [180, 181]. 
Thus the kinetic of S100B with regards to its passage through the blood brain 
barrier and the excretion in the kidneys may be different in children and adults 
(this may be similar to the different kinetic of drugs in children versus adults).  
Similarly, one may argue that running the IMPACT or the CRASH 
models might have been superior to TARN models as the IMPACT and 
CRASH models have been externally validated. Nevertheless, the IMPACT, 
CRASH and TARN models share the core TBI prognosticators as age, GCS (or 
  
424 
424 
motor GCS as in IMPACT) and pupillary reactivity. The differences of these 
models in terms of their covariates are the type of intracranial pathologies used 
or the inclusion of glucose and Hb in the IMPACT model. It appears unlikely 
that running the IMPACT or the CRASH models on the datasets would lead to 
substantially different results. 
In this study, the multivariate models as one type of prognostic tools in 
TBI were compared to S100B as a biomarker of brain injury. For this analysis, 
S100B was selected based on a search in PubMed to determine the relative 
amount of research/evidence for three commonly known brain injury 
biomarkers in TBI literature: S100B, GFAP and NSE. This approach does not 
necessarily reflect the better prognostic performance of S100B than the other 
two biomarkers. Vose et al.  compared the ROC curves of GFAP, NSE and 
S100B and observed GFAP and NSE have higher AUC to predict 6-month 
GOS < 4 than that for S100B (GFAP: 79.4, NSE: 78.2, S100B: 67.7). Although 
the confidence intervals are not supplied in this article, it may indicate that 
other brain injury biomarkers could be better TBI prognosticators than S100B.  
This study may not be accurate in the definition of severe TBI in 
refuting the hypotheses 3, 4 and 5. Since, cases were enrolled from a neruo-
ICU, this sample of TBI population represents perhaps only the extreme cases 
within the severity spectrum of TBI. Thus the dataset does not contain cases 
who sustained severe brain injury according to some factors such as GCS or 
pupillary reactivity but did not meet the requirements for admission/transfer to 
neuroICU (for example they did not need neurosurgical intervention). This 
may be an important selection bias as those patients who do not end up in 
nuero-ICU (or do not receive neurosurgical care) may not have necessarily a 
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more favourable outcome than those who are supplied with such specialist 
care. Furthermore, with respect to CT findings, the majority of cases (61%) 
sustained brain injury matched with Marshall Class VI followed by Marshall 
Class V (33%) with only 6% of cases holding Marshall Class II (the least 
severe Marshal class in the dataset). Similarly, 94% of cases had haemorrhage 
detectable by CT. This pattern of CT findings conspicuously is not 
representative of the heterogeneity in TBI severity.  
 Similar to the TARN project, some limitations of the S100B project 
arose due to its retrospective nature. This is particularly important with regards 
to the sampling time being 24 hours after injury. Although one may assume 
that at this time point the patient is stabilised and hence effect of secondary 
insult on the brain has settled, the admission sampling may be more important 
for management decisions which may need to be made at an earlier time point 
based on the prognosis.  
9.1.3.  Summary  
The approach taken in the modelling procedure might have been holistic in 
that the first constructed models do not seem to be significantly different to the 
final models as per AUC. Furthermore,  although the proposed models are 
targeted at severe cases of TBI,  the derivation dataset contained milder cases 
as per admission GCS (as being > 13) or as compared to the IMPACT data 
across GCS or pupillary reactivity. Regarding the external validity of the 
models, model B experienced a huge drop in performance when validated in 
the IMPACT data. Additionally,  due to the retrospective nature of PhD,  it was 
not possible to examine the value of Hb,  ICP or temperature as these factors 
are included in some TBI prognostic models but not recorded by TARN.  
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The small sample size of the S100B study poses an obvious limitation 
which undermines the power of the study. Furthermore,  since the IMPACT 
and CRASH models have been externally validated,  it might have been a better 
option to run the IMPACT and CRASH models on this data as well,  although 
it is not likely that the obtained results would have been substantially 
significantly different. Regarding comparing the prognostic value of brain 
injury biomarkers with prognostic models, S100B may not be the best 
representative of biomarkers because GFAP and NSE are proposed to perform 
better than S100B by some studies. Lastly, the S100B dataset included the 
extreme cases of TBI who were all cared in ICU and 94% of them sustained 
brain haemorrhage.  
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9.2. Comparison with the literature  
9.2.1. TARN project  
Summary from the respective papers  
So far each paper provides some aspects of comparing the results with the 
literature:  
Paper 3: the results with regards to GCS prognostic analysis is in 
consistence with Healey et al.  findings, however their dataset was from 
general trauma patients and no adjustments with confounders was made [22].  
Paper 5: with regards to prognostic value of various AIS severity 
scores, Gennarelli. et al.  [144] reported as AIS severity scores increase the 
chance for survival decrease but in the TARN dataset not every AIS severity 
score of brain injury (out of 3, 4 and 5/6) showed significant association with 
outcome. However, the Gennarelli‟s study was only on general trauma patients 
with no adjustments for confounders. Similarly, the prognostic value of the 
Marshall Classification has been assessed in many studies but similar to the 
results of this PhD, not every Marshall Class is significantly associated with 
outcome unless some classes are merged together [24, 36, 92, 140]. The results 
of PhD regarding various intracranial pathologies including SAH is not 
consistent with many other studies [23, 24, 36, 92, 140, 143, 148, 149, 151, 
152] which can be due to different case-mix as the TARN dataset includes 
relatively milder cases of TBI.  
Paper 6:  the proposed prognostic models in PhD can be added to the 
current list of TBI prognostic models including the CRASH and IMPACT 
models. The performance of TARN TBI models are slightly better than that of 
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the IMPACT and the CRASH models which may be due to the type or time of 
outcome prediction (disability at 6 months). However, since the TARN models 
have been derived from trauma registry data and been historically validated in 
a different dataset from TARN, the TARN models may be a better option for 
British trauma care assessment. However the CRASH and IMPACT models 
may better suit clinical trials as their derivation datasets were mainly from 
clinical trials. Regarding application of prognostic models in clinical setting, 
TARN models predict an acute outcome (i.e. survival at discharge) compared 
to the CRASH and the IMPACT models and therefore these models may offer 
different applications during trauma care (i.e. acute care versus chronic care).  
 
****** 
 
AIS scores, the Marshall Classification and various intracranial 
pathologies were added to the reference models in Paper 5 (reference models 
did not have intracranial pathologies but did contain other important TBI 
prognosticators such age, GCS or pupillary reactivity) and subsequently only a 
slight improvement in the performance (from 0.91 to 0.92) was noticed. This 
finding is in consistence with that by the CRASH collaboration when they 
added various intracranial pathologies detected by CT to the multivariate 
models and noticed a slight increase in AUC of only 0.02 (for models 
constructed for the third world) or no changes (for models constructed for the 
developed world). However, the IMPACT prognostic models demonstrated 
significant degrees of improvement in performance when CT findings were 
added to the baseline models (up to 0.08 increase in AUC). Regarding the time 
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of data collection in IMPACT as dating back to more than 13 years ago and 
more up to date data in the CRASH and the TARN datasets, the difference in 
results may be attributed to the improvement in trauma care policy for TBI 
victims. The other explanation may be more severe cases in the IMPACT 
dataset as they all had admission GCS of less than 9 whereas the CRASH and 
the TARN datasets include cases with higher GCS as well.  
TARN TBI datasets share age, GCS, pupillary reactivity with both 
CRASH and the IMPACT models. These are in fact the three core TBI 
predictors [88]. Further, among all the predictors in each model, pupillary 
reactivity: none reactive has the highest impact on outcome prediction 
according to odds ratio or the coefficient or its score in the scoring system (i.e. 
the IMPACT models). Extracranial injury was found important in the TARN 
TBI model B which is the case in the CRASH models but not in the IMAPCT 
models since this variable was not investigated in the IMPACT modelling. 
Low blood pressure is also included in the TARN and IMPACT models but not 
the CRASH models perhaps because this variables was not recoded in the 
CRASH data. However, with regards to CT findings, the results appear fairly 
heterogeneous. For example, whilst SAH is significant in both the CRASH and 
the IMPACT models, this variable was found non significant in our data. This 
is also the case for the Marshall Classification which is contained in the 
IMPACT model but not in TARN TBI models. There can be several 
explanations for this. It may be due to different case-mix of the studies as the 
IMPACT data contain more severe cases of TBI or the AIS intermediation in 
assigning the CT findings to TBI cases in TARN. However, with regards to 
brain swelling, it appears the three models (IMPACT, CRASH and TARN) are 
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in agreement in that the CRASH models include midline shift and obliteration 
of the 3
rd
 ventricles/basal cisterns (which can in part be due to brain swelling) 
and the IMPACT models include Marshall Class III/IV (merged) which 
partially represents brain swelling.  
9.2.2. S100B project  
Summary from the respective papers  
Paper 2: The cut-off and the prognostic characteristics found in the univariate 
analysis of S100B dataset are different to other studies. For example, whilst the 
cut-off by Nylen et al.  (0.55 μg/l) [79] was close to that obtained in the S100B 
dataset (0.53 μg/l), the specificity observed by Nylen et al.  was much higher 
(100% versus 60% for disability prediction or versus 49% for mortality 
prediction in our data). Similarly, whilst the sensitivity and specificity 
proposed by Vos et al.  [43] was close to what was observed in the S100B 
dataset, the cut-off was much higher (1.13 μg/l by Vos et al.  versus 0.53 in our 
study). These differences may be explained by differences in the case mix.  
Paper 7: the results of S100B study with regards to combination of 
S100B with other TBI prognosticators are inagreement with the findings by 
Dimiopoulou et al.  [43, 165] and Vos et al.  [43] as discussed in Paper 7. 
However, no study so far has attempted to compare the performance of 
prognostic models with a brain injury biomarker. 
 
****** 
 
It was observed that in our sample of TBI, the median S100B not only 
lacks significant difference in patients with and without extracranial injury, it is 
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in fact higher in isolated brain injury. This is in contrast with Savola‟s finding 
that major extracranial injury further increases the levels of S100B in TBI [66]. 
The reason for this difference may relate to the severity of brain injury. In 
Savola‟s study severe brain injury was defined as head trauma with amnesia, 
longer-than-24-hours unconsciousness, intracranial injury observed on CT or 
focal neurological deficit. Not all cases with these criteria of brain injury 
severity would end up in ICU which the subjects in our study were recruited 
from. Unfortunately, measures such as GCS or pupillary reactivity are not 
supplied in the Savola‟s study in order to make a rough comparison of the brain 
injury severity in the two studies. It may be that in more severe cases of TBI, 
the effect of extracranial injury on S100B declines. However, in moderate 
severities of TBI, extracranial injury may be able to increase S100B levels. In 
such case, it may be anticipated that severe brain injury has the same S100B 
concentration as moderate brain injury with extracranial injury.  
9.2.3. Summary  
Whilst TARN models appear better for trauma care benchmarking,  the 
IMPACT and CRASH models are particularly suitable for clinical trials. The 
results on various intracranial pathologies are different to the CRASH and 
IMPACT’s finding (such as the importance of haemorrhage and SAH) which 
can be due to different case-mix or the fact that intracranial pathologies in 
TARN are obtained from AIS codes rather than actual CT images. However,  it 
appears that all these models (TARN,  IMAPCT and CRASH) share the core 
TBI prognosticators i. e. age,  GCS and pupillary reactivity. It also appears 
that these models share brain swelling or pathologies which are likely to be 
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accompanied by brain swelling such as obliteration of the 3
rd
 ventricle/cisterns 
(CRASH) or Marshall Class III/IV (IMAPCT).  
According to univariate analysis of S100B data,  the results are 
different to other studies either on cut-off or the prognostic characteristics i. e. 
sensitivity and specificity. However, similar to our study,  it has been shown by 
Dimiopoulou et al. and Vos et al.  that S100B is one of the most important TBI 
prognosticators in multivariate analysis. However,  to the best knowledge of 
the investigator there is no studies so far which have attempted comparing 
S100B with prognostic models. Regarding the effect of extracranial injury,  the 
results are different to that by Savola’s group as unlike our study,  they found a 
significant effect of extracranial injury on serum S100B. It may be that in 
severe cases of TBI,  the effect of extracranial injury on S100B diminishes. 
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9.3. Implications  
9.3.1. TARN project  
Summary from the respective papers  
Some discussion on the interpretation and implication of the results is 
presented in papers 3, 4, 5, and 6.  
Paper 3: in the prognostic analysis of various GCS subscores, it was 
observed that motor and total GCS may have similar prognostic strength. This 
may indicate that measurement of eye and verbal subscores are not necessary 
as the motor subscores would be easier to learn with less inter- and intra- 
observer disagreement. On the other hand, total GCS has more content 
information and may be still superior to motor GCS for day-to-day monitoring 
of patient‟s course of of conciousness level. Moreover, it was observed that the 
admission scores/subscores are more predictive than scene scores/subscores 
which can be due to lingering effect of inebriation by the arrival at hospital or 
the level of skill to measure GCS at scene.  
Paper 5: considering prognostic value of various intracranial 
pathologies, the results of Paper 5 are important as it highlights the brain stem 
injury and brain swelling as strong predictors of outcome in TBI. This implies 
the necessity of research to improve current therapeutic approaches to patients 
who have sustained these types of injuries.  
Paper 6: regarding the two prognostic models constructed (models A 
and B), the models employ various charactristics to predict survival at 
discharge. Model A may be better for trauma registries as it uses ISS which is 
not commonly measured in clinical practice. On the other hand, model B may 
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be a better choice for clinicians. Moreover, Model A contains ISS instead of 
cause of injury, extracranial injury and brain swelling which are included in 
Model B. As both brain swelling and extracranial injury can influence ISS, 
there may be some relationship with intracranial injury and cause of injury 
which prohibits the two models holding exactly the same covariates. Further, 
as the proposed models contain pupillary reactivity as an important TBI 
predictor, it seems that recording this variable should be declared mandatory 
for all TBI submissions in trauma registries.  
 
****** 
 
For a number of reasons, the constructed models can be referred to as 
„well-developed‟ models. According to Perel‟s criteria [31] some indications of 
a well-developed model in our study are:  
 The patients had adequate follow-up as there was no missing 
information on the discharge survival status.  
 The predictors are included based on a reasonable rationale i.e. 
following the literature review and with consideration given to the clinical 
setting.  
 The variables were clearly defined.  This is reflected on the time point 
of measurement of the variables such as admission GCS or pupillary reactivity 
and clear definition of each category with regards to pupillary reactivity, cause 
of injury, extracranial injury, intracranial pathology (the brain stem injury and 
brain swelling) and hypoxia. For example, the category abnormal-both reactive 
in pupillary reactivity is when both eyes are reactive but one of them is 
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sluggish compared to the other. Similarly, the brain stem injury can include any 
types of injury such as compression, contusion, diffuse axonal injury etc whilst 
brain swelling excludes swelling in the brain stem or cerebellum. Furthermore, 
the diagnosis of these pathologies can be made based on clinical ground or any 
diagnostic modality including CT, MRI, operation notes etc. With regards to 
cause of injury, Table 38 (on page 287) should address any confusion. For 
example, if the patient has fallen following an assault, injury mechanism would 
be fall with the level of intent being assault. Using Table 38, the cause of injury 
would then be assault.  
 The missing information is handled with imputation strategies rather 
than complete case analysis.  Complete case analysis refers to when any case 
with a missing value on even one variable is excluded from the modelling. This 
did not occur during model construction as strategies were implemented to 
impute missing values.  
 Interactions between the variables were examined.  A number of 
interactions were examined based on the literature: age with cause of injury 
[160], systolic blood pressure with hypoxia and mean blood pressure with 
hypoxia [95]. However, the mean blood pressure/hypoxia interaction was not 
assessed since mean blood pressure was excluded from the modelling.  
 More than 10 outcome events (i. e. survival) were included per each 
predictor. Model A contains 7 covariates and model B contains 10 variables. 
According to this criteria, the dataset must include at least 7 × 10 survivals for 
model A and 10 × 10 survivals for model B. The number of survivals in the 
dataset was 599. Furthermore, this criteria was met at all times when various 
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models were constructed for comparison or assessment of the variables during 
various levels of the modelling procedure.  
 How to estimate the prognosis is explained.  The models are presented 
with the coefficients and the constant and the way to make the estimate on 
prognosis in presented in Paper 1 (section 2.6).  
 The models have high AUC (discrimination) (0. 92 and 0. 93 
respectively for models A and B) and a significant p value for HL statistics 
(calibration) (0. 32 and 0. 29 respectively for models A and B).  
 The confidence interval is given for the odds ratio of each covariate in 
the model.  
Mushkudiani et.al. [159] made some recommendations for developing 
and validating prognostic models. These recommendations are divided into 
study population, predictors, outcome, model development and model 
validation and overall are the same as the criteria proposed by Perel et al. . 
With regards to the study population, our sample size (i.e. > 500) and its 
representation of the current practice (since majority of cases sustained the 
injury following Sep. 2005) are some indicators of the strength of our study 
according to Mushkudiani et al. . Moreover, the predictors used in our models 
are readily available. For example, GCS and pupillary reactivity are commonly 
measured in TBI patients on admission and CT scan is widely in use in severe 
TBI to diagnose intracranial pathology. The recommendations regarding the 
model development and validity is overall the same as above-mentioned 
indicators according to Perel‟s criteria.  
Multivariate analysis in medical research is commonly used to account 
for the confounders. This is also referred to „adjustment for confounders‟. For 
  
437 
437 
example, one may be interested to investigate the association of factor A with 
factor X when there is possibility that factor B or C may also affect factor X. 
This is important since the effect of factor A may be „nullified‟ in the presence 
of factors B and C. To address this, a model is constructed where all factors A, 
B and C are supplied to this model and factor X is taken as outcome. Then the 
significance of association of each factor A, B or C  with factor X is explored. 
Whilst this is a common approach in adjustment for confounders, in this PhD, a 
different method was devised as employed in Paper 4 (to assess the prognostic 
strength of various GCS subscores and combinations) and Paper 5 (to assess 
the prognostic strength of various intracranial pathologies). In the „common 
approach of adjustment for confounders‟, all the prognosticators (including 
those of interest such as GCS subscores in Paper 6 along with the confounders 
as age and ISS) could have been supplied to a single model and then the 
significance of their associations with outcome could have been assessed. This 
approach was not taken in the PhD and instead „baseline models‟ were first 
constructed which only included the confounders. Then the factor(s) under 
investigation were added to the baseline model to firstly assess the degree and 
significance of the change in the model performance (as per deviance, AUC, R
2
 
Nagelkerke etc.) and secondly to assess the significance of association with the 
outcome of interest in the resulting model. The disadvantage with the „common 
approach of adjustment for confounders‟ is that firstly, it does not permit 
assessing the added value of the factor of interest when the outcome of interest 
can be predicted by other factors. Secondly, with the „baseline model 
approach‟, comparing the predictive performance of various factors is possible 
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such as comparing the prognostic value of various intracranial pathologies as it 
was done in Paper 6.  
9.3.2. S100B project  
Summary from the respective papers 
The results of this part were partially discussed in Papers 2 and 7.  
Paper 2: briefly, S100B showed low specificity for outcome prediction 
at 3 months (60% for unfavourable outcome and 49% for death) despite having 
a high sensitivity of over 80% for either unfavourable or death prediction. This 
degree of prognostic performance may not be suitable for clinicians.  
Paper 7: it was observed that the difference in S100B and prognostic 
models‟ performance is not significant. The importance of this relates to S100B 
as a simple blood test which is more familiar to clinicians to interpret (through 
knowing sensitivity and specificity) whereas prognostic models are unfamiliar 
tools in clinical context and the interpretation of their performance is more 
complicated. However, prognostic models use those characteristics of patients 
which are routinely measured and thus do not incur extra cost whereas S100B 
is not a part of routine laboratory tests. Moreover, a better prognostic tool may 
be  the combination of brain injury biomarkers with other TBI prognosticators.  
 
****** 
 
In order to compare the prognostic strength of S100B with multivariate 
models, TARN TBI models were run on 100 sample of TBI patients and their 
performance was measured for 3-month outcome prediction. TARN TBI 
models have AUCs and Nagelkerke R
2
s of respectively more than 90% and 
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60% whereas these measures decline in the S100B dataset (For example, AUC 
of model A and B declines respectively by 0.28 and 0.20 for survival 
prediction and by 0.16 and 0.18 for favourable outcome prediction). There are 
a number of possible reasons for this. It may be due to small sample size of 
S100B dataset. Furthermore, TARN models are yet to be externally validated 
in other larger samples of TBI recruited in the British trauma care system 
(methodological, spectrum, and follow-up interval validation) and the drop in 
performance can be due to inherent lack of external validity. However, TARN 
TBI models have been developed to predict the outcome in short-run i.e. at 
discharge and they may perform poorly for the long-term outcome prediction 
such as 3-month survival or favourable outcome. This in fact can be one reason 
that the external validation of TARN model B on the IMPACT dataset yields a 
huge drop in performance. During the study design of this project, the drop in 
performance of TARN models in S100B was expected in part due to the 
sample size, and thus it was decided that, rather than using the exact 
coefficients of the models, the logistic regression be run again to obtain the 
coefficients from the dataset. Had this method not been applied, the 
performance of the TARN models would have perhaps experienced further 
drop.  
9.3.3. Summary  
According to many criteria suggested by Perel et al.  and Mushkudiani et al.  
such as sample size,  model presentation and performance ect. , the 
constructed models A and B can be considered well-developed. Moreover, the 
drop of these models performance in the S100B dataset may be due to small 
sample size of S100B data, long term outcome prediction (3 months versus 
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discharge) or inherent lack of validity. Furthermore,  as S100B is the only TBI 
prognosticator which was found significant,  its daily measurement may be a 
better choice than GCS or pupillary reactivity to monitor TBI progress.  
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9.4. Conclusion  
9.4.1. PhD Hypotheses  
 
Hypothesis 1: the probability of survival is not influenced by the patient 
characteristics in severe TBI.  
 
Both TARN TBI models A and B contain information on patients 
characteristics. These characteristics are demographic (age), descriptive of 
severity and type of injury (ISS, major extracranial injury and CT findings) or 
physiological (GCS, pupillary reactivity, hypoxia and low blood pressure). 
Using these characteristics in the logistic regression formula provides 
the probability of death (or survival) for a given TBI patient. This means if one 
characteristic changes while the others remain constant, it is expected the 
probability of outcome changes too. This is because various patient‟s 
characteristics demonstrate a significant p value in logistic regression analysis. 
As presented in Paper 1 (Table 10), the p value in logistic regression assists in 
assessing the null hypothesis that the coefficient of the respective variable is 
zero. A zero coefficient means the variable has no effects on the probability of 
outcome. Since these models demonstrate that the probability of outcome 
cannot be independent of various patient‟s characteristics, the above hypothesis 
is refuted.  
The importance of this refuting is that if the probability of survival is 
influenced by the patients characteristics; using the patients characteristics can 
then help to make prediction about the subsequent outcome.  
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Hypothesis 2: the logistic regressing does not explain the pattern of mortality 
in severe TBI 
 
Explaining the pattern in mortality can be taken as equivalent to the ability to 
predict the mortality. In this manner, random death can be taken as equivalent 
to „absolute lack of pattern‟ and predicting the mortality with absolute accuracy 
can be taken as „ability to explain the pattern‟.  
In our dataset of 802 TBI cases, two multivariate models were 
constructed through logistic regression. According to several measures of 
performance, these models can predict the survival (or mortality which is 1 
minus probability of survival). However, none of the measures of performance 
demonstrate absolute accuracy. For example, both constructed models have 
Nagelkerke R
2 
of more than 60%. This means that each model is able to 
explain 60% (majority) of the variability in mortality. This is also the case for 
AUC and classification accuracy which are on the one hand above 0.50 
(random event) and on the other hand less than 1 (absolute accurate prediction 
or definitive event).  
Regarding the performance of the models, the above hypothesis can be 
refuted in that these models do not suggest „absolute lack of pattern‟ although 
they are not able to provide a definitive pattern for mortality as well. 
 
The difference in the performance of TARN models A and B in the dataset is 
not statistically significant to that from the S100B model for both survival and 
favourable outcome prediction as per AUC. This is because the CIs for AUCs 
overlap. TARN models A and B represent multivariate models which can be 
Being able to explain the pattern of mortality by logistic regression, 
despite not being absolutely accurate, suggests that this prediction is not 
random and different patients can be regarded as with various risks of 
mortality.  
The prediction of mortality can be made by using the patient‟s 
characteristics as per the covariates included in either model A or B. However, 
it is important to note that the models constructed in Paper 3 which use only 
age, ISS and GCS (Table 17) can help with refuting of the above hypotheses 
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used in prognostication of outcome in severe TBI and the lack of difference 
between the performances of these models with S100B model fails to refute the 
above hypothesis.  
 
Hypothesis 5: There is no difference in prognostic performance between 
multivariate models which do/do not contain S100B as a predictor in severe 
TBI.  
 
The performance of TARN TBI models A and B do not experience a 
statistically significant increase following addition of S100B to these models as 
per AUC (due to the overlap of CIs). Since TARN TBI models A and B can 
represent multivariate models, the study fails to refute the above hypothesis.  
 
The power of the S100B project: type II error in assessing hypotheses 3, 4 
and 5 is fairly strong due to the small sample size for logistic regression 
analysis. This means that the probability that the above hypotheses are failed to 
be rejected when they are not true in reality is high.  
However, despite from statistical perspective, the hypotheses 3, 4 and 5 
are failed to be refuted, there is tendency for hypotheses 3 and 5 to be refuted 
on the following basis: despite non-statistical significant difference between 
S100B and expanded models (for hypothesis 3) and between TARN TBI 
models with and without S100B (for hypothesis 5) as per AUC, the changes in 
AUCs are above the clinical significant cut-off point as discussed in Paper 7. 
The important of this relates to the future research on this topic (sections 8.5.4, 
9.4.2, 9.4.3 and 10).  
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9.4.2. PhD objectives 
 
Objective 1: to develop a prognostic tool to predict the survival in TBI 
applicable to the British trauma care.  
 
Two prognostic models (model A and B) have been developed which enable 
calculation of the survival probability at discharge for a given TBI patients. 
Both models share age, GCS, pupillary reactivity, the brain stem injury, 
hypoxia and low blood pressure. However, model A contains ISS which is 
absent in model B and instead Model B uses extracranial injury, cause of injury 
and brain swelling. The models are presented with the odds ratio and the 
coefficient is given for each covariate. Similarly the models performance is 
presented according to several measures of performance. The models hold a 
high AUC (0.92 and 0.93 respectively for model A and model B). Similarly, 
the models have acceptable calibration per HL statistics (p values 0.20 and 0.19 
respectively for model A and model B). Furthermore, the criteria for a well-
developed model as proposed by Perel et al.  [31] and Mushkudiani et al.  
[159] were followed during the modeling which implies the final models can 
be considered well-developed. The models are externally validated and they 
still hold their high performance.  
As these models perform well in different TBI series from TARN, it is 
reasonable to suggest these models for the purpose of benchmarking of TBI 
care delivery. However, in order for clinical validity they still need further 
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validation in other TBI datasets. Similarly, their use in clinical trials is still 
unclear as the derivation dataset was from a trauma registry.  
Unfortunately, S100B can not be suggested as a prognostic tool at this 
stage as its specificity was found low in a sample of 100 cases of TBI despite 
high sensitivity.  
 
Objective 2: to ascertain among a multivariate model and a blood test which 
one is better to be used for prognosis in TBI.  
 
TARN TBI models A and B and S100B (in isolation) were run on the data of 
100 cases and it was observed that their performance is not significantly 
different (either clinically or statistically). Due to the small sample size this 
finding is not conclusive. However, it highlights the importance of taking this 
issue further in large datasets of S100B to obtain more powerful results. It is 
only after demonstrating that prognostic models outperform S100B, any further 
research on this topic may be deemed less necessary.  
 
Objective 3: to determine whether a combination of multivariate models and 
a blood test can significantly improve the prognosis in TBI.  
 
In this PhD, it was observed that either addition of S100B to current prognostic 
models or considering other TBI prognosticators alongside S100B causes a 
clinically significant increase in the performance of each tool in isolation. This 
may lead to achieve a better prognostic tool than those currently available. 
Unfortunately, the small sample size was unable to offer neither powerful 
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results (which can provide statistical significance) nor a prognostic tool which 
employs a combination of S100B with other patients‟ characteristics.  
Despite lack of statistical significance, the clinical significance in 
change of models‟ performance highlights the importance of future research on 
this topic in larger datasets (adding S100B to prognostic models or considering 
other TBI prognosticators along with S100B). Furthermore, as a rise in S100B 
performance was observed according to AUC, this may explain the variation in 
AUCs reported in the literature as well. However, the issue as to clinical versus 
statistical significance stills holds in this matter as well.  
9.4.3. Aim of PhD: to improve our understanding of 
prognosis in TBI 
In this PhD, two prognostic models have been proposed for TBI prognosis. 
These models can compete with the IMPACT and the CRASH models in terms 
of the methodology employed for their derivation and also the performance. 
However and more importantly, they are suitable for the British trauma care 
system and take account of the cotemporary changes in trauma care. 
Furthermore, they are derived from an ongoing observational project.  
Although the results of S100B study are subject to significant type II 
error, this PhD also adds a new insight about brain injury biomarkers compared 
to prognostic models which have to be tested in the future. As the performance 
of these two prognostic tools do not appear significantly different, their usage 
may depend only on how they are accepted in various settings (clinical or 
trials) based on factors related to their practicality or popularity. However, it 
was observed the combination of these two tools may offer a better 
performance. This opens possibility for future research in construction of 
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prognostic tools in TBI. This might be in fact the reason why some studies 
achieved a much higher S100B predictability than prognostic models in 
contrast to other studies. It may be due to different case-mix according to 
various factors affecting TBI prognosis.  
9.4.4. Summary  
The PhD refutes hypotheses 1 and 2 but fails to refute hypotheses 3,  4 and 5. 
Regarding the objectives, two well-developed prognostic models have been 
proposed for the British TBI population. These models have a high 
performance. Moreover,  the idea of comparing the prognostic performance of 
S100B with that of prognostic models and also their combination needs to be 
taken forward in the future research on TBI prognosis.  
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10. Future directions
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Summary from the respective papers  
Various future directions were discussed in each paper tailored to the particular 
results of the paper and its suitability for a journal article: 
Paper 3: it is important that the GCS prognostic analysis be performed 
in a different dataset of TBI (based on locality or time) and also with 
adjustment with pupillary reactivity. Furthermore, survival at discharge is not 
the only endpoint of outcome as longer-term outcome and also disability are 
important to consider as well.  
Paper 4: the proposed method to use AIS codes to perform the 
Marshall CT Classification requires further validation to test how accurate the 
proposed method is.  
Paper 5: with regards to prognostic analysis of various intracranial 
pathologies or CT findings, it is important to investigate the effect of the 
number of pathologies on the outcome and also on the relationship of each 
pathology with outcome.  
Paper 6: the final TBI  prognostic models  proposed (models A and B), 
both require further external validation from various dimensions such as 
geographical, methodological, spectrum ect.. Moreover, as the models only 
predict survival at discharge, there is still scope for models which can predict 
disability or long-term outcome. Overall, in the future, it is important to assess 
the safety of prognostic models as they may lead to early withdrawal of 
therapy.  
Paper 7: regarding the S100B study, since this study suffers from lack 
of enough power and the results demonstrate that there may not be significant 
difference between S100B and prognostic models in outcome prediction, it is 
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important that the results be validated in a lager cohort of TBI cases and the 
idea of comparing prognostic models with S100B (or brain injury biomarkers) 
and the combination of these two, be taken forward.  
 
****** 
 
In Paper 3 we constructed a baseline model with only age and ISS to 
reach an AUC of 0.84. This degree of performance per AUC is somewhat 
similar to the CRAH and the IMPACT models although the CRASH and 
IMPACT models contain more variables such as pupillary reactivity and CT 
findings. Moreover, in this paper, following addition of GCS to the baseline 
model, a high AUC of 0.91 was reached with only three variables (age, GCS 
and ISS). Similarly Healey et al.  [22] constructed a survival prediction model 
with only GCS and achieved an AUC of 0.89 which is well above the AUCs in 
the CRASH and the IMPACT dataset (the models constructed by Healey et al.  
were for the purpose of assessing the prognostic value of various GCS 
components and not to suggest a prognostic tool. However, the models 
demonstrated that GCS on its own may offer a high AUC for outcome 
prediction). The reason for these differences is not clear but they highlight that 
less complicated models which contain less predictors may be able to provide 
the same degree of predictive performance. This requires a further 
investigation and consideration should be given to measures of model 
performance other than AUC. Although AUC is the most common index to 
measure the discrimination power of a model, other measures of discrimination 
(Nagelkerke R
2
) and also other measures of model calibration apart from HL 
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statistics such as brier score may be important. For instance this is reflected in 
the HL statistics of the GCS models in Paper 3 which, despite having high 
AUCs and Nagelkerke R
2
, have p values of close to 0 (a good model is 
expected to have a p value of above 0.05 by HL statistics). It may be that 
depending on the purpose of the model i.e. using in clinical settings, in clinical 
trials or for trauma care benchmarking, the desired performance of a model 
differ i.e. for instance, a high AUC of more than 0.85 of a model for a clinician 
may not be necessarily required for a model which is to be used in clinical 
trials.  
Investigating these issues requires joint clinical and statistical 
knowledge and expertise. On the one hand, multivariate statistics involves high 
level and meticulous knowledge of mathematical statistics which knowing all 
of the details involved may not be necessary for a clinician who is  interested in 
clinical and health care aspects of the results. As such, knowing the concept, 
essentiality and relevance of each statistical measure may suffice to conduct a 
valid study. This was one of the skills which the investigator developed. This 
skill continues to develop more by „bridging‟ the medical clinical knowledge 
with medical research and statistical knowledge. On the other hand, medical 
statisticians can not be left alone to perform their analysis and interpret the 
results without considering the clinical and practical context of the research. 
The simplest example of this reflects in the idea of clinical and statistical 
significance in that the blood pressures of two groups of patients may be 
significantly different in a statistical analysis but this difference may not hold 
clinical meaning with regards to the magnitude of the difference.  
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There are a number of variables which their prognostic value have been 
shown in multivariate analysis of other TBI datasets such as sodium [97], PH 
[97], haemoglobin [24, 97], Glucose[97], platelets count [97] and prothrombin 
time [97]. Since, TARN does not hold records of these variables and our 
S100B sample of TBI did not include enough cases with these observations 
(for example there were 93.6% anaemic patients), investigating the prognostic 
value of these laboratory variables on their own and also after adjustment with 
other TBI prognosticators such as age or GCS was not possible. Knowing this 
is important with regards to the timely and sufficient intervention in case of 
disturbance in any of these laboratory measures. It is a matter of future work to 
examine this in a larger up-to-date dataset of TBI cases recruited from a British 
trauma care centre(s) with an observational study design.  
One of the applications of our proposed models is in the clinical context 
of treatment and management of TBI patients. Although with the help of these 
models, more accurate prediction on outcome can be made, it is yet unclear 
how such prediction may or should affect the clinical decision making or 
allocation of recourses. Firstly, it has to be examined in a clinical trial that how 
using these models would affect the patient care / outcome. Secondly, as these 
models enable stratification of patients based on their risk of experiencing the 
death, more research is needed to investigate how this stratification can be 
performed. It may be that some cut-offs should be obtained to group TBI 
patients as low, moderate or high risk [36].  
The earliest research into possible S100B role in TBI prognosis may 
date back to the year 1998. However, despite all the huge amount of research 
into S100B so far (a Pubmed search for S100B and TBI using MeSH terms 
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results in 136 journal articles), this biomarker has not received the acceptance 
in clinical settings. The exact reason for this is unclear but it may be due to the 
lack of adequate prognostic performance of S100B in terms of sensitivity and 
specificity. For example, in our series of 100 TBI cases, S100B demonstrates a 
sensitivity of more than 80% for prediction of 3-month death or unfavourable 
outcome when the specificity is low (60% for unfavourable outcome prediction 
and 49% for death prediction). However, when using the same measure of 
performance as to those used for prognostic models (i.e. AUC or R
2 
Nagelkerke), it was observed that the difference between prognostic strength of 
S100B and multivariate models is not substantial. Thus if lack of clinical 
acceptance of S100B is due to its lack of prognostic strength, this may apply to 
multivariate models as well. Since the current reliable prognostic models have 
been introduced only recently (the introduction years of CRASH and IMPACT 
models is 2008 and that of TARN TBI models is 2010), the same „fate‟ may 
occur to prognostic models unless their usefulness over clinical judgment or 
„guessing‟ be shown in a clinical trial. 
It is important to validate the proposed models in this PhD on CRASH 
and IMPACT data. This would address the potential benefit of the models in 
clinical trials as CRASH and IMAPCT data are mainly trial data. In the same 
way, this validation would address the performance of the models in a different 
geographic regions as CRASH and IMPACT are not mainly British. On the 
other hand, validating the CRASH and IMPACT models on TARN data 
explores the performance of these models in a trauma registry or on 
observation data. The cross-validation of TARN, CRASH and IMPACT 
models is a matter of future research to explore the above issues.  
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Patel. et al. demonstrated that those TBI patients who receive 
neurosurgical care, have higher odds of survival [129]. Despite this, there is 
reluctance to transfer all brain injury patients to neurosurgical centres and 
currently, the preference is given to patients who have higher chance to benefit 
from surgical intervention. It appears this approach deprives many other TBI 
patients from effective trauma care. Using prognostic models to classify the 
patients in various risk categories may facilitate decisions on admission or 
transfer of the patient to a neurosurgical centre. This should be investigated in a 
clinical trial following determination of how TBI prognostic models can define 
high risk cases. However, supply of neurosurgical care to would-be-then-
defined high risk TBI patients is perhaps not the only adaptation which is 
required in the management and care of brain injury. Similar changes may be 
made in the rehabilitation of these patients by providing more immediate or 
aggressive rehabilitative interventions.  
The proposed TBI prognostic models are presented in tables of odds 
ratio with coefficients for each predictor and the constant. Thus, using the 
logistic regression formula, the survival probability of a TBI case with given 
characteristics can be calculated (section 2.6.1). There are other ways of model 
presentation such as scoring systems (by means of tables, graphs, nomogram or 
linear equation) or web-based calculators. It is unknown which presentation is 
most user-friendly. A web-based calculator may be an appealingly quick tool 
for clinicians in that the probability of outcome can be supplied without any 
onerous calculation by just putting the already-known patients‟ characteristics 
in the blank boxes of a web-page. However, there are issues with regards to 
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inter-observer and intra-observer reliability of each presentation including the 
web-based calculator. The clinical appeal is only one factor which has to be 
taken into account in examining which way of presentation is the best. 
However, the TARN TBI models may deserve to be presented as an on-line 
calculator in the future similar to current TARN TRISS calculator [89].  
In this study, the prognostic value of S100B at a certain time-point after 
injury (i.e. 24-hours after injury) was taken into account. Firstly, it is unclear 
what time point of S100B is the best for outcome prediction. On the one hand, 
24-hours following admission may be a better approach as the patient is 
expected to be stabilised following initial resuscitation which could eliminate 
the confounding effect of secondary insult (such as hypotension or hypoxia). 
These factors may relate both to S100B rise through causing ongoing brain 
damage and also outcome. On the other hand, even 24-hours after injury, 31% 
of our TBI population samples were hypotensive. Future direction should 
ascertain whether or not better option as to the time elapsed after injury for 
blood sampling is post-resuscitation irrespective when this is achieved; 
immediately after admission or some time after. In fact, the time point of 
sampling is one factor which differ across various studies on S100B prognosis. 
This factor may be able to explain different results on S100B prognostic 
performance observed in the literature review.  
The other option may be to account for the temporal pattern of S100B 
serum concentrations rather than reliance on a single blood measurement. 
Regarding this, one or more of these following factors in temporal course of 
S100B measured at certain intervals (such as daily) during a certain time period 
(such as till 7 days after injury) could be considered: (1) higher initial values, 
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(2) secondary increase over time [76], (3) the peak concentration [79] and (4) 
the average time for S100B to return to normal values [165, 182] . Similarly, it 
requires comparing prognostic value of S100B in this manner to multivariate 
models without S100B or combination of one single S100B measurement with 
other TBI prognosticators.  
It appears that if only the performance of the two prognostic tools (i.e. 
multivariate models and a brain injury blood biomarker) is taken into account, 
there is no difference in which one is being used for outcome prediction. 
However, performance is not the only factor important in using a prognostic 
tool. If application of a prognostic tool in clinical practice is regarded as 
application of a diagnostic test or an‟ intervention‟, then it is also important to 
compare the prognostic models with brain injury biomarker in a clinical trial. 
This off course has to be conducted following demonstrating that overall, using 
prognostic tools would be beneficial for the patients‟ outcome rather than 
exclusive reliance on clinical judgement or intuition in anther initial clinical 
trial.  
It is important that the prognostic strength of S100B and multivariate 
models be compared in another cohort of TBI patients from a different 
country/centre which includes more heterogeneous of TBI cases in a larger 
dataset than ours. The sampling procedure of the S100B study occurred only 
from the ICU patients which represents the extreme severity of brain damage. 
Furthermore, all 100 patients had abnormal CT findings. Thus the dataset can 
not represent those brain injury patients who have normal CT such as diffuse 
axonal injury (or the Marshal Class I). This is a confounding factor since the 
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TBI patients with observed abnormality in their CT have a poorer outcome 
than those with normal CT.  
The method of adjustment for confounders using the baseline models 
which was devised in Papers 3 and 5, requires to be further explored both from 
statistical and clinical perspective. Adjustment for cofounders can be done in 
either of the following ways: (1) to supply all factors (confounders and the 
factor of interest) to one single model and to assess the significance of 
association with outcome in the resulting model (the common method of 
adjustment for confounders), (2) to supply the factor of interest to a baseline 
model which includes the confounders and then to assess the significance of 
associations and changes in the model‟s performance. The latter particularly 
permits a better comparison of the association of several factors with the 
outcome of interest when confounders are taken into account. However, the 
statistical or clinical importance of the results is unclear if, for example, one 
factor appears non-significant in the model but significantly contributes to its 
performance or vice versa.  
10.1.1. Summary  
The proposed models are still required to be validated in a TBI dataset of 
different location,  spectrum of severity etc. Furthermore,  as these models 
were not developed for disability or long-term outcome prediction,  separate 
models are required for these predictions which are suitable for the British 
trauma care. In the same way,  the prognostic value of some factors such as 
Hb,  Glucose,  Plt count,  prothrombin time are still required to be examined in 
a recent British dataset as this can help with timely therapeutic decisions.  
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It is a matter of future research to determine why some models in the 
literature have high performance according to their AUC whereas they include 
only a few covariates. It may be that these models do not have acceptable 
performance as per other measures of performance or using less covariates 
truly does not change the performance.  
It is also important to determine how the clinical decision making can 
be affected by introducing prognostic models to the clinical setting. It is still 
unclear whether or not these models are useful or they are indeed harmful in 
clinical practice. However,  they may be helpful on stratifying TBI patients in 
various risk groups to allocate resources such as neuro-ICU.  
Moreover,  since the analysis of the small S100B dataset showed no 
significant difference in prognostic performance of S100B and prognostic 
models and also this analysis suggested the combination of these two tools 
might enhance the prognostic strength of either alone.  It is important that 
these findings be validated in a larger dataset which is more heterogeneous in 
terms of TBI severity as well. Despite the substantial type II error,  the S100B 
study demonstrates the importance of future research on brain injury 
biomarkers versus prognostic models.  
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11. Appendix  
In this appendix, models derived at each level of modelling procedure are 
presented. The models are presented in tables including the variables supplied 
to the logistic regression, significance (sig.), odds ratio, and the 95% 
confidence interval for the odds ratio. In this appendix, wherever ISS is 
referred to, it is in the form of 91.0
10
log
ISS
e
. 
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Model I  
 Sig.  Odds 
ration 
95. 0% C. I. for odds 
ratio 
Age .000 .952 .940 .965 
76.0
1
10
2
GCS
 
.000 .679 .588 .785 
Pupillary 
reactivity 
Brisk-brisk     
Sluggish-
sluggish 
.003 .299 .134 .669 
Brisk-sluggish .106 .324 .083 1.271 
Absent-brisk .424 2.428 .276 21.321 
Absent-
sluggish 
.002 .057 .009 .359 
Absent-absent .000 .076 .034 .167 
ISS .000 .141 .057 .351 
extracranial .041 2.146 1.033 4.460 
Constant .000 93.506   
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461 
Model II  
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .952 .939 .964 
76.0
1
10
2
GCS
 .057 .370 .133 1.030 
02.1
10
1
log
1
10
2
GCS
GCS
e
 .239 .558 .211 1.474 
Pupillary 
reactivity 
Brisk-brisk     
Sluggish-sluggish .008 .330 .145 .753 
Brisk-sluggish .143 .360 .092 1.414 
Absent-brisk .367 2.773 .303 25.376 
Absent-sluggish .003 .062 .010 .380 
Absent-absent .000 .081 .036 .181 
ISS .000 .147 .059 .365 
Extracranial injury .047 2.102 1.010 4.376 
Constant .000 53.629   
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Model IIIA (AUC: 0.91) 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .952 .940 .964 
76.0
1
10
2
GCS
 .010 .283 .108 .738 
02.1
10
1
log
1
10
2
GCS
GCS
e
 .092 .456 .183 1.137 
Pupillary 
category 
Both reactive     
Only one 
reactive 
.247 .556 .206 1.502 
None reactive .000 .127 .062 .261 
ISS .000 .272 .139 .529 
Constant .000 47.405   
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Model IIIB (AUC: 0.90) 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .955 .943 .967 
76.0
1
10
2
GCS
 .003 .240 .094 .615 
02.1
10
1
log
1
10
2
GCS
GCS
e
 .049 .407 .166 .996 
Pupillary 
category 
Both reactive     
Only one 
reactive 
.119 .462 .175 1.221 
None reactive .000 .122 .060 .247 
Extracranial injury .409 .797 .465 1.366 
Constant .000 43.937   
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Model IV  
 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds ratio 
Age .000 .950 .938 .963 
GCS 15     
14 .000 .058 .022 .148 
13 .009 .197 .058 .668 
12 .001 .093 .022 .397 
11 .275 .414 .085 2.014 
10 .028 .233 .063 .857 
9 .613 1.754 .199 15.500 
8 .161 .313 .062 1.586 
7 .004 .158 .044 .561 
6 .122 .353 .095 1.320 
5 .741 .769 .161 3.664 
4 .200 2.875 .571 14.459 
3 .752 1.166 .449 3.026 
Pupillary 
category 
Both reactive     
Only one reactive .318 .596 .216 1.646 
None reactive .000 .134 .064 .282 
ISS .000 .255 .128 .506 
Constant .000 154.557   
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Model V (AUC:  0.908) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .955 .943 .967 
GCS Mild     
moderate .001 .277 .129 .596 
severe .000 .138 .070 .272 
Pupillary 
category 
Both reactive     
Only one reactive .089 .437 .169 1.133 
None reactive .000 .077 .039 .152 
ISS .000 .234 .121 .452 
Constant .000 141.810   
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Model VI A (AUC: 0.916) 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .960 .947 .973 
76.0
1
10
2
GCS
 .006 .256 .097 .681 
02.1
10
1
log
1
10
2
GCS
GCS
e
 .068 .421 .166 1.066 
Pupillary 
reactivity 
Both reactive     
Only one reactive .190 .507 .184 1.401 
None reactive .000 .109 .051 .232 
ISS .000 .241 .118 .493 
Cause of 
injury 
RTA     
Fall .011 .403 .200 .813 
Assault .256 1.738 .670 4.507 
others .433 .541 .117 2.507 
Constant .000 46.058   
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Model VIIA (AUC: 0.922) 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .959 .946 .973 
76.0
1
10
2
GCS
 .034 .336 .123 .922 
02.1
10
1
log
1
10
2
GCS
GCS
e
 .190 .528 .203 1.371 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.009 .363 .170 .773 
Only one reactive .063 .372 .131 1.055 
None reactive .000 .077 .034 .173 
ISS .000 .237 .115 .489 
Cause of 
injury 
RTC     
fall .012 .404 .199 .822 
Assaults .253 1.742 .672 4.511 
others .425 .546 .123 2.415 
Constant .000 69.892   
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Model VIIB (AUC: 0.914) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds ratio 
Age .000 .955 .943 .967 
GCS mild     
moderate .003 .310 .143 .671 
severe .000 .179 .088 .360 
Pupillary 
reactivity 
Normal     
Abnormal-
both reactive 
.003 .337 .165 .689 
Only one 
reactive 
.020 .311 .117 .830 
None reactive .000 .053 .025 .110 
ISS .000 .232 .119 .454 
Constant .000 165.080   
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Model VIIIA (AUC: 0.917) 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio  
Age .000 .961 .948 .974 
76.0
1
10
2
GCS
 .019 .301 .111 .822 
02.1
10
1
log
1
10
2
GCS
GCS
e
 .124 .475 .183 1.228 
Pupillary 
reactivity 
Normal .    
Abnormal-both reactive .007 .358 .170 .755 
Only one reactive .036 .326 .115 .927 
None reactive .000 .061 .027 .140 
Extracranial injury .001 .283 .137 .585 
Cause of 
injury 
RTC     
fall .021 .438 .217 .883 
Assaults .178 1.894 .748 4.797 
others .531 .631 .150 2.664 
Constant .000 72.977   
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470 
Model VIIIB (AUC: 0.910) 
 
 
 Sig.  Odds ratio  95. 0% C. I. for odds 
ratio 
Age .000 .964 .951 .977 
GCS mild     
moderate .004 .312 .142 .688 
severe .000 .155 .077 .314 
Pupillary 
reactivity 
Normal     
Abnormal-
both reactive 
.003 .334 .163 .686 
Only one 
reactive 
.006 .247 .091 .671 
None 
reactive 
.000 .036 .017 .079 
Extracranial injury  .000 .241 .121 .482 
Cause of 
injury 
RTC     
fall .017 .436 .221 .863 
Assaults .180 1.846 .753 4.525 
others .536 .642 .157 2.619 
Constant .000 215.875   
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Model XIA1 (AUC: 0.92)  
 
 
 Sig.  Odds ratio 95. 0% C. I. for odds 
ratio 
Age .000 .952 .941 .963 
GCS mild     
moderate .020 .425 .206 .876 
severe .000 .225 .122 .414 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.004 .390 .205 .743 
Only one reactive .002 .253 .108 .592 
None reactive .000 .048 .024 .095 
ISS .000 .258 .138 .482 
Brain stem injury .000 .220 .100 .484 
Brain swelling .080 .637 .385 1.055 
haemorrhage .152 1.549 .851 2.817 
Cerebellar injury .072 .422 .165 1.081 
Constant .000 171.466   
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Model XIA2 (AUC: 0.92) 
 
 
 Sig.  Odds ratio 95. 0% C. I. for odds 
ratio 
Age .000 .954 .943 .965 
GCS mild     
moderate .017 .417 .203 .858 
severe .000 .228 .124 .420 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.004 .388 .204 .736 
Only one reactive .002 .251 .107 .590 
None reactive .000 .049 .025 .098 
ISS .000 .268 .143 .502 
Brain stem injury .000 .232 .17 .507 
Brain swelling .071 .630 .382 1.041 
Cerebellar injury .084 .442 .175 1.117 
Constant .000 220.067   
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Model XIA3 (AUC: 0.92) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .953 .942 .964 
GCS mild     
moderate .021 .430 .210 .881 
severe .000 .212 .116 .387 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.006 .413 .218 .780 
Only one reactive .003 .278 .120 .647 
None reactive .000 .049 .025 .097 
ISS .000 .219 .120 .403 
Brain stem injury .000 .185 .085 .402 
Haemorrhage .162 1.526 .844 2.760 
Constant .000 132.121   
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Model XIA4 (AUC: 0.92) 
 
 
 Sig.  Odds ratio 95. 0% C. I. for odds 
ratio 
Age .000 .955 .944 .966 
GCS mild     
moderate .019 .425 .208 .867 
severe .000 .216 .118 .393 
Pupillary 
reactivity 
Normal     
Abnormal-
both reactive 
.006 .411 .218 .775 
Only one 
reactive 
.003 .276 .118 .645 
None reactive .000 .051 .026 .100 
ISS .000 .229 .125 .420 
Brain stem injury .000 .194 .090 .421 
Constant .000 166.557   
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Model XIB1 (AUC: 0.92) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .957 .945 .969 
GCS mild     
moderate .015 .402 .193 .837 
severe .000 .217 .117 .402 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.006 .406 .212 .776 
Only one reactive .000 .210 .088 .501 
None reactive .000 .037 .018 .077 
Extracranial injury  .000 .227 .122 .422 
Cause of 
injury 
RTC     
fall .100 .605 .333 1.101 
Assaults .138 1.880 .817 4.329 
others .973 1.023 .278 3.768 
Brain stem injury .000 .164 .074 .364 
Brain swelling .003 .466 .282 .768 
Haemorrhage .529 1.213 .666 2.209 
Constant .000 295.630   
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Model XIB2 (AUC: 0.92) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .958 .946 .970 
GCS mild     
moderate .014 .401 .193 .833 
severe .000 .220 .119 .408 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.006 .402 .211 .767 
Only one reactive .000 .210 .088 .504 
None reactive .000 .038 .018 .077 
Extracranial injury .000 .225 .121 .418 
Cause of 
injury 
RTC     
fall .106 .611 .336 1.110 
Assaults .136 1.888 .819 4.353 
others .968 .974 .269 3.525 
Brain stem injury .000 .167 .075 .370 
Brain swelling .003 .468 .284 .772 
Constant .000 329.004   
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Model XIIA  
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds ratio 
Age .000 .952 .939 .964 
GCS mild     
moderate .064 .470 .211 1.046 
severe .000 .254 .128 .506 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.001 .303 .149 .617 
Only one 
reactive 
.001 .172 .062 .478 
None reactive .000 .063 .029 .138 
ISS .001 .283 .135 .594 
Systolic 
blood 
pressure 
Normtension     
Hypotension .507 .764 .345 1.694 
Hypertension .956 .983 .527 1.831 
Mean 
arterial 
blood 
pressure 
Normtension     
Hypotension .233 .394 .086 1.817 
Hypertension .700 .809 .276 2.374 
hypoxia .002 .270 .116 .627 
Brain stem haemorrhage .000 .139 .059 .327 
Constant .000 340.535   
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Model XIIB  
 
 
 Sig.  Odds ratio 95. 0% C. I. for odds ratio 
Age .000 .954 .941 .968 
GCS mild     
moderate .037 .411 .178 .947 
severe .000 .256 .125 .524 
Pupillary 
reactivity 
Normal     
Abnormal-
both reactive 
.001 .292 .141 .606 
Only one 
reactive 
.000 .111 .036 .338 
None reactive .000 .049 .022 .111 
extracranial_AIS4 .002 .316 .150 .666 
Cause of 
injury 
RTC     
fall .044 .488 .243 .981 
Assaults .833 1.105 .438 2.786 
others .919 .916 .168 5.004 
swelling .000 .322 .180 .576 
Brain stem haemorrhage .000 .148 .061 .354 
Systolic 
blood 
pressure 
Normtension     
Hypotension .597 .800 .350 1.827 
Hypertension .985 1.006 .531 1.908 
Mean 
arterial 
blood 
pressure 
Normtension     
Hypotension .154 .307 .060 1.557 
Hypertension .658 .776 .253 2.383 
hypoxia .001 .208 .085 .510 
Constant .000 922.011   
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Model XIVA1(AUC = 0.932) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for odds 
ratio 
Age .000 .954 .943 .964 
GCS Mild     
Moderate .012 .401 .196 .818 
Severe .000 .237 .129 .435 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.005 .396 .208 .753 
Only one reactive .006 .292 .122 .701 
None reactive .000 .052 .026 .103 
ISS .000 .249 .135 .457 
Brain stem injury .000 .179 .082 .391 
Hypoxia Yes .001 .270 .128 .568 
Missing .067 .501 .239 1.049 
Constant .000 215.422   
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Model XIVA2 (AUC=0.927) 
 
 
 Sig.  odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .952 .941 .964 
GCS Mild     
Moderate .030 .447 .216 .924 
Severe .000 .272 .146 .506 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.002 .360 .188 .688 
Only one reactive .002 .253 .104 .617 
None reactive .000 .060 .029 .123 
ISS .000 .262 .139 .493 
Brain stem injury .000 .159 .072 .351 
Hypoxia Yes .001 .291 .136 .621 
Missing .413 .702 .300 1.638 
Mean blood 
pressure 
Normotension     
Hypotension .013 .193 .053 .707 
Hypertension .702 1.173 .519 2.650 
Missing .159 .343 .078 1.519 
Constant .000 203.806   
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Model XIVA3 (AUC=0.927) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .953 .942 .964 
GCS Mild     
Moderate .029 .445 .215 .920 
Severe .000 .272 .146 .506 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.002 .359 .188 .688 
Only one reactive .002 .252 .103 .613 
None reactive .000 .059 .029 .121 
ISS .000 .260 .138 .490 
Brain stem injury .000 .159 .072 .351 
Hypoxia Yes .001 .286 .135 .608 
Missing .404 .697 .299 1.626 
Mean blood 
pressure 
No-hypotension     
Hypotension .001 .168 .056 .504 
missing .074 .300 .080 1.123 
Constant .000 233.249   
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Model XIVA4 (AUC= 0.924) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .951 .940 .963 
GCS Mild     
Moderate .019 .423 .206 .867 
Severe .000 .238 .128 .442 
Pupillary reactivity Normal     
Abnormal-both 
reactive 
.004 .379 .197 .730 
Only one reactive .005 .282 .116 .684 
None reactive .000 .057 .028 .115 
ISS .000 .255 .138 .472 
Brain stem injury .000 .180 .083 .391 
hypoxia Yes .001 .272 .128 .577 
Missing .225 .609 .273 1.356 
Systolic blood 
pressure 
Normotension     
Hypotension .057 .553 .300 1.019 
Hypertension .809 1.075 .599 1.928 
Missing .363 .483 .100 2.322 
Constant .000 275.198   
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Model XIVA5 (AUC=0.924) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .951 .940 .963 
GCS Mild     
Moderate .019 .423 .206 .866 
Severe .000 .241 .130 .444 
Pupillary reactivity Normal     
Abnormal-both 
reactive 
.003 .376 .196 .722 
Only one reactive .005 .281 .116 .683 
None reactive .000 .057 .028 .115 
ISS .000 .256 .138 .473 
Brain stem injury .000 .180 .083 .392 
Hypoxia Yes .001 .270 .127 .571 
Missing .225 .609 .273 1.357 
Systolic blood 
pressure 
No-hypotension     
Hypotension .022 .533 .311 .912 
missing .329 .465 .100 2.167 
Constant .000 279.830   
 
  
484 
484 
Model XIVB1 (AUC= 0.928) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
ratio 
Age .000 .956 .945 .969 
GCS Mild     
Moderate .010 .380 .183 .790 
Severe .000 .242 .129 .453 
Pupillary 
reactivity 
Normal .000    
Abnormal-both 
reactive 
.005 .388 .201 .748 
Only one reactive .001 .220 .088 .549 
None reactive .000 .040 .019 .082 
Injury 
cause 
RTC     
Fall .991 1.008 .269 3.779 
Assaults .471 .612 .161 2.328 
Others .393 1.908 .434 8.396 
Extracranial injury .000 .272 .145 .512 
Brain stem injury .000 .163 .073 .363 
swelling .001 .424 .253 .710 
Hypoxia Yes .001 .253 .115 .556 
Missing .134 .561 .263 1.196 
Constant .000 415.746   
 
  
485 
485 
Model XIVB2 (AUC=0.932) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .955 .943 .968 
GCS Mild     
Moderate .022 .418 .198 .884 
Severe .000 .280 .148 .530 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.002 .344 .178 .666 
Only one reactive .000 .189 .074 .481 
None reactive .000 .044 .021 .093 
Injury cause RTC     
Fall .104 .599 .323 1.110 
Assaults .109 2.040 .853 4.882 
Others .846 1.149 .283 4.672 
Extracranial injury .001 .325 .167 .631 
Brain stem injury .000 .150 .067 .337 
swelling .000 .383 .225 .652 
Hypoxia Yes .001 .244 .110 .541 
Missing .471 .729 .309 1.719 
Mean blood 
pressure 
Normotension     
Hypotension .005 .150 .040 .571 
Hypertension .947 1.029 .437 2.425 
Missing .134 .320 .072 1.419 
Constant .000 459.735   
 
  
486 
486 
Model XIVB3 (AUC=0.932) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .956 .943 .968 
GCS Mild     
Moderate .022 .417 .197 .882 
Severe .000 .280 .148 .529 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.002 .344 .178 .667 
Only one reactive .000 .189 .074 .480 
None reactive .000 .044 .021 .093 
Injury cause RTC     
Fall .102 .598 .323 1.108 
Assaults .108 2.043 .855 4.885 
Others .848 1.146 .283 4.651 
Extracranial injury .001 .324 .168 .624 
Brain stem injury .000 .150 .067 .336 
swelling .000 .384 .226 .652 
Hypoxia Yes .000 .243 .110 .539 
Missing .469 .729 .309 1.717 
Mean blood 
pressure 
No-hypotension     
Hypotension .001 .147 .048 .454 
missing .083 .312 .084 1.165 
Constant  470.994   
 
  
487 
487 
Model XIVB4 (AUC=0.930) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .954 .941 .966 
GCS Mild     
Moderate .016 .405 .194 .843 
Severe .000 .242 .128 .456 
Pupillary reactivity Normal     
Abnormal-both 
reactive 
.004 .372 .191 .723 
Only one reactive .001 .213 .084 .541 
None reactive .000 .042 .020 .089 
Injury cause RTC     
Fall .111 .605 .327 1.121 
Assaults .132 1.910 .822 4.437 
Others .875 1.117 .282 4.421 
extracranial_AIS4 .000 .311 .162 .594 
Brain stem injury .000 .168 .076 .373 
swelling .001 .401 .238 .676 
Hypoxia Yes .000 .240 .108 .534 
Missing .328 .665 .294 1.505 
Systolic blood 
pressure 
Normotension .190    
Hypotension  .589 .313 1.107 
Hypertension .658 1.143 .632 2.068 
Missing .416 .507 .099 2.600 
Constant .000 517.771   
 
  
488 
488 
Model XIVB5 (AUC=0.929) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .954 .942 .967 
GCS Mild     
Moderate .016 .405 .194 .843 
Severe .000 .247 .132 .463 
Pupillary reactivity Normal     
Abnormal-both 
reactive 
.003 .369 .190 .715 
Only one reactive .001 .214 .084 .542 
None reactive .000 .043 .020 .090 
Injury cause RTC     
Fall .116 .611 .330 1.129 
Assaults .135 1.902 .820 4.412 
Others .896 1.096 .278 4.318 
Extracranial injury  .000 .310 .162 .592 
Brain stem injury .000 .169 .076 .373 
swelling .001 .404 .240 .681 
Hypoxia Yes .000 .238 .107 .528 
Missing .329 .666 .294 1.507 
Systolic blood 
pressure 
No-hypotension     
Hypotension .039 .552 .314 .970 
missing .363 .475 .095 2.362 
Constant .000 529.858   
 
  
489 
489 
Model XVA1 (AUC=0.925) 
 
 
  Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .951 .940 .962 
GCS mild     
moderate .027 .441 .214 .909 
severe .000 .242 .130 .449 
Pupillary 
reactivity 
Normal .000    
Abnormal-both reactive .002 .359 .186 .694 
Only one reactive .003 .253 .102 .627 
None reactive .000 .055 .027 .113 
ISS .000 .266 .144 .493 
Brain stem injury .000 .183 .083 .403 
Hypoxia Yes .001 .230 .094 .566 
Missing .418 1.803 .433 7.509 
Systolic 
blood 
pressure 
Normotension     
Hypotension .100 .599 .325 1.103 
Missing .699 .621 .055 6.951 
Interaction 
of hypoxia 
and 
systolic 
blood 
pressure 
     
Hypoxia with 
hypotension 
.533 1.659 .337 8.155 
Hypoxia with missing 
systolic blood pressure 
1.000 .000 .000 . 
Missing hypoxia with 
normotension 
.042 .144 .022 .936 
Missing hypoxia with 
missing systolic blood 
pressure 
.393 .241 .009 6.331 
Constant .000 278.073   
 
  
490 
490 
Model XVB1 (AUC = 0.932) 
 
 
 Sig.  Odds 
ratio 
95. 0% C. I. for 
odds ratio 
Age .000 .962 .944 .981 
GCS mild .000    
moderate .013 .382 .178 .820 
severe .000 .236 .123 .456 
Pupillary 
reactivity 
Normal .000    
Abnormal-both reactive .002 .341 .172 .674 
Only one reactive .001 .192 .074 .496 
None reactive .000 .043 .020 .090 
Cause of 
injury 
RTC .425    
fall .263 2.245 .544 9.269 
Assaults .334 .380 .053 2.705 
others .844 1.478 .030 73.101 
Extracranial injury .000 .295 .153 .570 
Brain stem injury .000 .161 .071 .366 
Brain swelling .001 .400 .234 .684 
Hypoxia Yes .000 .182 .071 .463 
Missing .465 1.664 .425 6.519 
Systolic 
blood 
pressure 
Normotension     
Hypotension .077 .561 .295 1.066 
Missing .969 .952 .077 11.740 
Interaction 
of age and 
injury 
cause 
Age and RTC     
Age and fall .054 .976 .952 1.000 
Age and assault .105 1.043 .991 1.097 
Age and others .801 .989 .911 1.075 
Interaction 
of hypoxia 
and 
systolic 
blood 
pressure 
     
Hypoxia with hypotension .243 2.753 .502 15.100 
Hypoxia with missing 
systolic blood pressure 
1.000 .000 .000 . 
Missing hypoxia with 
normotension 
.108 .219 .035 1.392 
Missing hypoxia with 
missing systolic blood 
pressure 
.296 .162 .005 4.920 
Constant .000 430.839   
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491 
Model XVB2 (AUC= 0.931) 
 
 
 Sig. Odds 
ratio 
95.0% C.I. for odds 
ratio 
Age .000 .963 .945 .981 
GCS mild 
moderate 
severe 
    
.010 .370 .174 .788 
.000 .241 .126 .462 
Pupillary 
reactivity 
Normal     
Abnormal-both 
reactive 
.003 .362 .184 .712 
Only one reactive .001 .214 .084 .545 
None reactive .000 .044 .021 .092 
Cause of 
injury 
RTC     
fall .245 2.306 .564 9.428 
Assaults .308 .359 .050 2.569 
others .708 2.140 .040 114.995 
Extracranial injury .000 .283 .147 .546 
Brain stem injury .000 .157 .070 .353 
Brain swelling .001 .409 .241 .696 
Hypoxia Yes .000 .241 .108 .536 
Missing .356 .682 .302 1.538 
Systolic 
blood 
pressure 
Normotension     
Hypotension .040 .548 .309 .972 
Missing .391 .493 .098 2.481 
Interaction 
of age and 
injury 
cause 
Age and RTC     
Age and fall .049 .976 .952 1.000 
Age and assault .085 1.046 .994 1.102 
Age and others .692 .983 .904 1.069 
Constant .000 399.736   
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